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Summary:	
Leucine	rich	repeat	kinase	2	(LRRK2)	is	a	286	kDa	protein	expressed	in	a	variety	of	tissues	and	cell	
types,	 including	 neuronal	 tissue	 and	 innate	 immune	 cells.	 Mutations	 in	 LRRK2	 have	 been	 linked	 to	
inflammatory	 diseases,	 most	 notably	 Crohn’s	 disease	 and	 Parkinson’s	 disease.	 Further	 to	 this,	 LRRK2	
expression	 is	 induced	 by	 innate	 immune	 stimuli,	 and	 can	 be	 phosphorylated	 by	 Myd88	 directed	 TLR	
signalling.	Accordingly,	a	range	of	experiments	and	experimental	approaches	were	taken,	each	designed	to	
assess	the	role	of	LRRK2	in	innate	immunity.	
An	 initial	 focus	was	placed	upon	the	LRR	domain	of	LRRK2.	LRRs	play	an	 important	role	as	 ligand	
binding	domains	of	many	 innate	 immune	 receptors,	 including	 the	 TLR	 and	NLR	 families.	An	 attempt	was	
made	to	express	and	purify	the	LRR	domain	of	LRRK2	in	order	to	build	upon	results	form	earlier	work	that	
suggested	 nucleic	 acid	 binding	 activity	 of	 the	 domain	 through	 binding	 of	 heparin.	 Attempts	 to	 replicate	
initial	work	using	a	construct	termed	‘LRR6’	were	unsuccessful,	most	likely	due	to	batch	variation	associated	
with	baculoviral	expression	of	protein	using	insect	cell	lines.	Therefore	alternative	constructs	were	designed	
and	 successfully	 tested	 using	 insect	 cell	 expression.	 These	 constructs	 systematically	 incorporate	 VLR	
capping	 structures	 that	 have	 recently	 been	 utilised	 for	 the	 purification	 and	 expression	 of	 other	 LRR	
containing	receptors,	including	drosophila	Toll.	
Functional	experiments	were	performed	using	macrophages	 from	WT	and	LRRK2	knockout	mice.	
Many	 phenotypes	 and	 interactions	 have	 been	 described	 for	 LRRK2	 in	 a	 neuronal	 or	 in	 vitro	 context;	
therefore	 experiments	 in	 macrophages	 were	 specifically	 designed	 to	 investigate	 these	 phenotypes	 and	
interactions	 in	 an	 innate	 immune	 context.	 LRRK2	 interacts	 with	 a	 range	 of	 small	 GTPase	 proteins	 called	
Rabs,	 which	 coordinate	 and	 carry	 out	 vesicular	 trafficking,	 including	 that	 of	 innate	 immune	 receptors.	
Further	 interactions	 have	 been	 shown	 with	 clathrin-mediated	 endocytic	 machinery	 and	 phagocytic	
machinery;	 including	 cytoskeletal	 components	 actin	 and	 tubulin.	 Accordingly,	 the	 role	 of	 LRRK2	 in	 the	
expression,	membrane	localisation,	and	ligand-induced	endocytosis	of	the	innate	immune	receptors	such	as	
TLR4	were	assayed.	TLR4	plays	an	important	role	in	immune	responses	to	alpha-synuclein,	an	immunogenic	
protein	 aggregate	 that	 accumulates	 as	 part	 of	 Parkinson’s	 disease	 pathology,	 making	 it	 a	 particularly	
interesting	target	for	this	assay.	No	effect	was	shown	for	LRRK2	on	TLR4	expression	or	receptor	mediated	
endocytosis,	so	attention	was	focused	upon	LRRK2	cytoskeletal	 interactions.	An	unclear	role	of	LRRK2	has	
been	 described	 in	 phagocytosis.	 Application	 of	 LRRK2	 KO	 macrophages	 in	 a	 series	 of	 systematic	
phagocytosis	assays	was	used	to	demonstrate	and	clarify	that	there	is	no	role	of	LRRK2	in	the	phagocytosis	
of	 simple	 beads,	 opsonised	 material,	 or	 complex	 bacterial	 targets	 expressing	 a	 range	 of	 immunogenic	
molecules	such	as	LPS.	
A	genome	wide	approach	was	applied	 to	 further	 investigate	 the	 role	of	 LRRK2	 in	TLR4	mediated	
signalling,	as	well	as	NOD2	mediated	signalling.	Comparison	of	LPS	responses	between	WT	and	LRRK2	KO	
genotype	macrophages	identified	a	role	of	LRRK2	in	modulating	transcription	of	a	range	of	chemokines	and	
chemokine	receptors.	This	indicates	a	specific	role	of	LRRK2	in	regulating	chemotaxis	in	LPS	stimulated	cells.	
Knockout	of	 LRRK2	 resulted	 in	a	complete	 reversal	of	 the	 regulation	of	 the	expression	of	EPAC1,	a	cAMP	
inducible	protein	working	in	parallel	with	a	previously	described	LRRK2	interacting	protein	PKA.	EPAC1	acts,	
at	least	in	part,	via	Ca2+	signalling.	Modulation	of	signalling	through	pathways	such	as	Ca2+,	Wnt	and	cAMP	
appear	as	a	theme	in	results	described	in	this	transcriptomic	experiment.	A	parallel	metabolomic	approach	
allowed	analysis	of	ceramide	levels	in	resting	and	innate	immune	stimulated	macrophages.	Ceramides	are	
lipid	molecules	able	 to	activate	 the	NLRP3	 inflammasome,	as	well	as	modulate	alpha-synuclein	pathology	
via	ceramide	metabolomic	products.	In	contrast	to	results	described	in	neuronal	tissue,	LRRK2	has	no	effect	
on	ceramide	 levels	 in	resting	macrophages,	however	stimulation	of	NOD2	via	MDP	resulted	 in	a	dramatic	
LRRK2	 specific	 increase	 in	 ceramide	 levels.	 Together,	 these	 results	 indicate	 a	 role	 of	 LRRK2	 in	 activated	
innate	immune	cells.	A	differential	effect	of	LRRK2	is	described	under	different	innate	immune	stimuli;	with	
a	 range	 of	 transcriptional	 effects	 described	 upon	 LPS	 stimulation,	 compared	 to	 a	metabolomic	 effect	 on	
ceramide	levels	following	MDP	stimulation.	
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1.	Introduction	
1.1	Immunology	and	inflammation	
1.1.1	Innate	and	adaptive	immunity	
	 The	 immune	 system	 plays	 an	 important	 role	 in	 maintaining	 health.	 This	 role	 is	
extremely	broad	in	its	scope	due	to	the	sheer	diversity	of	threats	that	an	organism	will	face	
during	its	life.	Two	distinct	branches	of	the	immune	system	exist	which	reflect	this	diversity;	
these	are	the	 innate	and	the	adaptive	 immune	responses.	The	adaptive	 immune	response	
requires,	as	the	name	suggests,	adaptation	of	pre-existing	genes	to	overcome	a	pathogen	or	
threat.	 This	 is	 a	process	 that	 takes	an	extended	 length	of	 time	 to	occur.	 Innate	 immunity	
forms	 a	 complementary	 branch	 of	 the	 immune	 system,	 which	 informs	 adaptive	 immune	
responses	of	threats	through	a	degree	of	cross-talk	(Janeway,	1989;	Iwasaki	and	Medzhitov,	
2015),	while	directly	countering	threats	through	inflammatory	processes.	
	 The	 innate	 immune	 system	 is	 key	 to	 immunity	due	 to	 the	 immediate	nature	of	 its	
action.	 The	 term	 ‘innate’	 is	 used	 as	 germline-encoded	 receptors	 available	 to	 an	organism	
without	 any	 adaptation	 or	 genetic	 recombination	 are	 utilised.	 This	 facilitates	 rapid	
immunological	 responses,	allowing	 threats	 from	pathogens	 to	be	countered	quickly,	often	
negating	the	need	to	develop	an	adaptive	response	altogether	(Kumar	et	al.,	2011).	Innate	
immune	 responses	 are	 often	 pro-inflammatory	 in	 nature,	 relying	 on	 the	 secretion	 of	
inflammatory	cytokines	 (Dinarello,	2000).	Cytokines	such	as	 ‘tumour	necrosis	 factor-alpha’	
(TNFα)	act	on	cell	surface	receptors	to	induce	protective	processes	exemplified	by	apoptosis	
(Rath	and	Aggarwal,	1999),	while	others	such	as	interleukin-8	(IL-8)	can	act	to	recruit	further	
innate	immune	cells,	and	thus	amplify	the	pro-inflammatory	response	(Baggiolini	and	Clark-
Lewis,	1992).		
1.1.2	Pattern	recognition	receptors	program	the	inflammatory	response	
	 In	 the	 case	 of	 infection,	 innate	 immune	 responses	 are	 triggered	 by	 specifically	
recognised	molecules	termed	‘pathogen	associated	molecular	patterns’	(PAMPs).	Receptors	
have	 evolved	 which	 are	 tailored	 to	 the	 detection	 of	 PAMP	molecules;	 these	 are	 termed	
pattern	 recognition	 receptors	 (PRRs)	 (Kumar	 et	 al.,	 2011).	 The	most	well-established	 and	
studied	group	of	these	PRRs	 in	mammalian	species	are	the	‘Toll-like	receptors’	 (TLRs).	The	
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number	of	TLRs	varies	between	species,	with	the	human	genome	encoding	ten	members	of	
the	TLR	family	 (Barreiro	et	al.,	2009).	The	TLR	family	are	type-I	 transmembrane	receptors,	
each	 with	 a	 ‘leucine	 rich	 repeat’	 (LRR)	 ligand	 binding	 ectodomain	 and	 a	 transmembrane	
‘Toll/IL-1R’	(TIR)	domain	(Gay	and	Gangloff,	2007).	The	diversity	of	TLRs	reflects	the	range	of	
PAMPs	 expressed	 by	 pathogens.	 TLRs	 1,	 2,	 4,	 5,	 and	 6	 are	 expressed	 as	 membrane	
receptors,	 exposed	 to	 the	extracellular	 environment	 (Gay	et	 al.,	 2014).	Diversity	of	 ligand	
recognition	by	some	TLRs	such	as	TLRs	1,	2	and	6	is	extended	by	the	ability	and	functional	
requirement	for	the	formation	of	heterodimers	upon	ligand	binding.	The	classical	ligands	for	
these	TLRs	are	bacterial	associated	PAMPS,	ranging	from	acylated	lipopeptides	to	bacterial	
flagellin	 and	 lipopolysaccharide	 (LPS).	 TLR4	 is	 a	 particularly	 interesting	 receptor,	 and	 the	
focus	of	a	great	deal	of	study.	Unlike	other	TLRs,	TLR4	is	functionally	cycled	between	the	cell	
surface	 and	 acidified	 endosomes,	 with	 consequences	 for	 down-stream	 innate	 immune	
signalling	and	inflammatory	output	(Kagan	et	al.,	2008).	TLR4	recognises	bacterial	LPS	as	a	
heterodimer	 complexed	with	 ‘myeloid	 differentiation	 factor	 2’	 (MD2)	 (Chow	 et	 al.,	 1999;	
Kim	 et	 al.,	 2007).	 LPS	 is	 a	 highly	modified	 lipid	 found	 on	 the	 outer	membrane	 of	 Gram-
negative	bacteria	that	is	not	found	in	mammalian	cells	under	healthy	conditions	(Bryant	et	
al.,	2010).	Therefore,	detection	of	LPS	by	cells	expressing	TLR4	allows	an	immune	response	
tailored	 to	 intracellular	 Gram-negative	 bacteria	 such	 as	 Salmonella	 if	 signalling	 from	 the	
endosomal	 system,	 or	 extracellular	 Gram-negative	 bacteria	 such	 as	 Escherichia	 coli	 if	
signalling	 from	 the	 cell	 surface.	 TLRs	 3,	 7,	 8	 and	 9	 exist	 as	 pre-formed	 dimers	 in	 the	
endosomal	 system	 where	 they	 are	 tailored	 to	 the	 detection	 of	 viral	 infections	 through	
recognition	 and	 binding	 of	 nucleic	 acids	 (Gay	 et	 al,	 2014).	 Other	 pattern	 recognition	
receptors	 are	 also	 encoded	 in	 the	 mammalian	 genome	 including	 the	 ‘nucleotide-binding	
oligomerisation	 domain’	 (NOD)	 pattern	 recognition	 receptors;	 members	 of	 the	 ‘NOD-like	
receptor’	(NLR)	family.	These	cytosolic	receptors	contain	LRRs,	a	nucleotide	binding	domain,	
and	caspase	 recruitment	domains	 (CARDs)	 (Franchi	et	al.,	2009;	Boyle	et	al.,	2013).	NOD1	
and	NOD2	recognise	bacterial	peptidoglycan	during	infection,	and	perhaps	also	from	the	gut	
microbiota	–	tolerance	of	which	is	essential	as	part	of	gut	homeostasis	(Philpott	et	al.,	2014).	
Pattern	recognition	receptors	can	therefore	be	found	at	the	plasma	membrane,	at	endocytic	
vesicles,	and	in	the	cell	cytoplasm;	providing	a	wide	coverage	of	immune	surveillance	(fig	1).	
While	the	immune	system	is	classically	associated	with	the	cellular	response	to	infection	as	
discussed	above,	the	innate	immune	systems	role	is	more	nuanced,	with	a	continual	role	in	
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surveillance	not	 just	for	 infection,	but	also	for	signs	of	cellular	damage.	Harmful	processes	
often	result	in	cell	death.	This	can	occur	through	mechanical	injury	or	through	disruption	of	
cellular	 homeostasis.	 In	 either	 case,	 activation	 of	 innate	 immunity	 is	 achieved	 by	 ‘danger	
associated	molecular	patterns’	(DAMPs)	(Midwood	and	Piccinini,	2010).	These	are	molecules	
that,	 like	PAMPs,	are	able	 to	activate	 innate	 immune	 responses.	However	DAMPs	are	not	
derived	from	an	external	source	such	as	a	pathogen,	but	are	instead	released	from	cellular	
environments	where	they	would	not	normally	be	exposed	to	immune-surveillance	and	PRR	
detection.	A	good	example	of	this	is	‘adenosine	triphosphate’	(ATP),	a	molecule	that	would	
normally	 act	 as	 an	 energy	 source	 inside	 a	 cell,	 but	 in	 the	 external	 environment	 acts	 as	 a	
signal	 to	 innate	 immune	 cells	 that	 a	 disruptive	 process	 is	 occurring	 (Bours	 et	 al.,	 2006;	
Seiffert	et	al.,	2006).		
	
	
Figure	1:	Immune	surveillance	occurs	at	all	major	cellular	compartments.	Various	innate	
immune	 receptors	 are	 expressed	 at	 the	 cell	 surface	 and	 at	 endocytic	 vesicles.	 This	
arrangement	of	receptors	ensures	that	immune	responses	can	be	orchestrated	against	a	
range	of	threats:	from	viruses,	to	both	intracellular	and	extracellular	bacterial	pathogens.	
Illustrated	 are	 a	 range	 of	 TLRs	 located	 within	 the	 plasma	 membrane	 both	 at	 the	 cell	
surface	and	endocytic	vesicles,	while	NLRs	such	as	NOD2	can	detect	PAMPs	and	DAMPs	
within	the	cell	cytoplasm.		
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As	discussed,	innate	immune	responses	are	activated	by	stimuli	termed	PAMPs	and	
DAMPs,	 depending	 on	 the	 source	 of	 the	 activating	molecule.	 The	 specific	 combination	 of	
these	molecules	and	receptors	bring	about	corresponding	inflammatory	signalling	that	can	
dictate	the	type	of	 response	being	generated.	Some	 innate	 immune	responses	are	geared	
more	towards	repair	than	inflammation,	creating	a	polarisation	paradigm	where	cells	such	
as	macrophages	 can	 be	 activated	 towards	 a	 pro-inflammatory	 (M1)	 response,	 or	 an	 anti-
inflammatory,	 pro-repair	 response	 (M2)	 (Italiani	 and	 Boraschi,	 2014).	 While	 macrophage	
polarisation	is	a	helpful	concept	when	applied	broadly,	the	diversity	of	response	that	can	be	
employed	by	a	macrophage	means	the	M1/M2	paradigm	should	only	be	a	guide,	and	not	a	
phenotypical	definition	(Martinez	and	Gordon,	2014).	Importantly,	while	activation	of	innate	
immunity	 is	 activated	 with	 a	 great	 degree	 of	 molecular-specificity,	 the	 inflammatory	
response	 is	 inherently	non-specific	and	can	 lead	 to	pathology	 if	unregulated	 (Chaudhry	et	
al.,	2013).	An	example	of	this	can	be	seen	with	TLR4	recognition	of	LPS.	In	the	case	of	a	huge	
dose	 of	 LPS	 from	 an	 uncontrolled	 infection,	 sepsis	 can	 occur	 where	 the	 inflammatory	
response	causes	pathological	harm.	As	such,	it	is	the	dampening	of	inflammatory	responses	
that	is	the	aim	of	novel	therapies	for	sepsis	(Wittebole	et	al.,	2010).		
1.2	Immunology	in	the	brain	
1.2.1	Neuroinflammation	and	immune	privilege	
	 The	 nervous	 system	 consists	 of	 the	 peripheral	 nervous	 system,	 and	 the	 central	
nervous	system.	Within	the	central	nervous	system,	the	brain	has	long	been	considered	an	
immune-privileged	site	due	to	the	presence	of	the	blood	brain	barrier.	This	barrier	severely	
impairs	 the	ability	of	circulating	 immune	cells	and	stimuli	 in	 the	periphery	 to	access	brain	
tissues	and	induce	inflammatory	responses	(Ballabh	et	al.,	2004).		
The	 central	 reason	 for	 maintaining	 immune	 privilege	 of	 the	 brain	 is	 the	 delicate	
nature	of	neuronal	cells.	Neurons,	and	the	synapses	formed	between	them,	are	generated	
during	development	and	further	shaped	throughout	 life.	The	 intricate	networks	generated	
this	way	encode	 information	 in	ways	we	are	only	beginning	to	understand.	Neuronal	cells	
themselves,	unlike	the	vast	majority	of	other	cells,	typically	do	not	undergo	cellular	division	
in	order	to	maintain	their	populations	(Bond	et	al.,	2015).	Neuronal	cells	and	their	synaptic	
contacts	 are	 not	 only	 precious,	 but	 they	 are	 also	 extremely	 delicate.	 Neurones	 have	 an	
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extreme	 morphology	 and	 highly	 specialised	 structures	 and	 function.	 Maintaining	 the	
elongated	 morphology	 and	 meeting	 energetic	 demands	 placed	 on	 neurones	 results	 in	
significant	cellular	stress	(Cavanagh,	1984).	The	blood	brain	barrier	 is	the	major	reason	for	
the	 immune	privileged	nature	of	 the	brain;	effecting	 reduced	exposure	 to	 toxins	 from	the	
periphery,	 as	 well	 as	 inflammatory	 mediators	 such	 as	 cytokines,	 and	 infiltration	 of	
inflammatory	cells	(Ballabh	et	al.,	2004).	The	result	of	this	immune	privilege	is	not	absolute	
isolation	of	the	brain,	but	protection	from	stresses	that	would	otherwise	prove	deleterious	
to	 neuronal	 maintenance.	 Immune	 privilege	 is	 also	maintained	 by	 the	 action	 of	 resident	
immune	cells	present	within	the	brain,	namely	the	microglia	as	well	as	other	glial	cells	such	
as	 astrocytes	 (Ousman	 and	 Kubes,	 2012)	 –	 thus	 a	 degree	 of	 immunological	 protection	 is	
possible	without	the	input	of	non-neuronal	cells.	
1.2.2	Blood	brain	barrier	
The	blood	brain	barrier	is	a	multi-layered	structure	centred	around	endothelial	cells	
connected	by	tight-junctions	which	limit	the	ability	of	solutes	and	circulating	cells	to	transfer	
from	blood	to	the	brain,	while	still	maintaining	brain	oxygenation	through	efficient	transfer	
of	oxygen.	Barrier	function	is	enhanced	by	several	further	layers,	including	a	thick	glycocalyx	
that	 acts	 as	 a	 buffer	 between	 blood	 vessels	 and	 endothelial	 cells	 (Abbott	 and	 Friedman,	
2012).	 Pericytes	 can	 be	 found	wrapped	 around	 endothelial	 cells,	 where	 they	 are	 able	 to	
respond	to	extracellular	signals	to	regulate	aspects	of	blood	brain	barrier	function	through	
pericyte-endothelial	cell	signal	transduction	(Sweeney	et	al.,	2016).	A	basement	membrane	
of	extra-cellular	matrix	is	enhanced	by	the	glia	limitans	between	the	central	nervous	system	
and	the	blood	brain	barrier.	The	glia	limitans	forms	the	outer-most	layer	of	neuronal	tissue	
associated	 with	 the	 blood	 brain	 barrier,	 consisting	 of	 astrocytic-end-feet	 which	 provide	
support	 to	 the	 blood	 brain	 barrier,	 and	 promote	 the	 formation	 of	 tight	 junctions	 during	
development	(Abbott,	2002).	These	structures	together	form	a	unit	that	is	remarkably	tight	
when	 compared	 to	 the	 leaky	 vasculature	 found	 in	 peripheral	 regions	 of	 the	 body	 (fig	 2).	
Similar	structures	complement	 the	blood	brain	barrier	 to	separate	the	cerebrospinal	 fluid,	
neuronal	tissue,	and	the	blood	(Liddelow,	2015).	The	blood	brain	barrier	functions	as	both	a	
physical	 barrier	 and	 a	 molecular	 barrier.	 While	 the	 physical	 properties	 of	 the	 barrier	
discussed	above	can	prevent	movement	of	molecules	and	 infiltration	of	 cells	 through	and	
between	 epithelial	 cells,	 structures	 such	 as	 the	 glycocalyx	 are	 also	 thought	 to	 prevent	
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physical	interaction	of	molecules	such	as	toxins	in	the	blood	from	interacting	with	receptors	
on	the	vasculature	side	of	the	barrier	 (Lipowsky,	2012),	thus	providing	a	molecular	barrier	
between	the	brain	and	the	periphery.	Molecular	barrier	function	is	served	on	a	more	basic	
level	 through	 regulated	 expression	 of	 transporters	 and	 signalling	molecules	 on	 the	 blood	
brain	barrier	surface,	thus	regulating	the	interactions	between	central	nervous	system	and	
the	 periphery,	 as	 well	 as	 specifically	 tailoring	 the	 central	 nervous	 system	 cellular	
environment.		
	 	
	
Figure	 2:	 The	 blood	 brain	 barrier.	 Multiple	 layers	 of	 cells	 constitute	 the	 blood	 brain	 barrier	
neurovascular	 unit:	 including	 endothelial	 cells	 linked	 by	 tight	 junctions,	 pericytes,	 and	 astroglia.	
These	are	supported	by	secreted	glycoproteins	of	the	glycocalyx	layer	(facing	the	vasculature),	and	
the	extracellular	matrix	of	the	basement	membrane	(facing	the	brain	parenchyma).	Tight	junctions	
between	endothelial	cells	and	the	glycocalyx	create	an	obstacle	again	the	infiltration	of	peripheral	
immune	cells	from	the	circulatory	system,	while	still	allowing	the	diffusion	and	active	transport	of	
other	molecules.	Pericytes	and	astrocytic	end	feet	facilitate	communication	of	extracellular	signals	
to	endothelial	cells	and	provide	trophic	support.	Adapted	from	Sweeney	et	al.,	2016.	
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While	the	blood	brain	barrier	provides	a	remarkable	layer	of	separation	between	the	
periphery	and	the	brain	from	an	immunological	perspective,	limited	infiltration	of	peripheral	
immune	 cells	 does	 occur,	 and	 is	 part	 of	 healthy	 homeostasis	 of	 the	 brain;	 this	 is	 often	
upregulated	during	disease	 (Ransohoff	et	al.,	 2003;	Ousman	and	Kubes,	2012).	 Therefore,	
while	 the	 brain	 can	 be	 considered	 immune	 privileged,	 it	 is	 far	 from	 immunologically	
isolated.	Communication	between	the	central	nervous	system	and	the	periphery	is	essential	
for	 regulating	 homeostatic	 conditions	 such	 as	 body	 temperature	 via	 the	 autonomous	
nervous	 system.	 Small	 regions	 of	 interface	 between	 the	 blood	 and	 the	 brain	 where	 the	
tightly	 controlled	 blood	 brain	 barrier	 are	 lacking	make	 communication	 possible.	 At	 these	
regions,	 vascularised	 interfaces	 consisting	 of	 highly	 fenestrated	 capillaries	 are	 found	
between	 the	 circulatory	 system	 and	 neuronal	 parenchyma;	 these	 are	 termed	 the	
circumventricular	 organs	 (Ganong,	 2000).	 The	 choroid	 plexus	 and	 leptomeninges	 also	
present	 softer	 barriers	 that	 permit	 small	 molecule	 diffusion	 (Rivest,	 2009).	 Such	 leaky	
regions	of	 the	neuronal	 interface	 can	permit	 toxins	 such	 as	 LPS,	 from	outside	 the	 central	
nervous	system,	to	be	detected	by	immune	cells	in	the	brain	(Nadeau	and	Rivest,	2000).	
1.2.3	Microglia	
	Microglia	are	often	considered	to	be	tissue	resident	macrophages	of	the	brain,	and	
are	 present	 in	 the	 brain	 at	 much	 higher	 numbers	 than	 infiltrating	 immune	 cells	 under	
normal	 conditions	 (Vilhardt,	 2005).	 There	 is	 a	 significant	 amount	 of	 overlap	 between	 the	
known	functions	of	microglia	and	bone	marrow	derived	macrophages,	with	primary	roles	of	
both	 cell	 types	 including	 immune	 surveillance,	 phagocytosis	 of	 pathogenic	 material,	 and	
transduction	 of	 innate	 immune	 signals	 from	 PRRs	 (Ousman	 and	 Kubes,	 2012).	 Both	 cell	
types	 display	 encountered	 antigens	 on	MHC	molecules,	 release	 appropriate	 cytokines	 to	
promote	inflammation,	and	recruit	further	inflammatory	cells.	On	top	of	this,	both	microglia	
and	 bone	 marrow	 derived	 macrophages	 play	 a	 role	 in	 ‘cleaning-up’	 after	 pathological	
processes	through	phagocytosis	of	cell	debris,	and	the	release	of	growth	factors	to	promote	
repair	 and	 cell	 survival.	 Historically,	 the	 similarities	 between	 tissue	 resident	macrophages	
such	as	the	microglia,	and	bone	marrow	derived	macrophages	led	to	a	lack	of	appreciation	
of	the	differences	between	these	phagocytic	cell	types.	More	recently	however,	a	growing	
acceptance	 of	 the	 specialised	 nature	 of	microglia	 has	 been	 established	 (Prinz	 and	 Priller,	
2014).	 In	vivo	 fate	mapping	studies	 in	mice	have	demonstrated	 that	microglia	are	derived	
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from	the	embryonic	yolk	sac	from	embryonic	day	7,	and	are	found	to	colonise	the	brain	via	
the	blood	stream	by	embryonic	day	9,	confirming	earlier	reports	(Alliot	et	al.,	1991;	Alliot	et	
al.,	1999;	Ginhoux	et	al.,	2010).	In	the	adult	brain,	the	blood	brain	barrier	provides	a	layer	of	
isolation	to	microglia,	which	were	found	to	self-renew	from	within	the	brain	rather	than	rely	
on	infiltration	of	macrophages	from	the	blood	stream	to	maintain	phagocytic	cell	numbers	
(Ajami	 et	 al.,	 2007;	 Askew	 et	 al.,	 2017).	 Thus,	 while	 microglia	 and	 macrophages	 are	
remarkably	 similar,	 they	 are	 developmentally	 distinct,	 and	 differences	 in	 cellular	 function	
reflect	this.		
Microglia	 carry	 out	 many	 specialist	 tasks	 in	 the	 brain	 during	 development	 and	
homeostasis,	 and	play	 a	more	 conventional	 role	during	disease	 (Wolf	 et	 al.,	 2017).	 In	 the	
developing	brain,	microglia	promote	neurogenesis	as	well	as	outgrowth	of	neurons	(Walton	
et	 al.,	 2006).	 Under	 homeostatic	 conditions,	 microglia	 maintain	 a	 ramified	 morphology	
characterised	by	long	processes	extending	away	from	the	cell	body	(Glenn	et	al.,	1992).	This	
morphology	 assists	 in	 forming	 transient	 physical	 contacts	 with	 neuronal	 axons,	 dendritic	
spines,	 and	 the	 synapses	 between	 neurons.	 This	 permits	 efficient	 provision	 of	 trophic	
support	 to	healthy	and	developing	neurons,	 as	well	 as	phagocytosis	of	 apoptotic	neurons	
both	 in	neurogenesis	and	disease	 (Sierra	et	al.,	2010;	Nayak	et	al.,	2014).	Phagocytosis	of	
apoptotic	neurons	is	an	important	process	towards	maintaining	homeostasis,	and	avoiding	
unwanted	and	damaging	activation	of	pro-inflammatory	responses	to	cell	death	within	the	
delicate	neuronal	environment	of	the	brain.	Phagocytosis	of	neurons	by	microglia	may	also	
occur	as	part	of	a	process	known	as	synaptic	pruning,	a	developmental	process	involved	in	
learning	and	plasticity;	this	is	an	example	of	a	specialised	function	of	microglia	(Geier	et	al.,	
2012).	 Such	 pruning	may	 be	mediated	 by	 immunological	 signalling	 pathways	 such	 as	 the	
expression	 of	 complement	 component	 3	 in	 microglial	 exosomes	 (Bahrini	 et	 al.,	 2015),	
however	 it	 has	 been	 suggested	 that	 the	 relationship	 between	 microglia	 and	 synaptic	
pruning	may	 be	 one	 of	 association	 rather	 than	 a	 direct	mechanism	 (Perry	 and	O’Connor,	
2010).	Disruption	of	innate	immune	related	proteins	such	as	the	complement	or	fractalkine	
receptors	 were	 found	 to	 inhibit	 this	 process,	 and	 led	 to	 abnormalities	 in	 neuronal	
development	 (Hoshiko	 et	 al.,	 2012;	 Bialas	 and	 Stevens,	 2013;	 Hong	 et	 al.,	 2016).	 Recent	
research	has	also	highlighted	how	microglia	may	not	simply	react	to	apoptotic	extracellular	
exposure	 of	 ‘eat-me’	 signals	 such	 as	 phosphatidylcholine,	 but	 may	 actually	 drive	
phagocytosis	 of	 viable	 neurons	 or	 react	 to	 reversible	 (non-apoptotic)	 exposure	 of	
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phagocytosis	 signals,	 through	 a	 process	 known	 as	 phagoptosis	 (Brown	 and	Neher,	 2014).	
Destruction	 of	 neurons	 in	 this	manner	may	 act	 as	 a	 pathogenic	mechanism,	 through	 the	
destruction	of	otherwise	viable	neurons	as	an	aberrant	response	to	neuronal	stress	(Brown	
and	Neher,	2012).	
Our	understanding	of	how	the	immune	system	can	influence	the	nervous	system	is	
still	in	its	infancy,	with	microglia	and	inflammation	able	to	modulate	neuronal	development	
as	discussed,	but	also	able	to	modulate	behaviour	more	directly.	An	interesting	example	can	
be	seen	in	the	role	of	innate	immunity	in	the	compulsive	grooming	phenotype	of	Hoxb8	loss	
of	 function	 mutant	 mice.	 In	 this	 study,	 wild	 type	 (WT)	 bone	 marrow	 transplantation	 in	
conjunction	 with	 whole	 body	 irradiation	 of	 mice	 expressing	 mutant	 Hoxb8	 was	 able	 to	
reverse	 compulsive	 behaviour,	 thus	 a	 neuronal-driven	 behavioural	 disorder	 can	 be	
mechanistically	 accounted	 for	 by	 perturbation	 of	 peripheral	 immune	 cells	 (Chen	 et	 al.,	
2010).	 More	 recently,	 neuroinflammation	 has	 been	 strongly	 associated	 with	 behavioural	
and	 psychiatric	 disorders	 such	 as	 depression	 (Blank	 and	 Prinz,	 2013;	 Miller	 and	 Raison,	
2016).		These	revelations	suggest	we	may	be	able	to	better	understand	and	treat	psychiatric	
disorders	 by	 modulating	 immunity	 rather	 than	 overcoming	 challenges	 associated	 with	
treating	 neuronal	 circuitry	 directly.	 Overall	 these	 new	 areas	 of	 research	 highlight	 the	
significant	 and	 previously	 underappreciated	 interconnectivity	 of	 the	 immune	 system	 and	
the	nervous	system.	
The	 extended	 processes	 of	 ramified	 microglia	 allow	 efficient	 sampling	 not	 just	 of	
neurons	 and	 their	 synapses,	 but	 also	 of	 the	 extracellular	 environment	 in	 the	 brain	
(Nimmerjahn	et	al.,	2005)	 (fig	3).	This	 is	 important	 for	 immunosurveillance,	and	 the	more	
classical	 immunological	 roles	 of	 microglia.	 As	 mentioned	 previously,	 immunosurveillance	
revolves	around	detection	of	PAMPs	and	DAMPs,	which	can	signal	 to	 the	 immune	system	
that	 homeostasis	 has	 been	 disrupted	 and	 an	 inflammatory	 response	 may	 be	 required.	
Detection	of	such	molecules	is	achieved	by	the	expression	of	the	full	range	of	the	TLR	family	
of	PRRs	by	human	microglia	(Jack	et	al.,	2005),	which	as	resident	macrophages	of	the	brain,	
are	 the	 primary	 cell	 type	 involved	 in	 this	 process.	 In	 the	 context	 of	 neurodegenerative	
disease,	 microglial	 release	 of	 inflammatory	 cytokines	 is	 also	 the	 primary	 driver	 of	
neuroinflammation	 (Vilhardt,	 2005).	 Activation	 of	 microglia	 causes	 a	 dramatic	 change	 in	
morphology	from	ramified	to	amoeboid,	where	processes	are	retracted	towards	the	central	
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cell	body	(fig	3).	Activated,	amoeboid	microglia	display	an	enhanced	pro-inflammatory	and	
phagocytic	 phenotype	 compared	 to	 the	 ramified	 microglia	 which	 are	 involved	 in	
homeostatic	processes	 (Kreutzberg,	1996;	 Lull	 and	Block,	2010).	While	activated	microglia	
are	pro-inflammatory	in	nature,	 it	 is	generally	considered	that	inflammatory	responses	are	
dampened	as	compared	to	bone	marrow	macrophages	 from	the	periphery	 (Gautier	et	al.,	
2012;	Perry	and	Teeling,	2013).	This	is	a	further	example	of	the	immune	privileged	nature	of	
the	 brain,	 where	 an	 overabundance	 of	 inflammation	 can	 be	 pathological	 to	 delicate	
neuronal	networks	in	a	way	that	would	not	be	experienced	outside	of	the	brain.	
	 	
Figure	3:	Microglial	morphology	is	highly	dynamic,	and	varies	with	innate	immune	activation	state.	
The	 cellular	 and	 inflammatory	 properties	 of	 microglia	 change	 with	 their	 state	 of	 activation:	 with	
resting	 ramified	 microglia	 less	 proliferative	 and	 less	 inflammatory	 than	 fully	 activated	 amoeboid	
microglia.	
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The	 ‘immunologically	 dampened’	 nature	 of	 microglia	 in	 comparison	 to	 peripheral	
macrophages	 is	 comparable	 to	 the	 divergence	 of	 many	 different	 tissue	 resident	
macrophages	 from	 canonical	macrophage	 function	 and	 immunological	 reactivity	 to	 suit	 a	
particular	 environment	 and	 its	 associated	 functions	 (Davies	 et	 al.,	 2013).	 Other	 such	
examples	 include	 adipose	 tissue	macrophages	 involved	 in	 the	 development	 of	 conditions	
such	 as	 type	 2	 diabetes,	 and	 cardiac	 resident	 macrophages	 that	 facilitate	 electrical	
conduction	 in	 the	 heart	 (Boutens	 and	 Stienstra,	 2016;	 Hulsmans	 et	 al.,	 2017).	 While	
macrophages	clearly	vary	 in	activity	and	function	by	 localisation	within	the	body,	so	to	do	
microglia	within	different	neuronal	subsections.	This	has	been	highlighted	in	work	by	McColl	
and	 colleagues	 who	 identified	 brain	 region	 specific	 transcriptional	 identities	 that	 vary	
independently	 with	 age	 (Grabert	 et	 al.,	 2016).	 The	 use	 of	 such	 next-generation	
transcriptional	methodology	suggests	that	regulation	of	immunological	responses	varies	not	
just	 between	 peripheral	 immune	 cells,	 and	 those	 situated	 within	 the	 brain,	 but	 also	
between	brain	regions;	affected	by	 factors	such	as	where	 immunological	 function	 is	being	
carried	out,	and	where	microglia	are	 recruited	 from	within	 the	brain.	Further	 implications	
may	exist	in	the	immunological	contribution	known	to	be	made	by	microglia	towards	region-
specific	 neurodegenerative	 effects	 observed	 with	 ageing,	 and	 changes	 in	 microglial	
transcriptional	profiles	during	on-going	neurodegenerative	diseases	(Vincenti	et	al.,	2016).	
1.2.4	Astrocytes	and	glial	scarring	
Microglia	comprise	one	cell	type	within	a	larger	category	of	cells	known	as	the	glia.	
Astrocytes	are	another	major	glial	cell	type	with	a	role	in	the	innate	immune	response,	and	
have	been	discussed	in	the	context	of	the	blood	brain	barrier.	The	glia	collectively	have	been	
shown	 to	 provide	 support	 to	 neuronal	 cells	 through	 provision	 of	 growth	 factors	 and	
nutrients	 (Volterra	 and	 Meldolesi,	 2005).	 In	 particular,	 astrocytes	 regulate	 the	 cellular	
environment	 of	 the	 nervous	 system,	 and	 recycle	 valuable	 molecules	 such	 as	
neurotransmitters	 that	 may	 leak	 during	 synaptic	 transmission	 (Chaturvedi	 et	 al.,	 2014).	
Astrocytes	 form	 close	 contacts	 with	 neuronal	 cell	 bodies	 and	 the	 synapses	 between	
neurons;	 with	 a	 single	 astrocyte	 able	 to	 contact	 around	 100,000	 synapses	 forming	
‘tripartite’	synapses	(Halassa	et	al.,	2007;	Chung	et	al.,	2015).	
Secreted	 factors	 by	 astrocytes	 promote	 the	 formation	 of	 neuronal	 synapses,	 with	
cultures	grown	in	the	absence	of	astrocytes	displaying	fewer	synapses	than	mixed	astrocyte	
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and	neuronal	co-cultures	(Diniz	et	al.,	2012;	Korn	et	al.,	2012;	Farhy-Tselnicker	et	al.,	2017).	
Furthermore,	astrocytes	play	a	functional	role	in	the	synapse	remodelling	during	the	course	
of	 development	 and	 associated	 neuronal	 plasticity,	 but	 also	 following	 some	 instances	 of	
brain	pathology	(Kim	et	al.,	2016;	Kim	et	al.,	2017).	Such	remodelling	is	activity-dependent,	
suggesting	a	fundamental	sensitivity	of	astrocytes	to	neuronal	activity	at	the	synapse	(Flores	
and	Méndez,	2014).	More	recently,	astrocytes	have	been	suggested	to	contribute	towards	
the	 regulation	 of	 synaptic	 signalling	 directly,	 in	 a	 process	 known	 as	 gliotransmission	
(Panatier	 et	 al.,	 2011).	 This	 has	 stemmed	 form	 the	 discovery	 that	 astrocytes	 respond	 to	
various	 neurotransmitters	 or	 electrical	 stimulation,	 and	 as	 a	 consequence	 are	 able	 to	
secrete	neurotransmitters	such	as	glutamate,	D-serine,	ATP	and	‘gamma-Aminobutyric	acid’	
(GABA);	thus	demonstrating	neuronal	 like	properties	 (Auld	and	Robitaille,	2003;	Sahlender	
et	al.,	2014).	There	exists	an	on-going	debate	as	to	the	significance	of	the	contribution	of	the	
astrocyte	 neurotransmission	 machinery	 to	 established	 mechanisms	 of	 neuronal	 calcium	
transient	 transmission,	with	 some	groups	 suggesting	 astrocytic	 calcium	 transients	may	be	
artifactual	 rather	 than	 physiological	 (Fiacco	 et	 al.,	 2009).	 The	 advent	 of	 more	 sensitive	
calcium	 detection	 techniques	 such	 as	 two-photon	 fluorescence	methods	 have	 uncovered	
that	astrocyte	calcium	transients	at	astrocyte	extended	processes	occur	differentially	to	the	
easily	detected	calcium	transients	at	the	soma	(Kanemaru	et	al.,	2014).	The	ability	to	detect	
astrocyte	 electrical	 signalling	 at	 a	 subcellular	 compartment	 significantly	more	 proximal	 to	
neuronal	 synapses	 has	 helped	 to	 improve	 our	 understanding	 of	 gliotransmission	
substantially	(Bazargani	and	Attwell,	2016).	
Within	 an	 immunological	 context,	 astrocytes	 complement	 microglia	 in	 the	 innate	
immune	response,	and	provide	a	powerful	role	in	the	regulation	of	responses	in	a	way	that	
is	 made	 possible	 by	 unique	 and	 specific	 cellular	 distribution.	 Human	 astrocytes	 express	
some,	but	not	all	TLRs.	Human	astroglial	expression	of	TLR3,	and	lower	levels	of	TLR1,	4,	5,	
and	9	have	been	reported	(Jack	et	al.,	2005),	while	there	are	also	reports	of	the	expression	
of	 TLR2	 in	mice	 (Bowman	et	 al.,	 2003).	 This	 suggests	 that	 astrocytes	 are	 able	 to	detect	 a	
range	of	 innate	 immune	 ligands	 to	 complement	 the	microglial	 response.	Unlike	microglia,	
which	 are	 highly	 motile	 and	 dynamic,	 astrocytes	 form	 barriers	 both	 at	 the	 blood	 brain	
barrier,	 but	 also	 at	 the	 meninges,	 and	 around	 aggregates	 of	 inflammatory	 leukocytes	
(Sofroniew,	2015a).	Astrocytes	can	act	at	multiple	levels:	to	directly	induce	inflammation	by	
the	production	of	inflammatory	cytokines,	to	attract	peripheral	immune	cells	to	the	central	
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nervous	system	through	the	action	of	chemokines	such	as	‘chemokine	(C-C	motif)	ligand	2’	
(CCL2),	 to	 control	 diapedesis	 of	 recruited	 cells	 via	 controlled	 regulation	of	 astrocytic	 end-
feet	 at	 the	 glia	 limitans,	 and	 by	 regulating	 the	 micro-environment	 to	 which	 recruited	
lymphocytes	are	exposed	(Sofroniew,	2015a).	In	the	context	of	the	blood	brain	barrier,	the	
‘astrocyte	 functional	barrier’	exists	between	 the	neural	parenchyma	and	 the	parenchymal	
basement	 membranes,	 acting	 as	 a	 pool	 to	 which	 recruited	 immune	 cells	 collect	 before	
astrocyte-regulated	entry	 into	the	brain	parenchyma.	Regulation	of	this	microenvironment	
through	 controlled	 release	 of	 pro-inflammatory	 and/or	 anti-inflammatory	 cytokines	 and	
membrane	receptors	can	influence	the	activity	of	recruited	cells,	and	may	therefore	play	a	
role	 in	 the	 control,	 and	 eventual	 resolution	 of	 an	 inflammatory	 response.	 This	 has	
implications	 in	 disease	 and	 the	 protection	 of	 neurons	 from	 excessive	 or	 chronic	
inflammation	and	resulting	neuronal	damage	(Owens	et	al.,	2008).	
Another	 functional	 role	 of	 astrocytes	 is	 in	 the	 generation	 of	 glial	 scars.	 Such	
structures	have	long	been	considered	entirely	detrimental	to	the	brain,	however	this	view	is	
now	 being	 overturned,	 and	 an	 appreciation	 of	 their	 beneficial	 attributes	 is	 developing.		
Astrogliosis	 is	 interesting	as	 it	 is	a	process	that	can	be	activated	upon	insult	to	the	central	
nervous	system;	with	direct	immunological	consequences	(Sofroniew,	2015b).	Astrogliosis	is	
a	heterogeneous	process	with	a	range	of	severities:	from	simple	morphological	changes	 in	
individual	 astrocytes,	 to	 rapid	 proliferation	 of	 astrocytes	 and	 secretion	 of	 various	
extracellular	matrix	components,	which	results	 in	a	continuous	plasma	membrane	forming	
between	 cells,	 and	 the	 generation	 of	 a	 ‘glial	 scar’.	 This	web	 of	 cells,	 to	which	 other	 cells	
types	 such	 as	 microglia	 also	 contribute,	 can	 effectively	 act	 as	 a	 functional	 barrier	 with	
similarities	 to	 the	 previously	 discussed	 blood	 brain	 barrier	 (Sofroniew,	 2015b).	 The	
beneficial	or	damaging	nature	of	a	glial	scar	may	be	very	much	context	dependent,	defined	
by	 considerations	 such	 as	 the	 nature	 of	 the	 initial	 insult	 to	 the	 brain	 and	 the	 required	
response	to	manage	(Adams	and	Gallo,	2017).	For	instance,	glial	scars	have	classically	been	
considered	 to	 be	 inhibitory	 to	 axonal	 regrowth	 and	 myelination	 by	 inhibiting	 axonal	
outgrowth	 and	 oligodendrocyte	 access	 to	 the	 neuronal	 lesion	 (Fawcett	 and	Asher,	 1999).	
However	 in	 some	 contexts,	 the	 astrocytic	 scar	 may	 also	 inhibit	 the	 infiltration	 of	 pro-
inflammatory	 macrophages	 and	 microglia,	 and	 therefore	 reduce	 the	 inflammatory	
environment	of	 the	wound,	 thus	 reducing	neuronal	 stress	 and	promoting	neuronal	 repair	
(Wanner	et	al.,	2013).	Subsequently	it	has	also	been	shown	that	astrocytes	in	scars	express	
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molecules	which	promote	axon	repair,	and	that	inhibiting	scary	formation	limited	this	repair	
process	 (Anderson	et	al.,	2016).	Similarly,	 like	microglia,	using	next	generation	sequencing	
technology	a	growing	appreciation	is	developing	of	the	diversity	of	astrocyte	activity	across	
different	regions	of	the	central	nervous	system,	and	during	ageing	(Farmer	and	Murai,	2017;	
Lin	et	al.,	2017).	As	such,	it	should	be	expected	that	glial	scars	may	differ	in	their	functional	
activity	when	forming	in	different	brain	regions	of	the	brain	or	at	different	times	across	the	
lifespan	of	an	individual,	as	such	heterogeneity	should	be	expected	in	the	effect	of	glial	scar	
formation	of	neuronal	regeneration.	
The	 growing	 appreciation	 of	 astrocyte	 diversity	 has	 further	 implications	 upon	
neurobiology,	with	effects	not	just	on	glial	scarring	but	also	previously	mentioned	astrocytic	
roles	 including	electrochemical	signalling	at	the	synapse,	synaptic	development	and	innate	
immune	 responses.	 These	 considerations	 may	 contribute	 towards	 future	 astrocyte	 (or	
indeed	 microglial)	 targeted	 disease	 therapies	 by	 shifting	 cells	 of	 a	 detrimental	 gene	
expression	 profile,	 to	 that	 of	 a	 beneficial	 profile,	 potentially	 by	mimicking	 environmental	
cues	of	another	brain	region	(Anderson	et	al.,	2016;	Adams	and	Gallo,	2017).	
1.2.5	Neuroinflammatory	disease	
A	 relationship	between	 innate	 immunity	 and	 the	nervous	 system	 is	 clear	 from	 the	
diverse	 roles	 of	 glia	 in	 immunity,	 but	 also	 in	 maintaining	 neuronal	 function	 under	
homeostatic	 conditions.	 The	 interconnectivity	 of	 the	 innate	 immune	 system	 and	 the	
nervous	 system	 is	 strengthened	 by	 the	 expression	 of	 TLRs	 on	 neuronal	 cells	 themselves.	
Neuronal	TLR	expression	is	variable	during	development,	and	appears	to	play	a	specialised	
role	 in	 neurogenesis	 and	 development	 (Kaul	 et	 al.,	 2012).	 A	 prime	 example	 of	 the	
specialised	nature	of	TLR	expression	in	neurones	can	be	found	in	TLR7.	Cellular	localisation	
and	function	of	TLR7	are	variable	between	different	types	of	neurone	at	different	regions	of	
the	brain.	 Cortical	 and	hippocampal	 neurons	display	 endosomal	 localisation	 of	 TLR7,	with	
activation	bringing	about	neurodegeneration	(Lehmann	et	al.,	2012).	In	comparison,	sensory	
neurons	of	the	dorsal	root	ganglia	display	an	unusual	membrane	localisation	of	TLR7,	with	
activation	 of	 the	 receptor	 eliciting	 a	 pain	 response	 by	 coupling	 to	 the	 ion	 channel	 TRPA1	
(Park	et	al.,	2014).		
	 24	
TLR3	represents	another	 interesting	example	of	a	classical	 innate	 immune	receptor	
serving	 a	 neurological	 role	 in	 a	 neuronal	 context,	 as	 viral	 infections	 at	 foetal	 or	 neonatal	
stages	 has	 been	 linked	 to	 the	 development	 of	 autism	 and	 schizophrenia	 (Knuesel	 et	 al.,	
2014;	MacDowell	et	al.,	2017).	TLR3	is	the	innate	immune	receptor	for	double	stranded	RNA	
(Gay	et	al.,	2014).	Activation	of	neuronally	expressed	TLR3	has	been	shown	to	cause	down-
regulation	 of	 several	 psychiatric	 disorder	 associated	 genes	 including	 ‘Disrupted	 in	
schizophrenia	 1’	 (Disc1),	 leading	 to	 various	 developmental	 deficits	 including	 defective	
neuronal	arborisation	and	increased	density	of	neuronal	spines	(Chen	et	al.,	2017).	
While	 inflammatory	 processes	 must	 exist,	 as	 elsewhere	 in	 the	 body,	 to	 resolve	
infections	 and	 mop	 up	 immunogenic	 molecules;	 they	 also	 play	 a	 role	 in	 neurological	
processes	 including	 plasticity,	 development,	 and	 behaviour.	 As	 such,	 a	 wide	 range	 of	
diseases	 of	 the	 nervous	 system	 can	 be	 linked	 to	 when	 neuroinflammation	 goes	 wrong.	
These	include,	but	are	not	limited	to:	neurological	disorders	such	as	depression,	and	more	
classical	 inflammatory	 conditions	 such	 as	 meningitis,	 autoimmune	 encephalitis,	 multiple	
sclerosis	 (MS)	 and	 amyotrophic	 lateral	 sclerosis	 (ALS)	 (World	 Health	Organization	 (WHO),	
2006;	Dendrou	et	al.,	2016).	
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1.3	Parkinson’s	disease	
1.3.1	Introduction	to	Parkinson’s	disease	
	 Parkinson’s	 disease	 is	 a	 neurodegenerative	 disease	 characterised	 by	 the	 selective	
destruction	of	a	specific	subset	of	neurons	responsible	for	the	generation	of	dopamine	and	
fine	control	of	motor	function	(Orr	et	al.,	2002).	These	dopaminergic	neurons	are	located	at	
the	substantia	nigra	pars	compacta,	a	region	of	the	midbrain	that	is	specifically	affected	in	
Parkinson's	 sufferers	 at	 early	 stages	 of	 the	 disease	 (Naoi	 and	 Maruyama,	 1999)	 (fig	 4).	
Classical	 symptoms	 of	 Parkinson’s	 disease	 relate	 directly	 to	 the	 loss	 of	 the	 dopaminergic	
neural	 circuitry;	 and	 include	 tremor	 at	 rest,	 loss	 of	 gait	 control,	 and	 bradykinesia.	
Parkinson’s	disease	is	the	most	prevalent	neurodegenerative	movement	disorder,	affecting	
1	%	of	the	population	over	60,	increasing	to	5	%	of	the	population	over	85	years	of	age	(de	
Lau	 and	 Breteler,	 2006).	 With	 an	 ageing	 population,	 an	 improved	 understanding	 of	 the	
mechanisms	leading	to	the	onset	of	Parkinson’s	pathology	and/or	the	molecular	pathways	
involved	 in	 neuronal	 degradation	 are	 of	 increasing	 importance	 in	 order	 to	 develop	 the	
effective	long-term	therapeutic	strategies	that	are	currently	lacking	(Toulouse	and	Sullivan,	
2008).		
Parkinson’s	 disease	 is	 a	 progressive	 condition,	 with	 pathology	 and	 symptoms	
progressing	with	time.	At	 later	stages	of	pathology,	neurodegeneration	spreads	to	regions	
surrounding	 the	 substantia	 nigra,	 including	 higher-order	 sensory	 areas	 of	 the	 cortex.	 The	
uniform	progression	of	 the	disease	with	 little	 variation	between	 individuals	 is	 reflected	 in	
the	 progressive	 development	 of	 pathology	 at	 a	 cellular	 level;	 this	 has	 become	 known	 as	
‘Braak	staging’	 (Braak	et	al.,	2003).	Symptoms	resulting	 from	neurological	damage	 lead	 to	
devastating	 changes	 to	 the	quality	of	 life	 of	 individuals,	 affecting	not	 just	movement,	 but	
also	 mental	 acuity	 and	 behaviour	 (Fahn,	 2003;	 Wolters	 et	 al.,	 2008).	 As	 a	 chronic	 and	
progressive	degenerative	disease,	once	classical	movement	related	symptoms	are	prevalent	
and	Parkinson’s	disease	is	diagnosed,	there	is	no	known	way	to	half	or	reverse	progression	
of	 pathology.	 This	 is	 another	 example	 of	 the	 delicacy	 and	 irreplaceability	 of	 neuronal	
networks	within	the	brain.		
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Figure	 4:	 Schematic	 of	 dopaminergic	 neuronal	 pathways	 within	 the	 basal	 ganglia.	 The	
nigrostriatal	 pathway	 consists	 of	 dopaminergic	 neurons	between	 the	 substantia	 nigra	 and	 the	
striatum.	This	pathway	 is	part	of	a	 larger	neuronal	network	known	as	 the	basal	ganglia.	While	
loss	 of	 dopaminergic	 neurons	within	 the	 substantia	 nigra	 results	 in	 loss	 of	motor	 control	 and	
Parkinson’s	 disease,	 other	 regions	 of	 the	 basal	 ganglia	 such	 as	 the	 cortex	 are	 more	 closely	
associated	 with	 behaviour	 and	 may	 be	 affected	 at	 later	 stages	 of	 Parkinson’s	 disease	
progression.	Adapted	from	an	image	originally	created	by	the	National	Institute	of	Health.	VTA	=	
ventral	tegmental	area.	
Nigrostriatal	pathway	
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1.3.2	Parkinson's	disease	treatments	
Treatment	of	Parkinson’s	disease	has	not	progressed	significantly	since	the	first	use	
of	levodopa	(L-DOPA)	in	the	1960s.	L-DOPA	is	able	to	cross	the	blood	brain	barrier	where	is	
it	metabolised	to	dopamine,	and	is	able	to	attenuate	the	effect	of	the	loss	of	dopamine	from	
the	 degeneration	 of	 dopaminergic	 neurons	 that	 occurs	 as	 part	 of	 Parkinson’s	 pathology	
(Contin	and	Martinelli,	2010).	Unfortunately,	L-DOPA	acts	as	a	treatment	of	symptoms	and	
not	pathology,	 therefore	as	pathology	progresses,	 the	effectiveness	of	 the	drug	decreases	
significantly;	 and	 symptoms	 progress	 beyond	 motor	 control	 and	 dopamine-related	
pathology.	After	4-6	years	of	L-DOPA	therapy,	40	%	of	patients	begin	to	experience	L-DOPA	
induced	motor	fluctuations	and	dyskinesia	(Nutt,	2008).	
Another	 form	 of	 treatment	 developed	 is	 deep	 brain	 stimulation,	 which	 can	 be	
applied	 to	 initially	 alleviate	 disease	 burden	 and	 restore	 quality	 of	 life.	 But	 like	 levodopa,	
deep	brain	stimulation	only	acts	to	treat	symptoms	and	not	disease	pathology;	resulting	in	
decreased	 efficacy	 over	 time	 (Toulouse	 and	 Sullivan,	 2008).	 Application	 of	 deep	 brain	
stimulation	 also	 requires	 brain	 surgery,	 meaning	 therapeutic	 intervention	 is	 severe	 and	
carries	 risks	both	during	and	after	 the	procedure	 through	complications	 such	as	 infection.	
Therefore,	deep	brain	stimulation	is	most	often	not	considered	beneficial	for	older	patients	
who	 are	 most	 commonly	 affected	 by	 Parkinson’s	 disease.	 In	 spite	 of	 this,	 deep	 brain	
stimulation	 is	 considered	 a	 more	 effective	 method	 of	 treating	 motor	 disability	 and	
improving	quality	of	life	than	L-DOPA;	so	remains	an	appealing	route	for	treatment	of	fitter	
Parkinson’s	patients	 (Weaver	et	al.,	2009).	Patient	 response	to	deep	brain	stimulation	has	
been	 positively	 correlated	 to	 L-DOPA	 response,	 and	 has	 been	 shown	 to	 reduce	 the	
requirement	 for	 parallel	 L-DOPA	 treatments	 in	 ‘long-term’	 clinical	 follow-up	 case	 studies	
(Kleiner-Fisman	et	al.,	2003).	
	While	 Parkinson’s	 disease	 pathology	 is	 mostly	 considered	 and	 diagnosed	 as	 a	
movement	 disorder,	 it	 is	 believed	 that	 some	 non-motor	 symptoms	may	manifest	 before	
pathology	has	progressed	to	affect	the	substantia	nigra.	Such	symptoms	have	been	referred	
to	 as	 ‘pre-diagnostic’	 markers	 for	 Parkinson’s	 disease,	 and	 are	 thought	 to	 be	 less	
homogenous	than	the	later	pathology	of	Braak	staging	(Zis	et	al.,	2015;	Noyce	et	al.,	2016).	
Much	research	emphasis	is	placed	on	the	use	of	pre-diagnostic	symptoms	as	early	markers	
for	 Parkinson’s	 disease	 to	 allow	 early-intervention	 and	 preservation	 of	 dopaminergic	
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neurons.	Symptoms	such	as	anosmia	and	dizziness	are	examples	of	these	markers,	and	are	
thought	to	precede	clinical	Parkinson’s	disease	by	four	years	(Ross	et	al.,	2008;	Noyce	et	al.,	
2017).	 As	 a	 progressive	 disease,	 early	 diagnosis	 could	 help	 enhance	 currently	 applied	
treatments	by	allowing	 intervention	with	 lower	doses	of	 levodopa	before	disease	severity	
has	worsened.	Recent	 research	using	germ-free	mice	has	even	suggested	 that	Parkinson’s	
pathology	may	in	fact	not	originate	in	the	brain,	but	may	spread	from	the	gut	via	short	chain	
fatty	acid	signalling	from	the	gut	microbiota	(Sampson	et	al.,	2016).	If	substantiated,	such	a	
finding	not	only	changes	out	understanding	of	the	pathobiology	of	Parkinson’s	disease,	but	
also	raises	the	possibility	of	preventative	medical	interventions,	or	treatments	to	sever	the	
spread	of	disease	before	reaching	the	brain.	
1.3.3	Alpha-synuclein	in	Parkinson’s	disease	
The	hallmark	of	Parkinson’s	pathobiology	is	the	accumulation	of	toxic	aggregates	of	
misfolded	proteins	known	as	Lewy	bodies	within	cells;	these	classify	Parkinson’s	disease	as	a	
proteinopathy.	 Lewy	 bodies	 consist	 primarily	 of	 the	 archetypal	 Parkinson’s	 associated	
protein	alpha-synuclein,	decorated	with	an	array	of	other	proteins	 including	ubiquitin,	and	
tau	 (Spillantini	 et	 al.,	 1998;	 Giráldez-Pérez	 et	 al.,	 2014).	 The	 specific	morphology	 of	 Lewy	
bodies	 can	 vary	 in	 different	 brain	 regions,	 and	may	 reflect	 different	 stages	 in	 Lewy	 body	
development,	 but	 the	 core	 components	 of	 Lewy	 bodies	 remain	 the	 same.	 Lewy	 body	
formation	is	seeded	through	toxic	misfolding	of	alpha-synuclein.	The	role	of	non-pathogenic	
alpha-synuclein	 during	 health	 is	 not	 well	 established,	 however	 a	 function	 has	 been	
suggested	in	the	regulation	of	neurotransmitter	release	and	recycling	at	neuronal	synapses,	
with	 alpha-synuclein	 overexpression	 inhibiting	 neurotransmitter	 release	 (Nemani	 et	 al.,	
2010).	Mutations	 in	alpha-synuclein	which	make	 the	protein	more	prone	 to	aggregate,	or	
gene	multiplication	events,	have	been	shown	to	significantly	increase	the	risk	of	developing	
Parkinson’s	 disease,	 showing	 a	 clear	 mechanistic	 link	 between	 alpha-synuclein	 and	 the	
development	of	the	disease	(Polymeropoulos	et	al.,	1997;	Singleton,	2003;	Kay	et	al.,	2008).		
A	 prion-like	 spreading	 of	 toxic	 alpha-synuclein	 has	 been	 proposed,	 where	 the	
formation	of	the	toxic	β-amyloid	species	of	alpha-synuclein	is	capable	of	seeding	the	further	
misfolding	 of	 functional	 forms	 of	 alpha-synuclein	 in	 a	 prion-like	 manner	 (Olanow	 and	
Brundin,	2013).	This	phenomenon	was	first	observed	in	Parkinson’s	patients	who	developed	
Lewy	 body	 pathology	 in	 transplanted	 neurons	 which	 had	 previously	 been	 healthy,	
	 29	
suggesting	 host-to-graft	 disease	 propagation	 (Kordower	 et	 al.,	 2008;	 Li	 et	 al.,	 2008).	
Aggregation	of	β-fibrils	revolves	around	the	formation	of	stacks	of	extremely	thermostable	
hydrophobic	 β-sheets,	 which	 eventually	 grow	 into	 large	 hydrophobic	 structures.	 This	
stacking	 is	 brought	 about	 by	 a	 hydrophobic	 central	 region	 of	 alpha-synuclein	 termed	 the	
‘non-amyloid-β	 component	 of	 AD	 amyloid	 plaques’	 (NAC)	 domain	 (Giasson	 et	 al.,	 2001).	
Under	 normal	 conditions,	 large	 hydrophobic	 surfaces	 are	 inherently	 internalised	 and	
contribute	 a	 substantial	 energetic	 component	 of	 protein	 folding.	 The	 presence	 of	 such	 a	
large	hydrophobic	structure	within	cells	therefore	has	potential	to	disrupt	cellular	functions	
at	even	the	most	fundamental	 level.	The	nature	of	the	spread	of	alpha-synuclein	between	
cells	 is	 a	matter	 of	 current	 research,	with	 suggestions	 that	 seeds	 of	 toxic	 alpha-synuclein	
aggregates	could	be	transferred	between	cells	by	normal	cellular	exocytosis	and	endocytosis	
events,	released	from	cells	through	toxic	alpha-synuclein	mediated	cell	death,	or	ectopically	
released	 from	 cells	 through	 processes	 mediated	 by	 the	 biophysical	 properties	 of	 alpha-
synuclein	aggregates	themselves	(Lashuel	et	al.,	2013).		
Alpha-synuclein	 is	 clearly	 intricately	associated	with	Parkinson’s	disease	pathology,	
with	 increasing	 concentration	 and	 spread	 of	 toxic	 aggregates	 positively	 correlated	 with	
disease	severity.	As	such,	targeting	the	accumulation	and	aggregation	of	alpha-synuclein	has	
been	a	priority	for	the	development	of	novel	treatments	for	the	disease,	as	well	as	attempts	
to	 remove	 aggregated	 alpha-synuclein	 (Chu	 and	 Kordower,	 2007).	 Unfortunately	 no	
attempts	 so	 far	 have	 successfully	 halted	 disease	 progression,	 raising	 the	 possibility	 that	
other	important	processes	are	being	overlooked	that	work	either	in	conjunction	with,	or	as	
well	as,	alpha-synuclein	aggregation	in	the	pathobiology	of	Parkinson’s	disease.	An	example	
of	such	thinking	can	be	found	in	the	therapeutic	inhibition	of	the	unfolded	protein	response	
in	misfolded	prion	protein	(PrP)	diseased	mice.	PrP	is	a	prion	protein	with	some	similarities	
to	the	misfolded	proteins	 in	other	neurodegenerative	diseases	such	as	Parkinson’s	disease	
and	Alzheimer’s	disease.	Researchers	found	that	inhibition	of	the	unfolded	protein	response	
was	 able	 to	 ameliorate	 neurodegenerative	 processes	 in	 PrP	 mice	 by	 restoring	 normal	
protein	 translation	 (Moreno	 et	 al.,	 2012).	Most	 interestingly,	 recovery	 and	 prevention	 of	
disease	 in	 these	 mice	 was	 achieved	 after	 protein	 aggregation	 had	 already	 occurred,	
meaning	PrP	aggregates	were	tolerated	in	these	mice	(Moreno	et	al.,	2013).	This	would	be	
analogous	to	alpha-synuclein	aggregation	occurring	as	part	of	Parkinson’s	disease,	but	not	
leading	 to	 neuronal	 pathology	 due	 to	 treatment	 of	 pathological	 mechanisms	 other	 than	
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alpha-synuclein	aggregation	itself.	Neuroinflammation	is	an	example	of	such	a	pathological	
process.	
1.3.4	Parkinson’s	disease	is	a	neuroinflammatory	condition	
	 Advances	 in	 our	 understanding	 of	 neurodegenerative	 disease	 have	 highlighted	 an	
important	role	of	the	innate	immune	system	in	disease	pathology	(Long-Smith	et	al.,	2009).	
This	 involvement	 stems	 from	 peripheral	 immune	 cell	 activation,	 as	 well	 as	 the	 notable	
action	of	microglia,	the	brains	resident	macrophages	(Collins	et	al.,	2012).	Indeed,	microglial	
cells	 in	 particular	 have	 been	 demonstrated	 to	 have	 a	 close	 relationship	 to	 Parkinson’s	
disease.	For	instance,	post-mortem	biopsies	from	Parkinson’s	disease	sufferers	have	shown	
large	numbers	of	activated	microglia	at	the	substantia	nigra	(McGeer	et	al.,	1988),	and	these	
microglia	 exhibit	 the	 amoeboid	morphology	 associated	with	 activation	 by	 innate	 immune	
stimuli	 and	 inflammatory	 cytokine	 secretion	 (Lull	 and	 Block,	 2010).	 In	 tissue	 culture	
experiments,	 conditioned	 media	 from	 activated	 microglia	 has	 been	 demonstrated	 to	 be	
toxic	 to	 dopaminergic	 neurons,	 which	 suggests	 susceptibility	 of	 these	 physiologically	
relevant	 cells	 to	 innate	 immune	 processes.	 Accordingly,	 elevated	 levels	 of	 inflammatory	
cytokines	 have	 been	 observed	 in	 the	 blood	 and	 cerebrospinal	 fluid	 of	 patients	 suffering	
from	Parkinson’s	disease	 (Dobbs	et	al.,	1999;	Scalzo	et	al.,	2010;	Lindqvist	et	al.,	2012).	 In	
vitro	cultures	of	mixed	neurons	and	glia	also	facilitate	investigation	into	the	role	of	specific	
molecules	 on	 dopaminergic	 neuronal	 survival.	 For	 example,	 neuronal	 degeneration	 was	
shown	to	be	preceded	by	activation	of	microglia	upon	 innate	 immune	stimulation	of	such	
cultures,	 and	 the	 extent	 of	 degeneration	 was	 proportional	 to	 the	 level	 of	 microglial	
activation	as	measured	by	inflammatory	mediator	release	(Gao	et	al.,	2002).	
Alpha-synuclein	has	been	shown	by	several	groups	to	be	an	activator	of	the	 innate	
immune	 system.	 Alpha-synuclein	 acts	 as	 a	 DAMP	 and	 contributes	 to	 a	 strong	 immune	
response	 through	 detection	 by	 TLR2	 (Kim	 et	 al.,	 2014).	 Activation	 of	 microglial	 TLR2	 by	
oligomeric	 alpha-synuclein	 caused	 characteristic	 proliferation	 of	 microglia,	 as	 well	 as	
changes	 in	 microglial	 morphology	 from	 ramified	 to	 amoeboid,	 with	 corresponding	
production	and	release	of	 inflammatory	mediators	IL-1β	and	nitric	oxide.	More	recently,	 it	
has	 been	 shown	 that	 alpha-synuclein	 can	 be	 detected	 and	 signal	 through	 a	 TLR1/2	
heterodimer	(Daniele	et	al.,	2015).	TLR4	has	been	shown	to	mediate	phagocytosis	of	alpha-
synuclein	 and	 modulate	 an	 array	 of	 downstream	 pro-inflammatory	 responses	 such	 as	
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cytokine	release	and	‘reactive	oxygen	species’	(ROS)	production	in	microglia	(Fellner	et	al.,	
2013).	As	a	protein	aggregate,	alpha-synuclein	takes	on	crystalline	characteristics	and	is	able	
to	activate	the	NLRP3	inflammasome	(Codolo	et	al.,	2013).	The	NLRP3	inflammasome	acts	to	
cleave	pro-IL-1β	 and	pro-IL-18	 into	 their	mature	 forms	by	 activating	 caspase-1	processing	
(Martinon	 et	 al.,	 2002).	 NLRP3	 is	 highly	 promiscuous,	 and	 has	 been	 associated	 with	 a	
plethora	 of	 activators,	 including	 crystalline	 substances	 such	 as	 uric	 acid,	 silica,	 aluminium	
hydroxide,	 and	 protein	 aggregates	 including	 amyloid-beta	 and	 alpha-synuclein	 (Codolo	 et	
al.,	 2013;	 Heneka	 et	 al.,	 2013;	 Hari	 et	 al.,	 2014).	 Given	 the	 promiscuity	 of	 NLRP3,	 some	
believe	activation	may	not	occur	directly	through	interaction	with	these	molecules,	but	via	
induction	 of	 secondary	messengers	 such	 as	 ROS	or	 K+	 (Abderrazak	 et	 al.,	 2015).	NLRP3	 is	
expressed	in	microglia	but	not	astrocytes	(Gustin	et	al.,	2015),	suggesting	the	microglia	and	
macrophage	 lineages	 play	 an	 important	 and	 direct	 role	 in	 Parkinson’s	 associated	
neuroinflammation.	 Indeed,	 cultured	 TLR4	 knockout	 (KO)	 astrocytes	 have	 been	 shown	 a	
suppressed	pro-inflammatory	response	to	alpha-synuclein	(Fellner	et	al.,	2013;	Rannikko	et	
al.,	2015).	
	 	The	 link	 provided	 by	 alpha-synuclein	 between	 Parkinson’s	 as	 a	 protein	misfolding	
disease	and	as	a	neuroinflammatory	condition	has	not	gone	un-noticed	by	researchers.	The	
two	 processes	 are	 inter-linked	 and	 exacerbate	 each	 other	 through	 a	 process	 termed	
‘reactive	microgliosis’	 (Lull	and	Block,	2010)	 (fig	5).	Alpha-synuclein	oligomers	cause	stress	
to	cells	and	result	in	cell	death.	Dead	neurons	then	release	alpha-synuclein	aggregates	that	
are	able	to	activate	 inflammatory	processes	 in	microglia	and	other	 innate	 immune	cells	of	
the	brain.	Activated	innate	immune	cells	release	inflammatory	cytokines,	recruiting	further	
microglia	 to	 the	 affected	 regions	 of	 the	 brain	 and	 causing	 damage	 to	 the	 sensitive	
dopaminergic	 neurons	 located	 there.	 Death	 of	 dopaminergic	 neurons	 exacerbates	
Parkinson’s	symptoms	and	causes	the	release	of	fresh	alpha-synuclein	aggregates	(Block	et	
al.,	 2007).	 Understanding	 the	 interplay	 between	 inflammation	 and	 alpha-synuclein	
misfolding	is	important	as	a	‘chicken-or-the-egg’	scenario	currently	exists	between	the	two;	
does	 alpha-synuclein	 misfolding	 initiate	 inflammatory	 processes,	 or	 do	 underlying	
inflammatory	processes	initiate	alpha-synuclein	misfolding?	Alpha-synuclein,	and	Lewy	body	
pathology	levels	have	long	been	used	as	a	diagnostic	indicator	of	Parkinson’s	disease,	and	as	
a	marker	 for	 disease	 progression	 in	 post-mortem	 biopsy	 (Gibb	 and	 Lees,	 1988);	 however	
therapeutic	 strategies	 targeting	 alpha	 synuclein	 accumulation	 have	 not	 so	 far	 been	
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successfully	applied.	Efforts	are	being	made	 to	use	 inflammatory	profiling	as	a	marker	 for	
the	 progression	 of	 Parkinson’s	 disease,	 or	 to	 predict	 future	 prognosis	 of	 patients	 by	
classifying	 sufferers	 by	 inflammatory	 profile	 (Chen	 et	 al.,	 2008;	 Brockmann	 et	 al.,	 2017).	
Specific	targeting	of	 inflammatory	processes	 involved	 in	early	stages	of	disease,	or	 in	 later	
stage	 reactive	 microgliosis,	 could	 have	 potential	 in	 preventing,	 treating,	 or	 attenuating	
Parkinson’s	disease	pathology	and	its	progression.	
	 	
Figure	 5:	 Reactive	microgliosis.	A	 ‘vicious	 cycle’	of	neurodegeneration	and	microglial	 activation	
can	exist	within	the	diseased	brain.	Activation	of	microglia	causes	inflammatory	stress	to	neurons	
leading	to	neurodegeneration.	Resulting	release	of	debris	and	toxic	molecules	from	degenerating	
neurons	causes	further	activation	of	microglia.	As	such,	reactive	microgliosis	is	a	cycle	of	immune	
activation	leading	to	neuronal	damage.	 Intervention	to	control	this	process	may	provide	a	viable	
method	of	controlling	immunopathology	of	Parkinson’s	disease.	Adapted	from	Block	et	al.,	2009.	
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1.3.5	Genetic	advances	have	linked	LRRK2	to	Parkinson's	disease		
Genetic	 advances	 have	 taught	 us	 much	 about	 Parkinson’s	 disease	 and	
neurodegenerative	conditions	more	generally.	It	has	long	been	appreciated	that	Parkinson’s	
can	be	inherited	in	specific	families.	Familial	cases	of	Parkinson’s	disease	account	for	10	%	of	
cases,	with	the	remaining	90	%	of	cases	described	as	sporadic	in	western	populations.	Genes	
encoding	alpha-synuclein	 (Polymeropoulos	et	 al.,	 1997;	Krüger	et	 al.,	 1998;	 Zarranz	et	 al.,	
2004),	parkin	(Kitada	et	al.,	1998),	DJ-1	(Bonifati	et	al.,	2003),	‘PTEN	induced	putative	kinase	
1’	(PINK1)	(Valente	et	al.,	2004)	and	‘leucine	rich	repeat	kinase	2’	(LRRK2)	(Paisán-Ruíz	et	al.,	
2004;	Zimprich	et	al.,	2004),	have	been	linked	to	Parkinson’s	disease	this	way.	Interestingly,	
clinical	differences	were	observed	between	most	cases	of	genetic	Parkinson’s	disease	when	
opposed	 to	 sporadic	 cases.	 Namely,	 it	 was	 noted	 that	 genetic	 cases	 appeared	 to	 be	
predominantly	early-onset	(diagnosed	before	the	age	of	50)	as	compared	to	sporadic	cases,	
and	 levels	of	Lewy	body	pathology	observed	varied	between	genes	 (Pankratz	and	Foroud,	
2007).	 It	 is	 interesting	 therefore,	 that	 LRRK2	 associated	 cases	 are	 considered	 clinically	
indistinguishable	from	the	sporadic	disease,	with	late	disease	onset	and	classical	Lewy	body	
presentation	 focused	 around	 the	 brainstem	 (Adams	 et	 al.,	 2005;	 Ross	 et	 al.,	 2006).	 This	
suggests	 at	 the	 possibility	 that	 by	 understanding	 the	 role	 of	 LRRK2	 in	 the	 underlying	
pathobiology	 of	 Parkinson’s	 disease,	we	may	 gain	 an	 insight	 into	mechanisms	 that	 are	 at	
play	in	even	sporadic,	non-LRRK2	associated	Parkinson’s	cases.		
The	development	of	genome	wide	association	studies	(GWAS)	has	provided	a	deeper	
insight	 of	 the	 genetics	 of	 Parkinson’s	 disease,	 and	 has	 revealed	 that	 single	 nucleotide	
polymorphisms	 (SNPs)	 of	 the	 PARK8	 gene,	 encoding	 LRRK2,	 are	 associated	 not	 just	 with	
familiarly	inherited	Parkinson’s,	but	also	as	risk	factors	for	the	development	of	the	so-called	
sporadic	 disease	 (Satake	 et	 al.,	 2009;	 Simón-Sánchez	 et	 al.,	 2009).	 The	 most	 common	
mutation	in	the	LRRK2	gene	results	in	a	mutation	from	glycine	to	serine	at	amino	acid	2019	
(G2019S).	 This	 SNP	 is	 the	 highest	 known	 risk	 factor	 for	 the	 development	 of	 Parkinson’s	
disease,	accounting	 for	5-7	%	of	autosomal-dominant	 familial	cases	 (Di	Fonzo	et	al.,	2005;	
Nichols	et	al.,	2005),	and	1-2	%	of	sporadic	cases	in	western	populations	(Gilks	et	al.,	2005).	
In	 specific	 populations,	 the	 rates	 of	 G2019S	 associated	 Parkinson’s	 can	 be	 significantly	
higher.	 In	Ashkenazi	 Jews	 for	 instance,	 the	G2019S	LRRK2	mutations	 is	present	 in	30	%	of	
familial	cases	and	13	%	of	sporadic	cases	(Lesage	et	al.,	2006).	 In	North	African	Arabs,	the	
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mutation	is	present	in	37	%	of	familial	cases	and	40	%	of	sporadic	cases	(Lesage	et	al.,	2006).	
Mutations	 of	 the	 LRRK2	 gene	 increase	 in	 disease	 penetrance	with	 age	 (Goldwurm	 et	 al.,	
2007).	
1.4	Biochemistry	of	LRRK2	
1.4.1	LRRK2	possesses	both	GTPase	and	Kinase	activity	
LRRK2	is	a	large	protein	of	286	kDa	consisting	of	a	complex	and	unique	arrangement	
of	 protein-protein	 interaction	 and	 functional	 domains.	 This	 arrangement	 consists	 of	 N-
terminal	repeats,	including	ankyrin	repeats,	an	LRR	domain,	a	Ras	of	complex	proteins	(Roc)	
GTPase,	 with	 associated	 C-terminal	 of	 Roc	 (COR)	 domain,	 a	 Ser/Thr	 protein	 kinase,	 and	
finally	a	WD40	domain	at	the	C-terminus	of	the	protein	(Mills	et	al.,	2014).	The	presence	of	
a	Roc-COR	tandem	domain	defines	LRRK2	as	a	member	of	the	Roco	protein	family,	a	family	
first	detected	in	the	slime	mould	Dictyostelium	discoideum	(Marín	et	al.,	2008;	Russo	et	al.,	
2015).	While	similarities	 in	LRRK2	exist	to	Roco	proteins	 in	D.	discoideum,	LRRK2	 itself	has	
been	 shown	 to	 have	 emerged	 much	 later	 in	 animals,	 following	 the	 protostome-
deuterostome	split	 after	which	point	N-terminal	 repeats	were	acquired;	 separating	 LRRK2	
from	 its	 paralogues	 (Marín,	 2006).	 The	 array	 of	 domain	 types	 in	 LRRK2	 suggests	 that	 the	
cellular	role	of	LRRK2	is	complex	and	potentially	wide-ranging,	an	assertion	that	is	reflected	
Figure	 6:	 LRRK2	 domain	 organisation	 and	 associated	 pathogenic	 mutations.	 Pathogenic	
mutations	and	associated	domains	of	LRRK2	are	indicated.	Mutations	listed	are	non-exhaustive;	
taken	 from	 Greggio	 and	 Cookson,	 2009,	 and	 http://omim.org/allelicVariant/609007.	 Well-
characterised	 mutations	 are	 indicated	 in	 bold.	 M2387T	 is	 associated	 with	 non-Parkinson’s	
inflammatory	 disease.	 Domain	 boundaries	 adapted	 from	 Corti	 et	 al.,	 2011.	 ARM	 =	 Armadillo	
repeats,	ANK	=	Ankyrin	repeats,	LRR	=	Leucine	rich	repeats,	Roc	=	Ras	of	complex	proteins,	COR	=	
C-terminal	of	Roc.	
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in	 our	 shallow	 understanding	 of	 LRRK2	 biology.	 Over	 80	 mutations	 have	 been	 detected	
across	 the	 full	 range	 of	 LRRK2	 domains,	 making	 LRRK2	 the	 most	 frequently	 mutated	
Parkinson’s	 associated	 gene	 (Nuytemans	 et	 al.,	 2010).	 Confirmed	 pathological	 SNPs	 for	
Parkinson’s,	Crohn’s	Disease,	and	Leprosy	are	clustered	at	the	GTPase	and	kinase	functional	
domains	of	 the	protein,	which	suggests	 that	modulation	of	enzymatic	activity	 is	especially	
important	to	LRRK2	associated	pathology	(Corti	et	al.,	2011)	(fig	6).	Accordingly,	functional	
domains	of	LRRK2	have	been	the	most	intensely	studied,	and	so	are	the	best	understood	of	
LRRK2	domains. 
From	a	structural	perspective,	the	Roc-COR	tandem	domains	of	LRRK2	are	by	far	the	
best	understood,	having	been	resolved	by	X-ray	crystallography	to	reveal	a	dimeric	GTPase.		
(Deng	et	al.,	2008)	(fig	7).	The	back-to-back	dimer	is	stabilised	by	domain	swapping	between	
separate	monomers,	 resulting	 in	GTPase	active	sites	 that	are	each	 formed	 from	two	gene	
products.	Mutations	of	an	arginine	residue	at	position	1441	of	the	LRRK2	gene	are	strongly	
associated	 with	 Parkinson’s	 disease,	 and	 are	 the	most	 prevalent	 of	 Roc	 domain	 disease-
causing	mutations	(Nuytemans	et	al.,	2008).		This	arginine	residue	constitutes	a	mutational	
hotspot	within	LRRK2,	with	pathogenic	mutations	to	any	of	a	cysteine,	glycine,	or	histidine	
residue	(R1441C/G/H)	reported	(Simón-Sánchez	et	al.,	2006;	Haugarvoll	et	al.,	2008;	Ross		et	
al.,	2009).	This	 suggests	 that	 the	change	 from	arginine	may	be	more	 important	 for	 LRRK2	
pathogenicity	than	which	amino	acid	is	encoded	by	the	SNP.	Accordingly,	the	coordination	
of	 the	LRRK2	Roc	domain	positions	 residue	1441	at	 the	 interface	of	 the	homodimer;	with	
the	arginine	residue	providing	stabilising	hydrogen	bonds	and	stacking	forces.	Mutation	to	
smaller,	 or	 oppositely	 charged	 residues	 such	 as	 the	 cysteine,	 glycine	 or	 histidine	 residues	
associated	with	Parkinson’s,	would	therefore	act	to	destabilise	dimer	formation	(Deng	et	al.,	
2008).	 Interestingly,	 GTPase	 dimer	 formation	 is	 co-ordinated	 by	 complementation,	 with	
dimerisation	 generating	 completed	 β-sheets	 that	 span	 the	 dimer.	 Each	 monomer	
contributes	three	β-strands	to	each	sheet.	Pathogenic	mutations	within	the	Roc	domain	of	
LRRK2	do	not	affect	the	structure	of	the	GTPase	active	site	directly,	and	yet	a	consensus	is	
forming	that	R1441	mutations	decrease	GTPase	activity	(Lewis	et	al.,	2007).	There	is	a	less	
clear	relationship	between	the	Roc-COR	SNPs	at	position	1441	or	1699,	and	activity	of	the	
kinase	domain,	with	mixed	reports	as	to	whether	such	SNPs	increase	kinase	activity	(Smith	
et	 al.,	 2006;	 Guo	 et	 al.,	 2007),	 or	 simply	 have	 no	 effect	 (Jaleel	 et	 al.,	 2007).	 It	 has	 been	
suggested	 that	 GTP	 binding	 activity	may	 have	 a	more	 significant	 effect	 on	 LRRK2	 biology	
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than	GTP	hydrolysis	 (Taymans	et	al.,	2011),	with	GTP	binding	acting	to	stabilise	the	LRRK2	
dimer,	 as	 well	 as	 acting	 as	 a	 critical	 requirement	 for	 normal	 kinase	 activity	 (Biosa	 et	 al.,	
2013).	However	not	all	 reports	are	 in	agreement,	with	evidence	from	LRRK2	purified	from	
murine	brain	suggesting	that	GTP	binding	is	not	essential	for	kinase	activity	(Liu	et	al.,	2010).	
In	 comparison,	 mutations	 affecting	 kinase	 activity	 appear	 to	 have	 no	 effect	 on	 GTPase	
activity	(West	et	al.,	2007;	Biosa	et	al.,	2013).			
While	LRRK2	is	classified	as	a	Roco	protein	largely	due	to	its	domain	architecture,	the	
kinase	domain	of	LRRK2	bears	highest	homology	to	‘Mixed-Lineage	Kinase’	(MLK)	family	of	
serine/threonine	kinases	(West	et	al.,	2005).	The	MLKs	are	themselves	part	of	a	larger	family	
of	‘‘mitogen-activated-protein	kinase’	(MAPK)	kinase	kinases’	(MAPKKKs)	which	are	strongly	
associated	with	 inflammatory	signalling,	as	well	as	neurodegeneration	(Gallo	and	Johnson,	
2002;	 Kaminska,	 2005;	 Kim	 and	 Choi,	 2010).	 LRRK2	 has	 been	 shown	 to	 phosphorylate	
MKK3/6	and	MKK4/7,	which	 lead	 to	p38	and	 JNK	 signalling	 respectively	 (Gloeckner	et	 al.,	
2009).	As	mentioned	previously,	the	G2019S	SNP	is	positioned	within	the	kinase	domain	of	
LRRK2,	 specifically,	within	 the	 activation	 loop	 of	 the	 domain	 (fig	 8).	 The	 kinase	 activation	
loop	 can	be	phosphorylated	 resulting	 in	 conformation	 change	 in	an	N-terminal	 regulatory	
	
Figure	7:	Human	LRRK2	Roc	dimer	crystal	structure.	The	two	Roc	domains	of	LRRK2	form	a	
head-to-tail	 dimer.	 β-strand	 complementation	 between	 domains	 forms	 dimerisation	
stabilised	β-sheets	that	contribute	to	GTP	binding	coordination.	Arg1441	of	each	monomer	
is	labelled.	One	of	two	dimerisation	sites	and	GTP	molecules	labelled.	PBD:	2ZEJ	
		
GTP	
Complemented	β-sheet	
Mg2+	
R1441	
	 37	
helix	 initiated	 by	 electrostatic	 repulsion	 from	 the	 negatively	 charged	 phosphate	
modification.	This	conformational	change	activates	the	kinase	by	increasing	accessibility	of	
the	ATP	binding	pocket,	 permitting	 phosphoryl	 transfer	 to	 target	 proteins	 (Adams,	 2003).	
The	G2019S	mutation	of	LRRK2	 is	 the	single	most	studied	aspect	of	LRRK2	biology.	This	 is	
due	to	the	fact	that	this	mutation	is	the	most	frequent	LRRK2	SNP,	and	strongest	risk	factor	
for	 the	 development	 of	 Parkinson’s	 disease	 (Goldwurm	 et	 al.,	 2005).	 Mutation	 of	 the	
activation	loop	‘DFG	motif’	from	glycine	to	serine	has	been	suggested	to	promote	the	active	
conformation	 of	 the	 LRRK2	 kinase	 domain	 (Gilsbach	 et	 al.,	 2012).	 This	 results	 in	 a	 clear	
three-fold	 increase	 in	 kinase	 activity	 of	 mutant	 LRRK2	 as	 compared	 to	 wild-type	 protein	
(West	et	al.,	2005;	MacLeod	et	al.,	2006;	Jaleel	et	al.,	2007;	Greggio	and	Cookson,	2009).	The	
clarity	 and	 consistency	 of	 this	 result	 is	 in	 contrast	 to	 many	 of	 the	 contradictory	 results	
reported	 for	other	SNPs	 such	as	 the	1441	mutations	previously	described	within	 the	Roc-
COR	domains,	and	even	the	I2020T	mutation	just	a	single	amino	acid	away,	next	to	the	‘DFG	
motif’	(Gloeckner	et	al.,	2006;	Jaleel	et	al.,	2007).		
	 	
Figure	 8:	 Kinase	 domain	 of	 LRRK2	homologue	 Roco4	 (from	Dictyostelium	 discoideum).	An	ATP	
binding	site	 is	 formed	between	β-sheet	 rich	N-terminal,	and	α-helix	 rich	C-terminal	 lobes.	Kinase	
activity	 is	 enhanced	 by	 phosphorylation	 of	 the	 catalytic	 loop,	 which	 results	 in	 conformational	
change	 at	 the	 regulatory	 helix.	 The	 DFG	 motif	 (black)	 coordinates	 ATP	 via	 Mg2+,	 and	 may	 be	
mutated	to	DFS	in	the	G2019S	mutant,	resulting	in	hydrogen	bonding	with	R1077	of	the	regulatory	
helix	 (Gilsbach	et	al.,	 2012).	 	D.	 discoideum	 residues	 are	 labelled,	 bracketed	 residues	 are	human	
LRRK2	equivalent	residues.	PDB	code:	4F0F	
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1.4.2	Measuring	LRRK2	kinase	activity	
Biochemical	 evidence	 of	 LRRK2	 kinase	 activity	 suffers	 from	 a	 lack	 of	 consistency	
across	different	 experiments,	 as	 there	 is	 no	 known	and	 robust	 physiological	 substrate	 for	
LRRK2.	 Instead,	 analysis	 of	 kinase	 activity	 relies	 upon	 analysis	 of	 various	 sites	 of	 auto-
phosphorylation,	 phosphorylation	 of	 artificial	 substrates,	 or	 phosphorylation	 of	 biological	
substrates	of	unknown	physiological	significance	such	as	myelin	basic	protein.	
Auto-phosphorylation	 of	 the	 LRRK2	 dimer	 was	 first	 described	 in	 2007	 by	
autoradiography	experiments,	using	32P	as	a	substrate	to	label	phosphorylated	LRRK2	(Jaleel	
et	al.,	2007;	Luzón-Toro	et	al.,	2007).	Such	experiments	demonstrated	that	LRRK2	had	the	
capacity	to	phosphorylate	 itself,	and	that	auto-phosphorylation	activity	was	dependent	on	
an	 intact	 C-terminus	 of	 the	 protein	 (Greggio	 et	 al.,	 2008);	 but	 did	 not	 give	 detailed	
biochemical	 information	 as	 to	 which	 residues	 were	 phosphorylated.	 Modern,	 sensitive	
techniques	such	as	mass	spectroscopy	have	highlighted	over	20	auto-phosphorylation	sites	
across	 the	 length	 of	 the	 LRRK2	 protein,	 with	 a	 clear	 substrate	 preference	 of	 threonine	
residues	 over	 serine	 residues	 (Kamikawaji	 et	 al.,	 2009;	 Webber	 et	 al.,	 2011).	 Auto-
phosphorylation	 sites	 for	 LRRK2	 have	 been	 described	 as	 clustering	 within	 two	 regions,	
perhaps	reflecting	accessibility	to	the	LRRK2	kinase	domain	in	the	full-length	LRRK2	dimer.	
Of	 interest	 is	 that	one	of	 these	auto-phosphorylation	clusters	 falls	within	 the	GTP	binding	
pocket	of	the	Roc	domain;	perhaps	reflecting	the	cross-regulation	observed	by	some	groups	
between	 LRRK2	 GTPase	 and	 kinase	 domains.	 The	 other	 auto-phosphorylation	 cluster	 lies	
just	upstream	of	the	LRR	domain,	at	the	N-terminus	of	the	protein	(Gloeckner	et	al.,	2010).	
The	most	studied	LRRK2	auto-phosphorylation	site	is	Ser1292,	which	is	now	widely	used	as	a	
measure	of	 LRRK2	 kinase	 activity	 (Sheng	et	 al.,	 2012).	 The	use	of	 auto-phosphorylation	 is	
especially	 useful	 in	 vivo,	 where	more	 physical	methods	 are	 not	 amenable	 to	 experiment	
design.	 Further	 phosphorylation	 sites	 have	 been	 identified	 as	 targets	 for	 other	 kinases,	
notably	 ‘protein	kinase	A’	 	 (PKA)	(Muda	et	al.,	2014),	and	the	‘IkappaB	Kinase’	(IKK)	family	
(Dzamko	et	al.,	2012).	
One	 of	 the	 early	 proteins	 to	 be	 identified	 and	 validated	 as	 a	 substrate	 for	 LRRK2	
kinase	 activity	 was	 moesin,	 of	 the	 ERM	 family	 of	 proteins	 (along	 with	 ezrin	 and	 radixin)	
(Jaleel	et	al.,	2007).	Moesin	acts	to	bridge	the	actin	cytoskeleton	to	the	plasma	membrane,	
and	 is	 phosphorylated	 at	 a	 threonine	 residue	 at	 position	 558,	 responsible	 for	 binding	
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filamentous	 actin	 (F-actin)	 (Arpin	 et	 al.,	 2011).	 This	 suggests	 a	 potential	 role	 of	 LRRK2	 in	
controlling	 processes	 that	 require	 dynamics	 changes	 in	 cell	 shape	 and	 associated	
cytoskeletal	 structures;	 such	 as	 cell	 migration	 or	 endocytosis.	 The	 finding	 that	 other	
members	 of	 the	 ERM	 protein	 family	 are	 also	 phosphorylated	 by	 LRRK2	 has	 led	 to	 the	
development	 of	 a	 peptide	 substrate	 for	 LRRK2.	 This	 peptide,	 termed	 ‘LRRKtide’	 was	
designed	using	mass	spectroscopy	to	 identify	 the	LRRK2	phosphorylation	sites	of	 the	ERM	
proteins,	 then	 applying	 sequence	 homology	 analysis	 to	 identify	 favourable	 surrounding	
amino	acids	(Jaleel	et	al.,	2007).	Shortly	after,	a	positional	scanning	peptide	library	approach	
was	taken	to	generate	a	completely	artificial	substrate	for	LRRK2.	This	library	consisted	of	20	
amino	 acid	 long	 peptides,	 varying	 in	 the	 amino	 acid	 sequence	 around	 a	 central	 serine	 or	
threonine	residue.	Ultimately,	this	approach	led	to	the	generation	of	an	optimised	peptide	
for	 phosphorylation	 by	 LRRK2	 (Nichols	 et	 al.,	 2009).	 Known	 as	 ‘Nictide’,	 this	 peptide	
possesses	 favourable	 phosphorylation	 reaction	 kinetics	 as	 compared	 to	 LRRKtide.	 Both	
molecules	are	able	to	measure	LRRK2	kinase	activity	using	radiolabelled	32P,	but	neither	are	
physiological	substrates	of	LRRK2.	
The	final	method	for	LRRK2	kinase	activity	measurement	is	through	phosphorylation	
of	 a	 protein	 of	 interest.	 This	 was	 the	 method	 that	 led	 to	 the	 development	 of	 LRRKtide,	
however	 the	 approach	 was	 often	 used	 with	 other	 LRRK2	 ligands,	 such	 as	 myelin	 basic	
protein.	 (West	 et	 al.,	 2005).	 Myelin	 basic	 protein	 in	 particular	 was	 used	 before	 the	
development	of	artificial	 substrates.	These	experiments	are	suitable	 for	 individual	 studies,	
but	can	lead	to	confusion	when	comparing	the	effects	of	LRRK2	mutations	across	different	
studies,	as	the	effect	of	LRRK2	mutations	on	kinase	activity	is	likely	to	be	substrate	specific.	
Indeed,	there	is	no	lack	of	potential	LRRK2	substrates,	as	the	range	and	breadth	of	protein-
protein	 interactions	 for	 LRRK2	 is	breath-taking	 (Manzoni	 et	 al.,	 2015;	Porras	et	 al.,	 2015).	
Such	a	range	of	LRRK2	interactions	reflects	the	size	and	complexity	of	the	LRRK2	protein	and	
its	multiple	protein-protein	interaction	surfaces.	
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1.5	Functions	of	LRRK2	in	biology	
1.5.1	LRRK2	is	an	innate	immune	related	protein	
As	well	 as	 auto-phosphorylation,	 LRRK2	 is	 phosphorylated	 at	 a	 number	 of	 sites	 by	
other	kinases.	Particular	 interest	was	placed	on	Ser910	and	Ser935,	at	the	N-terminus	of	the	
predicted	 LRR	 domain	 of	 LRRK2.	 Before	 interest	 settled	 on	 Ser1292,	 Ser910	 and	 Ser935	were	
used	as	indirect	measures	of	LRRK2	kinase	activity	as	their	phosphorylation	status	correlated	
positively	with	chemical	inhibition	of	LRRK2	kinase	activity	(Zhao	et	al.,	2015).	While	use	of	
Ser910	 and	 Ser935	 phosphorylation	 to	 indicate	 LRRK2	 activity	 is	 no	 longer	 the	 most	
appropriate	approach	available	(Ito	et	al.,	2014),	the	finding	that	phosphorylation	status	can	
be	altered	by	TLR	signalling	provides	a	direct	link	between	LRRK2	physiological	function	and	
the	innate	immune	system	(Dzamko	et	al.,	2012)	(fig	9).	The	IkappaB	kinase	family,	which	is	
responsible	 for	 phosphorylation	 of	 these	 residues,	 is	 normally	 associated	 with	 the	
phosphorylation	of	IκB	proteins	that	sequester	‘nuclear	factor	kappa-light-chain-enhancer	of	
activated	 B	 cells’	 (NF-κB)	 in	 the	 cytoplasm.	 Phosphorylation	 and	 ubiquitination	 of	 IκB	
proteins	leads	to	proteolysis,	and	subsequent	transfer	of	NF-κB	into	the	nucleus;	resulting	in	
altered	 gene	 transcription	 (Karin,	 1999).	 In	 response	 to	 detection	 of	 pro-inflammatory	
stimuli	such	as	that	of	TLR4	signalling	in	response	to	LPS,	IκB	kinases	initiate	NF-κB	signalling,	
but	 also	 appear	 to	 directly	 phosphorylate	 LRRK2	 (Dzamko	 et	 al.,	 2012).	 This	 LRRK2	
phosphorylation	was	 shown	 to	be	dependent	on	 the	TLR	adaptor	 ‘myeloid	differentiation	
primary	 response	gene	88’	 (Myd88),	an	 innate	 immune	adaptor	molecule	which	mediates	
signalling	from	cell	surface	TLRs,	as	well	as	TLR7,	8,	and	9	which	signal	from	the	endosomal	
compartment	 (Dzamko	 et	 al.,	 2012).	 This	 suggests	 a	 level	 of	 specificity	 in	 the	
phosphorylation	 of	 LRRK2	 to	 particular	 innate	 immune	 stimuli,	 as	 TLR3	 activation	 or	 the	
non-TLR	immunogenic	 ligands	Zymosan	and	Curdlan	failed	to	cause	phosphorylation.	Later	
work	has	shown	that	Ser910	and	Ser935	can	also	be	phosphorylated	by	 the	action	of	PKA	 in	
response	to	cyclic	adenosine	mono-phosphate	(cAMP)	in	the	cell	(Li	et	al.,	2011).	cAMP	acts	
as	a	secondary	messenger	in	many	cell	signalling	contexts.	PKA	was	later	shown	to	further	
phosphorylate	 LRRK2	 at	 Ser1444	 (Muda	 et	 al.,	 2014).	 Ser910	 and	 Ser935	 phosphorylation	 is	
important	 for	 the	 binding	 of	 the	 chaperone	 protein	 14-3-3,	 with	 disruption	 of	 this	
interaction	causing	aberrant	LRRK2	localisation	 into	discrete	cytoplasmic	pools	 (Dzamko	et	
al.,	2010;	Nichols	et	al.,	2010),	and	affecting	the	secretion	of	LRRK2	into	exosomes	(Fraser	et	
	 41	
al.,	 2013).	 Ser1444	 phosphorylation	 was	 also	 demonstrated	 to	 be	 important	 for	 14-3-3	
binding.	 Interestingly,	 decreased	 Ser1444	 phosphorylation	 was	 described	 for	 R1441C/G/H	
SNPs	of	LRRK2,	resulting	 in	 increased	LRRK2	kinase	activity	 in	this	study;	this	suggests	that	
14-3-3	binding	modulates	LRRK2	kinase	activity	(Muda	et	al.,	2014).	Together,	these	cellular	
effects	 of	 14-3-3	 binding	 demonstrate	 a	 potentially	 important	 role	 of	 regulated	 LRRK2	
phosphorylation	for	maintaining	homeostasis	which	may	be	disrupted	by	LRRK2	pathogenic	
mutations	(Li	et	al.,	2011;	Muda	et	al.,	2014)	and	can	be	modulated	by	TLR	mediated	innate	
immune	signalling	(Dzamko	et	al.,	2012).		
Nucleus	
Figure	9:	LRRK2	interaction	with	14-3-3	is	regulated	by	immune	signalling	events.	Phosphorylation	
of	 LRRK2	 at	 14-3-3	 binding	 residues	 is	mediated	 by	Myd88	mediated	 TLR4	 signalling	 via	 the	 IκB	
Kinase	 family,	 and	PKA.	 LRRK2	phosphorylation	and	 relevant	 residues	are	 indicated	 in	 red.	These	
interactions	demonstrate	a	direct	signalling	interaction	between	innate	immune	stimuli	and	LRRK2	
with	 implications	 upon	 LRRK2	 localisation,	 secretion	 and	 kinase	 activity.	 As	 such	 downstream	
LRRK2	activity	is	regulated	at	least	in	part	by	innate	immune	signalling.	
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	 The	expression	profile	of	 LRRK2	mRNA	and	protein	 suggests	a	 fundamental	 role	of	
LRRK2	in	non-neuronal	processes,	 including	innate	immunity.	LRRK2	mRNA	is	detected	not	
just	 in	 the	 brain,	 but	 also	 at	 high	 levels	 in	 the	 kidney,	 spleen	 and	 lungs	 of	 normal	 mice	
(Maekawa	et	al.,	2010),	and	can	be	detected	 in	soluble	extracts	of	human	brain,	 liver	and	
heart	 (Miklossy	 et	 al.,	 2006).	 Notably,	 expression	 of	 LRRK2	 in	 systemic	 tissues	 is	 actually	
higher	than	 in	the	brain	(Biskup	et	al.,	2006;	Maekawa	et	al.,	2010).	 	TLR4	stimulation	has	
been	 shown	 to	 affect	 LRRK2	 localisation,	 causing	 translocation	 to	 the	 cell	 membrane	
(Schapansky	et	al.,	2014),	while	during	bacterial	 infection,	LRRK2	specifically	 localises	near	
bacterial	membranes	(Gardet	et	al.,	2010).		
Directly	linking	LRRK2	to	an	innate	immune	function	is	the	fact	that	LRRK2	expression	
is	 enriched	 in	 macrophages,	 B-cells	 and	 dendritic	 cells	 (Gardet	 et	 al.,	 2010),	 and	 innate	
immune	 stimuli	 such	 as	 interferon	 gamma	 (Ifn-γ)	 have	 been	 reported	 to	 stimulate	 LRRK2	
expression;	 revealing	 a	 responsiveness	 to	 the	 activation	 of	 innate	 immune	 signalling	
pathways	 (Thévenet	 et	 al.,	 2011).	 While	 Ifn-γ	 is	 reproducibly	 linked	 with	 an	 increase	 in	
LRRK2	expression	in	immune	cells,	other	stimuli	such	as	LPS	(Gardet	et	al.,	2010;	Hakimi	et	
al.,	2011;	Moehle	et	al.,	2012)	and	 IL-1β	 (Hongge	et	al.,	2014)	have	 less	well	documented	
effects	on	 LRRK2	expression.	 LRRK2	mRNA	expression	has	been	demonstrated	 in	 cultured	
human	astrocytes,	microglia	and	oligodendrocytes	(Miklossy	et	al.,	2006).	In	the	peripheral	
immune	 system,	 LRRK2	 expression	 is	 highly	 enriched	 in	monocytes	 and	 B-cells,	with	 very	
little	expression	detected	in	T	cells	(Thévenet	et	al.,	2011).	In	contrast,	a	more	recent	study	
has	examined	LRRK2	expression	in	primary	peripheral	immune	cells,	and	shown	LRRK2	to	be	
expressed	at	comparable	levels	in	B	and	T-lymphocytes,	but	that	there	is	greater	expression	
in	 monocytes.	 Further	 to	 this,	 this	 study	 showed	 enrichment	 of	 LRRK2	 expression	 in	
Parkinson’s	 patients	 as	 compared	 to	 healthy	 controls	 (Cook	 et	 al.,	 2017).	 A	 monocyte-
specific	increase	in	inflammatory	cytokine	release	was	detected	for	Parkinson’s	sufferers	as	
compared	to	healthy	controls	 in	this	study,	correlating	 inflammatory	cytokine	release	with	
LRRK2	expression	in	these	cells.	Interestingly,	these	results	were	recorded	independently	of	
LRRK2	genotyping,	which	suggests	an	underlying	role	of	LRRK2	in	regulating	inflammation	in	
idiopathic	 Parkinson’s	 disease.	 This	 agrees	with	 reports	 of	 LRRK2	 knockdown	 attenuating	
inflammatory	responsiveness	to	LPS	in	microglial	cultures	(Kim	et	al.,	2012),	and	a	reported	
increase	 in	 serum	 and	 cerebrospinal	 fluid	 inflammatory	 cytokine	 levels	 in	 patients	
expressing	 the	over-active	kinase	G2019S	mutant	 (Dzamko	et	al,	2016).	These	data	would	
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suggest	 a	 simple	 gain-of-function	 of	 LRRK2	 leading	 to	 pathogenic	 inflammation	 as	 a	
causative	model	 for	 Parkinson’s	 disease,	 however	 other	 reports	 suggest	 that	 LRRK2	over-
expression,	 or	 G2019S	mutant	 LRRK2	 have	 no	 bearing	 on	 classical	 inflammatory	 cytokine	
release	 (Moehle	et	al.,	2015).	There	are	also	mixed	reports	of	 the	effect	of	LRRK2	GTPase	
R1441G/C	 mutations.	 Microglia	 overexpressing	 the	 LRRK2	 R1441G	 mutation	 displayed	
enhanced	TNFα	release	in	response	to	LPS	stimulation,	while	another	report	showed	a	slight	
decrease	in	NF-κB	signalling	in	response	to	LPS	in	R1441C	expressing	microglia (Gillardon	et	
al.,	 2012;	 Kim	 et	 al.,	 2012).	 Differences	 in	 reports	 of	 inflammatory	 signalling	 by	 mice	
expressing	SNPs	at	R1441	may	be	accounted	 for	by	 the	different	amino	acids	encoded	by	
these	SNPs.	Different	mutations	may	drive	pathology	by	different	mechanisms.	Similarly,	it	
is	not	known	whether	mutations	 in	 the	Roc	domain	of	 LRRK2	would	drive	pathology	by	a	
common	mechanism	or	independently	of	the	G2019S	kinase	mutation.	
1.5.2	LRRK2	is	associated	with	non-neuronal	inflammatory	disease	
At	 the	 genetic	 level,	 GWAS	 studies	 have	 shown	 that	 LRRK2	 is	 not	 just	 linked	with	
Parkinson’s	 disease,	 but	 also	 with	 Crohn's	 disease	 and	 leprosy.	 Genetic	 links	 with	 these	
diseases	 demonstrate	 a	 non-neuronal,	 but	 firmly	 innate	 immune	 component	 to	 LRRK2	
biology	 (Greggio	 et	 al.,	 2012).	 The	 fact	 that	 LRRK2	 modulates	 susceptibility	 to	 multiple	
diseases,	with	pathology	ranging	from	the	gut	to	the	brain,	shows	a	remarkable	breadth	in	
function.	
Leprosy	is	a	chronic	disease	brought	about	through	infection	by	the	causative	agent	
Mycobacterium	 leprae.	 Skin,	 eyes	 and	peripheral	 nerves	 are	 affected	by	 the	 formation	of	
granulomas	 within	 macrophages	 and	 Schwann	 cells,	 leading	 to	 impairment	 of	 nerve	
function	 in	 the	 peripheries,	 skin	 lesions	 and	 potentially	 blindness	 (Britton	 and	 Lockwood,	
2004).	LRRK2	was	first	identified	as	a	risk	factor	for	leprosy	in	2009	(Zhang	et	al.,	2009)	and	
later	 confirmed	 in	2015,	 along	with	 four	 further	 LRRK2	polymorphisms,	 strengthening	 the	
link	 between	 LRRK2	 and	 leprosy	 (Wang	 et	 al.,	 2014).	 The	 capacity	 of	 LRRK2	 to	 affect	
susceptibility	 to	 bacterial	 infection	 directly	 links	 LRRK2	 function	 to	 the	 host	 anti-bacterial	
response;	including	immunological	inflammatory	processes.	
Crohn’s	disease	in	particular	is	an	archetypal	polygenic	inflammatory	disease	with	71	
susceptibility	 loci	 (Barrett	 et	 al.,	 2009;	 Franke	 et	 al.,	 2010).	 Pathology	 is	 thought	 to	 stem	
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from	 the	 aberrant	 interaction	 of	 gut	microbiota	 and	 environmental	 factors	with	 the	 host	
innate	 immune	 system.	 Experimental	 mouse	 models	 of	 colitis	 have	 shown	 that	 mice	
deficient	 in	 LRRK2	 expression	 are	 particularly	 susceptible	 to	 ‘dextran	 sodium	 sulphate’	
(DSS)-induced	colitis	(Liu	et	al.,	2011;	Liu	and	Lenardo,	2012).		
One	mechanism	believed	to	be	responsible	for	the	effect	of	LRRK2	on	experimental	
colitis	 revolves	around	 regulation	of	 the	 ‘nuclear	 factor	of	 activated	T-cells	 (NFAT)	and	 its	
translocation	to	the	nucleus.	NFAT	is	a	transcription	factor	that	regulates	gene	transcription	
in	immune	cells	including	T-cells	and	dendritic	cells	(Müller	and	Rao,	2010).	More	recently,	a	
role	 for	 NFAT	 has	 begun	 to	 be	 defined	 in	macrophages	 (Elloumi	 et	 al.,	 2012;	 Zanoni	 and	
Granucci,	 2012).	 Under	 homeostatic	 conditions,	 NFAT	 is	 highly	 phosphorylated,	 and	
retained	in	the	cytoplasm.	In	response	to	inflammatory	stimuli,	NFAT	is	able	to	translocate	
to	the	nucleus	via	dephosphorylation	by	calcineurin,	a	Ca2+	responsive	phosphatase	(Müller	
and	 Rao,	 2010).	 LRRK2	was	 shown	 to	modulate	 NFAT	 signalling	 through	 retention	 of	 the	
transcription	factor	in	a	cytoplasmic	complex	involving	LRRK2,	NFAT	and	a	large	noncoding	
RNA:	‘ncRNA	repressor	of	the	nuclear	factor	of	activated	T	cells’	(NRON);	this	constitutes	a	
non-canonical	Ca2+	independent	form	of	NFAT	regulation.	The	M2397	allele	of	LRRK2	led	to	
decreased	 inhibition	 of	 NFAT	 signalling,	 correlating	 with	 decreased	 detection	 of	 LRRK2	
protein	 (Liu	et	al.,	2011).	M2397	 is	 thought	 to	act	 independently	of	direct	perturbation	of	
LRRK2	 kinase	 activity	 (West	 et	 al.,	 2005),	 and	 has	 recently	 been	 linked	 to	 pathological	
immune	responses	in	leprosy	sufferers	(Fava	et	al.,	2016).	
Another	 potential	 role	 for	 LRRK2	 in	 Crohn’s	 disease	 was	 recently	 discovered	 in	
Paneth	 cells	 of	 the	 gut.	 Paneth	 cells	 sit	 within	 the	 crypts	 of	 the	 gut	 epithelium,	 and	 are	
responsible	 for	 secreting	 anti-microbial	 molecules	 to	 maintain	 sterility	 within	 the	 crypt	
itself,	and	to	control	microbial	growth	in	the	gut	to	promote	barrier	function	and	maintain	
microbiota	synergy	with	 the	host	 (Clevers	and	Bevins,	2013).	 LRRK2	was	 found	to	 interact	
with	another	Crohn’s	disease	associated	protein:	NOD2,	as	well	as	the	GTPase	Rab2	within	
Paneth	cells.	The	presence	of	each	of	these	components	was	shown	to	be	essential	for	the	
sorting	of	lysozyme	into	dense	core	vesicles	for	secretion	into	the	gut	lumen.	Disruption	of	
the	complex	led	to	lysosomal	degradation	of	lysozyme	(Zhang	et	al.,	2015).	While	lysozyme	
sorting	 appears	 to	 be	 a	 very	 specific	 function	 for	 Paneth	 cells,	 the	 process	 is	 initiated	 by	
NOD2	 mediated	 detection	 of	 ‘muramyl	 dipeptide’	 (MDP),	 a	 component	 of	 the	 bacterial	
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peptidoglycan,	which	 acts	 on	 the	 immune	 system	 as	 a	 PAMP.	 Interestingly,	 LPS	was	 also	
shown	 to	 activate	 lysozyme	 sorting	 by	 an	 unknown	 detection	 mechanism	 (Zhang	 et	 al.,	
2015).	 Later,	 ‘receptor-interacting	 serine/threonine-protein	 kinase	 2’	 (RIP2),	 a	 kinase	
intimately	associated	with	immunological	signalling	pathways	and	NF-κB	activation	was	also	
found	to	be	essential	for	lysosomal	sorting	(Wang	et	al.,	2017),	demonstrating	a	strong	link	
between	 LRRK2	 and	 innate	 immune	 signalling	 components.	 A	 recent	 report	 has	 further	
linked	LRRK2	and	NOD2	signalling	by	suggesting	that	LRRK2	acts	as	a	positive	regulator	for	
RIP2	phosphorylation	upon	stimulation	of	NOD2;	with	consequences	on	TNFα,	IL-6,	and	IL-
1β	production	in	response	to	LPS	and	MDP	co-stimulation	(Yan	and	Liu,	2017).	 
1.5.3	LRRK2	kinase	inhibition	has	misled	our	understanding	of	LRRK2	function	
	 Despite	 strong	 fundamental	 evidence	 that	 LRRK2	 plays	 an	 important	 role	 in	
inflammation	and	inflammatory	disease,	the	majority	of	attention	in	LRRK2	has	been	placed	
on	 a	 role	 in	 neuronal	 cells.	 This	 is	 because	 of	 LRRK2’s	 fundamental	 association	 with	 the	
degeneration	of	neurones,	 and	 status	as	a	 leading	 candidate	 for	pharmaceutical	 targeting	
for	the	treatment	of	Parkinson’s	disease;	but	also	as	a	consequence	of	setbacks	in	the	use	of	
LRRK2	kinase	inhibitors.	
	 An	ideal	method	for	investigating	the	role	of	a	kinase	in	disease	or	cellular	processes	
is	 the	 use	 of	 small	 molecule	 inhibitors.	 Much	 was	 initially	 made	 of	 evidence	 from	 the	
inhibitor	‘LRRK2-IN-1’	(L2in1),	a	cell	permeable	competitor	of	ATP	for	LRRK2	binding	(Deng	
et	 al.,	 2011).	 In	 particular,	 evidence	 from	 L2in1	 inhibition	 suggested	 that	 LRRK2	 kinase	
activity	played	a	key	role	in	innate	immune	processes,	with	results	ranging	from	a	change	in	
microglial	 activation	 in	 response	 to	 LPS	 (Moehle	 et	 al.,	 2012),	 phagocytosis	 of	 foreign	
protein	(Marker	et	al.,	2012),	macroautophagy	(Manzoni	et	al.,	2013),	cell	migration	(Caesar	
et	 al.,	 2013),	 and	 innate	 immune	 signalling	 pathways	 (Luerman	 et	 al.,	 2014).	 In	 2014,	 a	
quantitative	 phosphoproteomic	 screen	 was	 performed	 using	 ‘stable	 isotope	 labelling	 of	
amino	 acids	 in	 cell	 culture‘	 (SILAC).	 This	 experimental	 design	 was	 able	 to	 look	 at,	 and	
compare,	 protein	 phosphorylation	 significantly	 altered	 by	 L2in1	 inhibition	 of	 endogenous	
LRRK2,	 and	 G2019S	 LRRK2	 transduced	 cells.	 While	 this	 analysis	 was	 performed	 on	 the	
dopaminergic	 neuronal	 cell	 line	 SH-SY5Y,	 bioinformatic	 analysis	 of	 differential	 peptide	
phosphorylation	revealed	immunological	pathways	as	top	hits.	Notably	‘extracellular	signal-
regulated	kinase	5’	(ERK5)	signalling’	was	one	of	the	top	signalling	pathways	identified.	ERK5	
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is	 a	MAPK	 protein	 with	 a	 role	 in	 innate	 immune	 signalling	 (Luerman	 et	 al.,	 2014).	While	
these	results	coincided	with	many	previous	studies	at	the	time,	it	was	noted	that	L2in1	was	
originally	derived	from	XMD8-92,	an	inhibitor	of	ERK5	(Yang	et	al.,	2010;	Deng	et	al.,	2011).	
Further	 analysis	was	performed,	 this	 time	 in	 an	 immunological	 context	by	using	astroglial	
cells	cultures	from	mice.	It	was	noted	that	both	L2in1	and	XMD8-92	inhibited	LPS-stimulated	
cytokine	 production,	 and	 that	 L2in1	 had	 a	 stronger	 effect	 on	 LRRK2	 kinase	 activity	 than	
XMD8-92,	 as	measured	 using	 LRRK2	 S910	 phosphorylation	 as	 a	 read-out	 of	 LRRK2	 kinase	
activity.	This	suggested	that	L2in1	displays	improved	targeting	to	LRRK2	compared	to	XMD8-
92,	and	that	both	inhibitors	show	similar	immunological	effects	in	tissue	culture.	However,	
L2in1	was	then	applied	to	and	compared	between	WT	and	LRRK2	KO	astrocytes.	This	control	
experiment	 revealed	 inhibition	 of	 TNFα	 and	 CXCL10	 production	 in	 response	 to	 LPS	
stimulation	of	LRRK2	KO	astrocytes,	indicating	that	many	immunological	effects	ascribed	to	
inhibition	of	LRRK2	kinase	activity	may	in	fact	be	caused	by	significant	off-target	effects	of	
L2in1	 on	 other	 kinases;	 such	 as	 ERK5	 (Luerman	 et	 al.,	 2014).	 In	 light	 of	 this,	 evidence	 of	
LRRK2	function	using	L2in1	should	be	treated	with	caution,	and	considered	only	in	parallel	
with	structurally	unrelated	inhibitors	or	genetic	methods	of	LRRK2	manipulation.		
1.5.4	Modulation	of	protein	degradation	and	translation	by	LRRK2	
	 Other	 kinase	 inhibitors	 have	 subsequently	 been	 developed	 for	 LRRK2,	 and	 have	
indicated	that	LRRK2	kinase	activity	 is	 important	for	maintaining	LRRK2	protein	stability	by	
balancing	proteolytic	degradation.	
	 Inhibition	of	LRRK2	kinase	activity	by	any	of	a	panel	of	six	different	LRRK2	inhibitors	
led	 to	 increased	 proteosomal	 degradation	 of	 LRRK2	 in	 vitro.	 In	 a	 separate	 experiment,	
decreased	 LRRK2	 protein	 levels	 were	 observed	 in	 the	 brain,	 kidney	 and	 lungs	 of	 mice	
following	LRRK2	kinase	inhibition,	but	not	in	the	cortex	of	the	brain,	or	in	primary	astrocyte	
cultures	 (Lobbestael	 et	 al.,	 2016).	 Similar	 observations	 were	 made	 upon	 treatment	 with	
LRRK2	 inhibitors	 in	 human	 cultured	 peripheral	 blood	mononuclear	 cells,	 or	 primary	 cells	
cultured	 from	 patients	 suffering	 from	 Parkinson’s	 disease	 (Perera	 et	 al.,	 2016).	
Dephosphorylation	 of	 LRRK2	has	 been	 shown	 to	 result	 in	 hyper-ubiquitination,	 leading	 to	
proteosomal	 degradation	 (Zhao	 et	 al.,	 2015);	 possibly	 as	 a	 consequence	 of	 loss	 of	 14-3-3	
chaperone	 binding	 (Dzamko	 et	 al.,	 2010).	 Interestingly,	 loss	 of	 14-3-3	 binding	 by	 LRRK2	
kinase	inhibition	was	also	described	as	causing	LRRK2	to	accumulate	in	protein	aggregates.	
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A	 similar	observation	was	made	of	 LRRK2	over-expressing	mice,	where	 the	activity	of	 the	
ubiquitin-proteasome	 system	 was	 impaired;	 leading	 to	 accumulation	 of	 proteins	 and	
aggregate	formation	(Lichtenberg	et	al.,	2011).		
	 Accumulation	 of	 LRRK2	 has	 also	 been	 reported	 in	 a	 process	 associated	 with	
autophagy;	 the	other	major	protein	degradation	pathway.	LRRK2	stability	was	affected	by	
the	 expression	 of	 kinase-dead	 mutants	 of	 LRRK2.	 Mice	 expressing	 this	 mutant	 displayed	
markers	 of	 autophagic	 disease	 in	 the	 kidneys,	 while	 LRRK2	 KO	 mice	 showed	 similar	
pathology	in	the	kidneys	and	lungs	(Herzig	et	al.,	2011;	Tong	et	al.,	2012).	LRRK2	has	been	
linked	 to	 two	 major	 forms	 of	 autophagy;	 macroautophagy	 and	 ‘chaperone	 mediated	
autophagy’	(CMA).	Autophagy	is	particularly	interesting	in	the	context	of	neurodegenerative	
disease,	 as	 macromolecular	 protein	 aggregates	 are	 a	 hallmark	 of	 neurodegenerative	
pathology,	and	defective	degradation	of	such	aggregates	would	lead	to	toxic	accumulation	
and	cellular	stress	(Vogiatzi	et	al.,	2008;		Nixon,	2013).	Interestingly,	in	neurotoxic	models	of	
Parkinson’s	disease,	over-induction	of	autophagy	is	observed	(Zhu	et	al.,	2007),	however	the	
clinical	 significance	 of	 this	 is	 open	 to	 question	 and	 will	 be	 discussed	 in	 a	 later	 focus	 on	
animal	 models	 of	 Parkinson’s	 disease.	 Macroautophagy	 is	 the	 most	 common	 and	 well-
known	 form	 of	 autophagy,	 where	 material	 is	 sequestered	 within	 a	 double-membrane	
compartment,	 which	 matures	 into	 an	 autophagosome.	 Degradation	 of	 cargo	 occurs	
following	 lysosome-autophagosome	 fusion	 (Feng	 et	 al.,	 2014).	 Homeostasis	 of	 LRRK2	
macroautophagy	has	been	 suggested	 to	be	 regulated	via	direct	 LRRK2	phosphorylation	of	
the	macroautophagy	machinery	 (Park	 et	 al.,	 2016).	 Indeed,	 involvement	 of	 LRRK2	 in	 the	
modulation	of	macroautophagy	as	a	process	extends	to	substrates	other	than	LRRK2	itself.	
Therefore	 LRRK2	 associated	 pathology	 may	 result	 not	 just	 from	 dis-homeostasis	 of	 the	
LRRK2	protein,	but	also	of	other	substrates	(Gómez-Suaga	et	al.,	2012).	The	importance	of	
LRRK2	 affecting	 macroautophagy	 is	 highlighted	 by	 the	 fact	 that	 recruitment	 of	 LRRK2	 to	
autophagosome	membranes	occurs	 following	TLR4	 stimulation,	 suggesting	a	 link	between	
LRRK2	in	innate	immunity	and	autophagy	(Schapansky	et	al.,	2014).	LRRK2	has	been	linked	
not	 just	 with	 macroautophagy,	 but	 also	 with	 CMA.	 CMA	 is	 characterised	 by	 chaperone	
mediated	unfolding	and	transfer	of	targeted	cytosolic	proteins	directly	across	the	lysosomal	
membrane,	without	the	formation	of	new	membrane	bound	compartments	(Kaushik	et	al.,	
2011).	WT	LRRK2	 is	efficiently	degraded	by	CMA,	while	G2019S	mutant	LRRK2	 is	not;	with	
G2019S	LRRK2	depending	to	a	greater	extent	on	macroautophagy	for	proteolysis	(Orenstein	
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et	al.,	2013).	This	is	interesting	in	itself	as	it	suggests	the	balance	between	these	degradative	
pathways	 may	 play	 a	 role	 in	 disease.	 However,	 LRRK2	 binding	 to	 lysosomes	 was	 also	
enhanced	 in	 the	 presence	 of	 other	 CMA	 substrates,	 thus	 displaying	 the	 opposite	
degradative	dynamics	to	all	other	known	CMA	substrates.	LRRK2	at	the	lysosome	interfered	
with	organisation	of	 the	CMA	machinery;	 therefore	LRRK2	 interferes	not	 just	with	 its	own	
degradation,	but	also	with	the	degradation	of	other	CMA	substrates	(Orenstein	et	al.,	2013).	
While	 the	 proteasome	 and	 autophagy	 regulate	 protein	 homeostasis	 through	
proteolysis,	 LRRK2	 also	 interacts	 with,	 and	 modulates	 the	 protein	 synthesis	 machinery.	
Much	 of	 this	 work	 was	 performed	 using	 the	 drosophila	 homologue	 to	 LRRK2,	 dLRRK.	 In	
particular,	 ‘eukaryotic	 initiation	 factor	 4E	 (eIF4E)-binding	 protein’	 (4E-BP)	 has	 been	
suggested	as	a	substrate	for	dLRRK	(Imai	et	al.,	2008).	This	phosphorylation	event	was	also	
observed	 by	 human	 LRRK2.	 4E-BP	 acts	 as	 a	 negative	 regulator	 to	 protein	 translation	 by	
sequestering	 the	 eukaryotic	 translation	 initiation	 factor	 ‘eukaryotic	 translation	 initiation	
factor	4E’	(eIF4E)	from	the	ribosome	(Richter	and	Sonenberg,	2005).	Hyperphosphorylation	
of	4E-BP,	mediated	by	dLRRK,	is	proposed	to	cause	release	of	4E-BP	from	eIF4E.	Release	of	
eIF4E	then	permits	 formation	of	 the	protein	translation	 initiation	complex,	 involving	eIF4E	
and	 a	 target	 mRNA	 molecule	 for	 translation.	 dLRRK	 knockout	 conferred	 increased	
susceptibility	 to	 oxidative	 stress,	 and	 resultant	 dopaminergic	 neuronal	 degeneration	 in	
drosophila	 (Imai	et	al.,	2008).	A	separate	 report	has	shown	LRRK2	directly	phosphorylates	
the	small	ribosomal	subunit	protein	S15,	with	increased	phosphorylation	detected	for	LRRK2	
kinase	mutants	such	as	G2019S.	LRRK2	G2019S	toxicity	in	neuronal	cultures	as	measured	by	
DNA	fragmentation	was	seen	to	be	rescued	by	mutating	the	phosphorylation	site	of	the	S15	
subunit,	suggesting	a	direct	link	between	the	LRRK2/S15	interaction	and	Parkinson’s	disease	
pathology	(Martin	et	al.,	2014).		
	LRRK2	 has	 also	 been	 suggested	 to	 regulate	 protein	 translation,	 not	 just	 through	
interaction	with	cellular	translation	machinery,	but	also	by	modulating	microRNA-mediated	
translational	 repression	 (Gehrke	 et	 al.,	 2010).	 MicroRNAs	 are	 able	 to	 exert	 targeted	
translational	regulation	of	specific	genes	through	base-pair	complementarity	guided	binding	
between	 miRNA	 molecules	 and	 target	 mRNAs.	 The	 mechanism	 by	 which	 miRNA	 action	
occurs	is	not	fully	understood,	with	regulation	now	thought	to	function	at	the	level	of	mRNA	
degradation,	 as	 well	 as	 through	 translational	 repression	 by	 the	 RNA-induced	 silencing	
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complex	 (Huntzinger	 and	 Izaurralde,	 2011).	 This	 interaction	 of	 LRRK2	 with	 the	 miRNA	
machinery	 is	 intriguing,	 as	 miRNAs	 have	 previously	 been	 linked	 to	 neurodegenerative	
disease.	 Knockout	 of	 miRNA	 pathways	 is	 neurotoxic,	 and	 specific	 miRNA	molecules	 have	
been	 linked	 to	 the	 transcriptional	 regulation	 of	 proteins	 such	 as	 alpha-synuclein	 and	
amyloid-beta;	 which	 accumulate	 during	 Parkinson’s	 disease,	 and	 Alzheimer’s	 disease	
respectively	 (Eacker	 et	 al.,	 2009).	 LRRK2	 was	 shown	 to	 interact	 with	 and	 antagonise	 the	
action	 of	 Argonaut,	 one	 of	 the	 main	 components	 of	 the	 RNA-induced	 silencing	 complex	
(Gehrke	 et	 al.,	 2010).	 Translational	 profiling	 in	 drosophila	 showed	 that	 this	 interaction	
regulated	 the	 miRNAs	 let-7	 and	 miR-184,	 which	 in	 turn	 are	 transcriptional	 repressors	 of	
E2F1	 and	 DP.	 Therefore,	 LRRK2	 acts	 to	 antagonize	 the	 inhibition	 of	 translation	 of	 the	
E2F1/DP	 transcription	 factor	 complex.	 Mutant	 forms	 of	 LRRK2,	 including	 the	 over	 active	
kinase	mutant	G2019S	disinhibited	E2F1/DP	further.	This	suggests	that	the	role	for	LRRK2	in	
modulating	miRNA	 activity	may	 be	 a	 pathogenic	mechanism	 for	 Parkinson’s	 disease.	 The	
relevance	 of	 this	 role	 for	 LRRK2	 is	 highlighted	 by	 a	 previous	 report	 of	 over-expression	 of	
E2F1	 in	post-mortem	neuronal	biopsies	of	Parkinson’s	sufferers,	and	a	protective	effect	of	
E2F1	knockout	from	dopaminergic	neuronal	degeneration	in	a	neurotoxic	mouse	model	of	
Parkinson’s	disease	(Höglinger	et	al.,	2007).	It	is	also	intriguing	that	LRRK2	should	play	a	role	
in	 let-7	 mediated	 mRNA	 regulation,	 with	 mammalian	 let-7b	 having	 previously	 been	
associated	 with	 activation	 of	 the	 innate	 immune	 receptor	 TLR7,	 leading	 to	
neurodegeneration	 (Lehmann	 et	 al.,	 2012).	 The	 mammalian	 let-7	 family	 has	 also	 been	
associated	with	suppression	of	innate	immune	responses	including	transcription	of	IL-10,	IL-
6,	 and	 TLR4	 (Androulidaki	 et	 al.,	 2009;	 Schulte	 et	 al.,	 2011).	 Other	 notable	 interactions	
between	LRRK2	and	miRNAs	include	the	small	microRNA	NRON,	previously	discussed	for	its	
association	with	LRRK2	 in	 the	modulation	of	NFAT	signalling	 implicated	 in	Crohn’s	disease	
pathology	(Liu	et	al.,	2011);	and	a	reported	role	of	miR-712	in	transcriptional	regulation	of	
LRRK2	itself	(Talari	et	al.,	2017).	
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1.5.5	LRRK2	has	a	distinct	role	 in	regulating	neurone	specific	processes,	morphology	and	
function	
	 While	work	discussed	 in	this	 thesis	 focuses	on	the	role	of	LRRK2	 in	 innate	 immune	
cells,	the	majority	of	the	attention	of	LRRK2	research	has	been	placed	on	the	role	of	LRRK2	
in	a	neuronal	context.	This	is	owing	to	the	fact	that	the	majority	of	groups	studying	LRRK2	
are	interested	in	Parkinson’s	disease,	and	generally	come	from	a	neuroscience	background	
where	 a	 strong	 emphasis	 is	 placed	on	neuronal	 cells;	 little	 attention	 is	 paid	 to	 peripheral	
circulating	immune	cells.	On	top	of	this,	interest	that	existed	in	the	role	of	LRRK2	in	innate	
immune	pathways	has	been	set	back	by	the	revelation	that	many	effects	ascribed	to	LRRK2	
were	in	fact	a	result	of	off-target	effects	of	the	L2in1	LRRK2	kinase	inhibitor	(Luerman	et	al.,	
2014).	
	 Neuronal	 cells	 are	 most	 noticeable	 for	 their	 extreme	 morphology	 and	 functional	
specialisation	 of	 transducing	 and	 rapidly	 transmitting	 cellular	 signals	 in	 the	 form	 of	
electrochemical	 currents.	 The	 detection	 and	 propagation	 of	 such	 currents	 is	 achieved	
through	a	high	density	of	voltage-gated	ion	channels	that	populate	the	axonal	membrane	of	
neurons.	These	voltage-gated	channels	are	closed	under	the	negatively	charged	conditions	
of	 the	 resting	cell,	however	upon	detection	of	a	positive	membrane	potential	are	opened	
allowing	the	rapid	influx	of	Na+	or	Ca2+	ions	(Bean,	2007).	As	such,	these	channels	allow	the	
efficient	 propagation	 of	 an	 initial	 positive	 action	 potential	 along	 the	 axon.	 Specific	
morphology	of	neurons	can	be	extremely	diverse.	For	instance,	signals	from	the	peripheral	
nervous	system	need	to	travel	much	 longer	distances	along	the	spinal	cord	than	signals	 in	
relay	neurones,	which	must	only	travel	short	distances	within	the	brain.	Therefore,	while	all	
neurons	 possess	 an	 axon	 which	 gives	 neuronal	 cells	 their	 characteristic	 extended	
morphology,	the	axon	of	a	sensory	neurone	can	be	as	long	as	over	a	meter	in	order	to	span	
the	 length	 of	 the	 spinal	 cord.	 Therefore,	 neurons	 are	 highly	 specialised	 not	 just	 for	 their	
general	role	in	signal	propagation,	but	also	for	their	specific	role	within	the	nervous	system	
(Marmigère	and	Ernfors,	2007).		
Neurons	 within	 the	 central	 nervous	 system	 are	 highly	 networked,	 with	 multiple	
contacts	made	 between	 cells.	 These	 contacts	 are	made	 via	 synapses,	 often	 between	 the	
axon	 terminal	 of	 one	 cell,	 and	 spines	 localised	 to	 the	 highly	 branched	 structure	 of	 the	
dendrites	 of	 the	 next	 (Hering	 and	 Sheng,	 2001).	 Synapses	 are	 enclosed	 spaces	 through	
	 51	
which	electrical	impulses	are	transduced	via	diffusion	of	a	chemical	intermediates	known	as	
neurotransmitters	(Li	and	Sheng,	2003).	Acetylcholine	was	the	first	neurotransmitter	to	be	
identified,	 and	 is	 found	 at	 neuromuscular	 junctions.	 Secretion	 of	 acetylcholine	 by	 motor	
neurons	at	 the	neuromuscular	 junction	acts	 to	 transduce	a	neuronal	electrical	 signal	 from	
the	nervous	system	to	a	mechanical	responses	by	muscle	(Nishimaru	et	al.,	2005).	Between	
neurons,	synapses	can	be	broadly	classified	as	excitatory	or	inhibitory	in	nature.	The	balance	
of	 the	 input	 signals	 at	 these	 synapses	 controls	 whether	 an	 ‘excitatory	 post	 synaptic	
potential’	 is	 generated	 to	 continue	 downstream	 electrical	 signalling.	 One	 of	 the	 defining	
features	 as	 to	 the	 excitatory	 or	 inhibitory	 nature	 of	 a	 synapse	 is	 the	 neurotransmitter	
secreted	 at	 that	 synapse.	 Indeed,	 a	 vast	 array	 of	 neurotransmitters	 have	 been	 identified,	
and	 can	 be	 broadly	 classified	 as	 excitatory	 or	 inhibitory.	 For	 instance,	 the	 amino	 acid	
Glutamate	 is	 a	 classic	 neurotransmitter	 secreted	 at	 excitatory	 synapses,	 while	 GABA	 is	
classically	 found	 at	 inhibitory	 synapses	 (Mihic	 and	 Harris,	 1997;	Meldrum,	 2000).	 Recent	
evidence	 however	 shows	 that	 individual	 synapses	 may	 actually	 secrete	 multiple	
neurotransmitters,	suggesting	that	our	understanding	of	neurotransmission	may	in	fact	still	
be	in	its	infancy	(Tritsch	et	al.,	2016).		Dopaminergic	neurons	of	the	substantia	nigra	play	a	
specialised	 role	 in	 synthesising	 dopamine.	 Dopamine	 can	 be	 considered	 to	 be	 either	
excitatory	or	inhibitory	depending	on	the	receptor	repertoire	found	at	the	synapse	to	which	
it	 is	 secreted,	as	well	 as	neurotransmitters	with	which	 it	may	be	 co-secreted	 (Bucher	and	
Wightman,	2015).		
The	 nigrostriatal	 system	 is	 part	 of	 a	 larger	 neuronal	 network	 known	 as	 the	 basal	
ganglia,	 which	 is	 responsible	 for	 voluntary	 movement,	 as	 well	 as	 procedural	 learning,	
routine	 behaviours,	 cognition	 and	 emotion	 (Nelson	 and	 Kreitzer,	 2014).	 It	 is	 the	
degeneration	of	dopaminergic	neurons	within	this	pathway	that	leads	to	tremors	and	other	
motor	control	symptoms	associated	with	Parkinson’s	disease.	No	dopamine	can	be	supplied	
to	the	dorsal	striatum	of	the	basal	ganglia	neuronal	circuits	without	these	cells	(fig	4).	The	
input	 of	 the	 nigrostriatal	 pathway	 acts	 as	 part	 of	 a	 complex	 integration	 of	 basal	 ganglia	
signals	at	the	dorsal	striatum.	Indeed	the	striatum	forms	connections	to	various	regions	of	
the	brain	including	the	globus	pallidus	and	substantia	nigra	pars	reticula;	and	receives	input	
not	just	from	the	substantia	nigra	pars	compacta,	but	also	the	cortex,	thalamus	and	ventral	
tegmental	 area	 (Nelson	 and	 Kreitzer,	 2014).	 	 Connections	 to	 the	 striatum	 are	 spatially	
organised,	with	dopaminergic	neurons	from	the	substantia	nigra	pars	compacta	projecting	
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to	 the	 dorsal	 and	 lateral	 regions	 associated	 with	 sensorimotor	 function,	 while	 the	 more	
medial	 and	 ventral	 regions	 of	 the	 striatum	 are	 associated	 more	 with	 cognitive	 and	
behavioural	functions.	
It	 is	 thought	 that	 the	 extremely	 specialised	 nature	 of	 dopaminergic	 neurons,	 even	
compared	to	surrounding	neurons,	makes	them	vulnerable	to	degenerative	processes.	More	
specifically,	 dopaminergic	 neurons	 possess	 extended	 and	 highly	 branched	 axons	with	 low	
levels	 of	 myelination,	 meaning	 conducting	 electrical	 impulses	 is	 hugely	 energetically	
demanding	 (fig	 10).	 To	express	 this	 quantitatively,	 the	 rat	 substantia	nigra	pars	 compacta	
contains	 approximately	 12,000	 dopaminergic	 neurons,	 with	 each	 dopaminergic	 neurone	
contributing	between	100,000	and	250,000	synapses	to	neurons	of	the	striatum	(Matsuda	
et	 al.,	 2009;	 Bolam	 and	 Pissadaki,	 2012).	 To	 put	 this	 in	 perspective,	 the	 neuronal	 type	
contributing	 the	 next	 greatest	 number	 of	 synapses	 in	 the	 basal	 ganglia	 contributes	 only	
around	 5,000	 synapses.	 Each	 synapse	 requires	 active	 transport	 of	 molecules	 all	 the	 way	
from	the	cell	body,	as	well	as	maintenance	of	the	cytoskeleton,	maintenance	of	membrane	
potential,	and	the	generation	of	action	potentials	(Bolam	and	Pissadaki,	2012).	The	fact	that	
dopaminergic	 neurons	 lack	 an	 electrically	 insulating	 myelin	 sheath	 exacerbates	 the	
energetic	 demands	 of	 propagating	 action	 potentials,	 as	 without	 myelin,	 saltatory	
conduction	is	not	possible.	On	top	of	such	morphological	issues,	dopaminergic	neurons	face	
a	 considerable	 inherent	 metabolic	 burden	 of	 dopamine	 synthesis	 (Wang	 and	 Michaelis,	
2010).	Pathogenic	mutants	of	LRRK2	have	been	shown	to	modulate	many	of	the	facets	that	
render	dopaminergic	neurons	 sensitive	 to	 stress,	 and	 it	 is	 theorised	 that	 this	may	 lead	 to	
dopaminergic	neuronal	degeneration.		
At	 a	 cellular	 level,	 some	 of	 the	 most	 consistently	 reported	 phenotypes	 of	 LRRK2	
pathogenic	mutations	 have	 been	 reported	 in	 the	modulation	 of	 neuronal	morphology.	 In	
particular,	 there	 are	 reports	 of	 defects	 in	 neurite	 branching,	 both	 during	 neuronal	
development	 and	 neuronal	 ageing.	 Neurites	 are	 a	 general	 term	 for	 projections	 from	 a	
neuronal	 cell	 body,	 including	 axons	 and	 dendrites.	 Issues	 have	 been	 reported	 in	 the	
development	 of	 neurons	 using	 induced	 pluripotent	 stem	 cells,	 where	 dopaminergic	
neuronal	 differentiation	 from	 skin	 fibroblasts	 was	 shown	 to	 be	 less	 efficient	 for	 G2019S	
LRRK2	 mutation	 bearing	 neurons,	 compared	 to	 WT	 LRRK2	 controls	 (Borgs	 et	 al.,	 2016).	
Deficiencies	 in	 differentiation	 have	 previously	 been	 reported	 in	 human	 neural-stem-cell	
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populations	 (Liu	 et	 al.,	 2012).	While	 the	 physical	 reprogramming	 process	 of	 cells	 through	
induced	 pluripotency	 is	 somewhat	 artificial,	 it	 is	 interesting	 that	 G2019S	 dopaminergic	
neurons	possessed	a	hyper-branched	phenotype	at	early	stages	in	this	process,	as	compared	
to	WT	dopaminergic	neurons	(Borgs	et	al.,	2016).	Indeed	the	increased	complexity	of	axonal	
arborisation	observed	in	freshly	developed	G2019S	LRRK2	expressing	dopaminergic	neurons	
is	in	contrast	to	the	decreased	branching	complexity	observed	in	aged	induced	pluripotency	
derived	G2019S	LRRK2	dopaminergic	neurons	(Sánchez-Danés	et	al.,	2012).	This	suggests	a	
differential	role	of	LRRK2	and	its	pathogenic	mutations	both	in	neuronal	development,	and	
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Figure	 10:	 Dopaminergic	 neurons	 are	 exposed	 to	 oxidative	 stress.	 Intrinsic	and	extrinsic	
pressures	 faced	 by	 dopaminergic	 neurons	 lead	 to	 a	 vulnerability	 to	 oxidative	 stress.	
Specifically,	 dopaminergic	 neurons	 must	 produce	 large	 quantities	 of	 dopamine	 in	 an	
environment	of	 low	glutathione,	an	antioxidant	normally	associated	with	protection	 from	
oxidative	 stress.	 On	 top	 of	 this,	 dopaminergic	 neurons	 must	 transmit	 electrical	 impulses	
along	 an	 unmyelinated	 axon	 to	 an	 extensively	 arbourised	 axonal	 terminal,	 requiring	
significant	 energy	 input.	 Such	 intrinsic	 sources	 of	 oxidative	 stress	 are	 said	 to	 place	
dopaminergic	neurones	‘on	the	edge’,	and	are	therefore	highly	vulnerable	to	degeneration.	
Finally	dopaminergic	neurons	are	exposed	to	external	oxidative	stresses	from	sources	such	
as	environmental	toxins	and	inflammation	that	have	been	associated	with	the	development	
of	 Parkinson’s	 disease.	 It	 has	 been	 speculated	 that	 such	 sources	 of	 stress	 may	 push	
vulnerable	dopaminergic	neurons	‘over	the	edge’.	
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in	neuronal	ageing	where	factors	such	as	oxidative	stress	and	autophagy	are	thought	to	play	
a	 strong	 part.	 This	 latter	 reports	 correspond	 with	 findings	 made	 using	 primary	 midbrain	
cultures	 of	 LRRK2	 G2019S	 transgenic	 mice	 (Ramonet	 et	 al.,	 2011).	 A	 bi-phasic	 effect	 of	
LRRK2	on	neurite	branching	mirrors	findings	by	one	group	in	the	autophagy	field,	suggesting	
the	 cellular	 function	of	 LRRK2	may	be	 affected	by	 age	 (Tong	et	 al.,	 2012);	with	 increased	
autophagy	 thought	 to	 correlate	 with	 increased	 neurite	 branching	 (Sánchez-Danés	 et	 al.,	
2012).	Early	observations	of	the	effect	of	LRRK2	on	neurite	branching	were	made	in	vitro	by	
transfection	of	LRRK2	mutant	constructs,	or	knockdown	of	LRRK2.	These	cultures	revealed	
not	just	effects	on	neurite	branching,	but	also	on	neurite	length;	with	G2019S	LRRK2	causing	
a	 decrease	 in	 neurite	 length,	 and	 decreased	 branch	 complexity	 (MacLeod	 et	 al.,	 2006).	
These	 findings	 have	 subsequently	 been	 replicated	 in	 transgenic	 rodent	models	 that	 have	
also	 revealed	 that	 fewer	 dendritic	 spines	 develop	 in	 G2019S	 LRRK2	 transgenic	 animals	
(Winner	 et	 al.,	 2011;	Häbig	 et	 al.,	 2013).	 As	 discussed	previously,	 dopaminergic	 neurones	
display	 such	 extreme	 branching	 under	 homeostatic	 conditions	 that	 energetic	 demands	
makes	these	cells	extremely	vulnerable	to	stress	(Bolam	and	Pissadaki,	2012;	Pacelli	et	al.,	
2015).	 Perturbation	 of	 branch	 density	 and	 axonal	 length	 by	 pathogenic	 LRRK2	mutations	
could	 therefore	 be	 reasonably	 predicted	 to	 push	 these	 cells	 over-the-edge,	 leading	 to	
neurodegeneration	(Pissadaki	and	Bolam,	2013).		
Dopaminergic	 neurons	 are	 wholly	 responsible	 for	 the	 generation	 and	 supply	 of	
dopamine	 to	 the	 striatum.	 Dopamine	 is	 stable	 in	 synaptic	 vesicles,	 however	 in	 excess	
amounts,	 cytoplasmic	 dopamine	 has	 been	 shown	 to	 be	 neurotoxic	 to	 cells	 through	
formation	of	ROS	and	reactive	quinones	(Miyazaki	and	Asanuma,	2008).	In	whole	rat	brain	
lysate,	LRRK2	is	expressed	in	microsomal	and	synaptic	vesicle-enriched	cytosolic	fractions,	as	
well	 as	 on	 the	mitochondrial	 outer	membrane.	 Immunohistochemical	 analysis	 has	 shown	
this	expression	 to	be	prevalent	on	neuronal	 vesicular	 structures,	 and	mitochondria	of	 the	
cell	 body,	 dendrites	 and	 axons	 (Biskup	 et	 al.,	 2006).	 It	 is	 of	 note	 that	 the	 underlying	
vulnerability	 of	 dopaminergic	 neurons	 is	 thought	 to	 revolve,	 at	 least	 in	 part,	 around	 the	
action	of	oxidative	stress	(Pacelli	et	al.,	2015);	so	it	is	interesting	that	LRRK2	should	localise	
to	 mitochondrial	 membranes,	 and	 therefore	 associate	 with	 the	 cellular	 machinery	 most	
intimately	linked	to	the	energetic	demands	of	the	cell.	While	interaction	of	LRRK2	with	the	
mitochondria	 is	 not	 specific	 to	 the	 neuronal	 cell	 type,	 combination	 of	 mitochondrial	
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localisation	with	the	vulnerability	to	oxidative	stress	of	dopaminergic	neurons	is	particularly	
interesting.		
Mitochondria	are	 implicated	 in	Parkinson’s	disease	pathology	not	 just	due	 to	 their	
role	in	buffering	of	oxidative	species,	but	also	calcium.	As	previously	discussed,	calcium	ions	
flux	 contributes	 to	 action	 potential	 propagation	 in	 neurons,	 and	 so	 buffering	 of	 calcium	
carries	 functional	 significance	 to	 this	process.	 It	 is	 therefore	of	note	 that	 the	G2019S	and	
R1441C	 mutations	 of	 LRRK2	 have	 been	 shown	 to	 result	 in	 upregulated	 mitochondrial	
expression	of	the	up-regulation	of	the	‘mitochondrial	calcium	uniporter’	and	‘mitochondrial	
calcium	 uptake	 1’	 proteins,	 with	 a	 resulting	 increase	 in	 depolarisation-induced	
mitochondrial	calcium	uptake	(Verma	et	al.,	2017).	In	comparison,	another	group	has	shown	
a	decrease	in	the	calcium	buffering	capacity	of	neurons	expressing	the	same	LRRK2	mutants	
compared	 to	 wild	 type	 (Cherra	 et	 al.,	 2013).	 It	 is	 possible	 that	 as	 well	 as	 an	 effect	 on	
neuronal	 toxicity,	 calcium	 dis-homeostasis	 brought	 about	 by	 mutant	 LRRK2	 may	 be	
responsible	for	enhanced	current	responses	upon	stimulation	of	G2019S	or	R1441C	LRRK2	
expressing	neurons	(Plowey	et	al.,	2014).	A	further	role	of	LRRK2	in	signal	transduction	has	
been	 reported	 through	 an	 interaction	 with	 the	 voltage-gated	 Ca2+	 channel	 complex	 (Ca	
V2.1).		Such	Ca
2+	channels	are	expressed	at	the	membrane	of	presynaptic	terminal	of	many	
neurons,	 with	 a	 role	 in	 the	 regulation	 of	 neurotransmitter	 release	 and	 resulting	 post-
synaptic	 signal	 transduction.	 Indeed	 LRRK2	 co-expression	 was	 shown	 to	 increase	 cellular	
Ca2+	 current	 densities	 compared	 to	 cells	 expressing	 Ca	 V2.1	 alone	 (Bedford	 et	 al.,	 2016).	
While	LRRK2	may	affect	electrophysiology	of	neurons	through	the	indirect	mechanisms	such	
as	 the	 buffering	 of	 calcium	discussed	 here,	 there	 is	 also	 a	 body	 of	 evidence	 suggesting	 a	
more	direct	role	in	processes	such	as	vesicular	trafficking	of	neurotransmitters	for	synaptic	
secretion	 (Cirnaru	 et	 al.,	 2014;	 Penney	 et	 al.,	 2016),	 and	 endocytosis	 of	 synaptic	 vesicles	
(Arranz	et	al.,	2015);	as	well	as	surface	levels	of	dopamine	receptors	(Migheli	et	al.,	2013).	
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1.6	Animal	models	of	Parkinson’s	disease	
	 Much	 of	 the	 evidence	 discussed	 has	 been	 generated	 using	 animal	 models	 of	
Parkinson’s	 disease.	 Rodent	 models	 in	 particular	 are	 hugely	 important	 to	 our	 ability	 to	
mimic	 conditions	 that	may	 lead	 to	 Parkinson’s	 disease,	 or	 genetic	 backgrounds	 that	may	
lead	to	predisposition	towards	disease.	This	said,	it	is	also	important	that	these	models	are	
used	and	interpreted	with	an	understanding	of	their	relative	strengths	and	weaknesses.	
1.6.1	Chemically	induced	neurodegeneration	
Chemically	 induced	 models	 of	 Parkinson’s	 disease	 pathology	 are	 generally	 an	
excellent	 way	 of	 mimicking	 the	 degeneration	 of	 dopaminergic	 neurons,	 and	 generating	
animals	with	movement	 and	 behavioural	 deficits	 akin	 to	 that	 of	 Parkinson’s	 sufferers	 (fig	
11).	 Crucially,	 the	mimicking	 of	 pathophysiological	 loss	 of	 dopaminergic	 neurons	 in	 these	
models	allows	the	testing	of	disease	modifying	drugs	and	therapeutics	on	animals	without	
an	intact	dopaminergic-striatal	system.	By	these	means,	an	assessment	of	drug	efficacy	and	
amelioration	of	disease	 symptoms	can	be	made	 (Bové	et	al.,	2005).	A	 strong	 limitation	of	
such	models	however,	is	the	artificial	nature	of	the	mechanism	of	dopaminergic	destruction.	
Most	 chemical	models	 of	 Parkinson’s	 disease	 are	 completely	 artificial	 in	 their	method	 of	
action	 on	 dopaminergic	 neurons,	 and	 so	 tell	 us	 little	 of	 the	 pathophysiological	 processes	
underlying	 the	 disease,	 or	 the	 cause	 of	 the	 destruction	 of	 these	 dopamine-secreting	
neurons.	This	process	was	initially	termed	‘chemical	denervation’	following	the	discovery	of	
the	effect	of	6-Hydroxydopamine	(6-OHDA)	on	neuronal	cells	in	the	1970s	(Jonsson,	1980).	
	 	6-OHDA	 is	 a	 hydroxylated	 analogue	 of	 dopamine,	 which	 is	 able	 to	 target	
dopaminergic	 and	 noradrenergic	 neurons	 via	 an	 affinity	 for	 the	 dopamine	 and	
noradrenergic	 transporters	 (Ungerstedt,	 1968).	 Once	 present	 in	 the	 cytosol,	 6-OHDA	 is	
rapidly	oxidised	 causing	 the	 release	of	 a	 large	amount	of	ROS,	which	 results	 in	 cell	 death	
through	oxidative	stress.	The	size	of	the	lesions	resulting	from	6-OHDA	injection,	as	well	as	
the	timescale	required	for	damage	to	occur	varies	depending	on	the	site	of	injection.	These	
range	from	between	12	hours,	and	3	days	for	injection	into	the	substantia	nigra	(Jeon	et	al.,	
1995),	to	3	weeks	for	injection	to	the	striatum	(Sauer	and	Oertel,	1994).	6-OHDA	needs	to	
be	injected	past	the	blood	brain	barrier,	and	into	specific	brain	regions	in	order	to	avoid	off-
target	death	of	non-dopaminergic	neurons.	As	a	result,	6-OHDA	is	largely	restricted	to	use	in	
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rats	 rather	 than	 mice,	 and	 has	 largely	 been	 surpassed	 by	 other	 chemical	 models	 of	
Parkinson’s	disease.	While	6-OHDA	mimics	 the	degeneration	of	dopaminergic	neurons,	no	
Lewy	pathology	is	observed	in	6-OHDA	models	of	disease	(Tieu,	2011).	
	 The	most	commonly	used	chemical	model	of	Parkinson’s	disease	 in	mice	utilises	1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine	 (MPTP).	 The	 link	 between	 MPTP	 and	
Parkinsonism	 was	 made	 in	 1983,	 following	 accidental	 self-administration	 of	 MPTP	 by	
intravenous	drug	users	who	presented	with	symptoms	similar	to	severe	Parkinson’s	disease	
(Davis	et	al.,	1979).	Patients	were	responsive	to	L-DOPA	treatment,	demonstrating	similarity	
in	 pathology	 between	 MPTP	 damage	 and	 naturally	 occurring	 Parkinson’s	 disease.	 More	
recently,	 an	 MPTP	 exposed	 patient	 has	 been	 successfully	 treated	 with	 deep	 brain	
stimulation.	This	demonstrates	that	the	similarity	in	pathology	of	humans	exposed	to	MPTP	
to	Parkinson’s	disease	goes	beyond	simple	damage	to	dopaminergic	neurons,	and	into	the	
overall	electrophysiology	of	the	brain.	This	in	turn	suggests	great	translatability	of	the	MPTP	
model	to	Parkinson’s	patients	(Christine	et	al.,	2009).	MPTP	is	largely	employed	in	mice	and	
non-human	primates.	Non-human	primates	have	been	shown	to	be	more	sensitive	to	MPTP	
administration	 than	 mice,	 however	 MPTP	 none-the-less	 causes	 specific	 degeneration	 of	
dopaminergic	neurons	 in	the	substantia	nigra	 in	mice.	 Interestingly,	rats	have	been	shown	
to	 be	 less	 sensitive	 to	 MPTP,	 limiting	 their	 suitability	 as	 a	 model	 for	 MPTP	 induced	
Parkinson’s	disease	(Giovanni	et	al.,	1994).	MPTP,	unlike	6-OHDA,	is	systemically	active,	and	
can	pass	through	the	blood	brain	barrier	due	to	its	lipophilic	nature.	This	makes	MPTP	easier	
to	 use,	 requiring	 much	 less	 expertise	 in	 animal	 surgery	 through	 simple	 intraperitoneal	
injection.	As	a	result,	MPTP	administration	 is	 less	prone	to	human	error,	and	 is	thus	more	
reproducible	 than	 6-OHDA	 Parkinson’s	 models	 (Tieu,	 2011).	 MPTP	 itself	 is	 specifically	
metabolised	 in	 neuronal	 astrocytes	 to	 its	 toxic	 form	 of	 MPP+.	 MPP+	 is	 released	 from	
astrocytes	 (Cui	 et	 al.,	 2009),	 and	 taken	 up	 by	 the	 dopamine	 transporter	 of	 dopaminergic	
neurons	where	toxicity	is	achieved	through	inhibition	of	mitochondrial	complex	I,	resulting	
in	oxidative	stress	(Mizuno	et	al.,	1987).	While	the	pathology	of	MPTP	treated	mice	closely	
resembles	 Parkinson’s	 disease	 in	 terms	 of	 the	 loss	 of	 dopaminergic	 neurones	 and	
responsiveness	to	therapy,	like	6-OHDA	treatment,	Lewy	pathology	is	incomplete.	Low	dose	
MPTP	exposure	over	30	days	is	required	to	recreate	Lewy	pathology	(Fornai	et	al.,	2005).	
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	 Environmental	 toxins	 are	 thought	 to	 play	 a	 role	 in	 the	 pathophysiology	 of	
Parkinson’s	disease,	and	so	are	also	employed	in	the	lab	to	model	the	disease.	The	common	
environmental	contaminants	Paraquat	and	Rotenone	are	employed	in	this	way.	Paraquat	is	
a	 pesticide	 with	 a	 similar	 molecular	 structure	 to	MPP+.	 However,	 Paraquat	 can	 pass	 the	
blood-brain-barrier,	and	the	mechanism	of	Paraquat	toxicity	appears	to	be	independent	of	
mitochondrial	 complex	 I	 inhibition	 (Richardson	et	 al.,	 2005).	Neurodegeneration	observed	
following	 Paraquat	 exposure	 is	 also	 seen	 to	 be	 inconsistent	 compared	 to	 better-
characterised	 neurotoxins	 such	 as	 MPTP.	 This	 makes	 the	 Paraquat	 model	 somewhat	
interesting	to	investigate	the	role	of	environmental	toxins	on	the	brain,	but	not	necessarily	
to	model	Parkinson’s	disease	pathology	itself	(Tieu,	2011).	Rotenone	is	a	pesticide	employed	
in	 bodies	 of	 water.	 Rotenone	 readily	 passes	 the	 blood	 brain	 barrier	 and	 acts	 through	
inhibition	of	mitochondrial	complex	I	(Betarbet	et	al.,	2000).	Interest	in	Rotenone	as	a	model	
of	 Parkinson’s	 disease	 peaked	with	 the	 discovery	 that	 although	 the	molecule	 exhibits	 no	
specificity	of	action	to	dopaminergic	neurons,	and	inhibition	of	the	electron	transport	chain	
was	 seen	 across	 the	 brain,	 prolonged	 exposure	 to	 Rotenone	 at	 a	 low	 dose	 specifically	
caused	dopaminergic	neuronal	degeneration.	This	suggests	that	dopaminergic	neurons	are	
much	more	vulnerable	to	oxidative	stress	than	surrounding	neurons	(Betarbet	et	al.,	2000).	
Correspondingly,	 unlike	 most	 other	 chemically	 induced	 Parkinson’s	 models	 at	 the	 time,	
Rotenone	appeared	to	induce	lewy	body	pathology	following	prolonged	low	dose	exposure.	
However,	irreproducibility	and	variability	in	reports	of	such	Parkinson’s	disease	like	features	
has	 led	 to	 marginalisation	 of	 Rotenone	 exposure	 as	 a	 model	 of	 disease	 (Tieu,	 2011).	
Environmental	toxins	can	be	considered	more	meaningful	than	entirely	synthetic	molecules	
such	 as	MPTP	 or	 6-OHDA	 in	 terms	 of	 relevance	 to	 lifetime	 exposure	 to	 neurotoxins,	 but	
provide	less	consistent	models	of	degeneration.		
Some	of	 the	most	appreciable	evidence	 for	a	 role	of	 the	 innate	 immune	system	 in	
the	 pathology	 of	 Parkinson’s	 comes	 from	 an	 LPS	 model	 of	 the	 disease.	 As	 previously	
discussed,	 LPS	 is	 a	 very	 widely	 used	 molecule	 in	 immunological	 studies	 and	 is	 the	 well-
known	ligand	of	TLR4	(Chow	et	al.,	1999).	LPS	can	be	administered	directly	to	the	substantia	
nigra,	where	irreversible	degeneration	of	dopaminergic	neurons	of	the	substantia	nigra	pars	
compacta	 is	observed	a	week	after	 injection	(Castaño	et	al.,	2002;	 Iravani	et	al.,	2005).	Of	
note	 is	 the	 fact	 that	 non-dopaminergic	 neurons	 of	 the	 nigrostriatal	 system,	 as	 well	 as	
proximal	 dopaminergic	 neurons	 not	 associated	 with	 the	 nigrostriatal	 pathway,	 remain	
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unaffected	by	direct	 LPS	 injection.	Therefore	 LPS	 injection	and	 the	 resulting	 inflammatory	
insult	 demonstrates	 remarkable	 sensitivity	 and	 specificity	 to	 the	 dopaminergic	 circuitry	
associated	with	Parkinson’s	disease.	Unlike	molecules	 such	as	MPTP,	 this	 specificity	 is	not	
derived	 through	 targeting	 of	 dopaminergic	 neurone	 specific	 transporters,	 but	 as	 with	
Rotenone	exposure,	reflects	an	underlying	vulnerability	of	dopaminergic	neurons	which	may	
be	relevant	to	pathogenesis.	LPS	experiments	also	allow	the	coordination	of	immunological	
events	in	the	brain,	with	activation	of	microglia	and	up-regulation	of	inflammatory	cytokine	
release	occurring	within	hours	of	LPS	injection,	while	astrocyte	activation	occurs	only	a	week	
after	injection.	This	suggests	a	secondary	role	of	astrogliosis	in	observed	neurodegeneration	
(Herrera	et	al.,	2000;	Liu	and	Bing,	2011).	In	comparison	to	a	single	LPS	injection,	prolonged	
infusion	of	a	lower	dose	of	LPS	to	the	substantia	nigra	over	a	two-week	period	successfully	
delayed	the	onset	of	innate	immune	activation	and	resulting	Parkinson’s-like	pathology	(Gao	
et	 al.,	 2002).	 Activation	 of	 microglia	 in	 the	 substantia	 nigra	 occurred	 over	 the	 first	 two	
weeks	 of	 LPS	 exposure.	 Dopaminergic	 neuronal	 degeneration	was	 then	 observed	 by	 four	
weeks,	becoming	significant	by	six	weeks,	and	reaching	70	%	after	ten	weeks.	Degeneration	
was	again	found	to	be	specific	to	the	substantia	nigra	as	opposed	to	proximal	regions,	and	
to	dopaminergic	neurons	as	opposed	to	GABAergic	or	other	neurons	within	the	substantia	
nigra.	A	subsequent	study	demonstrated	that	the	same	pattern	of	Parkinson’s	disease-like	
microglial	activation,	followed	by	neurodegeneration	over	ten	months	was	observed	when	
LPS	or	TNFα	were	administered	systemically	in	mice	via	intraperitoneal	injection	(Qin	et	al.,	
2007).	 Activation	 and	 neuronal	 degeneration	was	 not	 observed	 in	mice	 lacking	 the	 TNFα	
receptors:	TNFR1	and	TNFR2.	This	suggests	systemic	innate	immune	activation	plays	a	role	
in	 the	 development	 of	 neurodegeneration	 over	 a	 prolonged	 time	 period,	 and	 that	
progressive	 dopaminergic	 neurodegeneration	 continues	 even	 following	 resolution	 of	 the	
inflammatory	cytokine	response	from	the	periphery	(Qin	et	al.,	2007).	The	fact	that	innate	
immune	activation	 can	be	 so	 closely	 linked	 to	neurodegeneration	by	 the	 LPS	model	 is	 an	
indication	 that	 inflammation	may	 be	more	 than	 just	 a	 consequence	 of	 neuronal	 damage,	
and	could	play	a	causative	role	in	disease	pathology	over	time.	The	ability	of	innate	immune	
receptors	 to	 transduce	 environmental	 signals	 to	 cellular	 events	 could,	 in	 this	 way,	
contribute	 towards	 the	 environmental	 component	 thought	 to	 underlie	 the	 onset	 of	
Parkinson’s,	in	the	same	way	that	environmental	contaminants	are	thought	to.	In	humans,	a	
laboratory	 worker	 accidentally	 exposed	 to	 Salmonella	 derived	 LPS	 developed	 many	
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symptoms	of	Parkinson’s	disease	including	bradykinesia,	rigidity	and	tremor	at	rest,	as	well	
as	other	neurological	problems	resulting	from	damage	to	the	substantia	nigra	as	well	as	the	
cerebral	cortex	(Niehaus	and	Lange,	2003).	Human	Parkinsonism	has	been	further	linked	to	
immune	 activation	 through	 the	 role	 of	 neurotrophic	 viral	 infection,	 and	 in	 particular,	
infection	 by	 the	 human	 influenza	 virus.	 Individual	 cases	 of	 viral	 infection	 leading	 to	
neuropathology	 and	 death	 have	 been	 reported,	 as	 well	 as	 increased	 incidence	 of	
Parkinson’s	disease	following	pandemic	flu,	such	as	experienced	in	1918	(Jang	et	al.,	2009).		
Unlike	some	of	the	previously	described	neurotoxins,	the	use	of	LPS	has	not	been	identified	
purely	 due	 to	 its	 ability	 to	 specifically	 destroy	 dopaminergic	 neurons.	 Rather,	
neurodegeneration	 can	 be	 observed	 as	 a	 consequence	 of	 the	 natural	 process	 of	
inflammation.		
Overall,	LPS	is	an	interesting	molecule	for	the	study	of	the	potential	 immunological	
mechanisms	 by	 which	 Parkinson’s	 may	 develop	 in	 the	 idiopathic	 disease	 state.	 The	 LPS	
system	 is	 also	 notably	more	 consistent	 in	 its	 neurological	 effects	 than	 the	 environmental	
contaminants,	 and	 benefits	 from	 a	 well	 studied	 and	 defined	 mechanism	 of	 action.	
Chemically	induced	Parkinsonism	in	rodent	models	by	molecules	such	as	6-OHDA	and	MPTP	
are	 the	 best-known	way	 to	 trial	 new	 therapeutics	 for	 capacity	 to	 ameliorate	 the	 physical	
symptoms	 of	 Parkinson’s	 disease,	 or	 overcome	 neurodegenerative	 processes	 specifically	
resulting	 from	oxidative	 stress.	 The	use	of	 environmental	 toxins	 and	 inflammatory	 stimuli	
such	 as	 LPS	 can	 be	 used	 to	model	 the	 role	 of	more	 feasibly	 encountered	 environmental	
contaminants	and	the	role	of	the	innate	immune	system	in	the	development	of	Parkinson’s	
disease.	Notably,	 LPS	 is	only	one	of	many	described	 ligands	 for	TLR4	 (Bryant	et	al.,	2015).	
Other	activators	of	TLR4	include	endogenous	DAMPs	which	may	also	be	able	to	lead	to	an	
over	activation	of	innate	immunity	which	could	lead	to	the	development	of	neuropathology	
with	 age.	Molecules	 capable	 of	 causing	 Parkinson’s	 through	 innate	 immune	 activation	 or	
oxidative	 stress	 can	 also	 be	 combined	 with	 genetic	 models	 of	 Parkinson’s	 disease	 to	
investigate	how	genetic	effects	modulate	processes	that	lead	to	Parkinson’s	symptoms.	
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Figure	 11:	 Characteristics	 of	 chemically	 induced	 Parkinson’s	 disease	 mouse	 models.	 a:	
Chemical	 structures	 of	 neurotoxins.	 b:	 Simplified	 mechanisms	 of	 neurotoxin	 uptake	 and	
neurotoxicity.	Specificity	of	some	neurotoxins	such	as	MPTP	and	Rotenone	is	brought	about	by	
targeting	dopamine	 transporters	 found	on	dopaminergic	neurons,	while	 LPS	and	6-OHDA	act	
more	generally.	c:	Level	of	specificity	of	toxin	introduction	required	for	targeted	dopaminergic	
neurodegeneration.	 In	 particular,	 the	 lack	 of	 specificity	 of	 6-OHDA	 as	 a	 neurotoxin	 requires	
specific	injection	to	the	substantia	nigra	to	act	as	a	model	of	Parkinson’s	disease.	LPS	structure	
taken	from	Dong	et	al.,	2014.	
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1.6.2	Genetic	models	
Models	 exist	 for	 the	 study	 of	 alpha-synuclein	 in	 mouse	 brains.	 Mice	 expressing	
mutant	 forms	 of	 alpha-synuclein:	 A30P,	 A53T	 and	 E46K,	 which	 cause	 familial	 Parkinson’s	
disease	 in	 humans,	 have	 been	 unsuccessful	 in	 replicating	 the	 pathology	 of	 the	 disease	 in	
mice.	 Such	mouse	models	 are	not	 uniform,	with	different	 promoters	 and	 forms	of	 alpha-
synuclein	 expressed,	 leading	 to	 different	 cellular	 effects.	 The	 most	 commonly	 used	
promoters	 include	 Prion	 and	 tyrosine	 hydroxylase	 promoters,	which	 generated	mice	with	
limited	 dopaminergic	 neuronal	 loss,	 and	 only	 moderate	 to	 mild	 motor	 phenotypes	 and	
microglial	 activation;	 without	 clear	 alpha-synuclein	 aggregation	 in	 the	 substantia	 nigra	
(Matsuoka	 et	 al.,	 2001;	 Giasson	 et	 al.,	 2002;	 Thiruchelvam	 et	 al.,	 2004;	 Su	 et	 al.,	 2009).	
These	results	can	be	 interpreted	as	an	 indication	that	overt	alpha-synuclein	aggregation	 is	
not	necessary	for	the	onset	of	limited	immunopathology,	or	that	these	mice	model	human	
Parkinson’s	 disease	 poorly.	 It	 seems	 the	 progressive	 pathology	 associated	 with	
dopaminergic	degeneration	 is	 poorly	 replicated	by	 genetic	mutations	 in	 a	 rodent	 context.	
Numerous	models	bearing	mutations	to	recessive	Parkinson’s	disease	associated	genes	have	
also	failed	to	replicate	the	disease	(Blesa	and	Przedborski,	2014).	Indeed,	a	triple	knockout	
mouse	lacking	the	mitochondrial-associated	genes:	Parkin,	DJ-1,	and	PINK1	lacks	any	kind	of	
neuronal	cell	pathology	(Kitada	et	al.,	2009).	Genetic	knockout	of	any	Parkinson’s	associated	
gene	has	failed	to	 lead	to	neurodegeneration.	 In	contrast	to	this,	overexpression	of	alpha-
synuclein	through	SNCA	gene	multiplication	in	mice	(Janezic	et	al.,	2013),	or	viral	delivery	of	
the	SNCA	gene	 in	rats,	does	 lead	to	alpha-synuclein	associated	pathology,	and	progressive	
dopaminergic	degeneration	 (Decressac	et	al.,	2012).	While	 it	 is	mechanistically	 interesting	
that	an	over-abundance	of	alpha-synuclein	can	lead	to	pathology	in	rodents,	it	should	not	be	
overlooked	 that	 such	 overexpression	 of	 alpha-synuclein	 is	 rarely	 observed	 in	 humans.	
Alpha-synuclein	 duplications	 or	 triplications	 are	 the	 cause	 of	 Parkinson’s	 disease	 in	 only	
individual	cases	(Singleton,	2003;	Ibáñez	et	al.,	2004).	
Multiple	 LRRK2	based	animal	models	 of	 Parkinson’s	 disease	have	been	developed,	
and	multiple	lines	of	evidence	pertaining	to	LRRK2	function	at	a	molecular	level	have	been	
referenced	previously.	Here,	LRRK2	mouse	models	will	be	considered	at	an	organismal	level.	
As	 with	 other	 genetic	 Parkinson’s	 disease	models,	 LRRK2	 KO	mice	 demonstrate	 no	 overt	
signs	 of	 nigrostriatal	 pathology	 (Tong	 et	 al.,	 2010;	 Hinkle	 et	 al.,	 2012).	 However,	 some	
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behavioural	 deficits	 are	 observed	 compared	 to	 WT	 mice.	 There	 are	 mixed	 reports	 of	
accumulation	of	alpha-synuclein	and	Tau	 in	 LRRK2	KO	mice.	 Interestingly,	histology	shows	
consistent	pathology	of	the	kidney	(Tong	et	al.,	2010;	Hinkle	et	al.,	2012;	Tong	et	al.,	2012),	
and	 some	 reports	 of	 lung	 pathology	 (Herzig	 et	 al.,	 2011).	 Kidney	 pathology	 consistently	
corresponds	with	 changes	 in	 autophagy,	 however	 these	 reports	 are	mixed	 as	 to	whether	
autophagy	is	enhanced	or	suppressed,	with	variation	evident	with	age.		
	 Knock-in	 mice	 for	 G2019S	 or	 R1441C	 mutant	 LRRK2	 show	 no	 obvious	 signs	 of	
dopaminergic	 neurodegeneration	 or	 alpha-synuclein	 related	 pathology	 (Tong	 et	 al.,	 2009;	
Herzig	et	al.,	2011);	with	no	pathology	reported	in	the	lung	or	kidneys	of	these	mice.	Mice	
overexpressing	G2019S	LRRK2	experience	some	dopaminergic	neuronal	loss	(Ramonet	et	al.,	
2011;	 Chen	 et	 al.,	 2012),	 and	 this	 loss	 was	 not	 experienced	 to	 the	 same	 extent	 when	
overexpressing	WT	LRRK2.	Mice	overexpressing	R1441C	mutant	LRRK2	showed	no	obvious	
signs	 of	 neurodegeneration	 in	 one	 study	 (Tsika	 et	 al.,	 2014),	 but	 mild	 dopaminergic	
neurodegeneration	 in	 another;	 alpha-synuclein	pathology	was	not	observed	 in	 this	model	
(Weng	et	al.,	2016).	Another	model	using	bacterial	artificial	 chromosome	 (BAC)	 transgene	
expression	 achieved	 5-10	 fold	 overexpression	 of	 R1441G	 LRRK2,	 leading	 to	 dopaminergic	
neurodegeneration	 and	 motor	 defects	 (Li	 et	 al.,	 2009).	 G2019S	 and	 WT	 LRRK2	
overexpression	in	BAC	transgenic	mice	both	led	to	abnormalities	in	dopamine	transmission,	
but	 no	 dopaminergic	 neurodegeneration	 (Melrose	 et	 al.,	 2010).	 It	 should	 be	 noted	 that	
LRRK2	 is	endogenously	expressed	 in	the	motor	cortex	and	striatum	of	both	mice	and	rats,	
however	 expression	 is	 only	 found	 in	 dopaminergic	 neurons	 of	 the	 substantia	 nigra	 pars	
compacta	in	mice,	not	rats	(West	et	al.,	2014).		
Evidence	 from	 LRRK2	 transgenic	 mice	 corresponds	 with	 observations	 made	 using	
other	 genetic	 rodent	 models	 of	 Parkinson’s,	 in	 that	 genetic	 risk	 factors	 associated	 with	
human	Parkinson’s	disease	are	not	directly	translatable	to	mice.	Overexpression	of	LRRK2	or	
other	Parkinson’s	disease	associated	genes	do	appear	to	cause	pathology,	but	these	systems	
lack	 the	 physiologically	 relevant	 conditions	 which	 transgenic	 animals	 should	mimic	 when	
studying	disease	pathogenesis.	There	are	many	reasons	why	rodent	models	of	disease	are	
limited,	not	least	that	in	human	disease	there	is	a	clear	but	ill-defined	interaction	between	
genetic	 and	 environmental	 factors	 that	 cannot	 be	 truly	 replicated	 in	 the	 lab.	 An	
environmental	component	of	Parkinson’s	disease	is	thought	to	contribute	to	the	incomplete	
	 64	
penetrance	of	most	 genetic	 risk	 factors	of	 the	disease	 (Horowitz	 and	Greenamyre,	 2010).	
Another	 factor	 at	 play,	 which	 an	 animal	model	 cannot	 easily	 replicate,	 is	 that	 of	 ageing.	
Ageing	 is	 a	 huge	 factor	 in	 Parkinson’s	 disease	 pathology,	 with	 disease	 prevalence	
quintupling	between	the	ages	of	60	and	85,	to	5	%	of	the	population	(de	Lau	and	Breteler,	
2006).	In	spite	of	this,	the	effects	of	ageing	at	the	molecular	level	are	not	truly	understood.	
The	 difference	 in	 the	 age	 of	 disease	 onset	 associated	 with	 SNPs	 in	 different	 Parkinson’s	
disease	 genes	 also	 hints	 that	 age-related	 processes	 are	 a	 strong	 modifier	 of	 underlying	
pathology.	 It	 is	 generally	 accepted	 that	 inflammatory	 processes	 become	 less	 tightly	
regulated	with	age,	a	process	colloquially	known	as	‘inflammaging’	(Franceschi	and	Campisi,	
2014).	 Increased	 basal	 levels	 of	 inflammation	 could	 very	 well	 play	 a	 role	 in	 Parkinson’s	
disease	pathology,	however	whether	rodents	and	humans	age	similarly	enough	to	mimic	the	
contribution	of	ageing	 to	Parkinson’s	pathology	 in	humans	 is	unknown.	Other	age	 related	
deficits	 in	processes	 such	as	protein	degradation	by	 the	proteasome	also	become	evident	
with	age,	and	may	play	a	role	in	the	clearance	of	toxic	alpha-synuclein	aggregates	(Collier	et	
al.,	2011).		
	 While	evidence	from	whole	animal	models	needs	to	be	carefully	considered	due	to	
their	 inherent	 limitations	 in	 modelling	 such	 a	 complicated	 age	 related	 human	 disease,	
genetic	models	 of	 Parkinson’s	 disease	 in	particular	 allow	 specific	 aspects	 of	 biology	 to	be	
studied	closely	for	effects	of	individual	genes	on	molecular	and	cellular	processes.	
1.7	Summary	
LRRK2	 is	 a	 complex	 protein	 with	 involvement	 in	 a	 range	 of	 cellular	 processes.	 A	
genetic	 association	between	 LRRK2	and	 the	archetypal	 inflammatory	and	 immune	 related	
conditions	of	Crohn’s	disease	and	leprosy	demonstrate	the	importance	of	understanding	the	
role	 of	 LRRK2	 in	 immune	 cells.	Much	 of	 the	 research	 attention	 focused	 on	 LRRK2	 comes	
from	a	neuronal	context	in	the	study	of	Parkinson’s	disease.	It	is	now	well	established	that	
Parkinson’s,	and	neurodegenerative	diseases	more	generally,	involve	a	strong	inflammatory	
component.	Therefore,	while	LRRK2	can	be	directly	associated	with	neurodegeneration	via	a	
role	 in	 neuronal	 cells	 themselves,	 understanding	 the	 role	 of	 LRRK2	 in	 an	 inflammatory	 or	
neuroinflammatory	 context	 may	 shine	 a	 light	 on	 the	 role	 of	 inflammation	 in	 Parkinson’s	
disease.		
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1.8	Hypothesis	and	aims	
The	 interaction	 between	 the	 innate	 immune	 and	 nervous	 systems	 is	 increasingly	
appreciated	as	 fundamental	both	 in	health	and	disease.	 In	particular,	 a	 role	of	 the	 innate	
immune	system	 in	neurodegenerative	conditions	such	as	Parkinson’s	disease	 is	now	clear.	
Given	 that	 LRRK2	 is	 associated	 with	 inflammatory	 disease	 such	 as	 Crohn’s	 disease	 and	
leprosy	 as	 well	 as	 Parkinson’s	 disease,	 is	 expressed	 in	 innate	 immune	 cells	 such	 as	
macrophages	 and	 microglia,	 is	 upregulated	 upon	 innate	 immune	 stimuli,	 and	 is	
phosphorylated	 and	 modulated	 upon	 Myd88	 associated	 activation	 such	 as	 by	 TLR4	
signalling;	 I	 hypothesise	 that	 LRRK2	 plays	 a	 role	 in	 immune	 cell	 processes	 that	 may	 be	
relevant	to	Parkinson’s	disease.		
The	 role	 of	 LRRK2	 in	 innate	 immunity	 is	 investigated	 at	 three	 levels,	 biophysical,	
cellular,	and	genome-wide;	each	with	a	specific	aim	towards	investigating	this	hypothesis.	
Aims	
Biophysical	 investigation	of	LRRK2	 is	 focused	upon	the	LRR	domain	of	LRRK2.	Early	
evidence	 suggested	 a	 nucleic	 acid	 binding	 function	 of	 this	 domain;	 a	 function	 associated	
with	 similar	 LRR	 domains	 of	 innate	 immune	 proteins	 such	 as	 TLR3.	Work	 described	 here	
aims	 to	 express	 the	 LRR	domain	of	 LRRK2	 in	 order	 to	 investigate	 potential	 ligand	binding	
activity	 of	 the	 LRR	 domain,	 which	 if	 confirmed	would	 provide	 a	 direct	 ligand	 recognition	
function	 of	 LRRK2	 in	 innate	 immunity.	 A	 range	 of	 approaches	 and	 optimisation	 of	 LRR	
domain	expression	are	described	towards	this	aim.	
Cellular	 investigation	of	LRRK2	described	in	this	work	follow	the	specific	hypothesis	
that	 known	 interactions	 between	 LRRK2	 and	 the	 cellular	 trafficking	machinery,	 as	well	 as	
components	of	the	extra	cellular	matrix	play	a	role	in	innate	immune	processes.	In	particular	
work	 described	 here	 aims	 to	 elucidate	 or	 clarify	 the	 role	 of	 LRRK2	 in	 TLR	 trafficking,	
phagocytosis	and	chemotaxis.	An	objective	of	this	work	is	to	build	upon	past	literature	that	
utilised	 the	non-specific	 LRRK2	 inhibitor	 L2-in-1	 by	utilising	a	 specific	 LRRK2	KO	 system.	A	
role	 of	 LRRK2	 in	 innate	 immune	 receptor	 trafficking,	 phagocytosis	 or	 chemotaxis	 would	
build	 upon	 described	 functions	 of	 LRRK2	 in	 neurons,	 and	 provide	 a	 new	 and	 potentially	
more	relevant	understanding	of	the	cellular	role	of	LRRK2	in	an	innate	immune	context.	
	 66	
Cellular	 investigation	 of	 LRRK2	 is	 further	 investigated	 at	 a	 ‘global’	 level	 through	
utilisation	 of	 RNA-seq	 and	 metabolomic	 technology.	 Work	 described	 here	 aims	 to	 use	
modern	 ‘-omics’	 technology	 to	 compare	 the	 transcriptomic	 and	 metabolomic	 profiles	 of	
cells	stimulated	with	LPS	or	MDP;	activators	of	the	innate	immune	system.	The	use	of	such	
technologies	allows	a	snapshot	of	the	innate	immune	response	to	be	captured	and	analysed	
for	genotypic	differences.	While	RNA-seq	analysis	facilitates	analysis	at	a	truly	global	scale,	a	
specific	objective	of	 the	use	of	metabolomic	data	 is	 to	compare	 the	effect	of	LRRK2	 in	an	
innate	 immune	 context	 to	 an	 effect	 upon	 ceramide	 levels	 recently	 described	 in	 neuronal	
tissue.	
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2.	Materials	and	Methods	
2.1	Secondary	structure	prediction	
Secondary	 structure	 predictions	 were	 made	 using	 GENESILICO	 Metaserver	 2	
(Kurowski	and	Bujnicki,	2003),	which	yields	secondary	structure	predictions	from	jnet	(Cuff	
and	Barton,	2000),	spinex	(Faraggi	et	al.,	2012),	spine	(Dor	and	Zhou,	2007),	psipred	(Jones,	
1999).	 For	 the	 design	 of	 N-terminal	 domain	 boundaries,	 the	 region	 P820-S990	 of	 human	
LRRK2	 (accession	number:	Q5S007)	 submitted	 to	 the	metaserver.	 For	 secondary	 structure	
prediction	of	the	predicted	LRR	domain	itself,	the	region	S979-A1329	was	submitted.	
2.2	Molecular	biology	techniques	
PCR	reactions	mixes	were	made	using	specific	primers	specified	for	each	construct,	
in	combination	with	a	recommended	mix	of	supplied	reagents	with	Vent	polymerase	PCR	kit	
(New	 England	 Biolabs,	 USA)	 	 (dNTPs,	 ‘Thermopol	 buffer’	 MgSO4,	 Vent	 polymerase),	 and	
MiliQ	 purified	 water	 (Merck	 Milipore,	 USA).	 DNA	 restriction	 digest	 reactions	 were	
performed	 using	 New	 England	 Bioloabs,	 USA	 restriction	 endonucleases	 following	 the	
manufacturers	recommended	protocols.	Restriction	digest	reactions	were	performed	for	a	
minimum	of	2	hours	at	37	°C	or	 left	overnight	at	the	same	temperature	when	required	to	
allow	restriction	digests	to	proceed	to	completion.	When	ligations	reactions	were	required	
T4	DNA	 Ligase	 (New	England	Biolabs,	USA)	was	used	with	 a	 typical	molar	 ratio	of	 vector:	
insert	 of	 1:3	 or	 1:6.	 Reaction	 mixes	 were	 made	 around	 these	 ratios	 using	 reagents	 and	
concentrations	 recommended	 by	 the	 manufacturer.	 Reactions	 were	 performed	 at	 room	
temperature	 for	 1	 hour.	 Bacterial	 transformations	were	made	 into	 chemically	 competent	
DH5α	 generated	 in	 lab,	 or	 DH5α-select	 gold	 efficiency	 cells	 (Bioline,	 UK).	 Bacterial	
transformation	was	performed	using	a	volumetric	ratio	of	1	:	20	DNA	:	competent	cells.	DNA	
was	mixed	with	cells	for	30	seconds	on	ice	before	being	transferred	to	a	42	°C	water	bath	for	
1	 minute.	 Transformations	 were	 then	 incubated	 for	 2	 minutes	 on	 ice	 before	 being	
supplemented	 with	 500	 µl	 SOC	 Medium	 (Thermo	 Fisher	 Scientific,	 USA).	 Cultures	 were	
incubated	for	1	hour	at	37	°C	before	being	plated	on	selection	medium.	DNA	was	extracted	
from	 bacterial	 cultures	 using	 QIAprep	 Spin	 Miniprep	 Kit	 (Qiagen,	 Germany).	 DNA	 was	
extracted	from	agarose	gels	by	extracting	DNA	bands	using	a	scalpel,	followed	by	Wizard	SV	
Gel	 and	 PCR	 Clean-Up	 system	 (Promega,	 USA),	 or	 QIAquick	 Gel	 Extraction	 Kit	 (Qiagen,	
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Germany).	 DNA	 concentrations	 were	 measured	 using	 a	 Nanodrop	 1000	 (Thermo	 Fisher	
Scientific,	USA). 
2.3	LRR6	baculovirus	and	protein	generation	
LRR6	 construct	 was	 initially	 cloned	 from	 full-length	 LRRK2	 using	 ‘Ligation	
independent	cloning’	(LIC)	primers	LIC	For_E980	and	LIC	Rev_M1335	(Table	1)		
	
	
	
	
PCR	 was	 performed	 using	 Vent	 DNA	 polymerase	 (New	 England	 Biolabs,	 USA)	 by	 the	
following	PCR	conditions:	
1. 94	°C	–	1	minute	
2. 94	°C	–	45	seconds	
3. 65	°C	–	45	seconds	
4. 72	°C	–	2	minutes	45	seconds	
5. Repeat	from	step	2	24x	
	
Resulting	 PCR	 product	 as	 well	 as	 LIC	 pFastBac-1	 transposition	 vectors	 (Bac-to-Bac;	
Invitrogen):	‘pFastBac	His6	MBP	N10	TEV	LIC’	cloning	vector	(4C)	(plasmid	30116,	Addgene,	
USA)	and	 ‘pFastBac	His6	TEV	LIC’	cloning	vector	(4B)	(plasmid	30115,	Addgene,	USA)	were	
digested	using	SspI	(New	England	Biolabs,	USA),	and	treated	with	T4	DNA	polymerase	(New	
England	Biolabs,	USA)	 in	the	presence	of	5	mM	dCTP	or	dGTP	(New	England	Biolabs,	USA)	
for	 PCR	 product	 and	 LIC	 vectors	 respectively.	 T4	 polymerase	 treated	 LRR6	 and	 each	 T4	
treated	LIC	pFastBac-1	transposition	vector	were	allowed	to	anneal,	generating	MBP-LRR6	
and	 His-LRR6	 constructs	 for	 bacmid	 generation.	 	 Bacmids	 and	 recombinant	 baculoviruses	
were	 generated	 according	 to	 the	 Bac-to-Bac	 procedure	 (Invitrogen,	 USA).	 10	 L	 of	
Spodoptera	frugiperda	Sf9	cells	at	approximately	1.3x106	cells/ml	were	infected	with	MBP-
LRR6	encoding	baculovirus	at	a	molarity	of	infection	of	one,	and	harvested	two	days	later.	2	
L	 of	 Sf9	 cells	 were	 similarly	 infected	 with	 His6-LRR6	 encoding	 baculovirus	 but	 harvested	
three	days	later. 
LIC	Primer	 DNA	Sequence	5’-3’	
LIC	For_E980	 TACTTCCAATCCAATGCAGAGAGAGAATATATTACA	
LIC	Rev_M1335	 TTATCCACTTCCAATGTTATTACATTCGGTTATAAGGCAC	
Table	1:	Primers	used	for	LIC	cloning	of	LRR6	
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2.4	Cell	pellet	harvesting,	cell	lysis,	and	Ni	affinity	purification	
	 Protein	cultures	generated	using	baculovirus	were	pelleted	at	4,000	rpm	for	10	mins	
at	 room	 temperature	 in	 a	 JLA8.100	 rotor	 (Beckman	 Coulter,	 USA),	 supernatant	 was	
discarded,	and	cell	pellet	split	into	5	x	2	L	pellets	of	MBP-LRR6	and	4x	0.5	L	His-LRR6	for	flash	
freezing	in	liquid	nitrogen	and	storage	at	-80	°C.	
	 2	L	pellets	of	MBP-LRR6	were	thawed	and	resuspended	in	a	basic	lysis	buffer	of	80	ml	
of	 20	 mM	 Tris	 pH	 7.5.	 This	 buffer	 and	 all	 subsequently	 described	 buffers	 were	
supplemented	with	 reducing	agents	or	 additives	 as	 indicated	 in	each	experiment.	 2	ml	of	
BugBuster	(Merck	&	Co,	USA)	and	1	ml	of	protease	inhibitor	cocktail	(Merck	&	Co,	USA)	was	
then	added.	 Lysis	was	performed	on	 ice	by	Vibra-Cell	VCX130	ultra-sonicator	with	13	mm	
horn	(Sonics	&	Materials	Inc,	USA).	Lysed	cells	were	incubated,	rolling	at	4	°C,	before	soluble	
extract	was	isolated	by	centrifugation	at	16,000	rpm	at	4	°C	for	90	mins	using	an	F0850	rotor	
(Beckman	Coulter,	USA).	Supernatant	was	supplemented	with	20	ml	of	5	x	lysis	additions	(20	
mM	Tris	pH	7.5,	2.5	M	NaCl,	100	mM	Imidazole).	This	volume	was	adjusted	based	on	 the	
original	 volume	 of	 soluble	 extract	 to	 give	 a	 1x	 final	 concentration	 of	 lysis	 additions.	 All	
volumes	were	adjusted	based	on	original	size	of	harvested	pellet.	
	 Supplemented	soluble	extracts	were	loaded	onto	a	Ni	chelated	5	ml	HiTrap	Chelating	
HP	column	(GE	Healthcare,	USA)	pre-equilibrated	 in	Ni	Binding	Buffer	(20	mM	Tris	pH	7.5,	
500	mM	NaCl,	 20	mM	 Imidazole).	Washing	 and	 elution	was	 performed	 on	 an	 ÄKTA	 FPLC	
system	 (GE	 Healthcare,	 USA),	 elution	 was	 performed	 over	 a	 linear	 gradient	 of	 10	 or	 15	
column	volumes	 from	Ni	binding	buffer	 to	Ni	elution	buffer	 (20	mM	Tris	pH	7.5,	200	mM	
NaCl,	250	mM	Imidazole).	
2.5	Anion	exchange	chromatography	
Pooled	 fractions	 of	 eluted	MBP-LRR6	 from	Ni	 affinity	 purification	was	 spun	 down,	
then	supernatant	diluted	1:10	in	20	mM	Tris	pH	8.0,	75	mM	NaCl	 in	order	to	raise	pH	and	
lower	 NaCl	 concentration.	 Diluted	 protein	 was	 loaded	 onto	 a	 5	 ml	 HiTrap	 Q	 HP	 (GE	
Healthcare,	USA)	pre-equilibrated	 in	Q	binding	buffer	 (20	mM	Tris	pH	8.0,	100	mM	NaCl).	
The	column	was	eluted	on	an	ÄKTA	FPLC	system	with	a	10	column	volume	gradient	to	50	%	
Q	elution	buffer	(20	mM	Tris	pH	8.0,	1	M	NaCl),	followed	by	a	step	to	100	%	Q	elution	buffer	
for	5	column	volumes.	
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2.6	Heparin	affinity	purification	
Pooled	 fractions	 of	 eluted	MBP-LRR6	 from	 Ni	 affinity	 purification	 were	 incubated	
with	Tobacco	Etch	Virus	protease	(TEV)	overnight	at	4	°C.	Precipitant	was	spun	down,	then	
supernatant	diluted	1:5	in	20	mM	Tris	pH	7.5	to	lower	NaCl	concentration.	Diluted	protein	
was	loaded	onto	a	5	ml	HiTrap	Heparin	HP	(GE	Healthcare,	USA)	equilibrated	in	Tris_Heparin	
binding	buffer	(20	mM	Tris	pH	7.5,	65	mM	NaCl).	The	column	was	eluted	on	an	ÄKTA	FPLC	
system	 (GE	 Healthcare,	 USA)	 with	 a	 10	 column	 volume	 gradient	 to	 100%	 Tris_Heparin	
elution	buffer	(20	mM	Tris	pH	7.5,	1	M	NaCl). 
Samples	loaded	and	eluted	from	heparin	in	Tris	buffer	was	pooled	and	dialysed	using	
Spectra/Por	 molecular	 porous	 membrane	 tubing	 6-8,000	 molecular	 weight	 cut	 off	
(Spectrum	Inc,	USA)	in	5	L	of	Phosphate_Heparin	binding	buffer	(20	mM	NaPO4
2-	pH	7.5,	50	
mM	NaCl)	mixed	 slowly	 overnight	 at	 4	 °C.	 Precipitant	 was	 spun	 down,	 then	 supernatant	
loaded	onto	a	pre-equilibrated	5	ml	HiTrap	Heparin	HP	 (GE	Healthcare,	USA).	The	column	
was	eluted	on	an	ÄKTA	FPLC	system	(GE	Healthcare,	USA)	with	a	10	column	volume	gradient	
to	100%	Phosphate_Heparin	elution	buffer	(20	mM	NaPO4	pH	7.5,	1	M	NaCl).	
2.7	Analytical	size	exclusion	chromatography	
	 A	 Superdex	 200	 10/300	 GL	 (GE	 Healthcare,	 USA)	 column	 was	 equilibrated	 with	
GF_buffer	(10	mM	NaPO4	pH	7,	250	mM	NaCl).	Samples	of	heparin	purified	MBP-LRR6	were	
prepared	by	taking	3	ml	of	protein	and	concentrating	3x	to	1	ml	using	a	Vivaspin	6	30,000	
MWCO	concentrator	(GE	Healthcare,	USA),	or	 incubating	a	1	ml	sample	with	TEV	protease	
overnight	at	4	°C.	Samples	were	run	with	1.2	column	volumes	of	GF_buffer	at	0.5	ml/min.	
2.8	SDS-PAGE	and	native	gels	
Proteins	were	generally	 analysed	by	10	%	SDS-PAGE	polyacrylamide	gels	using	 the	
Bolt	 Minigel	 tank	 (Life	 Technologies,	 USA).	 Samples	 were	 boiled	 and	 reduced	 using	 2-
mercaptoethanol	unless	stated	otherwise,	and	run	at	200	V	for	50	mins.	Gels	were	stained	
with	Coomassie	InstantBlue	(Expedeon	Ltd,	UK).		
6	%	polyacrylamide	native	PAGE	gels	were	cast	at	pH	9.4	and	samples	loaded	in	SDS	
free	loading	dye.	Samples	were	run	for	the	indicated	amount	of	time	at	100	V	using	the	Bolt	
Minigel	tank	(Life	Technologies,	USA).	Gels	were	stained	with	Coomassie	InstantBlue.	
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2.9	Western	blotting	
	 Proteins	from	SDS-PAGE	gel	were	transferred	to	Hybond-C	Nitrocellulose	membrane	
(GE	Healthcare,	USA)	using	a	Bolt	Mini	Blot	Module	(Life	Technologies,	USA)	in	Tris	Glycine	
transfer	 buffer.	Membranes	were	 blocked	 in	 3	%	milk	 in	 ‘phosphate	 buffered	 saline,	 1	%	
Tween’	(PBST)	overnight,	rolling	at	4	°C.	Membranes	were	probed	with	indicated	antibodies,	
either	monoclonal	mouse	 anti-human	 IgG	 Fc	 specific	 (GG-7	 clone;	 Sigma-Aldrich,	 USA)	 or	
mouse	 anti-His6	 (BD	Biosciences,	USA)	 at	 dilutions	 of	 1:2500	 and	 1:300	 respectively	 for	 1	
hour,	rolling	at	room	temperature.	Membranes	were	washed	for	15	mins,	10	mins,	5	mins	in	
PBST	then	incubated	with	an	horseradish	peroxidase	conjugated	goat-anti-mouse	secondary	
antibody	 (A4416;	 Sigma)	 diluted	 1:3000	 in	 3	 %	 milk-PBST	 for	 1	 hour	 rolling	 at	 room	
temperature.	 Membrane	 washes	 were	 repeated	 before	 incubation	 with	 ECL	 reagent	 (GE	
Healthcare,	USA)	and	development	on	Hyperfilm	ECL	(GE	Healthcare,	USA).	
2.10	Identification	of	leucine	rich	repeats	by	sequence	analysis	and	VLR-fusion	construct	
generation	
	 Computational	 identification	 and	 annotation	 of	 individual	 leucine	 rich	 repeats	was	
performed	 using	 the	 LRRfinder	 webserver	 (Offord	 et	 al.,	 2010).	 A	 region	 encompassing	
K951-M1335	of	human	LRRK2	(Accession	number:	Q5S007)	was	submitted	to	the	webserver	
for	this	purpose.	
	 LRRK2–VLR	 fusion	constructs	encompassing	LRRK2	 residues	Asn-992	 (LRR1)	 to	 Leu-
1302	(LRR14)	were	generated	as	fusions	with	residues	Ala-23	to	Leu-82	and	Asn-133	to	Thr-
201	 of	 hagﬁsh	 VLR	 B.61	 (termed	VLRN	 and	 VLRC	 respectively).	 A	 ‘Receptor	 for	 Advanced	
Glycation	 Endproducts’	 (RAGE)	 secretion	 signal	 fusion	 with	 VLRN	 and	 VLRC	 with	 TEV	
cleavable	Fc-His6	fusion	(Gangloff	et	al.,	2013)	were	cloned	into	the	pFastBac-1	transposition	
vector	 (Bac-to-Bac;	 Invitrogen,	USA)	using	BamHI	with	NheI	restriction	sites	and	NheI	with	
NotI	restriction	sites	respectively	(New	England	Biolabs,	USA).	Full	length	LRRK2	was	used	as	
a	PCR	template	using	combinations	of	primers	(table	2)	to	generate	various	LRR	constructs	
as	described	in	results.	
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Each	VLR	 construct	 therefore	 contains	 a	CAAGCA	 leader	 sequence	 followed	by	 a	GCTAGC	
NheI	site	for	restriction	digest	(5’-3’).	PCR	was	performed	using	Vent	DNA	polymerase	(New	
England	Biolabs,	USA)	by	the	following	PCR	conditions:	
1. 94	°C	–	4	minutes	
2. 95	°C	–	30	seconds	
3. 75	°C	–	30	seconds	
4. 72	°C	–	2	minutes	45	seconds	
5. Repeat	from	step	2	34x	
	
Each	 LRR	 PCR	 product	 was	 fused	 between	 VLRN	 and	 VLRC	 using	 NheI	 digestion	 (New	
England	 Biolabs,	 USA),	 combined	with	 Antarctic	 phosphatase	 (New	 England	 Biolabs,	 USA)	
treatment.	 Orientation	 of	 each	 insert	 was	 determined	 by	 sequencing	 using	 an	 external	
primer.	 RAGE-VLRN-LRR-VLRC-TEV-Fc-His6	 constructs	 were	 then	 cloned	 into	 a	 pCDNA3	
vector	 using	 BamHI	 and	 NotI	 restriction	 digest	 (New	 England	 Biolabs,	 USA),	 then	 finally	
transferred	to	pMT/V5-His	A	vector	using	KpnI	and	NotI	(New	England	Biolabs,	USA).	
2.11	S2	Cell	Test	Expression	of	VLR-fusion	constructs	
S2	 cells	 were	 plated	 in	 a	 6-well	 dish	 at	 3x106	 cells/well	 in	 insect-xpress	 medium	
(Lonza	Plc,	UK)	supplemented	with	10%	filtered,	heat-inactivated	Foetal	Bovine	Serum	(Life	
Technologies,	 USA).	 Once	 cells	 had	 settled,	 media	 was	 removed	 and	 replaced	 with	 2	 ml	
serum	 free	 insect-xpress	media.	 3	 µg	 of	 each	DNA	 construct	 in	 pMT/V5-His	A	 vector	was	
added	 to	100	µl	of	 serum	free	 insect-xpress	media	and	 filter	 sterilised	 through	a	0.22	µm	
CoStar	 SpinX	 filter	 (Sigma-Aldrich,	 USA),	 then	 transferred	 to	 a	 bijou.	 8	 µl	 of	 Cellfectin	 II	
reagent	 (Invitrogen,	 USA)	 was	 added	 to	 100	 µl	 of	 serum	 free	 insect-xpress	 media	 per	
transfection	reaction,	and	left	for	5	minutes	at	room	temperature.	100	µl	of	media:cellfectin	
mix	was	added	drop-wise	to	each	Bijou	bottle	containing	DNA	for	transfection.	Transfection	
Primer	 DNA	sequence	5’-3’	
LRR1_For	(N992)	 CAAGCAGCTAGCAATGAACTAAGAGATATTGAT	
LRR2_For	(N1021)	 CAAGCAGCTAGCAATGCACTCACGAGCTTTCCA	
LRR12_Rev	(L1252)	 TGCTTGGCTAGCAAGATGCAGTTTCTCTACTCT	
LRR13_Rev	(V1275)	 TGCTTGGCTAGCGACATCCAGAGATGTCAGATT	
LRR14_Rev	(L1302)	 TGCTTGGCTAGCCAGTTCATCCAAAGGAAGATC	
Table	2:	Primers	used	for	cloning	of	VLR	fusion	constructs	
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mixes	were	 left	at	 room	temperature	 for	30	minutes,	 then	topped	up	to	1	ml	with	serum	
free	 insect-xpress	media.	Media	was	gently	removed	from	S2	cells	and	replaced	with	1	ml	
transfection	 mix.	 Cells	 were	 incubated	 at	 27	 °C	 overnight,	 then	 transfection	 mix	 was	
removed	 from	cells	and	 replaced	with	 fresh	 insect-xpress	media	 supplemented	with	10	%	
FCS.	 Several	 hours	 later,	 10	 µl	 of	 100	 µg/ml	 sterile	 CuSO4	 was	 added	 to	 each	 well	 of	
transfected	 cells	 to	 induce	 protein	 expression.	 24	 hours	 later,	 cells	 were	 displaced	 and	
gently	spun	down	at	0.2	g	 for	5	mins.	Cell	pellets	were	harvested	 in	100	µl	of	 loading	dye	
and	flash	frozen,	while	an	aliquot	of	supernatant	was	prepared	for	SDS-PAGE	analysis,	with	
the	rest	flash	frozen	in	liquid	nitrogen.	
50	µl	Recombinant	Protein	A	Sepharose	Fast	Flow	 (GE	Healthcare,	USA)	 slurry	was	
spun	in	a	Pierce	Spin	Column	(Thermo	Fisher	Scientific,	USA)	at	500	g	for	30	secs.	Protein	A	
beads	were	washed	in	in	1	ml	PBS,	then	spun	again	at	500	g	for	1	min.	Washed	beads	were	
added	to	thawed	2	ml	test	expression	supernatant	and	incubated	with	gyration	at	4	°C	for	
90	mins.	Supernatant	was	then	transferred	back	to	a	spin	column	to	separate	protein	bound	
beads	by	centrifugation	at	500	g	until	all	beads	were	collected.	Beads	were	subsequently	re-
suspended	in	50	µl	of	non-reducing	loading	dye,	and	split	into	two	tubes,	one	of	which	was	
subsequently	reduced	with	1	µl	2-mercaptoethanol.	
2.12	Mice,	genotyping	and	routine	cell	culture	
WT	C57BL/6J	mice	were	 obtained	 from	Charles	 River,	UK.	 LRRK2-/-	 B6.129X1(FVB)-
Lrrk2tm1.1Cai/J	mice	was	obtained	from	The	Jackson	Laboratory,	United	States	(Parisiadou	et	
al.,	2009).	All	mice	strains	were	bred	independently.	All	work	involving	live	animals	complied	
with	 the	University	of	Cambridge	Ethics	Committee	 regulations	and	was	performed	under	
the	 Home	 Office	 Project	 License	 number	 80/2572.	 DNA	 from	 Ear	 snips	 of	 LRRK2-/-	
B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice	was	isolated	for	genotyping	using	the	Phire	animal	tissue	
digest	 PCR	 kit	 (Thermo	 Fisher	 Scientific,	 USA).	 Genotyping	 PCR	 was	 carried	 out	 in	
accordance	with	 recommendations	by	 The	 Jackson	 Laboratory	utilising	 the	 recommended	
genotyping	primers	(table	3)	and	reaction	conditions.	Genotyping	PCR	products	were	run	on	
a	 1	 %	 agarose	 gel	 made	 using	 ultra	 pure	 agarose	 (Thermo	 Fisher	 Scientific,	 USA)	 in	 a	
horizontal	electrophoresis	system	(Bio-Rad	Laboratories,	USA),	and	visualised	using	GelRed	
nucleic	 acid	 stain	 (Biotium,	 USA)	 and	 a	 Gel	 Doc	 XR+	 Gel	 documentation	 system	 (Bio-Rad	
Laboratories,	USA).	
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Routine	 tissue	 culture	 was	 performed	 in	 a	 containment	 level	 2	 laboratory	 in	 a	
steriled	tissue	culture	flow	hood.	Such	tissue	culture	hoods	were	routinely	wiped	with	70	%	
ethanol	both	before	and	after	work,	as	well	as	subjected	to	UV	radiation	after	each	use	in	
order	 to	 maintain	 sterility.	 During	 tissue	 culture	 work	 sterile	 and	 autoclaved	 disposable	
plastic	pipettes	and	pipette	tips	were	used	and	disposed	of	into	a	Virkon		(DuPont,	USA)	to	
maintain	 sterility.	 Sterility	 of	 cultures	 was	 checked	 by	 routine	 visual	 inspection	 and	 light	
microscopy.	Cell	 culture	media	was	 replaced	as	 indicated,	or	every	 three	days	 for	 routine	
work	such	as	with	cell	lines.	
For	 the	differentiation	and	culture	of	 ‘primary	bone	marrow	derived	macrophages’	
(pBMDMs),	mice	were	killed	between	8	and	16	weeks	of	age	by	cervical	dislocation,	skin	was	
sterilized	with	70	%	ethanol,	and	legs	removed.	Under	sterile	conditions,	the	tibia	and	femur	
were	 isolated,	 cleaned	 of	 muscle,	 and	 the	 proximal	 and	 distal	 epiphysis	 cut	 away.	 Bone	
marrow	 was	 flushed	 out	 of	 the	 bone	 using	 primary	 growth	 media	 (‘Dulbecco's	 modified	
Eagle's	medium’	 (DMEM)	 (Thermo	 Fisher	 Scientific,	USA)	 supplemented	with	 10	%	 ‘foetal	
calf	serum’	(FCS)	(Thermo	Fisher	Scientific,	USA),	20	%	L929	conditioned	media	and	8	mM	L-
glutamine	(Sigma-Aldrich,	USA)).	Isolated	cells	were	centrifuged	at	300	g	for	10	min	at	15	°C,	
and	re-suspended	in	60	ml	of	growth	media,	and	allowed	to	grow	at	37	°C	in	5	%	CO2.	Cells	
were	supplemented	with	a	further	60	ml	of	growth	media	after	2	days,	and	media	replaced	
every	3	days.	All	experiments	were	performed	on	cells	between	6	and	11	days	after	 initial	
bone	 marrow	 isolation.	 Live	 cell	 counts	 were	 performed	 using	 a	 haemocytometer	 with	
trypan	blue	staining	(Sigma	Aldrich,	USA).	
Immortalised	 WT	 and	 TLR4-/-	 BMDM	 cell	 lines	 were	 originally	 obtained	 from	
Professor	Doug	Golenbock,	University	of	Massachusetts	Medical	 School.	 TLR4-/-	 cells	were	
maintained	 in	 ‘Roswell	 Park	 Memorial	 Institute	 1640’	 (RPMI)	 medium	 (Thermo	 Fisher	
Scientific,	USA)	supplemented	with	10	%	FCS,	and	2	mM	L-glutamine.	
Primer	 DNA	sequence	5’-3’	
9940	 CTCTGAGAGCAGGAGCCGT	
9941	 TGCCTTCCTGGACATTATTCAGCC	
Table	3:	LRRK2-/-	B6.129X1(FVB)-Lrrk2tm1.1Cai/J	genotyping	primers	
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2.13	Cytokine	bead	array	
1x105	 cells/well	were	 plated	 in	 a	 96-well	 tissue	 culture	 plate	 (Corning,	USA)	 a	 day	
prior	to	treatment,	and	left	to	adhere	overnight	at	37	°C	in	5	%	CO2.	Cells	were	then	treated	
in	triplicate	with	100	ng/ml	ultrapure	LPS	from	E.	coli	O111:B4	(InvivoGen,	USA),	50	ng/ml	
recombinant	murine	Ifn-γ	(Peprotech,	UK),	10	µg/ml	MDP	(InvivoGen,	USA)	or	75	µM	alpha-
synuclein	 oligomers	 (αSyn	 Oligos)	 as	 indicated	 for	 each	 experiment.	 αSyn	 Oligos	 were	
supplied	by	Dr	Craig	Hughes,	the	preparation	of	oligomers	is	detailed	elsewhere	(Hughes	et	
al.,	 submitted	 for	 publication).	 LPS	 was	 sonicated	 prior	 to	 application	 to	 cells.	 After	
incubation	 for	 the	 indicated	 amount	 of	 time	 at	 37	 °C	 in	 5	 %	 CO2,	 supernatants	 were	
transferred	to	a	round-bottomed	96-well	tissue	culture	plate	and	stored	at	-80	°C.	Thawed	
triplicate	supernatants	were	 later	pooled	and	analysed	using	a	 ‘Mouse	Th1/Th2	10plex	Kit	
FlowCytomix’	 (eBioscience,	 USA)	 bead	 array	 kit	 following	 the	manufacturers	 instructions.	
Bead	array	was	analysed	on	an	Attune	NxT	acoustic	focusing	cytometer	(Life	Technologies,	
USA).	
2.14	RNA	isolation	and	qRT-PCR	
	 2.5x106	cells/well	were	plated	in	a	12-well	tissue	culture	plate	(Corning,	USA)	a	day	
prior	to	RNA	extraction,	and	 left	 to	adhere	overnight	at	37	°C	 in	5	%	CO2.	Cells	were	then	
treated	 with	 100	 ng/ml	 ultrapure	 LPS	 from	 E.	 coli	 O111:B4	 (InvivoGen,	 USA),	 50	 ng/ml	
recombinant	murine	Ifn-γ	(Peprotech,	UK),	10	µg/ml	MDP	(InvivoGen,	USA)	or	75	µM	alpha-
synuclein	 oligomers	 (αSyn	 Oligos)	 as	 indicated	 for	 each	 experiment.	 αSyn	 Oligos	 were	
supplied	by	Dr	Craig	Hughes,	the	preparation	of	oligomers	is	detailed	elsewhere	(Hughes	et	
al.,	submitted	for	publication).	LPS	was	sonicated	prior	to	application	to	cells.	After	2	hours	
incubation	 at	 37	 °C	 in	 5	 %	 CO2,	 cells	 were	 washed	 in	 ‘phosphate	 buffered	 saline’	 (PBS)	
(Thermo	 Fisher	 Scientific,	 USA)	 and	 scraped	 from	 tissue	 culture	 wells	 at	 4	 °C.	 RNA	 was	
isolated	 using	 RNeasy	 mini	 kit	 (Qiagen,	 Germany)	 in	 combination	 with	 QIAshredder	 cell	
homogenization	 (Qiagen,	 Germany)	 following	 the	 manufacturers	 instructions.	 To	 remove	
genomic	 DNA,	 extracted	 RNA	 was	 DNase	 treated	 using	 TURBO	 DNA-free	 kit	 (Applied	
Biosystems,	USA).	Resulting	RNA	was	analysed	using	a	Nanodrop	1000	spectrophotometer	
(Thermo	 Fisher	 Scientific,	 USA).	 ‘Quantitative	 reverse	 transcription	 polymerase	 chain	
reaction’	(qRT-PCR)	was	performed	using	SensiFAST	SYBR	No-ROX	One-Step	Kit	(Bioline,	UK)	
following	 the	manufacturers	 instructions	 and	 appropriate	 primers	 selected	based	on	data	
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submitted	to	the	primer	bank	database	(table	4)	(Spandidos	et	al.,	2009).	qRT-PCR	reactions	
were	 performed	 using	 a	 Rotor-Gene	 Q	 (Qiagen,	 Germany),	 and	 quantification	 of	 fold-
changes	of	 transcript	were	calculated	using	cycle	 threshold	values	accounting	 for	 reaction	
efficiency	(Pfaffl,	2001).		
	 	
Target	
Gene	
DNA	sequence	5’-3’	
Forward	primer	 Reverse	primer	
LRRK2		 ATCTCACCCTTCATGCTTTCTG	 TCTCAGGTCGATTGTCTAAGACT	
TLR4	 ATGGCATGGCTTACACCACC	 GAGGCCAATTTTGTCTCCACA	
TLR2	 GCAAACGCTGTTCTGCTCAG	 AGGCGTCTCCCTCTATTGTATT	
Ccl3	 TGCCTGCTGCTTCTCCTACA	 TGGACCCAGGTCTCTTTGGA	
Ccl4	 CCAGGGTTCTCAGCACCAA	 GCTCACTGGGGTTAGCACAGA	
Ccl5	 CTCACCATATGGCTCGGACA	 CTTCTCTGGGTTGGCACACA	
Ccrl2	 GCCCCGGACGATGAATATGAT	 CACCAAGATAAACACCGCCAG	
Rapgef3	 TCTTACCAGCTAGTGTTCGAGC	 AATGCCGATATAGTCGCAGATG	
Atf3	 CGAAGACTGGAGCAAAATGATG	 CAGGTTAGCAAAATCCTCAAATAC	
β-actin	 GGCTGTATTCCCCTCCATCG	 CCAGTTGGTAACAATGCCATGT	
GAPDH	 AGGTCGGTGTGAACGGATTTG	 TGTAGACCATGTAGTTGAGGTCA	
Table	4:	Primers	for	qRT-PCR	
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2.15	Flow	cytometry	of	cell	surface	proteins	
1x106	cells/well	were	plated	in	12-well	tissue	culture	plates	and	left	to	adhere	over	
night	at	37	°C	in	5	%	CO2.	Where	appropriate,	cells	were	treated	with	200	ng/ml	ultrapure	
LPS	 from	 E.	 coli	 O111:B4	 or	 10	 µg/ml	 MDP,	 and	 incubated	 at	 37	 °C	 in	 5	 %	 CO2	 for	 the	
indicated	 amount	 of	 time	 for	 each	 experiment.	 LPS	was	 sonicated	 prior	 to	 application	 to	
cells.	 Following	 any	 incubations,	 cells	were	washed	 2	 x	with	 PBS	 at	 4	 °C.	 Cells	were	 then	
scraped	 into	MACS	buffer	 (PBS	 supplemented	with	 2	%	 FCS,	 1	mM	EDTA	 (Merck	 and	Co,	
USA))	 and	 spun	 at	 300	g	 for	 6	minutes	 in	 a	 conical-bottom	 96-well	 plate	 (Thermo	 Fisher	
Scientific,	USA).	Cells	were	re-suspended	in	MACS	buffer	supplemented	with	1:100	rat	anti-
mouse	CD16/CD32	functional	grade	purified	(93	clone;	eBioscience,	USA)	and	incubated	at	4	
°C	for	15	minutes.	Cells	were	spun	at	300	g	for	6	minutes,	then	re-suspended	in	MACS	buffer	
supplemented	with	an	appropriate	antibody	for	fluorescent	analysis	(table	5).	Staining	was	
performed	 for	 30	mins	 at	 4	 °C.	 Cells	 were	 then	 centrifuged	 at	 300	 g	 for	 6	mins	 and	 re-
suspended	in	MACS	buffer	3	x	to	remove	unbound	antibody	before	finally	being	spun	at	300	
g	 for	6	minutes,	and	re-suspended	 in	MACS	buffer	supplemented	with	2	%	methanol-free	
formaldehyde	 (Thermo	 Fisher	 Scientific,	 USA)	 to	 fix.	 Fixed	 cells	 were	 stored	 at	 4	 °C	
overnight,	 then	 analysed	 using	 a	 BD	 Accuri	 C6	 flow	 cytometer	 (BD	 Biosciences,	 USA)	 for	
single	 stain	 experiments,	 or	 a	 Attune	NxT	 acoustic	 focusing	 cytometer	 (Life	 Technologies,	
USA)	for	F4/80,	CD11c,	CD11b	triple	labeling	experiments.	
	
Target	protein	 Fluorophore	
Host	
species	
Dilution	
for	use	
Clone	 Company	
CD16/CD32	 -	 Rat	 1:100	 93	 eBioscience	
TLR4/MD-2	 PE	 Rat	 1:80	 MTS510	 eBioscience	
Isotype	control	 PE	 Rat	 1:80	 eBR2a	 eBioscience	
TLR4	 PE	 Rat	 1:80	 Sa15-21	 BioLegend	
Isotype	control	 PE	 Rat	 1:80	 RTK2758	 BioLegend	
TLR2	 FITC	 Mouse	 1:10	 T2.5	 abcam	
Isotype	control	 FITC	 Mouse	 1:5	 ICIG1	 abcam	
F4/80	 FITC	 Rat	 1:200	 BM8	 eBioscience	
CD11c	 PE	 Hamster	 1:80	 N418	 eBioscience	
CD11b	 PerCP-Cyanine5.5	 Rat	 1:160	 M1/70	 eBioscience	
Table	5:	Flow	cytometry	antibodies	
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2.16	Phagocytosis	assays	
1	 µm	 yellow-green	 fluorescent	 labeled	 carboxylate-modified	 beads	 (L4655;	 Sigma-
Aldrich,	USA)	were	used	for	all	bead	phagocytosis	assays.	Appropriate	dilution	of	beads	was	
ascertained	 by	 counting	 on	 a	 haemocytoemeter	 in	 combination	 with	 a	 FV1200	 confocal	
microscope	(Olympus	Corporation,	Japan).	For	all	bead	phagocytosis	assays,	1x106	cells/well	
were	first	plated	in	a	12-well	tissue	culture	plates	and	left	to	adhere	over	night	at	37	°C	in	5	
%	 CO2.	 Cells	 could	 subsequently	 be	 incubated	 with	 inhibitors	 and	 appropriately	 diluted	
beads.	For	visualisation	of	bead	opsonisation,	2	µl	of	stock	beads	were	diluted	into	20	µl	of	
PBS	 with	 a	 range	 of	 dilutions	 of	 CF640R	 mouse	 anti	 florescein	 antibody	 (clone	 1F8-1E4;	
Thermo	Fisher	Scientific,	USA)	as	 indicated	in	the	experiment.	Beads	were	incubated	at	37	
°C	 for	 1	 hour,	 with	 occasional	 shaking.	 Stained	 cells	 were	 immediately	 mounted	 on	
microscope	slides	using	VECTASHIELD	antifade	mounting	medium	(Vector	Laboratories,	UK),	
and	imaged	on	an	FV1200	confocal	microscope	(Olympus	Corporation,	Japan).	
	For	 initial	 optimisation	 of	 beads/cell	 ratio	 for	 experiments,	 50	 µl	 of	 beads	 were	
diluted	 1:10	 in	 PBS	 (Thermo	 Fisher	 Scientific)	 and	 centrifuged	 at	 8000	 rpm	 in	 a	 Heraeus	
Biofuge	 Pico	 centrifuge	 (Thermo	 Fisher	 Scientific,	 USA)	 for	 1	 minute.	 400	 µl	 of	 PBS	 was	
carefully	 removed	 100	 µl	 at	 a	 time	 to	 leave	 beads	 unperturbed,	 then	 re-suspended	 in	 a	
further	400	µl	of	PBS.	Washed	beads	were	diluted	into	primary	growth	media	3:1000	for	10	
beads/cell,	 and	 3:100	 for	 100	 beads/cell.	 1	 ml	 of	 diluted	 beads	 was	 added	 to	 each	 well	
where	 appropriate,	 and	 incubated	 for	 the	 indicated	 amount	 of	 time	 at	 37	 °C	 in	 5	%	CO2.	
Cells	were	then	washed	and	fixed	for	analysis	by	flow	cytometry	as	follows:	Cells	were	then	
transferred	to	ice,	and	washed	3x	with	PBS	at	4	°C.	PBS	was	then	removed	and	replaced	with	
MACS	buffer	into	which	cells	were	scraped.	Cells	were	transferred	to	a	conical-bottom	96-
well	plate	(Thermo	Fisher	Scientific,	USA)	and	spun	at	300	g	for	6	minutes.	Cells	were	then	
re-suspended	 into	 MACS	 buffer	 supplemented	 with	 2	 %	 methanol-free	 formaldehyde	
(Thermo	 Fisher	 Scientific,	USA)	 to	 fix,	 and	 stored	 at	 4	 °C	overnight.	 Fixed	 cells	were	 then	
analysed	using	a	BD	Accuri	C6	flow	cytometer	(BD	Biosciences).	 	
For	optimised	bead	phagocytosis	experiments,	10	µl	of	beads	were	diluted	1:10	 in	
PBS,	or	for	experiments	utilising	opsonised	beads,	10	µl	of	beads	were	diluted	into	80	µl	of	
PBS	 with	 10	 µl	 of	 CF594	 mouse	 anti-fluorescein	 antibody	 (clone	 1F8-1E4;	 Sigma-Aldrich,	
USA).	Beads	were	incubated	at	37	°C	for	1	hour,	with	occasional	shaking.	Beads	were	then	
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diluted	with	 a	 further	 400	 µl	 of	 PBS	 to	wash,	 and	 centrifuged	 at	 8000	 rpm	 in	 a	 Heraeus	
Biofuge	 Pico	 centrifuge	 (Thermo	 Fisher	 Scientific,	 USA)	 for	 5	minutes.	 400	 µl	 of	 PBS	was	
carefully	removed	100	µl	at	a	time	to	leave	beads	unperturbed.	Beads	were	then	diluted	at	
a	 ratio	 of	 3:1000	 into	 primary	 growth	 media	 supplemented	 with	 either	 1	 %	 dimethyl	
sulfoxide	 (DMSO)	 (Sigma-Aldrich,	USA),	 or	 1	mM	cytochalesin	D	 (Thermo	Fisher	 Scientific,	
USA)	dissolved	 in	1	%	DMSO	 (final	 concentration:	10	µM)	as	 indicated	 in	 the	experiment.	
Before	 the	 application	 of	 beads,	 cells	 were	 incubated	 in	 primary	 growth	 media	
supplemented	 with	 1	 %	 DMSO	 or	 1	 mM	 cytochalesin	 D	 dissolved	 in	 1	 %	 DMSO	 (final	
concentration:	10	µM)	for	30	mins	at	37	°C	in	5	%	CO2.	Where	appropriate,	this	media	was	
replaced	with	1	ml	of	bead	containing	media	in	which	cells	were	incubated	for	2	hours	at	37	
°C	in	5	%	CO2.	Cells	were	then	washed	and	fixed	for	analysis	by	flow	cytometry	as	previously	
described.	
	 For	 bacterial	 phagocytosis	 assays,	 appropriate	 dilution	 of	 log-growth	 phase	 alpha-
select	 E.	 coli	 expressing	 ‘green	 fluorescent	 protein’	 (GFP)	 to	 give	 a	 final	 ‘multiplicity	 of	
infection’	 (MOI)	of	 10	was	 ascertained	by	 the	 counting	of	bacterial	 colonies	derived	 from	
streaked	 bacterial	 cultures	 on	 Lennox	 ‘Luria	 broth’	 (LB)	 agar	 (Sigma-Aldrich,	 USA)	 plates	
supplemented	with	100	µg/ml	ampicillin	(Sigma-Aldrich,	USA).	For	full	experiments,	0.2x106	
cells/well	were	first	added	to	an	8-well	chamber	slides	and	allowed	to	adhere	over	night	at	
37	°C	in	5	%	CO2.	On	the	same	day,	a	starter	culture	of	E.	coli	was	inoculated	in	LB	(Sigma-
Aldrich,	USA)	 supplemented	with	100	µg/ml	 ampicillin	 and	 grown	 for	 17.5	hours	 at	 37	 °C	
with	shaking.	The	next	day,	500	µl	of	E.	coli	culture	was	inoculated	into	5	ml	of	fresh	LB-amp	
pre-warmed	to	37	 °C,	and	 incubated	at	37	 °C	with	shaking	 for	2	hours	 to	 reach	 log-phase	
growth.	E.	coli	culture	was	then	centrifuged	at	5000	g	for	10	minutes	at	room	temperature.	
E.	coli	were	re-suspended	in	5	ml	of	primary	growth	media.	0.5	ml	of	this	culture	in	primary	
growth	media	was	then	diluted	into	a	final	volume	of	10	ml	of	primary	growth	media.	2	ml	
of	this	media	was	then	diluted	into	2	ml	of	primary	growth	media	supplemented	with	either	
1	%	DMSO,	or	1	mM	cytochalesin	D	dissolved	 in	1	%	DMSO	 (final	 concentration:	10	µM).	
Before	 the	application	of	E.	 coli	 cultures,	pBMDM	cells	were	 incubated	 in	primary	growth	
media	supplemented	with	1	%	DMSO	or	1	mM	cytochalesin	D	dissolved	in	1	%	DMSO	(final	
concentration:	10	µM)	for	30	mins	at	37	°C	in	5	%	CO2.	Where	appropriate,	this	media	was	
replaced	with	400	µl	of	E.	coli	culture	containing	media	in	which	cells	were	incubated	for	2	
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hours	at	37	°C	in	5	%	CO2.	Cells	were	then	transferred	to	ice	and	washed	5x	with	PBS	at	4	°C	
to	 remove	non-internalised	bacteria.	 Cells	were	 then	 fixed	by	 incubation	 in	 the	dark	with	
PBS	 supplemented	 with	 4	 %	 methanol-free	 formaldehyde	 for	 15	 minutes	 at	 room	
temperature.	 Cells	were	washed	 3x	 in	 PBS,	 and	mounted	 for	 imaging	 using	 VECTASHIELD	
antifade	 mounting	 medium	 containing	 DAPI	 (Vector	 Laboratories	 Ltd,	 UK).	 Slides	 were	
imaged	 on	 an	 FV1200	 confocal	 microscope	 (Olympus	 Corporation,	 Japan),	 with	
quantification	of	bacteria/cell	performed	using	the	‘find	maxima’	function	of	Fiji	for	ImageJ	
(Schindelin	et	al.,	2012;	Schindelin	et	al.,	2015).	
2.17	Chemotaxis	assays	
	 100	 µl	 of	 cells	 were	 added	 to	 the	membranes	 of	 8	 µm	 polycarbonate	membrane	
tissue	culture	treated	polystyrene	Costar	transwells	(6.5	mm	insert)	(Corning,	USA).	Prior	to	
addition	 to	 transwells,	 cells	were	counted	and	diluted	 to	an	appropriate	 concentration	 so	
that	the	indicated	number	of	cells	will	be	transferred	to	transwell	membranes	as	indicated	
for	each	experiment.	600	µl	of	‘primary	growth	media’	was	added	to	the	well	beneath	each	
transwell,	and	 incubated	 in	a	humidified	chamber	at	37	 °C	 in	5	%	CO2	 for	2	hours.	At	 this	
point,	 transwell	 inserts	 were	 transferred	 to	 fresh	 12-well	 tissue	 culture	 plates	 containing	
either	 fresh	 primary	 cell	 media	 or	 primary	 cell	 media	 supplemented	 with	 100	 µM	 ADP	
(Sigma-Aldrich,	 USA)	 as	 appropriate.	 Cells	 were	 placed	 within	 a	 humidified	 chamber	 and	
incubated	at	37	°C	in	5	%	CO2	for	the	indicated	amount	of	time	for	each	experiment.	At	the	
end	of	the	incubation	period,	transwells	were	moved	to	a	fresh	12-well	tissue	culture	plate,	
and	media	carefully	removed	from	above	the	transwell	membrane.	200	µl	PBS	was	added	to	
the	 transwell	membrane	 and	 swabbed	with	 a	Q-tip	 (Johnson	&	 Johnson,	USA)	 to	 remove	
cells	that	have	not	migrated	into	the	membrane.	PBS	was	again	removed	from	the	transwell	
and	replaced	with	a	further	200	µl	PBS;	this	process	was	repeated	3x	before	cells	within	the	
membrane	were	fixed	by	addition	of	200	µl	methanol-free	4	%	formaldehyde	in	PBS.	At	the	
same	time,	media	was	carefully	 removed	 from	the	original	wells	 in	which	 transwells	were	
incubated,	and	replaced	directly	with	200	µl	methanol-free	4	%	formaldehyde	in	PBS.	Cells	
in	 the	 transwell	membrane	and	 in	 the	 tissue	 culture	well	were	 incubated	 this	way	 for	 15	
minutes	at	room	temperature	in	the	dark,	after	which	formaldehyde	was	removed	and	cells	
again	washed	3x	 in	200	µl	PBS.	Cells	were	then	stained	with	200	µl	of	5	µg/ml	Hoechst	 in	
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PBS	ad	imaged	by	immufluorescent	microscopy.	Cell	counts	were	performed	using	the	‘find	
maxima’	function	of	Fiji	for	ImageJ	(Schindelin	et	al.,	2012;	Schindelin	et	al.,	2015).	
2.18	RNA	sequencing	and	transcriptomic	data	analysis	
Bone	marrow	was	isolated	from	16-week	old	female	mice	housed	in	the	same	facility	
for	 this	 study.	 3x106	 cells/well	were	plated	 in	Greiner	 6-well	 tissue	 culture	 plates	 (Sigma-
Aldrich,	USA)	a	day	prior	to	RNA	extraction	and	left	to	adhere	over	night	at	37	°C	in	5	%	CO2.	
Where	 appropriate,	 cells	 were	 then	 treated	 with	 100	 ng/ml	 ultrapure	 LPS	 from	 E.	 coli	
O111:B4,	 or	 10	µg/ml	MDP.	 LPS	was	 sonicated	prior	 to	 application	 to	 cells.	After	 2	hours	
incubation	at	37	°C	in	5	%	CO2,	cells	were	washed	in	PBS,	then	scraped	into	PBS	at	4	°C.	RNA	
was	 isolated	 using	 RNeasy	mini	 kit	 in	 combination	with	QIAshredder	 cell	 homogenization	
following	 the	 manufacturers	 instructions.	 To	 remove	 genomic	 DNA,	 extracted	 RNA	 was	
DNase	 treated	 using	 TURBO	DNA-free	 kit.	 Resulting	 RNA	was	 analysed	 using	 a	 Nanodrop	
1000	 spectrophotometer.	 Samples	 with	 A260/230	 <	 1.8	 were	 further	 purified	 with	 RNeasy	
MinElute	Cleanup	Kit	(Qiagen,	Germany).	Samples	were	then	flash	frozen	in	liquid	nitrogen,	
and	transferred	to	‘Cambridge	Genomic	Services’	where	RNA	was	quantified	using	a	Qubit	
Fluorometer	 (Thermo	 Fisher	 Scientific,	 USA).	 RNA	 integrity	 was	 verified	 using	 2100	
Bioanlyser	 (Agilent	 Genomics,	 USA),	 and	 mRNA	 library	 preparation	 was	 performed	 using	
TruSeq	 Stranded	 mRNA	 Library	 Prep	 Kit	 (Illumina,	 USA)	 with	 quality	 control	 by	 2200	
Tapestation	(Agilent	Genomics,	USA).	High	output	sequencing	runs	of	single-end	75	bp	read	
length	were	performed	on	NextSeq500	(Illumina,	USA)	using	NextSeq	500/550	High	Output	
v2	Kit	 (75	cycles)	 (Illumina,	USA).	A	minimum	read	depth	of	18x106	 reads	per	sample	was	
achieved.	 Read	 pre-processing,	 mapping	 with	 quality	 control	 was	 performed	 using	 a	
standard	 pipeline	 by	 ‘Cambridge	 Genomic	 Services’.	 Ensembl	
Mus_musculus.GRCm38.dna.primary_assembly.fa	 (release	 84)	 reference	 genome	 file	 was	
used	 to	 do	 the	 mapping	 of	 reads,	 using	 the	 annotated	 transcripts	 from	 the	 ensembl	
Mus_musculus.GRCm38.84.gtf.	 Differential	 gene	 expression	 analysis	 was	 performed	 using	
DESeq2	(Love	et	al.,	2014).	Analysis	was	performed	as	a	‘paired	comparison	experiment’	for	
each	 treatment	 group	 as	 comparisons	 between	 genotype	 are	 made	 between	 different	
samples	 of	 different	mice	 (unpaired),	while	 comparisons	 of	 treated	 vs	 untreated	 samples	
are	made	 using	 samples	 from	 the	 same	mice	 (paired).	 A	 target	 frame	 and	 design	matrix	
were	 adapted	 from	 an	 analogous	 scenario	 laid	 out	 in	 the	 EdgeR	 user	 guide	 section	 3.5:	
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“Comparisons	both	between	and	within	subjects”	(Chen	et	al.,	2008;	Robinson	et	al.,	2009).	
This	analysis	enabled	simple	differential	gene	expression	analysis	between	genotypes,	and	
2-parameter	analysis	to	compare	responses	of	each	genotype	to	innate	immune	stimuli	by	
interrogation	of	a	targets	frame.	This	targets	frame	identifies	each	sample	as	belonging	to	a	
mouse	(mouse.n),	and	each	of	these	mice	as	being	treated	with	LPS,	MDP,	or	left	untreated	
(media)	(table	6).	
	
		
	
	
	
	
	
	
	
	
		
	
	
	
Pathway	 analysis	 was	 performed	 by	 calculating	 gene	 enrichment	 against	 the	
Reactome	database	(www.reactome.org)	of	biological	signaling	pathways	(Joshi-Tope	et	al.,	
2005).	To	explore	the	data	thoroughly,	differential	gene	expression	datasets	were	filtered	at	
multiple	 levels	 of	 statistical	 significance	 of	 differential	 gene	 expression	 before	 being	
analysed	for	pathway	enrichment.	Datasets	filtered	for	differential	gene	expression	adjusted	
p	value	<	0.01,	0.05	and	0.1	were	submitted	 for	pathway	enrichment	analysis	using	CARD	
	
genotype	 mouse	 treatment	 mouse.n	
1	 ko	 1	 lps	 1	
2	 ko	 1	 mdp	 1	
3	 ko	 1	 media	 1	
4	 ko	 2	 lps	 2	
5	 ko	 2	 mdp	 2	
6	 ko	 2	 media	 2	
7	 ko	 3	 lps	 3	
8	 ko	 3	 mdp	 3	
9	 ko	 3	 media	 3	
10	 wt	 4	 lps	 1	
11	 wt	 4	 mdp	 1	
12	 wt	 4	 media	 1	
13	 wt	 5	 lps	 2	
14	 wt	 5	 mdp	 2	
15	 wt	 5	 media	 2	
16	 wt	 6	 lps	 3	
17	 wt	 6	 mdp	 3	
18	 wt	 6	 media	 3	
Table	6:	Targets	frame	for	samples	in	DEseq2	analysis	
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(www.card.niaid.nih.gov)	 (Dutta	 et	 al.,	 2016).	 RNA	 sequencing	 reads	 were	 converted	 for	
CARD	 compatibility	 by	 Sam	 Katz	 (PhD	 student,	 Department	 of	 Veterinary	 Medicine,	
University	 of	 Cambridge).	 Enriched	 pathways	 shared	 between	 WT	 and	 LRRK2	 KO	
macrophages	were	identified	using	only	pathways	identified	at	differential	gene	expression	
adjusted	p	<	0.01	and	pathway	enrichment	adjusted	p	<	0.01.	To	robustly	identify	genotype	
specific	 enriched	 pathways;	 pathway	 enrichment	 at	 all	 three	 differential	 gene	 expression	
confidence	 levels	 was	 filtered	 for	 those	 pathways	 that	 were	 uniquely	 statistically	
significantly	enriched	in	only	one	LRRK2	genotype:	at	pathway	enrichment	adjusted	p	<	0.05	
and/or	0.1.	For	each	 treatment,	pathways	were	scored	by	 resilience	as	 to	how	 frequently	
they	were	calculated	to	be	statistically	significantly	enriched	across	the	six	configurations	of	
pathway	analysis	performed.	
2.19	Metabolomics	
Bone	marrow	was	isolated	from	16	week-old	female	mice	housed	in	the	same	facility	
for	 this	 study.	Macrophages	 were	 derived	 in	 the	 previously	 described	method,	 but	 from	
bone	marrow	 frozen	 at	 -80	 °C	 after	 extraction.	 1.5x106	 cells/well	 were	 plated	 in	 12-well	
tissue	culture	and	 left	 to	adhere	over	night	at	37	 °C	 in	5	%	CO2.	Where	appropriate,	 cells	
were	 then	 treated	with	100	ng/ml	ultrapure	 LPS	 from	E.	 coli	O111:B4,	 10	µg/ml	MDP,	or	
serum	 starved	 by	 replacement	 of	 primary	 growth	 media	 with	 	 ‘Earle's	 Balanced	 Salt	
Solution’	 (EBSS)	 (Thermo	Fisher	 Scientific,	USA).	 LPS	was	 sonicated	prior	 to	 application	 to	
cells.	 After	 2	 hours	 incubation	 at	 37	 °C	 in	 5	%	CO2,	 cells	were	washed	 in	 PBS,	 then	 high-
performance	liquid	chromatography’	(HPLC)	grade	methanol	(Sigma-Aldrich,	USA)	was	used	
to	 precipitate	 proteins	 and	 dissolve	 lipids.	 Cells	 were	 incubated	 for	 10	 minutes	 at	 room	
temperature,	before	being	scraped	and	transferred	to	tubes,	 then	vortexed	and	sonicated	
thoroughly	 to	 achieve	 a	 homogenous	 solution.	 Samples	 were	 then	 flash	 frozen	 in	 liquid	
nitrogen,	and	transferred	to	Helene	Mobbs	(PhD	student,	Dept.	Biochemistry,	University	of	
Cambridge)	 for	 further	preparation,	mass	 spec	analysis,	and	peak	picking.	Briefly,	 samples	
were	thawed	and	sonicated	for	15	minutes,	then	centrifuged	for	5	minutes	at	12,000	g	or	
until	 the	 crashed	 protein	 formed	 a	 pellet.	 	The	 resulting	 liquid	was	 transferred	 and	 dried	
under	 nitrogen.	 	The	 sample	 was	 re-suspended	 in	 50	 µl	 of	 HPLC	 grade	 methanol	 and	
sonicated	for	5	minutes.	 	100	µl	of	HPLC	grade	water	 (Sigma-Aldrich,	USA)	was	added	and	
the	sample	vortexed.	
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A	well	described	‘intact	lipid	method’	was	adapted	for	mass	spec	analysis	of	lipids	in	
this	 study	 (Ament	et	al.,	2016).	This	analysis	was	performed	using	a	Xevo	G2	 ‘Quadrupole	
Time	 of	 Flight’	 (QToF)	 mass	 spectrometer	 with	 a	 Z-spray	 ‘electrospray	 ionisation’	 (ESI)	
source	(Waters	Ltd,	UK),	coupled	to	an	ACQUITY	Ultra	Performance	Liquid	Chromatography	
system	with	an	Acquity	CSH	C18,	1.7	mm	(2.1	x	100	mm)	column	(Waters	Ltd,	UK).	Precise	
chromatographic	 conditions	 (appendix	 table	 1),	 and	 conditions	 for	 mass	 spectrometry	
(appendix	 table	 2)	 are	 described	 in	 the	 appendix.	 Peak	 picking	 was	 performed	 using	 a	
custom	 R	 code	 described	 in	 the	 thesis	 of	 Helene	Mobbs	 (in	 preparation).	 This	 code	 was	
originally	compiled	by	Dr	Zoe	Hall	of	the	 lab	of	Professor	Jules	Griffin	(Dept.	Biochemistry,	
and	MRC	Human	Nutrition	Research,	University	of	Cambridge).	
	85	
	
3.	Expression	and	purification	trials	of	the	LRR	domain	of	LRRK2	
3.1	Aims	
• Express	and	purify	the	LRR	domain	of	LRRK2	in	order	to	carry	out	biophysical	studies	
• Optimise	the	expression	and	purification	of	the	‘MBP-LRR6’	construct	
• Explore	different	expression	systems	and	novel	construct	design	for	LRR	expression	
3.2	Background	and	initial	work	
	 From	 a	 structural	 perspective	 alone,	 LRRK2	 is	 extremely	 complex.	 A	 catalytic	 core	
bearing	 both	 GTPase	 activity	 and	 kinase	 activity	 is	 surrounded	 by	 a	 series	 of	 repeat	
structures	(fig	12)	(Mills	et	al.,	2014).	The	catalytic	core	of	LRRK2	has	been	the	focus	of	much	
attention	due	to	the	clustering	of	disease	causing	SNPs	within	these	domains,	and	the	fact	
that	enzymatic	readouts	are	a	relatively	simple	method	for	assessing	the	functional	impact	
of	 an	 amino	 acid	 mutation	 (Corti	 et	 al.,	 2011).	 However,	 proteins	 are	 three-dimensional	
structures	 subject	 to	 evolutionary	 pressures	 not	 just	 within	 enzymatic	 domains,	 but	 as	 a	
complete	 unit.	 In	 spite	 of	 this,	 the	 repeat	 structures	 flanking	 the	 catalytic	 core	 of	 LRRK2	
have	 been	 relatively	 under-studied.	 As	 an	 example	 of	 the	 importance	 of	 non-enzymatic	
domains	of	LRRK2,	 it	has	been	shown	that	 the	presence	of	 the	WD40	domain	adjacent	 to	
the	kinase	domain,	at	 the	C-terminus	of	 the	protein,	 is	essential	 to	kinase	activity	 (fig	12)	
(Jorgensen	 et	 al.,	 2009).	 Human	 LRRK2	 expression	 in	 zebrafish	 has	 also	 been	 used	 to	
demonstrate	that	deletion	of	the	WD40	domain	leads	to	a	levodopa	responsive	locomotor	
defects	(Sheng	et	al.,	2010).	This	suggests	functional	significance	of	the	structural	domains	
of	 LRRK2,	 and	 is	 an	 illustration	 of	 how	 structure	 and	 function	 are	 inter-linked.	 Another	
example	 of	 a	 structure-function	 relationship	 is	 in	 the	 biological	 significance	 of	 ligand	
binding.	 Interactions	 mediated	 through	 domains	 with	 no	 inherent	 enzymatic	 activity	 can	
dictate	 the	 localisation	 of	 enzymes,	 as	 well	 as	 substrate	 recruitment	 and	 co-ordination	
towards	enzymatic	domains.	
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The	domains	either	side	of	the	catalytic	core	of	LRRK2	are	an	LRR	domain	at	the	N-
terminus	of	the	GTPase	domain,	and	WD40	domain	at	the	C-terminus	of	the	Kinase	domain	
(fig	 12).	 Indeed,	 every	 domain	 outside	 of	 the	 catalytic	 core	 is	 predicted	 to	 be	 a	 repeat	
structure.	 Repeat	 structures	 are	 thought	 to	 be	 beneficial	 in	 evolutionary	 terms,	 as	
recombination	 allows	 the	 simple	 generation	 of	 new	 variants.	 This	 is	 exploited	 in	 the	
evolution	of	LRR-containing	disease	resistance	genes	in	plants,	through	a	process	known	as	
effector-triggered	 immunity	 (DeYoung	 and	 Innes,	 2006).	 In	 comparison	 to	 LRR	 domains,	
WD40	 repeats	 are	 relatively	 stable	 as	 they	 are	 formed	 of	 toroidal	 folds	 (simple,	 non-
interleaved	 super-secondary	 structure	 units	 folded	 into	 a	 closed	 structure),	 which	 are	
halfway	between	 the	extended	solenoid	 structures	 formed	by	LRRs,	and	globular	proteins	
such	 as	 kinases;	 thus	 generating	 a	 ‘happy-medium’	 between	 flexibility	 and	 stability	
(Chaudhuri	et	al.,	2008;	Stirnimann	et	al.,	2010).	
	 Given	 the	 clear	 involvement	 of	 LRRK2	 in	 inflammatory	 disease,	 initial	 interest	was	
placed	in	the	LRR	domain	of	LRRK2.	LRR	domains	play	a	fundamental	role	in	the	detection	of	
PAMP	and	DAMP	molecules	by	innate	immune	proteins	best	exemplified	by	the	TLR	family	
of	 PRRs,	 but	 are	 also	 found	 on	 other	 receptors	 such	 as	NLR	 family	 of	 PRRs	 (Botos	 et	 al.,	
2011).	The	TLR	family	consists	of	ten	members	in	humans,	with	the	greatest	source	of	amino	
acid	sequence	variability	between	receptors	 identified	at	LRR	ectodomains	(Barreiro	et	al.,	
2009).	 The	 LRR	 domains	 of	 these	 receptors	 are	 responsible	 for	 ligand	 binding,	 therefore,	
variability	 between	 these	 domains	 accounts	 for	 differential	 ligand	 binding	 between	
Figure	 12:	 LRRK2	 domain	 organisation.	 Boundaries	 adapted	 from	 Corti	 et	 al.,	 2011.	 LRRK2	
catalytic	core	is	highlighted	within	a	red	box.	ARM	=	Armadillo	repeats,	ANK	=	Ankyrin	repeats,	
LRR	=	Leucine	rich	repeats,	Roc	=	Ras	of	complex	proteins,	COR	=	C-terminal	of	Roc.	
C	
690	 860	 984	 1278	 1335	 1510	 1511	 1878	 1879	 2138	 2142	 2498	
ANK	 LRR	 Roc	 COR	 Kinase	 WD40	 2527	
Catalytic	core	
13	 621	
ARM	
	
	87	
	
receptors	that	is	fundamental	to	their	function.	X-ray	crystallography	allows	the	building	of	
atomic	resolution	models	of	protein	structures,	and	protein-ligand	interactions.	TLR	crystal	
structures	were	initially	solved	of	TLR1-TLR2,	and	TLR2-TLR6	heterodimers	(Jin	et	al.,	2007;	
Kang	et	al.,	2009);	as	well	as	a	TLR3	homodimer	(Liu	et	al.,	2008),	and	TLR4	homodimer	with	
MD2	co-receptors	 (Kim	et	al.,	2007).	Subsequently,	 the	LRR	ectodomains	of	TLR5	(Yoon	et	
al.,	2012),	TLR7	(Zhang	et	al.,	2016),	TLR8	(Tanji	et	al.,	2013),	and	TLR9	(Ohto	et	al.,	2015)	
have	 been	 solved	 largely	 through	 use	 of	 non-human	 orthologues	 of	 TLRs,	 as	 well	 as	 the	
discovery	of	new	VLR	fusion	technologies	for	LRR	expression	(Jin	and	Lee,	2008).	Elucidating	
the	atomic	 resolution	 structures	of	 the	TLRs	has	 revealed	 the	 ligand	binding	mechanisms,	
dimerisation	 interfaces,	and,	when	un-ligated	structures	are	also	available,	conformational	
changes	of	TLRs	indued	by	ligand-binding.	With	this	in	mind,	it	is	interesting	that	PSI-pBLAST	
analysis	identifies	bovine	TLR3	(uniprot	accession:	Q5TJ59)	as	having	the	highest	homology	
of	 the	 TLRs	 to	 the	 predicted	 LRR	domain	 of	 LRRK2	with	 an	 e-value	 of	 5e-7	 at	 the	 time	of	
writing.	 The	 highest	 homology	 to	 a	 human	 TLR	 by	 the	 same	 analysis	 was	 again,	 TLR3	
(uniprot	 accession:	 O15455)	 with	 an	 e-value	 of	 1e-06.	 TLR3	 is	 localised	 to	 endosomal	
membranes,	 and	 recognises	 40-50	 base	 pair	 lengths	 of	 double-stranded	 RNA	 (Liu	 et	 al.,	
2008).	
LRRs	 are	 characterised	 by	 stretches	 of	 20-29	 amino	 acid	 repeats,	 with	 a	 highly	
variable	but	leucine-rich	11	amino	acid	repeat	of	LxxLxLxxNxL,	where	‘L’	is	typically	leucine	
but	 can	 be	 substituted	 for	 another	 hydrophobic	 residue	 such	 as	 isoleucine,	 valine,	 or	
phenylalanine.	 ‘N’	 is	 classically	 asparagine,	 but	 can	 also	 be	 cysteine,	 threonine	 or	 serine	
(Enkhbayar	et	al.,	2004).	The	 initial	discovery	of	 the	 structure	of	 the	porcine	 ribonuclease	
inhibitor	 in	 1993	 laid	 the	 groundwork	 for	 our	 understanding	 of	 LRR	 domains,	 as	 this	
structure	 consisted	 of	 an	 extremely	 regular	 consensus	 sequence	 (Kobe	 and	 Deisenhofer,	
1993).		From	the	ribonuclease	inhibitor	structure,	it	was	observed	that	each	repeat	forms	a	
structural	unit	 consisting	of	a	β-strand	and	an	α-helix	 linked	by	unstructured	 loops.	These	
repeats	 stack	 so	 that	 an	 overall	 solenoid	 is	 formed	 which	 curves	 like	 a	 horseshoe.	 The	
concave	side	of	this	solenoid	stacks	so	that	the	β-strands	of	each	repeat	form	a	hydrogen-
bond	stabilised	parallel	β-sheet	(fig	13).	Repeated	asparagine	or	cysteine	residues	form	an	
‘asparagine	ladder’	with	continuous	hydrogen	bonding	between	backbone	carbonyl	groups	
across	 the	 length	 of	 the	 LRR	 solenoid.	With	 the	 discovery	 of	 subsequent	 LRR	 containing	
structures,	 it	has	become	clear	 that	 variability	 in	 the	helical	 elements	which	decorate	 the	
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convex	 side	 of	 the	 solenoid	 help	 to	 determine	 the	 curvature	 of	 the	 overall	 domain.	 The	
amount	 of	 curvature	 provided	 by	 each	 repeat	 depends	 on	 the	 fold	 of	 that	 helix.	 For	
example,	 310	 helices	 have	 a	 smaller	 radius	 than	 a	 classical	 α-helix,	 and	 therefore	 LRRs	
containing	310	 helices	 have	 lower	 curvature	 (Enkhbayar	 et	 al.,	 2004).	 It	 is	 also	possible	 to	
find	 short	 segments	 of	 β-sheet,	 simple	 unstructured	 loops,	 or	 even	 polyproline	 II	 helices	
within	this	variable	region	of	the	LRR	structure.		
	
	 	
Figure	13:	The	regular	LRRs	of	the	ribonuclease	 Inhibitor.	The	Porcine	Ribonuclease	inhibitor	
demonstrates	extremely	regular	leucine	rich	repeats,	with	a	single	β-strand	and	α-helix	in	each	
repeat;	forming	a	horseshow	shaped	super	structure.	Domains	are	coloured	blue	to	red	from	N	
to	C-termini	of	the	protein	amino	acid	sequence.	PBD	code:	2BNH	
45°	
α-helical	convex	
features	
β-sheet	
concave	surface	
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In	 order	 to	 better	 understand	 the	 fold	 and	 ligand	 binding	 potential	 of	 the	 LRR	
domain	of	LRRK2,	efforts	have	been	made	to	express	the	domain	recombinantly.	It	was	the	
long-term	 goal	 to	 use	 protein	 expressed	 in	 this	 way	 for	 ligand	 binding	 assays,	 and	
crystallisation	 with	 a	 view	 towards	 determining	 an	 X-ray	 structure.	 Initial	 work	 towards	
expressing	 soluble	 protein	 revolved	 around	 exploring	 potential	 domain	 boundaries	 of	 the	
LRR	 domain	 of	 LRRK2.	 As	 mentioned,	 LRR	 folding	 results	 in	 an	 extended	 solenoid	 with	
hydrophobic	 residues	 packed	 towards	 a	 hydrophobic	 core.	 The	 means	 by	 which	 this	
extended	structure	is	sealed	on	each	side	in	order	to	protect	the	hydrophobic	core	is	highly	
variable	 between	 LRR	 proteins;	 but	 that	 the	 core	 is	 not	 exposed	 is	 fundamental	 to	 LRR	
stability	 (Bella	 et	 al.,	 2008).	 It	 is	 thought	 that	 exposure	 of	 the	 hydrophobic	 core	 of	 these	
non-globular	domains	is	at	least	partly	responsible	for	what	makes	LRR	proteins	notoriously	
difficult	 to	 handle.	 Consequently,	 early	 work	 on	 LRR	 protein	 expression	 revolved	 around	
exploring	domain	boundaries	for	LRR	construct	design	in	an	attempt	to	obtain	a	soluble	and	
stable	construct	(appendix	poster:	Levy	MRes	2013).	The	Roc	domain	of	LRRK2	remains	the	
only	segment	of	LRRK2	to	have	been	successfully	crystallised	to	date	(Deng	et	al.,	2008).	This	
Roc	 domain	 lies	 at	 the	 C-terminus	 of	 the	 LRR	 domain,	 thus	 providing	 a	 good	 C-terminal	
domain	boundary	of	the	LRR	domain.	 In	comparison,	the	N-terminus	of	the	LRR	domain	 is	
disordered	with	 predicted	Ankyrin	 repeats	 but	 no	 confirmed	boundary.	 Interpro	 classifies	
the	LRR	domain	of	human	LRRK2	to	begin	just	prior	to	residue	1000	of	the	protein	(fig	14a).	
Uniprot	classifies	the	N-terminal	LRR	of	this	domain	to	begin	at	residue	983	(table	7).	
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Feature	Key	 Amino	Acid	Position	 Description	 Length	
Repeat	 983	-	1004	 LRR	 22	
Repeat	 1012	-	1033	 LRR	 22	
Repeat	 1036	-	1057	 LRR	 22	
Repeat	 1059	-	1080	 LRR	 22	
Repeat	 1084	-	1105	 LRR	 22	
Repeat	 1108	-	1129	 LRR	 22	
Repeat	 1130	-	1150	 LRR	 21	
Repeat	 1174	-	1196	 LRR	 23	
Repeat	 1197	-	1218	 LRR	 22	
Repeat	 1221	-	1241	 LRR	 21	
Repeat	 1246	-	1267	 LRR	 22	
Repeat	 1269	-	1291	 LRR	 23	
Domain	 1328	-	1511	 Roc	 184	
Domain	 1879	-	2138	 Protein	Kinase	 260	
Repeat	 2139	-	2183	 WD	1	 45	
Repeat	 2188	-	2327	 WD	2	 41	
Repeat	 2233	-	2276	 WD	3	 44	
Repeat	 2281	-	2327	 WD	4	 47	
Repeat	 2333	-	2377	 WD	5	 45	
Repeat	 2402	-	2438	 WD	6	 37	
Repeat	 2443	-	2397	 WD	7	 55	
Table	7:	Uniprot	Family	&	Domains.	Taken	from	‘Domains	and	Repeats’	of	Human	LRRK2	(Q5S007)	
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ARM	 ANK	 LRR	 Roc	 COR	 WD40	Kinase	a	
Figure	14:	LRR	construct	design.	a:	 Interpro	visualisation	of	predicted	LRRK2	domains.	ARM	=	Armadillo	repeats,	ANK	=	Ankyrin	repeats,	LRR	=	
Leucine	rich	repeats,	Roc	=	Ras	of	complex	proteins,	COR	=	C-terminal	of	Roc.	b:	Schematic	of	LRR	construct	design.	The	construct	LRR6	contains	
an	N-terminus	at	E980,	only	three	amino	acids	before	the	predicted	LRR	domain	boundary	at	Y983	made	by	Uniprot.	The	crystal	structure	of	the	
LRRK2	Roc	domain	informs	the	use	of	a	C-terminal	domain	boundary	at	M1335	for	the	LRR6	construct.	
b	
C-terminus:	M1335	
LRR	 Roc	
N-terminus:	E980	
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As	 part	 of	 an	 earlier	 degree,	 initial	 success	 was	 achieved	 in	 the	 expression	 of	 a	
construct	 termed	 LRR6	 with	 an	 N-terminal	 boundary	 at	 E980,	 very	 close	 to	 the	 Uniprot	
predicted	 N-terminus	 of	 the	 LRR	 domain	 (fig	 14b).	 Expression	 of	 the	 LRR6	 construct	 was	
trialed	in	different	protein	expression	systems,	with	the	presence	and	absence	of	a	‘tobacco	
etch	 virus’	 (TEV)	protease	 cleavable	 ‘maltose	binding	protein’	 (MBP)	 solubilisation	 tag	 (fig	
15a).	Bacterial	and	 insect	cell	expression	systems	were	 trialed.	Specifically,	BL21(DE3)	and	
Rosetta(DE3)pLysS	strains	of	E.	coli,	were	used,	as	well	as		Spodoptera	frugiperda	(Sf9)	and	
Tn5B1-4	 (High	 Fives)	 insect	 cell	 lines.	 Attempts	 to	 express	 LRR6	 in	 bacterial	 cell	 culture	
resulted	in	very	low	expressions	levels	of	protein,	which	required	chaotropic	agents	such	as	
urea	to	dissolve.	This	held	true	for	both	BL21(DE3)	and	Rosetta(DE3)pLysS	strains	of	E.	coli,	
suggesting	 that	 codon	 usage	 was	 not	 responsible	 for	 poor	 expression.	 In	 comparison,	
soluble	 protein	 was	 obtained	 using	 insect	 cell	 expression	 systems,	 with	 Sf9	 cells	 proving	
most	amenable	to	downstream	purification	(Table	8).	As	part	of	this	earlier	work,	a	multi-
step	 purification	 of	 Sf9	 expressed	 MBP-LRR6	 was	 described.	 It	 was	 noted	 that	 a	 large	
amount	of	protein	was	lost	during	anion	exchange	chromatography,	suggesting	LRR6	is	not	
amenable	 to	 this	 form	 of	 purification	 (fig	 15b).	 Interestingly	 however	 resulting	 purified	
protein	 could	 be	 successfully	 bound	 to,	 and	 eluted	 from	 heparin,	 a	 negatively	 charged	
glycosaminoglycan	used	for	 the	purification	of	DNA	binding	proteins	 (fig	16).	Such	binding	
suggested	 that	 the	 LRR6	 construct	 was	 correctly	 folded	 in	 spite	 of	 poor	 purification	
characteristics	 by	 anion	 exchange	 chromatography,	 and	 also	 reinforced	 the	 idea	 that	 the	
LRR	domain	of	LRRK2	may	carry	out	a	DNA	binding	function	as	suggested	by	the	previously	
described	homology	 to	TLR3	 (MRes	work	 summarised	 in	appendix	poster).	 If	proven	 true,	
such	binding	would	suggest	a	role	for	LRRK2	as	a	PRR	of	the	innate	immune	system.	
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Expression	System	 Tag	 Comment	
BL21(DE3)	 None	 Poor	expression,	Insoluble	
BL21(DE3)	 MBP	 Insoluble	
Rosetta(DE3)pLysS	 None	 Poor	expression,	Insoluble	
Rosetta(DE3)pLysS	 MBP	 Insoluble	
Sf9	 MBP	 Soluble	
Tn5B1-4	(High-Five)	 MBP	 Soluble,	Viscous	
Table	8:	Expression	trials	of	LRR	constructs.	(Levy,	MRes	2013)	
Figure	15:	MBP-LRR6	construct	design	and	purification.	a:	MBP-LRR6	construct	design.	MBP	is	
His6	tagged	and	can	be	cleaved	from	LRR6	construct	by	TEV	protease.	b:	Summary	gel	from	the	
optimised	 purification	 protocol	 of	 the	 MBP-LRR6	 construct.	 Significant	 protein	 losses	 were	
observed	during	anion	exchange	chromatography.	10%	SDS-PAGE,	coomassie	blue	staining	(Levy,	
MRes	2013).	
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Figure	16:	Purified	TEV	cleaved	MBP-LRR6	binds	heparin,	suggesting	DNA	binding	properties.	
a:	Elution	profile	of	purified	TEV	cleaved	MBP-LRR6	on	Heparin	column.	b:	Heparin	purification	
analysed	 by	 10	 %	 SDS-PAGE	 gel.	 Left:	 coomassie	 staining.	 Right:	 Western	 blot	 with	 α-His6	
antibody	(Levy,	MRes	2013).	
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3.3	Results	
	 Work	 performed	 previously	 showed	 promising	 purification	 and	 solubility	
characteristics	 for	 the	 construct	 MBP-LRR6	 as	 well	 as	 an	 affinity	 for	 heparin,	 which	
suggested	a	potential	DNA	binding	role	for	the	LRR	domain	of	LRRK2	(appendix	poster).	 In	
order	to	build	upon	this	work,	and	progress	to	biophysical	analysis	of	the	LRR	domain,	it	was	
deemed	 necessary	 to	 generate	 fresh	 P1	 baculovirus	 for	MBP-LRR6	 expression.	 The	 initial	
aim	 of	 biophysical	 work	 was	 to	 reproduce	 and	 build	 upon	 the	 previously	 observed	
purification	characteristics	of	LRR6.	Unfortunately,	new	batches	of	the	MBP-LRR6	construct	
did	 not	 reproduce	 the	 previously	 observed	 solubility	 of	 the	 construct.	 Here,	work	 on	 the	
LRR6	construct,	as	well	as	the	design,	test	expression,	and	proof-of	principle	purification	of	
novel	VLR-capped	constructs	is	described.		
3.3.1	Purification	trials	of	baculovirally	prepared	MBP-LRR6	
	 Fresh	P1	baculovirus	was	generated	 in	an	attempt	to	maximise	yield	of	MBP-LRR6.	
Protein	 harvested	 from	 Sf9	 cells	 infected	 with	 freshly	 generated	 MBP-LRR6	 baculovirus	
yielded	 protein	 of	 approximately	 80	 kDa;	 the	 expected	molecular	mass	 of	 the	MBP-LRR6	
construct.	Ni	 affinity	purification	was	performed,	utilising	 the	affinity	of	 the	poly-histidine	
tag	on	the	N-terminus	of	the	protein	for	nickel	ions.	Elution	of	MBP-LRR6	from	Ni2+	chelating	
column	was	optimised	to	not	only	increase	concentration	of	Imidazole	from	20	mM	to	250	
mM	 in	 order	 to	 outcompete	 the	 binding	 interaction	 between	His6-tagged	protein	 and	Ni-
chelated	column,	but	also	to	decrease	the	concentration	of	NaCl	from	500	mM	to	200	mM	
(fig	17a).	This	decrease	in	NaCl	concentration	was	introduced	as	binding	to	the	column	was	
performed	 at	 a	 high	 salt	 concentration,	 taking	 advantage	 of	 the	 observation	 that	 higher	
NaCl	concentrations	decreased	sample	viscosity.	One	explanation	for	this	effect	is	that	high	
salt	 concentrations	 may	 outcompete	 DNA	 for	 interaction	 with	 MBP-LRR6.	 Evaluation	 of	
eluted	 protein	 by	 SDS-PAGE	 analysis	 verified	 successful	 purification	 of	MBP-LRR6,	 with	 a	
concentrated	band	of	protein	at	the	constructs	expected	of	85	kDa	eluted	in	a	single	peak	
(fig	17b).	SDS-PAGE	also	revealed	a	major	contaminant	of	<	25	kDa	was	consistently	purified	
away	 from	 MBP-LRR6	 at	 low	 concentrations	 of	 NaCl	 at	 this	 stage	 (fig	 17b).	 These	
preparations	of	MBP-LRR6	yielded	a	total	of	2	mg	protein	per	 liter	of	culture	at	 this	stage	
when	eluted	by	this	optimised	protocol.	
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	 Nickel-affinity	purified	protein	was	next	pooled	for	application	to	an	anion	exchange	
column.	MBP-LRR6	has	a	theoretical	isoelectric	point	of	5.86,	making	the	protein	negatively	
charged	 at	 neutral	 pH.	 Pooled	 protein	was	 diluted	 into	 75	mM	NaCl	 at	 pH	 8	 in	 order	 to	
increase	 the	 negative	 charge	 of	 the	 protein,	 and	 decrease	 the	 competition	 for	 binding	
presented	by	Cl-	ions.	Protein	was	then	loaded	onto	an	anion	exchange	column.		
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Figure	17:	Optimised	Ni	affinity	purification	of	MBP-LRR6.	a:	Elution	profile	of	2	L	Sf9	prep	of	MBP-LRR6	
on	HiTrap	Chelating	HP	5	ml	column.	Peaks	annotated	1	and	2.		b:	Purification	analysed	by	10	%	SDS-PAGE	
gel,	Coomassie	staining.	
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	 MBP-LRR6	eluted	from	the	anion	exchange	column	as	a	broad	peak	over	30	ml	of	the	
linear	gradient	of	NaCl	(fig	18a).	This	behaviour	is	indicative	of	heterogeneity	in	the	protein	
sample,	 as	 a	 range	 of	 NaCl	 concentrations	 are	 able	 to	 outcompete	 the	 ionic	 interaction	
between	the	anion	exchange	matrix	and	the	charged	binding	surface	of	MBP-LRR6.	This	fact	
is	 confirmed	by	SDS-PAGE	analysis,	 identifying	a	band	of	 the	expected	mass	of	MBP-LRR6	
across	the	broad	elution	peak,	as	well	as	in	the	tail	of	the	elution	peak	(fig	18b).	This	result	
shows	 that	anion	exchange	chromatography	 is	not	a	 suitable	 technique	 for	purification	of	
fresh	 MBP-LRR6.	 The	 ineffectiveness	 of	 anion	 exchange	 chromatography	 for	 MBP-LRR6	
purification	 was	 observed	 for	 protein	 preparations	 used	 here,	 and	 also	 in	 preparations	
described	in	previous	work	(Levy,	MRes	2013).	Earlier	work	at	a	smaller	expression	scale	had	
shown	affinity	of	LRR6	for	heparin.	The	extremely	tight	elution	profile	of	LRR6	in	this	study	
suggested	 that	 this	 interaction	 could	 be	 utilised	 after	 Ni	 affinity	 purification	 in	 order	 to	
bypass	poorly	resolving	anion	exchange	chromatography.	
	 Nickel	affinity	purified	MBP-LRR6	was	cleaved	to	its	constituent	domains	of	MBP	and	
LRR6	 by	 incubation	 with	 TEV	 protease	 overnight,	 then	 diluted	 in	 order	 to	 lower	 NaCl	
concentration,	before	being	 loaded	onto	heparin.	Elution	 from	the	heparin	column	with	a	
gradient	of	NaCl	resulted	in	very	efficient	separation	of	the	cleaved	MBP	tag,	which	failed	to	
bind	 heparin	 (fig	 19b).	 	 Binding	 of	 LRR6	 to	 heparin	 was	 observed	 with	 a	 40	 kDa	 band	
corresponding	to	the	expected	molecular	mass	of	LRR6	detected	in	eluates	by	SDS-PAGE	(fig	
19b).	Protein	was	seen	to	elute	 from	heparin	 in	 three	peaks,	 suggesting	 the	separation	of	
two	major	species	from	LRR6	(fig	19a),	however	SDS-PAGE	analysis	of	these	peaks	showed	
protein	 at	 the	 expected	 mass	 of	 LRR6	 across	 all	 three	 of	 these	 peaks	 (fig	 19b).	 This	
behaviour	 is	 reminiscent	 of	what	was	observed	by	 anion	 exchange	 chromatography,	with	
LRR6	 protein	 appearing	 to	 have	 a	 range	 of	 different	 strengths	 of	 interaction,	 again	
suggesting	 heterogeneity.	 Additionally,	 significant	 amounts	 of	 contaminant	 bound	 to	
heparin	as	well	as	the	TEV	protease,	showing	that	heparin	binding	is	not	a	specific	enough	
purification	technique	to	replace	anion	exchange	chromatography	(fig	19b).		
	 	
	99	
	
	 	
Figure	18:	Poor	purification	of	MBP-LRR6	by	anion	exchange	chromatography.	a:	Broad	elution	
spectrum	 of	 Ni	 affinity	 purified	 MBP-LRR6	 from	 HiTrap	 Q	 5	 ml	 column	 with	 increasing	 NaCl	
concentrations.	b:	 10%	 SDS-PAGE	 gel	 analysis	 of	 eluted	 protein	 reveals	 presence	 of	MBP-LRR6	
across	the	broad	peak,	Coomassie	staining.	
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One	 significant	 variable	 between	 early	 indications	 of	 heparin	 binding	 and	 the	
currently	described	experiments	that	may	account	for	the	difference	 in	behaviour	of	LRR6	
on	 heparin	 is	 buffer	 conditions.	 To	 investigate	 this,	 pooled	 samples	 eluted	 from	 heparin	
were	dialysed	from	a	Tris	buffer	at	pH	7.5,	to	a	phosphate	buffer	at	the	same	pH.	However,	
a	very	similar	elution	profile	to	that	seen	in	Tris	buffer	was	observed	(fig	19c).	Three	major	
elution	peaks	were	present,	all	containing	different	contaminants,	as	well	as	LRR6	at	40	kDa	
(fig	19d).	 It	was	also	 clear	 that	 the	amount	of	 soluble	protein	was	decreasing	appreciably	
with	each	step	in	the	purification	procedure.	
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Figure	19:	Purification	of	cleaved	MBP-LRR6	by	heparin	affinity.	a:	Elution	spectrum	of	Ni	affinity	
purified	MBP	+	LRR6	from	HiTrap	Heparin	5	ml	column	with	increasing	NaCl	concentrations	in	Tris	
buffer.	 b:	 10%	 SDS-PAGE	 gel	 analysis	 of	 eluted	 protein	 reveals	 presence	 of	 LRR6	 across	 the	
spectrum	 of	 eluted	 protein	 in	 Tris	 buffer,	 Coomassie	 staining.	 c:	 Elution	 spectrum	 of	 protein	
purified	by	HiTrap	Heparin	5	ml	column	with	increasing	NaCl	concentrations	in	phosphate	buffer.	
d:	10%	SDS-PAGE	gel	analysis	of	eluted	protein	reveals	presence	of	LRR6	across	the	spectrum	of	
eluted	protein	in	phosphate	buffer,	Coomassie	staining.	
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To	investigate	the	folding	of	MBP-LRR6,	Ni	affinity	purified	MBP-LRR6	was	run	on	a	
native	PAGE	gel	to	assess	basic	physical	properties	of	the	protein	 including	 its	size,	charge	
and	shape.	After	two	hours,	the	majority	of	protein	was	seen	in	the	well	of	the	gel,	giving	an	
indication	that	the	protein	has	formed	an	aggregate	too	large	to	enter	the	polyacrylamide	
matrix	 (fig	 20a).	 Discrete	 bands	 were	 also	 seen,	 possibly	 demonstrating	 the	 existence	 of	
oligomeric	species	of	MBP-LRR6.	Native	gels	were	cast	at	pH	9.4,	while	the	theoretical	pI	of	
the	MBP-LRR6	construct	 is	5.86,	 indicating	that	the	effect	observed	is	a	product	of	protein	
shape	and	 size	 rather	 than	a	 charge	effect.	 The	 sequence	of	 LRR6	 shows	 the	presence	of	
nine	cysteine	residues	which	could	be	responsible	for	aggregation	by	forming	intermolecular	
disulphide	bonds	 in	the	oxidizing	conditions	to	which	they	are	exposed	following	cell	 lysis.	
Fresh	MBP-LRR6	purified	in	the	presence	of	10	mM	2-mercaptoethanol	demonstrated	that	
interaction	of	MBP-LRR6	with	 the	Ni	 affinity	 column	was	 indistinguishable	 from	 that	 seen	
under	non-reducing	conditions.	This	MBP-LRR6	isolated	under	reducing	conditions	was	then	
run	on	native	PAGE	gel	to	investigate	the	effect	of	reducing	agent	on	physical	properties	of	
MBP-LRR6.	 Again,	 results	 with	 MBP-LRR6	 isolated	 under	 reducing	 conditions	 were	
indistinguishable	from	that	 isolated	under	non-reducing	conditions	(fig	20b).	This	 indicates	
that	disulphide	bonding	is	not	causing	MBP-LRR6	to	aggregate.	It	is	possible	that	the	protein	
is	partially	folded,	leading	to	hydrophobic	aggregation.	
To	 gain	 a	 better	 understanding	 of	 this	 protein	 aggregation,	 size	 exclusion	
chromatography	was	applied.	MBP-LRR6	purified	using	heparin	affinity	was	seen	to	elute	at	
8	 ml,	 corresponding	 to	 the	 expected	 void	 volume	 of	 the	 column,	 indicating	 that	 large	
aggregates	 of	MBP-LRR6	 are	 present	 (fig	 20c).	 Concentration	 of	MBP-LRR6	 by	 a	 factor	 of	
three	increased	the	proportion	of	this	void	volume	peak	over	other	components	of	the	gel	
filtration	 profile,	 indicating	 that	 the	 proportion	 of	 aggregated	 protein	 increases	 as	 the	
concentration	of	MBP-LRR6	 increases.	Concentrations	of	protein	were	high	enough	 in	 this	
sample	 to	verify	 the	presence	of	80	kDa	MBP-LRR6	 in	 the	8	ml	void	volume	peak	by	SDS-
PAGE	 (fig	 20d).	 TEV	 cleavage	 of	 the	 sample	 overnight	 incompletely	 cleaved	 80	 kDa	MBP-
LRR6	 into	 40	 kDa	 and	 45	 kDa	 bands,	 corresponding	 to	 the	 expected	masses	 of	 LRR6	 and	
MBP	respectively	 (fig	20e).	Cleavage	caused	an	 increased	proportion	of	an	elution	peak	at	
16	ml,	identified	by	SDS-PAGE	to	be	MBP	(fig	20f),	and	a	smaller,	unresolved	peak	at	21	ml	
which	could	not	be	identified	by	SDS-PAGE.	
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Figure	20:	Analysis	of	MBP-LRR6	physical	properties.	a,	b:	Coomassie	stained	native	gel	analysis	of	
Ni	affinity	purified	MBP-LRR6	 isolated	under	a:	non-reducing	conditions,.	b:	 reducing	conditions.	c:	
Analytical	 size	 exclusion	 analysis	 of	 Ni	 and	 heparin	 affinity	 purified	 MBP-LRR6	 using	 S200	
HiLoad10/300	 GL	 column.	 Annotated	 with	 peak	 names.	 d:	 10%	 SDS-PAGE	 gel	 of	 3x	 concentrated	
MBP-LRR6	after	analytical	size	exclusion,	Coomassie	staining.	e:	 	TEV	cleavage	analysis	by	10%	SDS-
PAGE,	 Coomassie	 staining.	 f:	 10%	 SDS-PAGE	 gel	 of	 TEV	 cleaved	 MBP-LRR6	 after	 analytical	 size	
exclusion,	Coomassie	staining.	
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3.3.2	Expression	and	Purification	of	His-LRR6	
	 A	 His-tagged	 LRR6	 construct	was	 generated	 in	 parallel	with	MBP-LRR6	 in	 order	 to	
compare	expression	and	purification	characteristics	of	protein	without	a	bulky	MBP	fusion	
tag.	Test	expression	of	the	construct	was	promising	with	a	large	band	at	the	expected	mass	
for	His-LRR6	of	40	kDa	detectable	by	western	blotting	in	harvested	pellets	of	Sf9	cells,	from	
three	days	 after	baculoviral	 infection.	 Significant	 cleavage	products	were	also	detected	 at	
around	35	kDa,	and	another	at	low	molecular	weight	(fig	21a).	A	significant	amount	of	His-
LRR6	was	 also	 detected	 in	 supernatants	 of	 harvested	 Sf9	 cultures,	 indicating	 that	 protein	
was	being	released	from	cells	lysed	following	baculoviral	infection.	A	500	ml	prep	of	Sf9	cells	
was	harvested	then	protein	extracted	and	purified	using	the	established	protocol	for	MBP-
LRR6	Ni	affinity	purification.	
	 The	elution	profile	for	His-LRR6	consisted	of	a	single,	extended	elution	peak	(fig	21b).	
Analysis	of	the	eluted	proteins	by	SDS-PAGE	gel	show	that	this	peak	does	not	contain	His-
LRR6	but	is	a	contaminant	eluting	at	low	concentrations	of	imidazole,	similar	to	that	seen	for	
MBP-LRR6.	 Small	 amounts	 of	 His-LRR6	 were	 seen	 to	 be	 eluted	 at	 a	 slightly	 higher	
concentration	of	 imidazole	as	MBP-LRR6	of	approximately	125	mM	(fig	21c),	however	 the	
lack	of	overexpressed,	undegraded,	soluble	protein	in	this	system,	meant	this	construct	was	
not	pursued	any	further.		
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Figure	 21:	 Expression	 and	 purification	 trials	 of	 His-LRR6.	 a:	 Time	course	evaluation	 of	His-LRR6	
expression	 in	Sf9	 cell	pellets.	Western	 blot,	 anti-His6	primary	antibody,	10	 s	 exposure.	b:	Elution	
spectrum	of	Ni	affinity	purified	His-LRR6	isolated	from	Sf9	cell	pellets	MOI:	1	Day	3.	c:	10	%	SDS-
PAGE	 gel	 analysis	 of	 eluted	 protein	 reveals	 presence	 of	 40	 kDa	 His-LRR6	 after	 peak	 of	 protein	
elution	indicating	a	lack	of	overexpressed	soluble	protein,	Coomassie	staining.	
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3.3.3	VLR-LRR	Fusion	Construct	
	 As	discussed	previously,	one	potential	 cause	of	protein	aggregation	 is	hydrophobic	
interactions	 between	 incorrectly	 folded	 proteins.	 A	 remarkable	 development	 in	 the	
expression	 of	 LRR	 proteins	 was	 made	 in	 2007	 with	 the	 generation	 of	 fusion	 proteins	
between	LRRs	and	the	hagfish	‘variable	lymphocyte	receptor’	(VLR)	to	form	‘VLR-LRR’	fusion	
constructs.	 These	 fusion	 constructs	 have	 been	 demonstrated	 to	 improve	 LRR	 protein	
expression,	solubility	and	crystallisability	(Jin	and	Lee,	2008b).	Such	characteristics	of	fusion	
proteins	 have	 led	 to	 the	 structures	 of	 a	 range	 of	 LRR	 containing	 proteins	 being	 solved,	
including	TLRs	5	and	6	(Jin	et	al.,	2007;	Kim	et	al.,	2007;	Kang	et	al.,	2009;	Yoon	et	al.,	2012).	
The	technique	has	also	been	successfully	employed	 in	our	 lab	to	 investigate	and	solve	the	
prototypical	drosophila	Toll	receptor	structure	(Gangloff	et	al.,	2013;	Lewis	et	al.,	2013).		
	 The	 highly	 conserved	 LxxLxLxxNxL	 motif	 of	 LRR	 proteins,	 where	 ‘L’	 is	 normally	
leucine,	 but	 is	 commonly	 replaced	 by	 other	 hydrophobic	 amino	 acids,	 can	 be	 used	 to	
generate	precise	fusions	of	hagfish	LRR-containing	VLR	‘caps’	to	the	LRR	repeats	of	LRRK2.	N	
and	C-terminal	 caps	 from	hagfish	protein	 ‘VLR	B.61’	have	been	 shown	 to	 successfully	 cap	
the	 regular	 23-24	 amino	 acid	 repeats	 of	 extracellular	 LRR	 containing	 proteins	 (Kim	 et	 al.,	
2007;	Lewis	et	al.,	2013).	As	discussed	previously,	the	specific	characteristics	of	each	repeat	
can	affect	physical	properties	of	 the	LRR	solenoid,	 for	example:	 longer	repeats	will	have	a	
larger	diameter	than	shorter	repeats.	This	is	important	as	it	means	different	repeats	will	be	
capped	 by	 the	 hagfish	 VLR	with	 different	 degrees	 of	 success.	 Such	 design	 considerations	
require	 a	more	 precise	 understanding	 of	 the	 LRR	 repeats	 that	make	 up	 the	 LRR	 domain.	
Submission	 of	 the	 amino	 acid	 sequence	 of	 the	 predicted	 LRR	 region	 of	 human	 LRRK2	 to	
‘LRRfinder’	webserver	 identified	 12	 LRR	 repeats,	 however	 it	was	 noted	 that	 two	 of	 these	
predicted	repeats	were	far	longer	than	would	be	expected	for	a	normal	LRR	protein		(table	
9).	 Secondary	 structure	 prediction	 was	 performed	 using	 Genesilico	Metaserver2	 and	 the	
resulting	 secondary	 structure	 predictions	 were	manually	 scanned	 for	 predicted	 β-strands	
aligning	with	amino-acid	sequence	regions	approximating	to	the	LRR	consensus	sequence	of	
LxxLxLxxNxL	(fig	22).	Computationally	predicted	LRR	consensus	motifs	aligned	perfectly	with	
predicted	β-strands,	and	two	LRR-like	motifs	were	manually	detected	in	regions	of	unclear	
secondary	structure,	potentially	explaining	why	computational	methods	had	not	predicted	
an	 LRR	 at	 these	 positions	 (fig	 22).	Manually	 assigning	 these	 sequences	 as	 LRR	 consensus	
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motifs	results	in	regularly	spaced	predicted	LRR	repeats	of	between	20	and	29	amino	acids,	
as	 would	 be	 expected	 for	 an	 LRR	 fold	 (table	 10).	 These	 predicted	 repeats	 would	 also	
maintain	a	uniform	pattern	of	 repeating	β-strands	and	helices	 that	would	be	expected	 to	
form	the	concave	and	convex	surfaces	of	the	LRR	solenoid	respectively.	
In	 order	 to	 maximise	 the	 possibility	 of	 generating	 a	 successfully	 capped	 VLR-LRR	
construct,	different	LRR-VLR	fusions	were	generated,	each	truncating	and	capping	different	
repeats	of	 the	LRR	domain.	The	LRR	 repeats	of	 LRRK2	contain	an	 irregular	 repeat	at	each	
end	of	the	domain;	LRR1	and	LRR14	(table	10).	LRR1	has	a	repeat	length	of	29	amino	acids,	
the	 very-upper	 end	 of	 what	 would	 be	 expected	 within	 an	 LRR	 domain,	 and	 the	 LRR	
consensus	motif	of	LRR14	ends	in	polar	aspartic	acid	rather	than	the	expected	hydrophobic	
residue.	Therefore,	constructs	were	designed	to	truncate	the	LRR	domain	of	one,	or	both	of	
these	irregular	repeats.	Construct	VLR1	is	designed	to	cap	the	full	length	of	the	LRR	domain,	
VLR2	 truncates	 the	 irregular	 repeat	 LRR14,	 and	 VLR3	 truncates	 both	 LRR1	 and	 LRR14.	
Constructs	 VLR4	 was	 designed	 to	 cap	 the	 domain	 between	 LRR2	 and	 LRR12	 -	 two	 very	
regular	 repeats	 (table	 11).	 Each	 VLR	 fusion	 construct	 was	 cloned	 into	 baculoviral	 and	
Schneider	 2	 (S2)	 cell	 expression	 vectors;	 pFastBac-1	 and	 pMT/V5-His	 A	 respectively.	 Each	
construct	 contains	 an	 N-terminal	 ‘receptor	 for	 advanced	 glycation	 endproducts’	 (RAGE)	
secretion	signal,	and	a	C-terminal	TEV	cleavable	Fc-His6	tag	(fig	23).		
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Score	 E-Value	 Sequence	 Length	
17.78	 0.00	 ITSLDLSANEL	RDIDALSQKCCISVHLEH	 29	
16.45	 0.00	 LEKLELHQNAL	TSFPQQLCETLKS	 24	
21.46	 0.00	 LTHLDLHSNKF	TSFPSYLLKMSC	 23	
14.07	 0.01	 IANLDVSRNDI	GPSVVLDPTVKCPT	 25	
18.65	 0.00	 LKQFNLSYNQL	SFVPENLTDVVEK	 24	
19.96	 0.00	 LEQLILEGNKI	SGICSPLRLKE	 22	
22.34	 0.00	 LKILNLSKNHI	SSLSENFLEACPKVESFSARMNFLAAMPFLPPS	 44	
15.30	 0.00	 MTILKLSQNKF	SCIPEAILNLPH	 23	
19.73	 0.00	 LRSLDMSSNDI	QYLPGPAHWKSLN	 24	
19.04	 0.00	 LRELLFSHNQI	SILDLSEKAYLWSR	 25	
18.45	 0.00	 VEKLHLSHNKL	KEIPPEIGCLEN	 23	
15.77	 0.00	 LTSLDVSYNLE	LRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLK	 59	
Table	 9:	 Predicted	 LRRs.	 Results	 of	 LRR	 predictor	 webserver.	 Identified	 LxxLxLxxNxL	 motif	
highlighted	in	yellow.	
Figure	 22:	 Manually	 identified	 LRR	 repeats.	 Metaserver2	 alignment	 of	 secondary	 structure	
predictions	 of	 C-terminal	 half	 of	 LRRK2	 LRR	 domain.	 H	 =	 helix,	 E	 =	 β-strand.	 LxxLxLxxNxL	 motifs	
identified	by	LRRPredictor	highlighted	in	yellow,	manually	identified	LxxLxLxxNxL	motifs	highlighted	in	
purple.		
            
  GPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKA 
jnet -------HHHHHH------EEE------------EEEEE------HHHHHHH-------E--------HHHHHHHHH---HHHHH------------------HHHHHHHHHHHH-- 
spineX --HHHHHHH--EEE------------HHHHHHHH--EEE-----------HHHH-----EEE--------HHHHHHHH-----EE----------HHHHHHHHHHHHHHHH-H-H-- 
spine    -HHH-------EEEE----------HHHHHHH----EEE---------HHHH-------EEE-----------HHHHH-----EEE-----EEE-HHHH---HHHHEEE----EE-- 
psipred ----HHH----HHH------------HHHHHH----EEE----------HHHH------EE--------------HHH-----------------HHHH---HHHHHHHHHHHHHHH 
consensus---HHHHH--HH--------------HHHHHH----EEE----------HHHH------EE---------HHHHHHHH-----------------HHHH---HHHHHHHHHHHHH-- 
	
 
  SFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLP 
jnet -HHHHHHHHHHHH-HHHHH------------------EE----------HHHHHHH---HHHHHH----------------E--------HHHHHHHH-----EEEE---------- 
spineX --------HHHHHHHHHHH--EEE-------------------EEE----------HHHHHH-----EEE-----------------EEE-------HHHHHHHH-----EEE---- 
spine    -----HHHHH-----EEEEE----EE----------EEEEEE---------HHHH------EEEE----------------EEEE----------HHH-------EEE--------- 
psipred ----HHHHHHHHH--EEE-------------------EEE----------HHHHHH-------------------------EEE----------HHH-------EEE---------- 
consensus --HHHHHHHHHH--EEE-------------------EEE----------HHHHHH-------------------------EEE-------HHHHHHH------EEE----------- 
	
 SEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQL 
jnet ----EEEEEE-----HHHHHHHHHHHHHHHHHHHHHHH-----HHHHHHHHHHHHHHHHHHHH----HHHHHHHHHHHH----EEE-------------------HHHHH------- 
spineX HHHHH--EEE-----------H-H-HHHHHH-----EEE----------HHHHHH-----EEE--------HHHHHHH-----EEE-------------H-HH-----EEE------ 
spine ------EEEE---------HHHHHHH-HH----HHHEEEE---------HHHHHH-----EEEE--------HHHHHH----EEEEE--------------------EEEE----E- 
psipred HH-----EEE-----------HHHHHHHHH------EEE----------HHHHH------EEE----------HHHHH-----EEE----------------------EEE------ 
consensusHH--H-EEEE---------HHHHHHHHHHHH--HHHEEE----------HHHHHH-----EEE---------HHHHHH-----EEE---------------------HEEE------ 
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Repeat	 Sequence	 Length	
LRR1*	 ITSLDLSANEL  RDIDALSQKCCISVHLEH 29	
LRR2	 LEKLELHQNAL  TSFPQQLCETLKS 24	
LRR3	 LTHLDLHSNKF  TSFPSYLLKMSC 23	
LRR4	 IANLDVSRNDI  GPSVVLDPTVKCPT 25	
LRR5	 LKQFNLSYNQL  SFVPENLTDVVEK 24	
LRR6	 LEQLILEGNKI  SGICSPLRLKE 22	
LRR7	 LKILNLSKNHI  SSLSENFLEACPK 24	
LRR8	 VESFSARMNFL  AAMPFLPPS 20	
LRR9	 MTILKLSQNKF  SCIPEAILNLPH 23	
LRR10	 LRSLDMSSNDI  QYLPGPAHWKSLN 24	
LRR11	 LRELLFSHNQI  SILDLSEKAYLWSR 25	
LRR12	 VEKLHLSHNKL  KEIPPEIGCLEN 23	
LRR13	 LTSLDVSYNLE  LRSFPNEMGKLSKIWD 27	
LRR14*	 LPLDELHLNFD  FKHIGCKAKDII 23	
Table	10:	LRRK2	LRR	identification.	LxxLxLxxNxL	sequence	annotated	and	separated	from	variable	
loop	regions	of	each	repeat.	Each	repeat	is	defined	by	its	beta-sheet.	*	indicates	a	highly	irregular	
repeat.	
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VLR	Fusion	Construct	
Name	
LRR	Repeats	Included	in	
Construct	
Full	length	
mass	
TEV	cleaved	
mass	
VLR1	 LRR1	-	LRR14	 79.8	kDa	 51.8	kDa	
VLR2	 LRR1	-	LRR13	 76.6	kDa	 48.6	kDa	
VLR3	 LRR2	-	LRR13	 73.2	kDa	 45.2	kDa	
VLR4	 LRR2	-	LRR12	 70.7	kDa	 42.7	kDa	
Table	 11:	 VLR	 fusion	 constructs.	 Four	VLR	 fusions	were	designed,	 each	 truncating	 individual	
LRRs	as	identified	in	table	10.	Fusions	were	generated	after	Asn	residue	of	repeat.	
LRR	Domain	 Fc	
TEV	cleavage	site	
His	-	C	N	–	RAGE	
VLRN	 VLRC	
28	kDa	70-80	kDa	
Figure	23:	VLR	fusion	construct	design.		Each	LRR	domain	is	fused	to	N	and	C	terminal	VLR	caps	
(VLRN	and	VLRC),	and	an	N	terminal	RAGE	secretion	signal.	Fc	 fusion	tag	is	attached	by	a	TEV	
cleavable	linker.	Approximate	masses	annotated.	
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	 Transient	 expression	 of	 VLR-LRR	 constructs	 was	 first	 trialed	 in	 S2	 cells,	 as	 this	
expression	 system	 does	 not	 require	 the	 lengthy	 process	 of	 generating	 baculovirus.	 A	
construct	termed	‘TollN6-VLR’	was	included	in	expression	trials	as	a	positive	control	(Gangloff	
et	 al.,	 2013),	 as	 this	 protein	 has	 been	 shown	 to	 give	 good	 expression	 in	 the	 S2	 system	
(Lewis,	 personal	 communication).	 SDS-PAGE	 gels	 showed	 that	 constructs	 VLR2,	 VLR3	 and	
VLR4	 gave	 expression	 in	 the	 S2	 system,	with	VLR3	 giving	by	 far	 the	best	 expression,	 only	
slightly	 less	than	the	TollN6-VLR	positive	control	expression.	Lack	of	expression	of	the	VLR1	
construct	verifies	that	the	irregularity	of	LRR14	makes	it	unsuitable	for	the	applied	VLR	cap,	
with	 remarkable	 improvement	 in	 expression	 also	 observed	 upon	 truncation	 of	 irregular	
repeat	LRR1.	Bands	for	these	proteins,	detected	by	western	blotting	against	the	Fc	tag,	were	
seen	 to	 run	 with	 an	 apparent	 mass	 of	 around	 150	 kDa,	 running	 slightly	 larger,	 but	
corresponding	approximately	to	VLR	construct	dimers	of	expected	mass	ranging	from	140	-	
160	kDa,	and	126	kDa	TollN6-VLR	(fig	24a).		
As	 constructs	 were	 observed	 to	 run	 at	 a	 slightly	 higher	 mass	 than	 expected,	
attention	 was	 focused	 on	 the	 TollN6-VLR	 hybrid	 construct,	 which	 has	 been	 successfully	
expressed	previously	in	the	lab.	The	aim	of	this	experiment	was	to	verify	overexpression	of	
the	 construct,	 and	 that	 detection	 by	 western	 blot	 was	 not	 a	 high	 molecular	 weight	
background	 signal	 detected	 by	 the	 anti-Fc	 antibody.	 2	 ml	 of	 TollN6-VLR	 test	 expression	
culture	was	obtained	and	purified	by	protein	A	affinity	 chromatography,	exploiting	 the	Fc	
tag	of	the	construct.	Protein	purified	on	protein	A	beads	was	run	on	SDS-PAGE	to	reveal	a	
clean	 band	 at	 the	 expected	 mass	 of	 the	 TollN6-VLR	 construct	 of	 63	 kDa	 under	 reducing	
conditions	(fig	24b).	Western	blot	analysis	verified	this	band	to	be	the	TollN6-VLR	construct	
via	detection	of	the	Fc	tag	of	the	construct	(fig	24c).	A	band	corresponding	to	28	kDa	Fc	tag	
was	also	detected	suggesting	proteolytic	cleavage	of	the	Fc	tag	linker	of	the	construct	in	cell	
supernatant	during	incubation.	Under	non-reducing	conditions,	a	large	signal	was	detected	
at	high	molecular	mass	and	lost	under	reducing	conditions	for	the	Protein	A	purified	sample	
(fig	24c).	This	signal	at	high	molecular	weight	at	a	greater	mass	than	that	observed	during	
test	 expressions	 (fig	 24a).	 The	 large	 molecular	 weight	 signal	 was	 found	 in	 the	 unbound	
fraction	 of	 protein	 as	 well	 as	 appearing	 to	 be	 concentrated	 in	 the	 non-reducing	 bound	
fraction	of	protein	(fig	24c),	however	no	high	molecular	weight	protein	contaminant	can	be	
detected	 by	 Coomassie	 staining.	 This	 approach	 demonstrated	 that	 TollN6-VLR	 could	 be	
expressed	in	S2	cells,	and	purified	from	supernatant	using	Protein	A	beads	in	a	single	step.		
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Figure	 24:	 VLR	 capped	 construct	 test	 expressions.	 Western	 blots	 probed	 with	 anti-Fc	
primary	 antibody	 a:	 Test	 expression	 non-reducing	 conditions,	 15	 mins	 exposure,	 α-Fc	
antibody.	b,	c:	Test	purification	of	TollN6-VLR	from	test	expression	supernatant,	non-reduced	
samples	 except	 where	 stated	 otherwise,	 b:	 Coomassie	 stain.	 c:	 Western	 blot	 5	 min	
exposure,	α-Fc	antibody.	
c	
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3.4	Discussion	
	 Work	described	here	details	two	parallel	approaches	to	generate	soluble	protein	of	
the	 LRR	 domain	 of	 LRRK2.	 This	 includes	 an	 approach	 using	 a	 routine	 domain	 boundary	
prediction	and	optimisation	of	purification;	as	well	as	a	VLR	fusion	approach,	which	makes	
use	 of	 new	 VLR-LRR	 fusion	 technology.	 The	 former	 of	 these	 approaches	 focused	 on	 the	
construct	MBP-LRR6	after	promising	initial	findings	(figs	15,	16,	appendix	poster).		
Results	obtained	from	fresh	MBP-LRR6	baculovirus	mirrored	that	of	previous	work	in	
terms	 of	 protein	 solubility	 and	 behaviour	 during	 nickel	 chromatography.	 Predictable	
behaviour	 and	 sharp	 elution	 from	 a	 nickel	 chelating	 column	 suggests	 that	 if	 protein	 is	
aggregating,	as	suggested	during	downstream	purification	and	analysis,	 it	may	be	doing	so	
after	 initial	 nickel	 binding	 steps.	 In	 an	 attempt	 to	 investigate	 this,	 nickel	 affinity	 purified	
protein	 was	 analysed	 by	 native	 gel	 electrophoresis,	 where	 MBP-LRR6	 formed	 the	 major	
component	of	the	constituent	protein	of	the	0.8	mg/ml	sample,	as	determined	by	SDS-PAGE	
analysis.	 This	 analysis	 suggested	 that	 even	 immediately	 after	 elution	 from	 the	 nickel	
chelating	column,	a	large	aggregate	with	smaller	oligomeric	species	forms;	seen	as	protein	
stuck	 in	 the	 well	 and	 forming	 evenly	 distributed	 bands	 below	 this	 point.	 Analytical	 gel	
filtration	of	protein	purified	by	nickel	and	heparin	affinity	chromatography	confirmed	that	
purified	 protein	 is	 forming	 a	 large	 species	 that	 enters	 the	 column	 void	 volume.	 The	
proportion	 of	 protein	 eluting	 from	 the	 void	 volume	 was	 increased	 by	 concentration	 of	
purified	 protein,	 reaffirming	 that	 protein	 aggregation	 is	 occurring	 that	 is	 responsive	 to	
concentration	 effects.	 Analysis	 by	 SDS-PAGE	 of	 species	 identified	 and	 purified	 during	
analytical	 gel	 filtration,	 confirms	 that	 the	 aggregated	 protein	 is	 MBP-LRR6,	 with	 a	 band	
corresponding	 to	 the	 expected	mass	 of	 full	 length	MBP-LRR6	 that	 can	 be	 TEV	 cleaved	 to	
MBP	and	LRR6.	Protein	aggregation	explains	the	poor	behaviour	of	the	construct	on	anion	
exchange	 media	 and	 heparin	 chromatography.	 Instead	 of	 aggregation	 over	 time,	
aggregation	of	MBP-LRR6	may	occur	from	initial	protein	expression.	Such	aggregation	may	
have	 been	 masked	 from	 nickel	 affinity	 chromatography	 by	 virtue	 of	 the	 fact	 that	 nickel	
binding	 makes	 specific	 use	 of	 the	 His6	 tag	 at	 the	 N-terminus	 of	 the	 protein,	 while	
subsequent	 purification	 methods	 are	 reliant	 on	 the	 overall	 fold	 of	 the	 protein.	 What	 is	
puzzling	is	that	while	behaviour	on	anion	exchange	media	was	common	between	previously	
prepared	 MBP-LRR6	 and	 protein	 generated	 from	 fresh	 baculovirus,	 only	 previous	
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experiments	 utilising	 protein	 generated	 from	 old	 baculovirus	 performed	 predictably	 and	
cleanly	on	heparin;	eluting	as	a	single	species,	as	a	single	sharp	peak	on	the	heparin	elution	
profile	 (fig	 16).	 Specific	 conditions	 for	 protein	 binding	 to	 heparin	were	 investigated	 using	
dialysis	into	different	buffers	with	no	notable	improvement.	One	variable	between	old	and	
new	MBP-LRR6	preps	 is	 the	prep	scale	and	 initial	 lysis	conditions.	As	discussed	previously,	
the	 lysis	 and	 purification	 conditions	 of	 new	 MBP-LRR6	 was	 optimised	 with	 higher	 salt	
concentrations	than	had	been	used	previously.	This	was	necessary	to	decrease	total	extract	
viscosity	to	facilitate	 loading	onto	Ni	chelating	column	for	 initial	purification,	however	 it	 is	
possible	 these	 initial	 lysis	 conditions	 have	 an	 effect	 on	 the	 protein;	 although	 this	 is	 not	
reflected	 in	 the	 behavior	 of	 the	 proteins	 during	 nickel	 affinity	 chromatography.	 The	
possibility	that	disulphide	linkages	between	free	cysteines	was	responsible	for	aggregation,	
especially	 after	 exposure	 to	 the	 oxidizing	 effect	 of	 the	 Ni	 rich	 chelating	 column	 was	
investigated,	 even	 though	 this	 had	 not	 been	 an	 issue	 to	 obtain	 heparin	 binding	 protein	
previously.	The	 introduction	of	 the	 reducing	agent,	2-mercaptoethanol,	had	no	noticeable	
effect	on	protein	yield,	or	aggregation	as	analysed	by	native	gel	electrophoresis.	Ultimately,	
it	would	appear	that	MBP-LRR6	folding	suffers	from	batch	variation	between	preparations;	
an	inherent	weakness	of	baculoviral	protein	expression	in	insect	cells.	Other	LRR	constructs	
with	an	extended	N-terminus	may	prove	more	stable,	and	warrant	expression	trials.	
While	batch-to-batch	variation	 is	an	 issue	with	baculoviral	protein	expression,	such	
an	 expression	 system	was	 considered	necessary	 following	 the	 limited	 success	 of	 bacterial	
systems	 for	 LRR-containing	 Toll	 and	 TLR	 construct	 expression	 by	 our	 lab,	 and	 LRRK2	 LRR	
expression	by	others	 (Vancraenenbroeck	et	al.,	2012).	Protein	production	strains	of	E.	coli	
are	 optimised	 for	 the	 generation	 of	 large	 quantities	 of	 protein	 very	 rapidly,	 with	 crude	
measures	 such	 as	 the	 reduction	 of	 growth	 temperature	 used	 to	 control	 this	 process	 and	
allow	 for	efficient	 folding	 (Rosano	and	Ceccarelli,	2014).	 In	contrast,	 insect	cell	expression	
systems	 make	 use	 of	 higher	 order	 cellular	 quality	 control	 mechanisms	 for	 protein	
production,	and	carry	out	some	post-translational	modifications	that	may	be	important	for	
folding	of	LRR6,	as	 is	known	for	other	human	proteins	(Kost	et	al.,	2005).	Sf9	and	Tn5B1-4	
cell	 lines	 require	 baculoviral	 transfection,	 a	 process	 that	 makes	 insect	 cell	 expression	
significantly	 less	 reproducible	 than	 bacterial	 cell	 expression.	 On	 top	 of	 this,	 insect	 cell	
doubling	time	is	roughly	24	hours	under	optimum	conditions,	compared	to	20	minutes	for	
E.coli;	 this	makes	 insect	 cell	 expression	 a	much	more	drawn	out	 process.	One	method	 to	
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limit	batch	effects	for	the	expression	of	constructs	such	as	MBP-LRR6	is	the	use	of	S2	cells.	
This	consideration	was	taken	into	account	for	the	generation	of	VLR-LRR	hybrid	constructs.	
S2	 cells	 are	 an	 immortalised	 drosophila	 cell	 line	 that	may	 be	 either	 stably	 or	 transiently	
transfected	 for	 inducible	 protein	 expression.	 S2	 cells	 have	 recently	 been	 used	 for	 the	
elucidation	 of	 the	 TLR8	 crystal	 structure	 (Tanji	 et	 al.,	 2013).	 Bulk	 maintenance	 of	 stably	
transfected	 S2	 cultures	 in	 selective	 media	 does	 come	 at	 considerable	 expense,	 and	 is	
comparable	in	methodology	to	mammalian	protein	expression	in	stably	transfected	HEK293	
cells.	Expression	in	HEK293	cells	represents	a	future	direction	in	which	LRR	expression	may	
be	 taken,	 as	 constructs	 were	 cloned	 from	 human	 cDNA,	 and	 so	 may	 require	 cofactors,	
chaperones,	 post-translational	modifications,	 and	 folding	 quality-control	mechanisms	 that	
are	not	available	even	in	insect	cells.	Dependence	of	LRRK2	on	chaperones	for	stabilisation	
has	been	demonstrated	via	an	interaction	with	‘heat-shock	protein	90’	(HSP90)	and	14-3-3	
(Wang	et	al.,	2008;	Nichols	et	al.,	2010).	While	 the	LRR6	construct	excludes	 the	S910	and	
S935	major	interaction	sites	of	14-3-3,	a	more	extended	N-terminal	domain	boundary	could	
be	 designed	 to	 incorporate	 both	 of	 these	 phosphorylation	 sites	 (Stevers	 et	 al.,	 2017).	
Expression	 of	 a	 construct	 containing	 residues	 S910	 and	 S935	 may	 benefit	 from	 co-
expression	 of	 the	 14-3-3	 chaperone.	 A	 short	 peptide	 containing	 S910	 and	 S935	 was	
sufficient	 to	 bind	 14-3-3	 during	 in	 vitro	 assays,	 suggesting	 the	 absence	 of	 S1444	 in	 these	
constructs	may	not	entirely	negate	potential	stabilising	effects	of	14-3-3	binding	(Stevers	et	
al.,	 2017).	 Interaction	 of	 LRRK2	 has	 also	 been	 shown	 with	 ‘heat	 shock	 chaperone	 70’	
(HSC70),	 a	 constitutively	 expressed	 eukaryotic	 chaperone,	 directly	 involved	 in	 protein	
folding	at	the	ribosome	(Young	et	al.,	2004;	Orenstein	et	al.,	2013).	An	alternative	approach	
for	LRR	protein	expression,	as	proved	successful	in	the	expression	of	TLR	ectodomains,	is	to	
re-clone	 the	 LRR	 domain	 of	 LRRK2	 from	 alternative	 species.	 Expression	 of	 non-human	
orthologous	 LRRK2	 may	 be	 performed	 independently,	 or	 in	 combination	 with	 use	 of	
mammalian	protein	expression.	
A	 recent	 molecular	 model	 of	 the	 full-length	 LRRK2	 protein	 has	 been	 developed	
through	 the	 use	 of	 biochemical	 restraints	 provided	 by	 evidence	 such	 as	 the	 Roc	 domain	
crystal	 structure	 (Deng	 et	 al.,	 2008),	 negative-stain	 electron	 microscopy,	 biochemical	
crosslinking,	 homology	 modelling,	 and	 small	 angle	 X-ray	 scattering	 to	 predict	 the	
organisation	and	packing	of	the	full	length	LRRK2	dimer	(Guaitoli	et	al.,	2016).	Strikingly,	this	
model	 of	 LRRK2	 has	 revealed	 how	 tightly	 packed	 the	 various	 domains	 of	 LRRK2	 are	
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predicted	 to	 be,	 forming	 a	 compact	 bundle	 with	 many	 domain-domain	 interactions	 as	
opposed	 to	 following	 a	 ‘bead-on-a-string’	 archetype	 (fig	 25).	 Such	 a	model	 suggests	 that	
small	 conformational	 changes	 in	 one	 domain	 from	 ligand	or	 protein-binding	 events	 could	
have	dramatic	effects	on	LRRK2	function,	and	that	potential	protein-binding	domains,	such	
as	 LRR	 or	 WD40	 domains,	 can,	 for	 example,	 bring	 substrates	 into	 close	 proximity	 for	
phosphorylation	 by	 the	 kinase	 domain.	 This	 model	 has	 subsequently	 had	 a	 level	 of	
verification	provided	by	a	low-resolution	16	Å	electron	microscopy	study,	revealing	a	similar	
‘envelope’	to	that	which	had	been	modeled.	Unfortunately	the	resolution	provided	by	this	
study	was	too	low	to	accurately	place	individually	modeled	domains	(Sejwal	et	al.,	2017).		
From	a	biophysical	point	of	view,	the	close	interactions	between	domains	could	help	explain	
difficulties	 in	 expressing	 individual	 domains	 for	 structural	 analysis.	 This	 is	 because	
physiologically	 expressed	 full-length	 protein	would	 be	 expected	 to	 be	 stabilised	 by	 inter-
domain	 interactions,	 while	 ectopically	 expressed	 individual	 domains	 will	 not.	 Indeed,	 an	
attempt	 in	2012	 to	express	 the	LRR	domain	of	 LRRK2	necessitated	 the	use	of	 zwitterionic	
detergents	 to	overcome	aggregation	 speculated	 to	occur	due	 to	exposed	hydrophobics	of	
the	domain.	This	detergent,	 ‘Empigen	BB’	formed	large	micelles	to	stabilize	these	exposed	
hydrophobic	 patches,	 but	 in	 doing	 so	 compromised	 their	 ability	 to	 perform	 useful	
biophysical	 analysis	 on	 the	 soluble	 protein	 obtained	 (Vancraenenbroeck	 et	 al.,	 2012).	
Questions	must	 also	 be	 raised	 over	 the	 usefulness	 of	 protein	 generated	 this	way,	 as	 the	
need	to	artificially	mask	hydrophobic	patches	does	suggest	at	least	a	degree	of	protein	mis-
folding,	which	would	not	reflect	LRRK2	in	its	native	state.	One	hindrance	of	studying	a	non-
Figure	 25:	 Structural	 model	 of	 dimeric	 LRRK2	 model	 reveals	 a	 compact	 architecture	
involving	 distant	 interdomain	 contacts.	 Taken	 directly	 from	 Guaitoli	 et	 al.,	 2016.	 ARM	 =	
Armadillo	repeats,	ANK	=	Ankyrin	repeats,	LRR	=	Leucine	rich	repeats,	Roc	=	Ras	of	complex	
proteins,	COR	=	C-terminal	of	Roc,	KIN	=	Kinase.	
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enzymatic	 protein	 domain	 is	 the	 inability	 to	 experimentally	 test	 the	 function	 of	 purified	
protein	to	ascertain	the	correctness	of	folding.	The	construct	used	by	Vancraenenbroeck	et	
al	was	designed	with	an	N-terminus	at	Y983	of	LRRK2;	only	 three	 residues	away	 from	the	
E980	of	the	LRR6	construct	described	in	the	present	study,	and	a	C-terminus	lying	very	close	
to	the	predicted	14th	LRR	of	LRRK2	made	in	this	study.	
It	 is	 possible	 that	 MBP-LRR6	 as	 well	 as	 the	 construct	 of	 Vancraenenbroeck	 et	 al.	
experienced	a	 lack	of	 solubility	 through	 the	exposure	of	 the	hydrophobic	 core	of	 the	 LRR	
solenoid	 at	 the	 terminal	 repeats	 which	 were	 not	 appropriately	 capped	 by	 neighboring	
domains	or	secondary	structure	elements.		The	use	of	VLR-capped	LRR	constructs	provides	
an	alternative	to	trial	and	error	probing	of	such	domain	boundary	considerations	or	the	use	
of	strong	additives	such	as	Empigen	BB	(Jin	and	Lee,	2008b).	The	strength	of	VLR	capping	as	
a	 technique,	 is	 the	 introduction	 of	 a	 known	 and	 well-characterized	 element	 to	 seal	 the	
individual	LRRs	to	which	the	fusion	is	made.	The	introduction	of	a	VLR	cap	is	not	expected	to	
perturb	the	3D	architecture	of	the	LRRs	to	which	the	VLR	has	been	fused.	Evidence	for	this	
comes	from	initial	use	of	VLR	fusions	in	the	generation	of	TLR4,	TLR2	and	TLR1	hybrids	with	
VLR	capping	structures.	Multiple	hybrids	were	generated	of	these	proteins,	using	different	
VLR	 capping	 structures.	 Resulting	 crystal	 structures	 showed	 very	 little	 variation	 in	 LRR	
structure	between	different	 hybrids	 for	 each	 TLR	molecule	 (Kim	et	 al.,	 2007;	 Jin	 and	 Lee,	
2008b).	 VLR	 hybrids	 have	 previously	 been	 used	 to	 express,	 solubilise	 and	 crystallise	 LRR	
domains	 from	 extracellular,	 but	 not	 intracellular	 proteins.	 Differences	 in	 LRR	 regularity	
account	 for	 varying	 success	 of	 the	 application	 of	 VLRs	 to	 LRR-containing	 proteins.	 This	 is	
reflected	 in	 different	 truncations	 of	 the	 LRRK2	 LRR	 domain	 by	 the	 VLR-LRR	 constructs	
described	 here;	 as	 the	 VLR3	 construct,	 which	 corresponds	 to	 fusion	 of	 one	 of	 the	 most	
regular	 predicted	 LRRs,	 resulted	 in	 the	 greatest	 protein	 expression	 of	 constructs	 trialed,	
while	constructs	incorporating	the	highly	irregular	N-terminal	repeat	gave	almost	no	protein	
expression.	Further	work	is	now	required	to	build	upon	this.		
While	 VLR	 capped	 constructs	 may	 overcome	 issues	 with	 LRR	 domain	 boundary	
prediction,	another	approach	is	to	attempt	full-length	protein	expression.	Such	expression	is	
made	difficult	 for	extremely	 large	proteins	 such	as	 LRRK2	by	proteolytic	degradation,	 and	
the	 need	 to	 optimise	 expression	 conditions	 under	 which	 the	 whole	 protein	 may	 be	
successfully	folded.	These	difficulties	of	expressing	full-length	LRRK2	are	demonstrated	in	a	
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recent	study	using	a	mammalian	HEK293	expression	system	(Sejwal	et	al.,	2017).	Negative	
stain	 transmission	 electron	 microscopy	 revealed	 that	 expressed	 full-length	 LRRK2	
aggregated	 into	 globular	 particles	 of	 various	 sizes	 without	 the	 use	 of	 detergents	 for	
stabilisation	of	hydrophobic	surfaces,	and	that	even	in	the	presence	of	stabilising	detergent,	
heterogeneity	 of	 LRRK2	 protein	 could	 still	 be	 observed.	 In	 spite	 of	 these	 limitations,	 this	
study	 represents	a	big	 step	 forward	 in	 the	expression	of	 full-length	 LRRK2.	Refinement	of	
this	approach	may	well	pave	 the	way	 for	 LRRK2	structural	 studies,	especially	given	 recent	
advances	 in	 the	 generation	 of	 high-resolution	 structures	 by	 cryo-electron	 microscopy	 of	
macromolecules	 (Frank,	 2017).	 Having	 said	 this,	 such	 results	 also	 demonstrate	 that	 bulk	
expression	 of	 full	 length	 LRRK2	 is	 currently	 not	 able	 to	 generate	 protein	 homogenous	
enough	 for	 biophysical	 studies.	 In	 comparison,	 expression	 of	 full-length	 LRRK2	 as	 part	 of	
‘standard’	tissue	culture	experiments	typically	results	in	yields	incompatible	to	biochemical	
and	 structural	 analysis	 techniques	 such	 as	 Biacore	 ligand	 binding	 assays,	 or	 X-ray	
crystallography.	These	considerations	in	conjunction	with	the	inherent	difficulties	associated	
with	the	expression	of	proteins	as	large	as	LRRK2	account	for	the	focus	paid	upon	individual	
domain	 expression	 during	 this	 project.	 The	 on-going	 establishment	 of	 a	 non-adherent	
HEK293	 cell	 line,	 in	 combination	with	 a	WAVE	 bioreactor	will	make	 the	mammalian	 bulk	
expression	of	full-length	LRRK2	within	the	lab	a	viable	option	for	the	near	future.	
Purification	 of	 the	 LRR6	 construct	 proved	 unsuccessful,	 however	 results	 described	
here	 do	 verify	 that	 VLR	 capped	proteins	 can	 be	 successfully	 expressed	 and	purified	 in	 an	
insect	 cell	 expression	 system.	More	 specifically,	 careful	 analysis	 of	 the	 LRRs	 of	 the	 LRRK2	
LRR	 domain	 has	 allowed	 the	 cloning	 of	 VLR	 capped	 constructs	 for	 insect	 cell	 expression.	
Truncation	 of	 irregular	 repeats	 found	 at	 the	 extremities	 of	 the	 LRR	 domain	 improved	
expression	levels,	corresponding	with	a	predicted	improvement	of	fit	for	the	VLR	cap	to	the	
LRR.	These	constructs	have	been	cloned	into	expression	vectors	for	S2	cells,	or	baculoviral	
expression	 in	Sf9	 cells.	 Together	with	 the	more	conventional	 constructs	designed	 through	
exploration	of	LRR	domain	boundaries;	a	range	of	constructs	have	been	generated	for	the	
continued	expression	 and	purification	 trials	 of	 the	 LRR	domain	of	 LRRK2,	 and	 initial	 steps	
towards	protein	characterisation	of	protein	expression	have	been	 taken.	These	constructs	
and	 the	 LRR	 characterisation	 that	 has	 gone	 into	 the	 design	 of	 constructs	 will	 facilitate	
progress	towards	physical	analysis	of	the	LRR	domain	of	LRRK2.	
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4.	 Investigating	 the	 role	of	 LRRK2	 in	 immune	 receptor	 trafficking	
and	cytoskeletal	dependent	processes	using	primary	macrophages		
4.1	Aims	
- Characterise	primary	WT	and	LRRK2	KO	bone	marrow	derived	macrophages	
for	LRRK2	expression	and	innate	immune	inducibility.	
- Assess	the	role	of	LRRK2	on	expression	and	trafficking	of	TLR4	and	TLR2.	
- Utilise	LRRK2	KO	macrophages	to	clarify	the	role	of	LRRK2	on	phagocytosis,	in	
a	range	of	innate	immune	contexts.	
4.2	Background	
	 LRRK2	 is	 expressed	 in	 both	 cells	 of	 the	 innate	 immune	 system	 and	 the	
nervous	 system	 (Maekawa	 et	 al.,	 2010).	 There	 is	 a	 growing	 appreciation	 of	 the	
overlap	between	 the	 functions	of	 these	 two	 systems,	which	have	historically	been	
considered	to	be	 largely	separated;	a	concept	termed	‘immune	privilege’.	 It	 is	now	
known	 that	 both	 resident	 immune	 cells	 in	 the	 brain,	 and	 infiltrating	 immune	 cells	
circulating	 from	 the	 blood	 play	 a	 role	 in	moulding	 the	 brain	 in	 health,	 but	 also	 in	
disease	(Wolf	et	al.,	2017).			
The	fact	that	LRRK2	mutations	are	a	genetic	cause	of	Parkinson’s	disease,	and	
that	 the	 protein	 has	 apparent	 functions	 in	 both	 a	 neuronal	 and	 immunological	
context,	makes	 it	 a	 particularly	 interesting	 case	 study	 of	 neuroinflammation.	 That	
said,	the	wide	role	of	LRRK2	may	also	be	confounding;	many	functions	of	LRRK2	have	
been	 described,	 but	 it	 is	 unlikely	 that	 all	 of	 these	 are	 truly	 the	 route	 of	 LRRK2	
mutation	 pathogenicity	 –	 so	 are	mutations	 of	 LRRK2	more	 relevant	 to	 Parkinson’s	
disease	pathology	 in	an	 inflammatory	or	neuronal	 context?	The	discovery	 that	 the	
commonly	used	LRRK2	kinase	inhibitor,	L2in1,	is	highly	non-specific	and	inhibited	off-
target	 innate	 immune	 signalling	 proteins	 such	 as	 ERK5	 suggested	 that	 disease	
relevance	may	be	 found	 in	 neuronal	 cells;	where	many	described	 LRRK2	 functions	
still	hold	true	(Luerman	et	al.,	2014).	That	said,	interesting	immunological	effects	of	
LRRK2	 have	 subsequently	 been	 described	 that	 are	 independent	 of	 L2in1,	many	 of	
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which	 have	 been	 discussed	 previously.	 Work	 described	 here	 attempts	 to	 explore	
ways	in	which	LRRK2	interactions	and	cellular	effects	discovered	biochemically	or	in	
a	 neuronal	 cell	 context	 may	 be	 relevant	 to	 immunological	 processes.	 This	 was	
achieved	 by	 investigating	 the	 role	 of	 LRRK2	 in	 immune	 receptor	 trafficking	 and	
phagocytosis.	
LRRK2	regulates	vesicular	trafficking	in	neurons	
One	reported	 function	of	LRRK2	 is	 in	 the	process	of	vesicular	 trafficking.	As	
discussed	 previously,	 neuronal	 morphology	 and	 functional	 specialisation	 places	
extreme	demands	on	many	aspects	of	cell	biology.	Such	demands	 include	vesicular	
trafficking,	as	proteins	and	lipids	generated	at	the	cell	body	require	transport	along	
extremely	extended	neuronal	axons,	 to	 synapses	at	 the	 cell	periphery	 (Millecamps	
and	Julien,	2013).	The	strongest	link	between	LRRK2	and	vesicular	trafficking	may	lie	
in	the	process	of	autophagy.	Autophagy	is	a	process	that	is	fundamentally	reliant	on	
a	 functional	 vesicular	 trafficking	 system;	 with	 the	 autophagosome	 essentially	 a	
highly	 specialised	 vesicle	 optimised	 for	 protein	 degradation.	 The	 formation	 of	 the	
autophagosome	relies	upon	maturation	processes	involving	the	initial	nucleation	of	
a	 phagophore,	 elongation	 around	 a	 target	 molecule,	 and	 targeted	 delivery	 of	
endosomal	and	lysosomal	vesicles	during	maturation	(Glick	et	al.,	2010).	LRRK2	has	
been	associated	with	changes	 in	autophagic	markers,	as	well	as	resulting	substrate	
degradation	 and	 neuronal	 morphological	 changes;	 these	 processes	 have	 been	
discussed	in	detail	previously	(Herzig	et	al.,	2011;	Sánchez-Danés	et	al.,	2012;	Tong	et	
al.,	 2012).	 Here	 LRRK2	 interactions	 that	 modulate	 the	 trafficking	 events	 that	
underpin	autophagy	and	vesicular	transport	as	a	whole	will	be	discussed.	
Vesicular	 trafficking	 is	 regulated	 by	 small	 GTPases	 known	 as	 Rab	 proteins.	
Rab	GTPases	 attach	 to	 vesicular	membranes	by	 a	 covalently	 bonded	 lipid	 tail,	 and	
modulate	the	trafficking	of	the	vesicle	to	which	they	are	attached.	Combinations	of	
Rab	 proteins	 attach	 to	 vesicles	 over	 time,	 resulting	 in	 the	 programming	 of	 a	 path	
through	 which	 that	 vesicle	 will	 travel.	 For	 example,	 early	 endosomes	 expressing	
Rab5	 can	 mature	 into	 Rab7	 expressing	 late	 endosomes,	 which,	 in	 the	 context	 of	
autophagy,	may	fuse	with	the	autophagosome,	or	may	be	recycled	to	the	golgi	in	a	
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process	 involving	Rab9	and	 the	 retromer	complex	 (Lombardi	et	al.,	 1993;	Vieira	et	
al.,	2003).	In	the	other	direction,	Rab8	is	involved	in	regulating	vesicle	transport	from	
the	golgi	network	to	the	plasma	membrane	(Huber	et	al.,	1993).	There	are	over	60	
known	members	of	the	Rab	family	of	GTPases,	demonstrating	the	overall	complexity	
of	 this	 process	 (Stenmark,	 2009).	 LRRK2	was	 initially	 shown	 to	 interact	with	 Rab5	
(Shin	et	al.,	2008;	Yun	et	al.,	2015),	then	later	Rab32	was	identified	as	an	interaction	
partner	 (Waschbüsch	 et	 al.,	 2014).	 	 Subsequently,	 interactions	 have	 been	 shown	
with	 a	 whole	 range	 of	 Rab	 proteins.	 A	 phosphoproteomic	 screen	 has	 identified	 a	
subset	of	Rabs	as	LRRK2	ligands.	Phosphorylation	of	these	Rabs	was	increased	by	the	
G2019S	pathogenic	mutation	of	 LRRK2	 (Steger	et	 al.,	 2016).	 Identified	Rabs	 in	 this	
study	 included	 Rab10,	 Rab8a,	 Rab1a	 and	 Rab1b	 which	 each	 contain	 a	 conserved	
Thr73	phosphorylation	site	at	the	GTPase	switch	II	region	for	LRRK2	phosphorylation.	
Rabs	 with	 a	 serine	 residue	 at	 this	 switch	 II	 region	 were	 less	 efficiently	
phosphorylated;	a	 finding	which	 is	 in	 line	with	previous	reports	of	LRRK2	substrate	
preference	 for	 threonine	 residues	 (Kamikawaji	 et	 al.,	 2009;	Webber	 et	 al.,	 2011).	
Rab7L1	has	also	been	identified	as	a	further	LRRK2	interaction	partner	(Beilina	et	al.,	
2014).	 This	 is	 interesting	 as	 Rab7L1	 has	 been	 identified	 as	 a	 risk	 factor	 for	
Parkinson’s	disease	independently	of	LRRK2;	suggesting	the	possibility	of	a	common	
pathogenic	 mechanism	 (Nalls	 et	 al.,	 2014).	 Furthermore,	 deficiency	 of	 Rab7L1	 or	
LRRK2	leads	to	common	golgi	sorting	defects,	and	a	deficiency	of	VPS35;	which	can	
otherwise	 be	 immunoprecipitated	 with	 LRRK2	 (MacLeod	 et	 al.,	 2013).	 VPS35	 is	 a	
component	of	 the	 retromer	complex,	 involved	 in	endosomal/golgi	 sorting,	and	has	
been	linked	to	a	rare	form	of	Parkinson’s	disease	independently	of	LRRK2	(Vilariño-
Güell	 et	 al.,	 2011;	 Zimprich	 et	 al.,	 2011;	 Zavodszky	 et	 al.,	 2014).	 The	 LRRK2-Rab	
interactions	 described	 above	 have	 been	 linked	 to	 perturbations	 of	 autophagy	
(Beilina	et	al.,	2014;	Kuwahara	et	al.,	2016)	synaptic	vesicle	endocytosis	(Shin	et	al.,	
2008;	Arranz	et	al.,	2015),	neuron	axonal	elongation	(Kuwahara	et	al.,	2016),	and	the	
retromer	protein-sorting	pathway	(MacLeod	et	al.,	2013).		
	 A	 further	 connection	 between	 LRRK2	 and	 vesicular	 dynamics	 exists	 in	
EndophilinA.	 LRRK2	 has	 been	 shown	 phosphorylate	 EndophilinA	 at	 S75,	 a	 residue	
thought	 to	 be	 important	 for	 EndophilinA	 interaction	 with	 the	 cell	 membrane.	
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EndophilinA	 is	 enriched	 at	 pre-synaptic	 terminals,	 where	 its	 phosphorylation	 is	
thought	 to	 induce	 or	 detect	 membrane	 curvature,	 and	 drive	 vesicular	 formation.	
Either	 an	 increase	 or	 a	 decrease	 in	 EndophilinA	 S75	 phosphorylation	 by	 LRRK2	 is	
thought	to	adversely	affect	vesicle	formation	and	synaptic	endocytosis	(Matta	et	al.,	
2012;	Arranz	et	al.,	2015).	 Interestingly,	EndophilinA	S75	phosphorylation	by	LRRK2	
has	 subsequently	 been	 shown	 to	 induce	 not	 just	 endocytosis,	 but	 also	
macroautophagy	 by	 allowing	 the	 docking	 of	 autophagic	 proteins	 at	 presynaptic	
terminal	membranes	curved	by	EndophilinA	(Soukup	et	al.,	2016).	
TLR	localisation	is	regulated	by	trafficking	events	
	 Vesicular	trafficking	is	important	in	all	cell	types,	including	those	of	the	innate	
immune	 system.	 For	 instance,	 one	 level	 of	 regulation	 of	 TLR	 signalling	 is	 receptor	
localisation	and	trafficking.	At	the	most	basic	level	TLRs	1,	2,	4,	5	and	6	are	found	at	
the	cell	surface	for	the	detection	of	extracellular	bacterial	PAMPs	(Gay	et	al.,	2014),	
while	 TLRs	 3,	 7,	 8,	 and	 9	 are	 localised	 to	 the	 endosomal	 compartment	 for	 the	
recognition	of	nucleic	acids	(Gay	et	al.,	2014).	Of	these,	work	here	focuses	on	TLR4	
and	TLR2.		
TLR4	 is	 localised	 at	 the	 cell	membrane	 as	 a	 heterodimer	with	MD2,	 and	 is	
internalised	to	the	endosome	upon	ligand	binding	(Akira	and	Takeda,	2004).	At	the	
cell	 surface,	 TLR4	 signals	 through	 the	 signalling	 adaptor	 proteins	 Myd88	 and	
‘MyD88-adapter-like’	 (MAL).	 Within	 the	 endosomal	 compartment,	 signalling	 is	
achieved	 through	 the	 ‘TIR	domain-containing	adaptor	protein	 inducing	 IFNβ’	 (TRIF)	
adaptor	 protein.	 The	 result	 of	 this	 is	 that	 changes	 of	 TLR4	 localisation	 affect	
downstream	 signalling,	 with	 immunological	 implications	 (Kagan	 et	 al.,	 2008).	 The	
trafficking	 of	 TLR4	 in	 particular	 has	 been	 of	 particular	 interest	 since	 the	
characterisation	 of	 ‘transmembrane	 emp24	 domain-containing	 protein	 7’	 (TMED7)	
as	 an	 adaptor	 for	 TLR4	 packaging	 at	 the	 endoplasmic	 reticulum,	 for	 trafficking	
towards	the	cell	membrane	via	the	golgi	apparatus	(Liaunardy-Jopeace	et	al.,	2014).	
Termination	of	TLR4	signalling	 is	achieved	by	 internalisation	of	 receptor	complexes	
into	lysosomes	for	degradation	upon	ligand	binding	(Husebye	et	al.,	2006).	Rab10,	a	
reported	 substrate	 for	 LRRK2,	 regulates	 trafficking	 of	 TLR4	 from	 the	 golgi	 to	 the	
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plasma	membrane;	an	 important	process	 required	 to	 replenish	 surface	TLR4	 levels	
(Wang	et	al.,	2010).	Rab11a	has	been	shown	to	be	fundamental	to	TLR4	trafficking	
dynamics,	 in	 particular	 for	 localisation	 of	 TLR4	 to	 E.	 coli	 phagosomes,	 and	 the	
resulting	 ‘interferon	 regulatory	 factor	 3’	 (IRF3)	 signalling	 with	 downstream	
interferon-β	 induction	(Husebye	et	al.,	2010).	CD14,	a	pattern	recognition	receptor	
for	LPS,	is	also	implicated	in	regulating	TLR4	endocytosis,	and	IRF3	activation	(Zanoni	
et	al.,	2011).	It	is	interesting	to	note	that	Rab8a,	another	reported	LRRK2	ligand,	has	
been	suggested	to	regulate	Phosphoinositide	3-kinase	(PI3K)/Akt	signalling	 induced	
by	 cell	 surface	 localised	 TLR4	 (Luo	 et	 al.,	 2014).	 These	 examples	 demonstrate	 a	
pattern	 recognition	 receptor	 modulating	 TLR4	 trafficking,	 while	 a	 Rab	 GTPase	
modulates	 TLR4	 signalling	 directly	 from	 the	 cell	 surface;	 suggesting	 TLR	 signalling	
and	localisation	are	intimately	linked	(fig	26).		 	
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Figure	26:	Simplified	scheme	of	TLR4	vesicular	trafficking	and	implications	for	inflammatory	
signalling.	 TLR4	 signals	 via	 Mal/Myd88	 at	 the	 cell	 surface,	 and	 TRAM/TRIF	 in	 endosomal	
compartments.	 Trafficking	 of	 TLR4	 is	 regulated	 by	 Rab	 proteins,	 with	 implications	 on	
inflammatory	 signalling,	 but	 also	 signal	 termination	 via	 proteosomal	 degradation	 of	 TLR4	
complexes,	and	replenishment	of	TLR4	to	the	cell	surface.		
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In	comparison	to	TLR4,	the	dynamics	of	TLR2	trafficking	are	little	understood.	
TLR2	 can	 form	 functional	 heterodimers	 with	 TLR1	 and	 TLR6,	 and	 interacts	 with	 a	
variety	 of	 non-TLR	 accessory	 proteins	 that	 influence	 ligand	 recognition.	 Overall,	
these	 factors	 contribute	 to	 an	 exceptionally	 broad	 TLR2	 ligand	 specificity.	
Lipoproteins	 and	 lipopeptides	 are	 considered	 canonical	 TLR2	 ligands,	 however	 a	
plethora	of	further	proteins	and	polysaccharides	have	also	been	described	(Oliveira-
Nascimento	et	al.,	2012).	TLR2	is	classically	considered	to	signal	from	the	cell	surface,	
however	 internalisation	 and	 trafficking	 of	 TLR1/2	 and	 TLR2/6	 heterodimers	 to	 the	
golgi	has	been	shown	to	occur	in	response	to	binding	of	triacylated	lipoproteins,	or	
either	of	 lipoteichoic	acid	 (LTA)	or	diacylated	 lipoproteins	 respectively	 (Triantafilou	
et	 al.,	 2006).	 Therefore,	 there	 is	 some	 similarity	 between	 TLR2	 and	 TLR4	 dynamic	
trafficking	 (Latz	 et	 al.,	 2002).	 For	 TLR2	 however,	 evidence	 suggests	 that	
internalisation	 is	 not	 required	 for	 TLR2	 signalling	 (Trianiafilou	 et	 al.,	 2004;	
Triantafilou	 et	 al.,	 2006).	 Indeed,	 recent	 evidence	 suggests	 that	 while	 TLR2	
heterodimers	are	endocytosed	after	binding	LTA	or	bacteria,	this	process	is	actually	
inhibitory	 to	 TLR2	 signalling	 (Nilsen	 et	 al.,	 2008).	 Of	 particular	 interest	 to	
neuroinflammation	 and	 Parkinson’s	 disease,	 the	 inflammatory	 response	 to	 alpha-
synuclein	 oligomers	 is	 thought	 to	 be	 mediated	 through	 TLR1/2	 heterodimers	
(Daniele	et	al.,	2015),	with	amelioration	of	inflammation	evident	in	TLR2	knock	down	
animals	(Kim	et	al.,	2014).	It	has	also	been	observed	that	TLR2	inhibition	can	prevent	
alpha-synuclein	 accumulation	 by	 promoting	 autophagy,	 and	 clearance	 of	 alpha-
synuclein	aggregates	(Kim	et	al.,	2015).	
To	 summarise,	 there	 is	 extensive	 involvement	 of	 LRRK2	 in	 modulating	 the	
cellular	 trafficking	 machinery,	 in	 particular	 via	 interactions	 with	 a	 range	 of	 Rab	
proteins.	This	machinery	is	involved	in	the	trafficking	of	TLRs	generally,	but	also	the	
highly	dynamic	 trafficking	of	 TLR4	 in	 response	 to	 ligand	 recognition	 that	occurs	 as	
part	 of	 the	 macrophage	 innate	 immune	 response.	 TLR2	 similarly	 undergoes	
trafficking	 upon	 ligand	 recognition	 as	 part	 of	 a	 less	 well-characterised	 process.	 It	
stands	 to	 reason	 that	 LRRK2	may	modulate	TLR	 localisation	and	dynamics	 through	
interactions	with	the	cellular	trafficking	machinery.	
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LRRK2	regulates	the	cytoskeleton	and	cytoskeletal	dynamics	in	neurons	
	 An	extensively	documented	function	of	LRRK2	in	neurons	is	the	regulation	of	
axonal	elongation	and	axonal	branching.	Perturbation	of	 this	process	 is	 thought	 to	
be	 neurotoxic	 due	 to	 the	 extreme	 energetic	 demands	 placed	 in	 particular	 on	
dopaminergic	 neurons	 (Cavanagh,	 1984;	 Bolam	 and	 Pissadaki,	 2012).	 Axonal	
elongation	 and	 cell	 morphology	 more	 generally	 are	 dependent	 on	 the	 cell	
cytoskeleton,	 a	 network	 consisting	 of	 three	 elements:	 intermediate	 filaments,	
microtubules,	and	actin	 (Fletcher	and	Mullins,	2010).	Neurofilaments	are	a	class	of	
intermediate	filaments	 in	neurons	 in	which	microtubules	are	embedded.	 It	 is	along	
these	microtubules	 that	 the	majority	 of	 vesicular	 transport	 proceeds.	 Advances	 in	
super-resolution	microscopy	have	revealed	that	regularly	spaced	rings	of	actin	exist	
along	 the	 length	of	 the	axon,	 linked	by	 the	protein	adaptor,	 spectrin	 (Zhong	et	al.,	
2014).	 These	 structures	 are	 relatively	 static,	 providing	 a	 physical	 framework	 for	
neurons.	During	neurogenesis,	dynamic	actin	structures	are	responsible	for	continual	
guidance	 of	 the	 extending	 neuronal	 axon	 in	 response	 to	 environmental	 cues	
(Strasser	et	al.,	2004).	A	 further	neuronal	phenotype	of	LRRK2	perturbation	can	be	
seen	in	a	reduction	in	the	number	of	dendritic	spines	in	neurons	expressing	G2019S	
LRRK2	 (Winner	 et	 al.,	 2011;	 Häbig	 et	 al.,	 2013).	 Dendritic	 spines	 form	 the	
postsynaptic	 part	 of	 most	 excitatory	 synapses,	 and	 like	 the	 extending	 axon,	 are	
primarily	 composed	 of	 highly	 dynamic	 actin.	 Mechanisms	 of	 actin	 regulation	 are	
described	as	“integral	to	the	formation,	maturation,	and	plasticity	of	dendritic	spines	
and	 to	 learning	 and	 memory”	 (Hotulainen	 and	 Hoogenraad,	 2010).	 That	
perturbations	 to	 the	 actin	 of	 dendritic	 spines	 alone	 affects	 so	many	 neuronal	 and	
behavioural	properties	demonstrates	how	important	the	interactions	of	LRRK2	with	
the	 cytoskeleton	 may	 be.	 LRRK2	 has	 been	 shown	 to	 interact	 both	 directly	 and	
indirectly	with	the	cellular	cytoskeleton.	
	 Direct	 interactions	 have	 been	 shown	 between	 LRRK2	 and	 microtubules,	
facilitated	 by	 the	 Roc	 domain	 of	 LRRK2	 (Gandhi	 et	 al.,	 2008).	 Parkinson’s	 disease	
associated	 mutant	 forms	 of	 LRRK2	 have	 been	 described	 as	 preferentially	 forming	
filamentous	structures	linked	to	microtubules;	interestingly	the	commonly	described	
G2019S	mutant	was	 an	 exception	 to	 this	 (Kett	 et	 al.,	 2012).	 Later	work	 has	 found	
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that	genetic	knockout	of	LRRK2	led	to	increased	microtubule	acetylation,	resulting	in	
neuronal	growth	cone	defects	(Law	et	al.,	2014).	In	another	study,	LRRK2	containing	
GTPase	 mutations	 showed	 increased	 association	 with	 deacetylated	 microtubules,	
and	associated	deficits	in	axonal	transport.	Acetylation	of	microtubules	via	inhibition	
or	genetic	knockdown	of	 cellular	deacetylases	was	 sufficient	 to	 rescue	both	LRRK2	
microtubule	association,	and	axonal	 transport	 (Godena	et	al.,	2014).	β-tubulin	was	
also	 found	 to	 be	 phosphorylated	 by	 LRRK2,	 leading	 to	 microtubule	 stabilisation	
(Gillardon,	 2009).	 Further	 LRRK2	 associations	 exist	 with	 the	 cytoskeleton	 through	
interaction	 with	 cytoskeletal	 adaptor	 proteins.	 Tau	 decorates	 microtubules	 under	
homeostatic	 conditions,	 resulting	 in	 a	microtubule	 stabilising	 effect	 and	 enhanced	
axonal	transport.	Tau	can	be	found	to	be	hyper-phosphorylated	and	associated	with	
Lewy	body	pathology	during	Parkinson’s	disease	 (Lei	et	al.,	2010).	Multiple	 reports	
suggest	 LRRK2	 contributes	 to	 Tau	 hyper-phosphorylation	 (Kawakami	 et	 al.,	 2012;	
Bailey	et	al.,	2013)	while	also	promoting	accumulation	and	aggregation	of	Tau	 into	
toxic	 protein	 inclusions	 (MacLeod	 et	 al.,	 2006;	 Guerreiro	 et	 al.,	 2016).	 A	 further	
report	 suggests	 phosphorylation	 of	 Tau	 is	 promoted	 by	 the	 G2019S	 over-active	
kinase	mutant	 of	 LRRK2	 via	 GSK3β,	 but	 did	 not	 find	 evidence	 showing	 Tau	 to	 be	
directly	phosphorylated	by	LRRK2	(Lin	et	al.,	2010).	
In	 contrast	 to	 direct	 microtubule	 interactions,	 LRRK2	 influences	 actin	
dynamics	 indirectly,	 through	 a	 number	 of	 actin	 interacting	 proteins	 and	 dynamic	
regulators.	 The	 ERM	 proteins,	 Ezrin,	 Moesin	 and	 Radixin,	 have	 been	 discussed	
previously	as	substrates	for	LRRK2,	and	are	the	basis	for	the	generation	of	‘LRRKtide’,	
an	artificial	substrate	for	LRRK2	(Jaleel	et	al.,	2007).	The	ERM	family	of	proteins	are	
phosphorylated	by	LRRK2	at	a	conserved	residue	responsible	for	the	ability	to	bind	F-
actin	(Arpin	et	al.,	2011).	Therefore,	LRRK2	is	considered	a	modulator	of	ERM	protein	
function	by	affecting	physical	association	of	the	actin	cytoskeleton	with	the	plasma	
membrane.	ERM	proteins	are	found	at	actin-rich	filopodia,	where	they	control	actin	
dynamics	within	the	filopodia,	and	thus	modulate	neurite	outgrowth	(Paglini	et	al.,	
1998).	 The	 G2019S	 over-active	 kinase	 mutation	 of	 LRRK2	 increases	 ERM	 protein	
association	with	 F-actin,	 and	 inhibits	 neurite	 outgrowth,	while	 LRRK2	 KO	 achieved	
the	 opposite	 effect	 (Parisiadou	 et	 al.,	 2009).	 LRRK2	 also	 binds	 strongly	 to	 the	 Rho	
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GTPase	 Rac1,	 and	 more	 weakly	 to	 Cdc42,	 resulting	 in	 activation	 of	 downstream	
processes	 (Chan	 et	 al.,	 2011).	 Rho	 GTPases	 activate	 signalling	 cascades	 beginning	
with	the	‘p-21	activated	kinase’	(PAK)	family,	which	result	in	modulation	of	the	actin	
cytoskeleton.	For	example,	downstream	activation	of	 the	MAPK	proteins	ERK1	and	
ERK2	modulate	 actin	 polymerisation	 and	 cell	 spreading	 (Smith	 et	 al.,	 2008).	While	
activation	 of	 LIM	 kinase	 acts	 to	 inhibit	 the	 action	 of	 the	 cytoskeletally	 associated	
protein	cofilin,	ultimately	blocking	actin	depolymerisation	and	leading	to	membrane	
ruffles	 (Edwards	 et	 al.,	 1999).	 The	 interaction	 between	 Rho	 GTPase	 proteins	 and	
LRRK2	is	affected	by	disease	causing	mutations	of	LRRK2,	with	the	G2019S	mutation	
weakening	 the	 interaction	 and	 activation	 of	 Rac1.	 Co-expression	 of	 Rac1	 with	
G2019S	LRRK2	was	sufficient	to	rescue	G2019S-LRRK2	induced	neurite	shortening	in	
SH-SY5Y	cultures,	demonstrating	 relevance	 to	neuronal	 toxicity	 (Chan	et	al.,	2011).		
Another	 group	 has	 demonstrated	 the	 opposite	 relationship	 between	 LRRK2	 and	
Rac1,	 with	 knockout	 of	 LRRK2	 resulting	 in	 Rac1	 activation,	 perturbing	 neuronal	
branching	and	dendritic	spine	prevalence	(Schreij	et	al.,	2015).	In	spite	of	phenotypic	
effects	 of	 these	 associations,	 LRRK2	 is	 not	 thought	 to	 directly	 phosphorylate	 Rho	
GTPases	(Moehle	et	al.,	2015).	A	direct	association	of	LRRK2	with	PAK6	has	also	been	
demonstrated	 (Civiero	 et	 al.,	 2015).	 Finally,	 the	 only	 guanine	 nucleotide	 exchange	
factor	 (GEF)	of	LRRK2	reported	so	 far	 is	ARHGEF7	 (Haebig	et	al.,	2010).	 Interaction	
between	 ARHGEF7	 and	 LRRK2	was	 perturbed	 by	 R1141C	mutation.	 An	 interaction	
between	LRRK2	and	Cdc42	was	also	reported	in	this	study.	ARHGEF7	acts	upon	Rac1	
and	 Cdc42,	 catalysing	 the	 release	 of	 GDP	 for	 GTP,	 as	 well	 as	 interacting	 with	
downstream	PAK	 kinases.	 Knockout	 of	 LRRK2	 leads	 to	 increased	branching	 and	 an	
enhanced	number	of	neuronal	growth	cones,	along	with	mislocalisation	of	ARHGEF7	
within	those	growth	cones	(Häbig	et	al.,	2013).		
The	cytoskeleton	is	vital	to	many	aspects	of	innate	immune	cell	function	
The	 direct	 interaction	 of	 LRRK2	 with	 microtubules,	 and	 interaction	 with	
multiple	 levels	 of	 actin	 dynamic	 regulators	 strengthens	 the	 idea	 that	 regulation	of	
cytoskeletal	 dynamics	 may	 be	 a	 primary	 physiological	 role	 of	 LRRK2.	 As	 with	
vesicular	 trafficking	 however,	 the	 importance	 of	 a	 regulated	 cytoskeleton	 is	 not	
limited	to	a	neuronal	context.	
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	 Cytoskeletal	 dynamics	 underpin	 many	 of	 the	 functions	 of	 innate	 immune	
cells,	 from	 migration	 to	 sites	 of	 inflammation,	 to	 active	 processes	 such	 as	
phagocytosis.	 Macrophages	 and	 monocyte	 precursors	 are	 highly	 motile	 cells,	
travelling	 long	 distances	 in	 the	 blood	 and	 within	 tissues.	 Within	 tissues,	
macrophages	sense	environmental	cues,	resulting	in	efficient	migration	to	sources	of	
inflammation	 and	 disease	 (Shi	 and	 Pamer,	 2011).	 This	 high	 level	 of	 motility	 of	
macrophages	 is	 in	 stark	 contrast	 to	 what	 is	 seen	 in	 neuronal	 cells,	 where	 after	
neurogenesis	and	motility	of	the	growth	cone,	the	physical	position	of	axons	is	fixed	
(Ghashghaei	et	al.,	2007).	Motility	of	cells	is	chiefly	governed	by	dynamic	changes	of	
the	cytoskeleton.	The	actin	cytoskeleton	plays	a	prominent	role	at	the	leading	edge	
of	motile	 cells.	 Lamellipodia	 are	 thin	 sheet-like	 structures	 formed	 of	 a	 network	 of	
highly	 branched	 actin	 filaments.	 This	 branching	 pattern	 is	 facilitated	 by	 the	 actin-
related	protein-2/3	(ARP2/3)	complex,	which	nucleates	actin	polymerisation	from	an	
existing	 actin	 fibre	 in	 conjunction	 with	 the	 WASP/WAVE	 family	 of	 proteins	
(Machesky	 et	 al.,	 1999;	 Takenawa	 and	 Suetsugu,	 2007).	While	 both	 filopodia	 and	
lamellipodia	 are	 structures	 formed	 of	 actin,	 lamellipodia	 are	 formed	 of	 thin	 actin	
sheets,	while	actin	in	filopodia	forms	tight	parallel	bundles	that	push	against	the	cell	
membrane	to	produce	finger-like	protrusions	(Fletcher	and	Mullins,	2010).	Filopodia	
and	lamellipodia	are	linked,	as	filopodia	are	found	embedded	within,	and	protruding	
from,	the	branched	lamellipodial	actin	network	(Svitkina	et	al.,	2003).	The	extended	
nature	of	filopodia	allow	macrophages	to	probe	the	environment	for	pathogens	and	
chemoattractant	gradients;	a	 function	enhanced	by	the	enrichment	of	extracellular	
receptors	within	 these	 structures	 (Mattila	and	Lappalainen,	2008).	Actin	 structures	
and	dynamics	are	therefore	functionally	involved	in	the	innate	immune	response	by	
exerting	a	level	of	control	upon	macrophage	migration	and	environmental	sensing.		
Filopodia	are	also	involved	in	the	active	process	of	phagocytosis;	a	process	by	
which	 extracellular	 material	 is	 taken	 up	 by	 a	 cell.	 Phagocytosis	 facilitates	
macrophage	 killing	 of	 extracellular	 pathogens,	 and	 clearance	 of	 cellular	 debris.	
Debris	 clearance	 in	 particular	 bears	 importance	 in	 the	 context	 of	 degenerative	
disease	 such	 as	 Parkinson’s,	where	 reactive	microgliosis	 and	 immunogenic	 protein	
aggregate	formation	correlate	with	pathology.	Phagocytosis	at	face	value	appears	to	
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be	a	simple	process	of	particle	engulfment,	however	massive	coordination	of	cellular	
machinery	 is	 in-fact	 involved	 (Niedergang	 and	 Chavrier,	 2004;	 Swanson,	 2008).	
Mechanically,	filopodia-like	extensions	are	required	to	extend	around	particles	to	be	
engulfed	as	part	of	this	process,	and	a	phagocytic	cup	is	formed	underneath	material	
to	 be	 phagocytosed.	 This	 phagocytic	 cup	 is	 a	 structure	 formed	 by	 actin	
rearrangement	that	induces	membrane	curvature,	and	excludes	membrane	proteins	
at	the	site	of	contact	with	material	to	be	phagocytosed	(Lee	et	al.,	2007).	Formation	
of	membrane	structures	for	phagocytosis	can	be	triggered	by	activation	of	receptors,	
and	 in	 particular	 Fc-receptors,	 at	 the	 cell	 surface.	 Receptor	 engagement	 results	 in	
signalling	 to	 trigger	 actin	 rearrangement.	 Such	 signalling	 involves	 Rho	 GTPases	
including	 Rac1	 and	 Cdc42;	 interaction	 partners	 of	 LRRK2	 (Beemiller	 et	 al.,	 2010;	
Rougerie	 et	 al.,	 2013).	 Cdc42	 regulates	 the	 induction	 of	 the	 ARP2/3	 complex,	
classically	 through	 activation	 of	 WASP;	 leading	 to	 the	 formation	 of	 lamellipodia	
sheets,	and	filopodia	protrusions	(Nobes	and	Hall,	1995;	Park	and	Cox,	2009).	Rac1	
signalling	 overlaps	 with	 that	 of	 Cdc42,	 however	 during	 Fcγ	 receptor-mediated	
phagocytosis,	 Rac1	 is	 distributed	 differentially	 to	 Cdc42.	 That	 is,	 Rac1	 is	 present	
throughout	the	phagocytic	cup,	while	Cdc42	is	restricted	to	the	leading	edge	of	the	
cell	(Hoppe	and	Swanson,	2004).	This	suggests	distinct	roles	of	Rho	GTPase	proteins	
during	phagocytosis,	and	demonstrates	an	intricacy	in	Rho	GTPase	signalling	that	has	
immunological	 importance	 (fig	 27).	 Phagocytosis	 could	 therefore	 be	 affected	 by	
perturbation	of	 LRRK2	 interaction	with	Rho	GTPases.	 Interestingly,	 Rac1	 activation	
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can	 be	 stimulated	 by	 the	 growth	 of	 microtubules,	 resulting	 in	 the	 formation	 of	
lamellipodia	 (Waterman-Storer	 et	 al.,	 1999).	 This	 highlights	 the	 interconnectivity	
between	 the	microtubule	 and	 actin	 networks	which	 are	 often	 studied	 in	 isolation	
(Etienne-Manneville,	2004).			
The	 role	 of	 LRRK2	 in	 phagocytosis	 is	 confused	 by	 conflicting	 data.	 Early	
reports	 of	 LRRK2	 function	 in	 macrophages	 using	 the	 inhibitor	 L2in1	 suggested	 a	
direct	role	for	LRRK2	in	phagocytosis.	These	experiments	used	the	HIV	tat	protein	to	
stimulate	BV-2	immortalised	microglia	to	phagocytose	latex	beads	or	neuronal	axons	
(Marker	et	al.,	2012).	 In	comparison,	a	more	recent	report	comparing	phagocytosis	
of	 zymosan-coated	 beads	 by	 thioglycolate-elicited	 primary	 macrophages	
(overexpressing	 WT	 or	 G2019S	 mutant	 LRRK2)	 showed	 no	 effect	 of	 the	 G2019S	
LRRK2	mutation	 on	 bead	 phagocytosis	 (Moehle	 et	 al.,	 2015).	 ShRNA	 was	 used	 to	
knock	 down	 LRRK2	 in	 RAW264.7	 cells	 by	 a	 further	 group.	 Results	 from	 this	
experiment	indicated	that	LRRK2	did	not	affect	phagocytosis	of	beads	stimulated	by	
extensive	 LPS	 treatment	 (Schapansky	 et	 al.,	 2014).	 Primary	 macrophages	 derived	
from	 LRRK2	 KO	mice	 are	 a	 better	 model	 to	 definitively	 test	 the	 role	 of	 LRRK2	 in	
phagocytosis	 owing	 to	 the	 specific	 nature	 of	 using	 a	 genetic	 model	 compared	 to	
chemical	 inhibitors,	 and	 knockout	 of	 LRRK2	 compared	 to	 knock	 down.	 Further	 to	
this,	 extraction	 of	 primary	 cells	 by	 thioglycolate	 has	 been	 suggested	 to	 lead	 to	
physiological	 changes	 in	 macrophages	 that	 may	 perturb	 their	 physiology	 (Hoover	
and	Nacy,	1984;	Ray	and	Dittel,	2010).	This	is	similarly	true	for	cell	lines	such	as	BV-2	
or	RAW264.3	cells	which	have	undergone	an	immortalisation	process.	pBMDM	cells	
are	 routinely	 used	 as	 a	 ‘gold	 standard’	 model	 for	 mouse	 macrophages,	 as	 they	
undergo	 a	 reproducible	 maturation	 process	 from	 bone	 marrow,	 analogous	 to	
haematopoiesis	(Weischenfeldt	and	Porse,	2008).	
Summary	
Neuronal	processes	 such	as	axonal	 transport	and	neurite	extension,	as	well	
as	autophagy,	are	perturbed	by	LRRK2	knockout	or	pathogenic	mutation.	Direct	and	
indirect	interactions	between	LRRK2	and	a	range	of	cellular	machinery	including	Rab	
proteins	 and	 cytoskeletal	 dynamic	 regulators	 are	 thought	 to	 underpin	 the	 role	 of	
LRRK2	 in	 these	processes.	Many	 innate	 immune	 cell	 functions	 rely	upon	 the	 same	
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cellular	machinery	that	LRRK2	has	been	shown	to	interact	with	in	neurons	and	other	
cell	types.	Work	detailed	in	this	chapter	is	performed	using	macrophages,	and	aims	
to	explore	the	role	of	LRRK2	in	such	processes.	A	focus	is	placed	upon	the	expression	
and	 trafficking	 of	 innate	 immune	 receptors,	 as	 well	 as	 with	 the	 process	 of	
phagocytosis.	 Experiments	 to	 study	 the	 involvement	 of	 LRRK2	 in	 innate	 immune	
receptor	trafficking	are	novel,	while	studies	of	the	role	of	LRRK2	in	phagocytosis	are	
designed	to	clarify,	and	build	upon	conflicting	existing	data	in	the	LRRK2	literature.	
	
4.3	Results	
4.3.1	 Effective	 knockout	 of	 LRRK2	 in	 primary	 macrophages	 derived	 from	
B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice	
	 To	 investigate	 the	 role	 of	 LRRK2	 in	 innate	 immunity,	 a	 genetic	 system	was	
employed	 utilising	 LRRK2	 KO	 mice.	 The	 use	 of	 this	 system	 is	 key	 to	 overcoming	
limitations	of	some	previous	work	in	the	field,	which	utilised	the	non-specific	LRRK2	
inhibitor	 L2in1	 (Deng	et	al.,	2011).	Heterozygous	B6.129X1(FVB)-Lrrk2tm1.1Cai/J	were	
bred,	 and	 offspring	 genotyped	 to	 obtain	 a	 homozygous	 mating	 pair	 from	 which	
LRRK2	 KO	 mice	 could	 be	 derived	 (fig	 28a).	 Bone	 marrow	 from	 homozygous	
B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice	was	obtained	and	differentiated	into	primary	bone	
marrow	derived	macrophages	 (pBMDM)	 for	 these	experiments.	 The	LRRK2	gene	 is	
not	 removed	 in	 B6.129X1(FVB)-Lrrk2tm1.1Cai/J	 mice,	 but	 rather	 interrupted	 by	
specific	excision	of	exon	2,	resulting	 in	a	premature	stop	codon	in	exon	3	of	LRRK2	
mRNA	(fig	28b)	(Parisiadou	et	al.,	2009).	LRRK2	mRNA	containing	a	premature	stop	
codon	 will	 be	 degraded	 by	 nonsense-mediated	 decay	 at	 the	 ribosome,	 this	 is	
reflected	by	a	reduction	of	49	%	in	LRRK2	mRNA	levels	in	macrophages	derived	from	
B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice	when	 compared	 to	WT	mice	 as	measured	 by	
qRT-PCR	 (fig	 28c).	 Therefore	 mRNA	 levels	 verify	 that	 the	 LRRK2	 gene	 has	 been	
perturbed	successfully	in	LRRK2	KO	pBMDMs.		
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Figure	28:	 LRRK2	knockout	 in	B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice.	
a:	Representative	genotyping	PCR	 result.	 	 Ladder	 sizes	 in	base	pairs	
(bp)	indicated	in	white	text.	Expected	results:	WT	=	145	bp,	LRRK2	KO	
=	 200	 bp,	 Heterozygote	 =	 both.	 b:	 Simplified	 schematic	 of	 LRRK2	
knockout	by	the	generation	of	a	premature	stop	codon	within	LRRK2	
exon	3	(Parisiadou	et	al.,	2009).	Resulting	mRNA	will	be	degraded	by	
nonsense-mediated	 decay.	 c:	 Decreased	 LRRK2	 expression	 in	
pBMDMs	derived	from	B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice.	qRT-PCR	
with	 beta-actin	 and	 GAPDH	 as	 housekeeping	 genes.	 Error	 bars	 are	
S.E.M.	of	three	independent	experiments.	
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4.3.2	LRRK2	transcription	is	responsive	to	inflammatory	stimuli	in	pBMDM	cells	
		 Having	 established	 successful	 knockout	 of	 LRRK2	 in	 pBMDM	 cells,	 the	
transcription	 of	 LRRK2	 in	 WT	 macrophages	 was	 next	 investigated	 in	 response	 to	
inflammatory	 stimuli.	 WT	 macrophages	 were	 incubated	 with	 a	 range	 of	
inflammatory	stimuli;	 including	LPS,	 Ifn-γ,	MDP	and	αSyn	oligos.	After	two	hours	of	
stimulation,	 RNA	 extraction	 and	 qRT-PCR	 analysis	 was	 performed.	 An	 increase	 of	
over	 two-fold	 was	 observed	 upon	 treatment	 with	 LPS,	 and	more	modest	 1.5-fold	
changes	 upon	 stimulation	 with	 Ifn-γ	 or	 αSyn	 oligos	 (fig	 29).	 While	 the	 LRRK2	
transcriptional	 response	 to	 LPS	 was	 greatest,	 it	 was	 also	 the	 most	 variable.	 A	
subsequent	RNA	sequencing	experiment	confirmed	3.5-fold	induction	of	LRRK2	upon	
LPS	 stimulation.	 An	 MDP	 treatment	 was	 included	 as,	 despite	 several	 functional	
connections	to	LRRK2,	there	is	no	existing	data	for	the	effect	of	NOD2	activation	on	
LRRK2	expression.	αSyn	oligos	were	similarly	tested	as	there	is	joint	involvement	of	
LRRK2	 and	 alpha-synuclein	 in	 many	 cellular	 processes:	 including	 inflammation,	
protein	transport,	mitochondrial	function,	autophagy,	and	proteosomal	degradation	
(Liu	 et	 al.,	 2012).	 Neither	MDP	 nor	 αSyn	 oligos	 had	 a	 noticeable	 effect	 on	 LRRK2	
transcription	at	two	hours	(fig	29).	These	results	indicate	that	LRRK2	transcription	is	
affected	by	specific	perturbations	to	the	innate	immune	system	in	pBMDMs,	but	that	
this	responsiveness	is	modest.		
		 	
Figure	 29:	 LRRK2	 transcript	 levels	 upon	
innate	 immune	 activation.	 qRT-PCR	 with	
beta-actin	 and	 GAPDH	 as	 housekeeping	
genes.	 Errors	 bars	 are	 S.E.M.	 of	 three	
independent	experiments	for	LPS,	 Ifn-γ	and	
MDP.	 Two	 independent	 experiments	 for	
αSyn	 oligos.	 paired	 two-tailed	 t-tests	
compared	to	a	value	of	1.	
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	4.3.3	 LRRK2	 has	 no	 obvious	 effect	 on	 cytokine	 secretion	 in	 response	 to	
inflammatory	stimuli	
	 Given	that	LRRK2	transcription	is	responsive	to	inflammatory	stimuli,	a	bead	
array	was	performed	in	order	to	measure	the	secretion	of	inflammatory	cytokines	in	
response	to	inflammatory	stimuli.	LPS,	IFN-γ,	MDP	and	αSyn	oligos	were	again	used	
to	stimulate	WT	and	LRRK2	KO	macrophages	for	2	hours,	6	hours	and	24	hours.	At	
these	 time	 points	 supernatants	 were	 removed	 and	 assayed	 for	 inflammatory	
cytokine	content.		Although	results	were	from	a	single	experiment,	it	was	noted	that	
no	obvious	differences	were	observed	between	WT	and	LRRK2	KO	macrophages,	in	
line	with	previous	reports	 (fig	30).	Specifically,	of	 the	 inflammatory	stimuli	applied,	
only	 LPS	 and	 αSyn	 oligos	 led	 to	 a	 notable	 increase	 in	 cytokine	 secretion	 by	
macrophages,	with	Ifn-γ	and	MDP	stimulated	macrophages	resulting	in	only	slightly	
increased	 levels	 of	 cytokine	 secretion	 compared	 to	 unstimulated	 macrophages,	 a	
baseline	of	200	pg/ml	was	ascertained	from	such	unstimulated	cells.	One	exception	
to	 this	 is	 at	24	hours,	where	 Ifn-γ	 stimulation	 resulted	 in	a	 slight	 increase	 in	TNFα	
secretion,	but	no	obvious	difference	between	WT	and	LRRK2	KO	macrophages.	LPS	
stimulation	resulted	in	increased	secretion	of	Il-1α,	Il-6,	Il-10	and	TNFα	especially	at	
6	 and	 24	 hour	 time	 points.	 Again,	 no	 differences	 were	 observed	 between	 LRRK2	
genotypes	that	was	consistent	across	multiple	time	points.	Similar	observations	were	
made	upon	stimulation	with	αSyn	oligos	with	cytokine	secretion	peaking	at	6	hours	
and	 remaining	 elevated	 by	 24	 hours,	with	 no	 obvious	 LRRK2	 genotype	 dependent	
differences	 observed.	 After	 2	 hours	 of	 stimulation	 with	 αSyn	 oligos,	 only	 TNFα	
secretion	 was	 seen	 to	 be	 elevated,	 with	 secretion	 apparently	 elevated	 in	 WT	
macrophages	compared	to	LRRK2	KO	equivalent	cells	with	380	pg/ml	detected	in	WT	
supernatants	 compared	 to	 170	 pg/ml	 in	 those	 of	 LRRK2	 KO	 cells	 (fig	 30).	 This	
observation	 was	 time	 point	 specific	 however,	 and	 was	 not	 observed	 at	 6	 hours,	
when	TNFα	levels	were	much	more	significantly	elevated,	at	20,000	pg/ml.	
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			 	Figure	 30:	 Preliminary	 experiments	 show	 no	 effect	 of	 LRRK2	 knockout	 on	 cytokine	 secretion	 in	
response	 to	 simple	 inflammatory	 stimuli.	Cells	were	stimulated	as	 indicated	for	each	row	of	graphs	
and	 supernatant	 cytokine	 concentrations	measured	 at	 the	 time	 point	 indicated	 for	 each	 column	 of	
graphs.	 TNFα	 concentrations	 occasionally	 exceeded	 detection	 limits	 as	 indicated	 by	 ‘max’.	 A	 single	
independent	experiment	was	performed.	
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4.3.4	LRRK2	has	no	effect	on	TLR4	expression	or	trafficking	dynamics		
Up-regulation	 of	 LRRK2	 transcription	 upon	 LPS	 stimulation	 verifies	 an	
association	 between	 TLR4	 and	 LRRK2	 in	 pBMDM	 cells,	 while	 the	 fact	 that	 no	
observed	differences	were	made	 in	 cytokine	 secretion	between	WT	and	LRRK2	KO	
macrophages	 suggests	 that	 this	 may	 manifest	 at	 a	 different	 level.	 Indeed,	 as	
discussed	previously,	some	of	the	earliest	evidence	of	the	 involvement	of	LRRK2	 in	
innate	immune	signalling	came	from	an	association	of	LRRK2	with	TLR4	signalling	in	
macrophages.	 However,	 while	 the	 effect	 of	 TLR4	 signalling	 on	 LRRK2	 has	 been	
studied,	 little	 has	 been	 shown	 on	 the	 effect	 of	 LRRK2	 on	 TLR4.	 As	 LRRK2	 is	
upregulated	upon	LPS	treatment,	LRRK2	KO	and	WT	pBMDMs	were	treated	with	LPS	
to	establish	if	transcription	of	TLR4	was	affected.	Cells	were	treated	with	LPS	for	two	
hours	 and	mRNA	extracted	 for	 qRT-PCR	 analysis.	 A	 decrease	 of	 TLR4	 transcription	
after	 LPS	 stimulation	 was	 detected,	 with	 a	 30	 %	 attenuation	 in	 transcription	
observed	as	part	of	a	negative-feedback	loop;	confirming	that	derived	pBMDM	cells	
are	 behaving	 as	 expected	 (Nhu	 et	 al,	 2006).	 Importantly,	 no	 significant	 difference	
was	 seen	 in	 this	 attenuation	 of	 TLR4	 transcription	 between	 WT	 and	 LRRK2	 KO	
macrophages	 (fig	 31).	 This	 indicates	 that	 LRRK2	 has	 no	 effect	 on	 transcription	 of	
TLR4.	
	 	
Figure	 31:	 TLR4	 transcript	 levels	 upon	 LPS	
stimulation.	 qRT-PCR	 with	 beta-actin	 and	 GAPDH	
as	 housekeeping	 genes.	 Errors	 bars	 are	 S.E.M.	 of	
three	 independent	 experiments,	 unpaired	 two-
tailed	t-tests	between	genotypes.	
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In	 order	 to	 compare	 TLR4	 endocytosis	 between	 LRRK2	 genotypes,	 the	
propensity	 of	 TLR4	 to	 undergo	 endocytosis	 in	 response	 to	 LPS	was	 first	measured	
using	 flow	 cytometry	 on	WT	 pBMDM	 cells.	 Cells	 were	 left	 unstimulated,	 or	 were	
stimulated	with	a	range	of	LPS	doses	for	one	or	two	hours,	then	stained	for	surface	
TLR4.	Mean	 fluorescent	 intensity	 (MFI)	measurements	were	 used	 to	 calculate	 the	
percentage	of	endocytosis	as	described	in	the	following	equation:	
	
 
 
 
 
 
 
 
	Results	 demonstrated	 a	 clear	 increase	 in	 endocytosis	 with	 increasing	
concentrations	 of	 LPS,	 with	 more	 endocytosis	 observed	 after	 two	 hours	 of	
incubation	 than	after	 one	hour	 (fig	 32a,b).	 TLR4	endocytosis	was	 seen	 to	begin	 to	
plateau	between	100	ng/ml	and	200	ng/ml	LPS	after	two	hours	incubation,	so	it	was	
not	 considered	 necessary	 to	 explore	 higher	 LPS	 concentrations	 or	 incubation	
durations	(fig	32b).		
	
	 	
	 139	
	
	
	
	
	
	
	
	 To	measure	cell	surface	levels	of	TLR4,	fixed	pBMDM	cells	were	stained	using	
one	of	 two	anti-TLR4	antibody	clones:	MTS510	or	Sa15-21.	The	specificity	of	 these	
clones	to	TLR4	was	verified	using	unstimulated	pBMDM	cells	derived	from	TLR4	KO	
mice.	 No	 shift	 in	 fluorescent	 intensity	 was	 observed	 between	 cells	 stained	 for	
surface	 TLR4	 using	MTS510	 or	 Sa15-21	 and	 cells	 stained	with	 appropriate	 isotype	
control	 antibodies	 (fig	 33a).	 In	 comparison,	 WT	 pBMDM	 cells	 clearly	 showed	 an	
increase	 in	 fluoresence	 intensity	 when	 stained	 with	 either	 MTS510	 or	 Sa15-21	
antibodies	 as	 compared	 to	 appropriate	 isotype	 controls	 (fig	 33b).	 These	 results	
indicate	 high	 specificity	 of	 anti-TLR4	 antibodies	 and	 successful	 application	 of	 flow	
cytometry	to	the	measurement	of	cell	surface	TLR4.	
	
	
	
Figure	32:	Optimisation	of	TLR4	endocytosis	conditions.	TLR4	stained	with	Sa15-21	antibody	a:	
WT	 pBMDMs	 incubated	 in	 LPS	 for	 one	 hour	 in	 a	 single	 independent	 experiment.	 b:	 WT	
pBMDMs	 incubated	 in	 LPS	 for	 2	 hours.	 Error	 bars	 are	within	 symbols;	 these	 are	 S.D.	 of	 two	
independent	experiments.	
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a
b
Figure	 33:	 Verification	 of	 anti-TLR4	 antibody	 binding	 specificity.	 Representative	 FACS	
histograms.	Unfilled	red	peak	is	TLR4	stained	cells,	filled	grey	peak	is	isotype	control	staining.	a:	
TLR4	KO	pBMDM	cells	stained	with	MTS510	or	Sa15-21	clones	as	indicated.	b:	WT	pBMDM	cells	
stained	with	MTS510	or	Sa15-21	clones	as	indicated.	
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The	 effect	 of	 LRRK2	 knockout	 on	 TLR4	 endocytosis	 was	 then	 assayed	 by	
comparing	 surface	 TLR4	 levels	 between	WT	and	 LRRK2	KO	pBMDM	cells	 following	
LPS	stimulation.	LRRK2	KO	had	no	significant	effect	on	resting	surface	TLR4	levels	in	
pBMDM	 cells	 as	 measured	 using	 the	 MTS510	 antibody	 (fig	 34a).	 The	 epitope	 for	
MTS510	 on	 TLR4	 is	 reported	 to	 be	 hidden	 prior	 to	 receptor	 endocytosis,	 perhaps	
during	 LPS	 induced	 dimerisation	 (Akashi	 et	 al.,	 2003);	 a	 step	 which	 precedes	
endocytosis.	Therefore,	the	use	of	MTS510	is	thought	to	give	a	better	 indication	of	
steps	leading	to	endocytosis,	rather	than	TLR4	endocytosis	itself.	For	simplicity,	the	
term	endocytosis	will	be	used	for	the	LPS	induced	loss	of	TLR4	signal	as	measured	by	
MTS510	in	this	report.	After	one	hour	of	LPS	stimulation,		35	%	of	cell	surface	TLR4	
was	endocytosed.	This	increased	to	around	75	%	after	two	hours	of	LPS	stimulation	
(fig	34b).	No	significant	differences	in	TLR4	endocytosis	were	observed	between	WT	
and	 KO	 macrophages	 upon	 stimulation	 with	 LPS	 when	 staining	 with	 the	 MTS510	
antibody	 (fig	 34b).	 This	 provides	 an	 indication	 that	 the	 early	 steps	 induced	by	 LPS	
binding	which	 lead	 to	 TLR4	endocytosis	 are	not	 influenced	by	 LRRK2.	 The	 Sa15-21	
antibody	is	thought	to	give	a	clear	indication	of	TLR4	endocytosis	itself,	owing	to	an	
epitope	which	is	distinct	from	that	of	MTS510	and	that	can	still	be	recognised	after	
LPS	 binding	 (Akashi	 et	 al.,	 2003).	 In	 agreement	with	MTS510	 data,	 there	were	 no	
significant	differences	in	resting	cell	surface	TLR4	expression	between	unstimulated	
WT	and	LRRK2	KO	macrophages	as	measured	using	the	Sa15-21	antibody	 (fig	34c).	
After	one	hour	of	LPS	stimulation,	50	%	of	TLR4	was	seen	to	have	been	endocytosed,	
increasing	 to	 70	 %	 after	 two	 hours	 (fig	 34d).	 It	 is	 interesting	 that	 more	 TLR4	
endocytosis	was	observed	using	Sa15-21	antibody	than	using	the	MTS510	antibody	
after	one	hour,	however	 this	disparity	was	 lost	after	 two	hours	of	 incubation	with	
LPS	(fig	34b,d).	No	differences	in	TLR4	endocytosis	were	observed	observed	between	
LRRK2	WT	and	KO	macrophages	using	the	Sa15-21	antibody	(fig	34d).	
	All	 together,	 these	data	provide	a	clear	 indication	that	LRRK2	has	no	effect	
on	 resting	 surface	 levels	 TLR4,	 or	 LPS	 induced	 TLR4	 changes	 such	 as	 TLR4	
transcription	or	dynamic	trafficking.	
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Figure	 34:	 LRRK2	 has	 no	 effect	 on	 TLR4	 dynamic	 trafficking	 or	 resting	 surface	 expression.	
pBMDM	cells	incubated	with	200	ng/ml	LPS	for	indicated	lengths	of	time	or	unstimulated	if	not	
indicated.	 Error	 bars	 are	 S.E.M.	 Statistics	 are	 unpaired	 two-tailed	 t-tests	 between	 genotypes	
where	relevant,	otherwise	paired	two-tailed	t-tests	compared	to	a	value	of	1.		a,b:	Cells	stained	
with	MTS510	anti-TLR4	antibody,	three	independent	experiments.	c,d:	Cells	stained	with	Sa15-
21	anti-TLR4	antibody,	five	independent	experiments.	
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4.3.5	LRRK2	perturbs	TLR2	transcription	in	response	to	innate	immune	stimulation,	
but	not	cell	surface	expression	
Before	 investigating	 cell	 surface	 expression	 levels	 of	 TLR2,	 transcription	 of	
TLR2	was	assessed	following	innate	immune	stimulation	by	LPS,	Ifn-γ,	MDP	and	αSyn	
oligos;	all	stimuli	except	Ifn-γ	were	seen	to	cause	up-regulation	of	TLR2	transcription	
(fig	35a).	 LPS	 stimulation	caused	 the	greatest	 increase	 in	TLR2	 transcription	with	a	
ten-fold	change	compared	to	untreated	cells.	MDP	and	αSyn	oligos	caused	a	slightly	
more	modest	increase	of	between	five	and	ten-fold.	 Interestingly,	MDP	stimulation	
resulted	in	a	significant	difference	in	TLR2	transcription	between	LRRK2	KO	and	WT	
pBMDM	cells	(fig	35a).	Specifically,	LRRK2	KO	macrophages	experienced	a	mean	10-
fold	 induction	 of	 TLR2	 transcription,	 compared	 to	 6.3-fold	 for	 WT	 macrophages	
across	three	experiments.	Whilst	statistically	significant	differences	in	the	induction	
of	 TLR2	 transcription	 were	 not	 observed	 for	 other	 treatments,	 it	 was	 noted	 that	
LRRK2	KO	macrophages	also	experienced	a	greater	increase	than	WT	equivalent	cells	
after	 incubation	with	either	LPS	or	αSyn	oligos.	No	difference	 in	TLR2	transcription	
was	 observed	 between	 LRRK2	 genotypes	 in	 untreated	 cells	 across	 three	
experiments,	suggesting	that	observations	made	relate	to	innate	immune	responses,	
and	not	underlying	differences	under	resting	conditions	(fig	35b).		
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Figure	35:	TLR2	 transcription	 is	modulated	by	LRRK2	 in	 response	 to	 immune	 activation.	
qRT-PCR	with	beta-actin	and	GAPDH	as	housekeeping	genes.	Errors	bars	are	S.E.M.	of	two	
independent	 experiments	 for	 αSyn	 oligos,	 three	 independent	 experiments	 for	 all	 other	
conditions.	 a:	 Statistics	 are	 unpaired	 two-tailed	 t-tests	 between	 genotypes.	 b:	 TLR2	
transcription	in	untreated	cells.	Statistics	are	paired	two-tailed	t-tests	compared	to	a	value	
of	1.	
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		Given	 the	 apparent	 effect	 of	 LRRK2	 on	 the	 MDP	 response	 and	 TLR2	
transcription,	flow	cytometry	was	used	to	measure	cell	surface	levels	of	TLR2	over	a	
longer	 time-course	of	MDP	stimulation.	 In	agreement	with	 transcriptional	data,	no	
differences	 in	 cell	 surface	 levels	 of	 TLR2	 were	 observed	 between	 unstimulated	
pBMDM	cells	 (fig	 36a).	MDP	 stimulation	 resulted	 in	 a	modest	 increase	 in	 levels	of	
TLR2	observed	at	the	cell	surface	between	six	and	24	hours,	with	a	1.5-fold	increase	
in	 TLR2	 observed	 compared	 to	 untreated	 cells.	 At	 two	 hours,	 a	 small	 refractory	
period	 was	 observed,	 where	 TLR2	 surface	 levels	 were	 slightly	 diminished.	 No	
statistically	 significant	 differences	 were	 observed	 between	 WT	 and	 LRRK2	 KO	
macrophage	surface	TLR2	levels	 in	response	to	MDP	stimulation	over	the	 length	of	
the	time-course	(fig	36b).		 	
Figure	 36:	 LRRK2	 has	 no	 effect	 on	 TLR2	 surface	 expression	 in	 resting	 or	 MDP	 treated	
macrophages.	 Error	 bars	 are	 S.E.M.	 of	 three	 independent	 experiments.	 a:	 Unstimulated	
pBMDM	 stained	 for	 surface	 TLR2.	 b:	 pBMDM	 cells	 incubated	 with	 10	 μg/ml	 MDP	 for	
indicated	lengths	of	time.	
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4.3.6	 Interaction	 of	 LRRK2	 with	 cytoskeletal	 components	 does	 not	 affect	
phagocytosis	
To	 comprehensively	 test	 for	 a	 role	 or	 LRRK2	 in	 phagocytosis,	 a	 series	 of	
phagocytic	targets	were	applied	to	pBMDM	cells	in	culture,	starting	with	fluorescein	
labelled,	 carboxylate	 modified	 latex	 beads.	 First,	 optimisation	 of	 the	 number	 of	
target	 beads	 incubated	 per	 macrophage	 was	 established	 over	 a	 time-course	 of	
incubation.	 Using	 either	 10	 or	 100	 latex	 beads	 per	 WT	 pBMDM,	 the	 number	 of	
phagocytic	events	undertaken	per	cell	(to	an	upper	limit	of	5)	could	be	distinguished	
using	 flow	 cytometry;	 with	 each	 bead	 observable	 as	 a	 small	 jump	 in	 fluorescent	
intensity	(fig	37a).	The	number	of	cells	which	had	undergone	a	phagocytic	event	was	
seen	 to	 increase	with	 time	 for	 both	 10	 and	 100	 beads	 per	 cell.	 Neither	 condition	
reached	a	plateau	over	the	maximum	two-hour	incubation	period.	After	two	hours,	
around	 50	 %	 of	 cells	 had	 undergone	 a	 phagocytic	 event	 when	 incubated	with	 10	
beads	per	cell,	while	around	90	%	of	cells	had	undergone	a	phagocytic	event	when	
incubated	with	100	beads	per	cell	 	 (fig	37b).	Although	a	greater	proportion	of	cells	
were	 phagocytically	 positive	 at	 100	 beads	 per	 cell,	 even	 within	 half	 an	 hour	 the	
majority	of	phagocytically	positive	cells	had	already	 taken	up	5+	beads.	Above	 five	
beads,	 the	 ability	 of	 flow	 cytometry	 to	measure	 the	 number	 of	 phagocytic	 events	
occurring	was	 compromised.	 In	 comparison,	 after	 two	 hours,	 the	majority	 of	 cells	
had	phagocytosed	1-5	beads	and	so	could	still	be	resolved	when	incubated	with	only	
10	beads	per	cell.	Therefore,	a	two-hour	incubation	with	10	beads	per	cell	was	taken	
forward	for	future	experiments	(fig	37c).		
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Figure	37:	Phagocytosis	of	carboxylate	modified	latex	beads.	a:	Representative	FACS	histograms	of	
WT	cells	after	two	hours	incubation	with	10	or	100	beads	per	cell	as	indicated.	Numbers	 indicate	
the	 number	 of	 beads	 corresponding	 to	 the	 labelled	 peak.	 Blue	 histogram	 is	 cells	 incubated	with	
beads,	 grey	histograms	 are	 cells	 only.	 b:	 Proportion	of	 cells	which	have	 undergone	 a	phagocytic	
event.	Error	bars	are	S.D.	calculated	from	cell	counts	in	a	single	experiment.	c:	Proportion	of	cells	
which	 have	 undergone	 a	 specific	 number	 of	 phagocytic	 events	 as	 indicated	 to	 the	 right	 of	 each	
dataset.	Error	bars	are	S.D.	calculated	from	cell	counts	in	a	single	experiment.	
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WT	and	LRRK2	KO	macrophages	were	next	incubated	with	10	beads	per	cell	
for	two	hours	and	phagocytic	events	were	measured	by	flow	cytometry.	To	account	
for	 the	 possibility	 that	 beads	may	 stick	 to	 the	 surface	 of	 cells	without	 being	 truly	
phagocytosed,	as	well	as	to	verify	that	the	process	under	observation	was	truly	actin	
dependent,	cells	were	pre-incubated	and	then	maintained	in	either	cytochalesin	D,	a	
potent	 inhibitor	 of	 actin	 polymerisation,	 or	 a	 mock	 ‘dimethyl	 sulfoxide’	 (DMSO)	
treatment.	WT	and	 LRRK2	KO	macrophages	 treated	with	only	DMSO	showed	clear	
phagocytosis	of	fluorescent	beads,	again	with	1-5	beads	being	clearly	distinguishable	
on	flow	cytometry	histograms.	In	contrast,	WT	and	LRRK2	KO	macrophages	treated	
with	cytochalesin	D	showed	a	marked	decrease	in	phagocytosis	(fig	38a).	Around	35	
%	of	cells	were	seen	to	be	phagocytically	active	after	two	hours	of	incubation	during	
this	 round	of	experiments.	No	 significant	differences	were	 seen	 in	phagocytosis	of	
beads	between	WT	and	LRRK2	KO	genotypes	(fig	38b).	This	was	further	confirmed	by	
closer	 inspection	 of	 the	 distribution	 of	 cell	 number	 within	 phagocytically	 positive	
cells,	 where	 the	 proportion	 of	 cells	 containing	 each	 number	 of	 beads	 (up	 to	 five	
beads)	was	close	to	identical	(fig	38c).	These	results	show	that	LRRK2	has	no	effect	
on	the	propensity	of	macrophages	to	phagocytose	negatively	charged	latex	beads.	
Next,	 phagocytosis	 of	 opsonised	 beads	 was	 tested.	 Macrophages	 are	
professional	 phagocytes,	 expressing	 Fcγ	 receptors	 and	 ‘complement	 receptor	 3’,	
which	can	induce	phagocytosis	of	material.	Fcγ	receptor	engagement	and	clustering	
by	antibody	coated	particles	leads	to	activation	of	the	Rho	type	GTPases:	Cdc42	and	
Rac1	(Hoppe	and	Swanson,	2004).	The	precise	involvement	of	Cdc42	and	Rac1	on	Fcγ	
receptor	 mediated	 phagocytosis	 are	 incompletely	 understood,	 but	 as	 LRRK2	
interactors	 may	 show	 an	 LRRK2	 phenotype	 not	 seen	 without	 Fcγ	 receptor	
engagement.	 In	 order	 to	 achieve	 this,	 fluorescein-labelled	 beads	were	 shaken	 and	
incubated	 with	 a	 range	 of	 concentrations	 of	 anti-fluorescein	 IgG.	 Visualisation	 by	
confocal	 microscopy	 revealed	 a	 halo	 of	 IgG	 surrounding	 beads.	 An	 increasing	
intensity	 of	 halo	 fluorescence	was	 observed	with	 increasing	 concentrations	 of	 IgG	
(fig	 39).	 All	 tested	 concentrations	 of	 IgG	 displayed	 successful	 opsonisation.	 A	
concentration	 of	 0.2	 mg/ml	 of	 anti-fluorescein	 IgG	 was	 taken	 forward	 for	 future	
experiments.	
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Figure	38:	Phagocytosis	of	carboxylate-modified	latex	beads.	Error	bars	are	S.E.M.	across	three	
experiments.	a:	Representative	FACS	histograms	of	WT	or	LRRK2	KO	pBMDM	cells	after	two	hours	
incubation	with	10	beads	per	cell.	Numbers	 indicate	the	number	of	beads	corresponding	to	the	
labelled	peak.	Coloured	histograms	DMSO	treated,	grey	histograms	are	cytochalesin	D	treated.	b:	
Proportion	of	cells	which	have	undergone	a	phagocytic	event.	c:	Proportion	of	cells	which	have	
undergone	a	specific	number	of	phagocytic	events.	
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	 Opsonised	beads	were	 incubated	with	cells	as	 in	previous	experiments	with	
un-opsonised	beads;	a	two-hour	incubation	with	10	opsonised	beads	per	cell.	Once	
again,	phagocytosis	could	be	visualised	by	flow	cytometry	with	clear	peaks	visible	in	
flow	cytometry	histograms	for	up	to	3	beads,	and	lower	resolution	peaks	visible	up	
to	 5	beads.	A	 greater	 proportion	of	 cells	 containing	 5+	beads	were	observed	 in	 in	
both	 WT	 and	 LRRK2	 KO	 macrophages,	 revealing	 increased	 phagocytic	 activity	
towards	 opsonised	 beads.	 Cytochalesin	 D	 again	 demonstrated	 that	 observed	
phagocytosis	was	an	actin	polymerisation	dependent	process	(fig	40a).		Around	45	%	
of	 cells	 were	 seen	 to	 be	 phagocytically	 active,	 an	 increase	 of	 10	 %	 upon	 that	
measured	 using	 un-opsonised	 beads.	 No	 significant	 differences	 were	 seen	 in	
phagocytosis	 of	 beads	 between	WT	 and	 LRRK2	 KO	 genotypes	 (fig	 40b).	 The	most	
significant	difference	compared	 to	un-opsonised	beads	was	 the	proportion	of	 cells	
containing	5+	beads,	an	increase	from	5	%	to	around	15	%.	However,	no	significant	
differences	in	the	proportion	of	cells	containing	any	particular	number	of	beads	were	
observed	using	opsonised	beads	(fig	40c).	These	results	 indicate	that	LRRK2	has	no	
effect	on	the	propensity	of	a	macrophage	to	phagocytose	opsonised	latex	beads.	
Figure	 39:	 Fluorescein	 bead	opsonisation.	Representative	confocal	 images	of	beads	opsonised	with	
increasing	concentrations	of	anti-fluorescein	IgG	antibody.	Beads	are	1	µm. 
Untreated	 0.01	mg/ml	 0.1	mg/ml	 0.2	mg/ml	 1	mg/ml		
IgG	
Fluorescein	Beads	
IgG	Concentration	
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Figure	 40:	 Phagocytosis	 of	 IgG	 opsonised	 latex	 beads.	 Error	 bars	 are	 S.E.M.	 across	 three	
experiments.	a:	Representative	FACS	histograms	of	WT	or	LRRK2	KO	pBMDM	cells	after	two	hours	
incubation	with	10	beads	per	cell.	Numbers	 indicate	the	number	of	beads	corresponding	to	the	
labelled	peak.	Coloured	histograms	DMSO	treated,	grey	histograms	are	cytochalesin	D	treated.	b:	
Proportion	of	cells	which	have	undergone	a	phagocytic	event.	c:	 Proportion	of	cells	which	have	
undergone	a	specific	number	of	phagocytic	events.	
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	 A	final	assay	was	performed	using	green	fluorescent	protein	(GFP)	expressing	
E.	coli;	a	physiological	 target	 for	macrophage	phagocytosis.	E.	coli	are	non-invasive	
Gram-negative	 bacteria	 which	 express	 an	 array	 of	 PAMPS,	 including	 LPS	 	 and	
flagellin.	These	PAMPS	are	 recognised	by	macrophage	surface	 receptors,	 causing	a	
pro-phagocytic	 phenotype	 (Ribes	 et	 al.,	 2010).	 Log-phase	E.	 coli	 were	 diluted	 to	 a	
MOI	of	10	into	DMSO	or	cytochalesin	D	containing	media.	Macrophages	were	then	
incubated	with	E.	coli	for	two	hours	before	being	washed	and	fixed	for	microscopy.	
Confocal	microscopy	 revealed	 that	 cytochalesin	D	 treatment	had	been	effective	 in	
limiting	phagocytosis	of	E.	coli,	confirming	that	this	assay	was	successfully	measuring	
an	 actin-dependent	 process	 (fig	 41a).	 At	 least	 500	macrophages	 were	 counted	 in	
each	 quantified	 experiment	 with	 an	 average	 of	 1.5-2	 bacteria	 detected	 per	
macrophage.	 No	 statistically	 significant	 difference	 in	 E.	 coli	 phagocytosis	 was	
observed	between	WT	and	LRRK2	KO	macrophages	(fig	41b).	
	 Between	 these	 phagocytosis	 assays,	 it	 is	 clear	 that	 LRRK2	 has	 no	 effect	 on	
phagocytosis	in	primary	macrophages.	This	finding	suggests	that	an	earlier	report	of	
LRRK2	modulating	phagocytosis	is	most	likely	an	off-target	effect	of	the	L2in1	LRRK2	
inhibitor.	
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Figure	 41:	 Phagocytosis	 of	 GFP	 expressing	 Escherichia	 coli.	 a:	 Representative	 images	 of	
pBMDM	 cells	 after	 incubation	 with	 GFP	 E.	 coli	 for	 two	 hours.	 Nuclei	 stained	 in	 blue,	 green	
fluorescence	is	GFP	E.	coli.	Scale	bar	is	25	μm.	b:	Quantification	of	E.	coli	phagocytosis	in	DMSO	
or	cytochalesin	D	treated	cells	as	ratio	of	bacteria	per	macrophage.	Error	bars	are	S.E.M.	across	
three	experiments	for	DMSO,	a	single	experiment	was	quantified	for	cytochalesin	D.	
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4.3.7	Measuring	the	effect	of	LRRK2	on	chemotaxis	using	Boyden	chambers	
	 Having	 observed	 no	 effect	 of	 LRRK2	 upon	 phagocytosis,	 an	 attempt	 was	
made	to	quantify	the	effect	of	LRRK2	interactions	with	the	cellular	cytoskeleton	on	
chemotaxis	 towards	 the	 chemoattractant	 ADP.	 A	 Boyden	 chamber	 assay	 was	
established	 towards	 this	 purpose.	 Cells	 were	 plated	 on	 the	 Boyden	 chamber	
membrane,	and	the	tissue	culture	well	below	this	membrane	was	treated	with	ADP.	
After	 a	period	of	 incubation	 to	 allow	 for	 chemotaxis	 to	occur,	migration	both	 into	
and	through	the	membrane	was	quantified	by	staining	and	quantifying	macrophage	
nuclei	within	the	membrane,	and	at	the	bottom	of	the	tissue	culture	well.	A	range	of	
parameters	were	tested	in	this	experimental	setup	to	establish	optimum	conditions	
under	which	to	perform	comparative	chemotaxis	assays	between	LRRK2	genotypes.	
First,	a	range	of	numbers	of	WT	macrophages	were	plated	on	the	membrane.	After	a	
24	hour	incubation,	a	significant	effect	of	ADP	could	be	observed	upon	chemotaxis	of	
macrophages	 in	 chambers	 with	 25,000,	 50,000	 and	 100,000	 cells	 plated.	
Quantification	showed	a	clear	 increase	 in	cell	number	could	be	observed	as	having	
migrated	 into	 the	 Boyden	 chamber	membrane,	 as	well	 as	 through	 the	membrane	
and	into	the	bottom	of	these	tissue	culture	wells	when	incubated	with	ADP	(fig	42a).	
The	 separation	 in	 cell	 numbers	 counted	 between	 ADP	 treated	 samples	 and	
untreated	 samples	 increased	with	 the	number	of	 cells	 plated,	with	 a	mean	of	 958	
cells	counted	 in	 the	membrane	of	ADP	treated	cells,	and	only	158	cells	counted	 in	
untreated	Boyden	chambers.	An	effect	could	also	be	observed	in	the	tissue	culture	
well,	however	the	cell	numbers	were	much	lower	and	more	variable	by	this	method	
of	quantification,	with	a	mean	of	85	cells	counted	in	ADP	treated	samples,	and	only	8	
in	untreated	samples.	The	parameter	of	100,000	plated	cells	was	taken	forward	to	
further	optimisation,	with	cells	treated	with	ADP	for	a	range	of	different	incubation	
times.	Cells	were	incubated	with	ADP	for	6,	18,	24,	or	30	hours	and	chemotaxis	was	
quantified	 as	 before	 (fig	 42b).	 An	 observable	 effect	 of	 ADP	 upon	 chemotaxis	 was	
observable	 immediately	 at	 6	 hours	 in	 the	 Boyden	membrane	with	 a	mean	 of	 614	
cells	counted	in	ADP	treated	chambers,	compared	to	99	cells	in	untreated	cells.	The	
absolute	difference	in	quantified	cell	numbers	in	the	Boyden	membrane	did	not	vary	
greatly	up	to	24	hours	with	a	mean	of	1180	cells	counted	in	ADP	treated	chambers,	
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and	379	counted	in	unstimulated	chambers,	however	this	difference	decreased	after	
24	 hours.	 The	 effect	 of	 chemotaxis	 in	 cells	 counted	 at	 the	 bottom	 of	 the	 tissue	
culture	well	increased	with	time,	becoming	observable	at	16	hours	and	increasing	up	
to	the	longest	incubation	time	of	30	hours.	This	suggests	that	chemotaxis	was	still	on	
going	at	this	 late	time	point.	With	these	considerations	 in	mind,	a	time	point	of	24	
hours	with	100,000	cells	played	was	deemed	appropriate	for	experiments.		
	
Figure	 42:	 Chemotaxis	 assay	 optimisation.	Quantification	 of	 cells	migrating	 into	 the	 Boyden	
membrane,	or	to	the	bottom	of	tissue	culture	well	as	indicated	in	the	presence	of	absence	of	
ADP	 chemoattractant.	 a:	 Optimisation	 of	 cell	 numbers	 for	 chemotaxis	 assay.	 24	 hour	
incubation.	 S.E.M.	across	 three	 independent	experiments.	b:	Optimisation	 of	 incubation	 time	
over	which	chemotaxis	can	occur.	100,000	cells/chamber	plated.	S.D	of	triplicate	wells	from	a	
single	experiment.	
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	 Upon	taking	optimised	parameters	forward	for	full	experiments	with	WT	and	
LRRK2	KO	macrophages,	the	previously	observed	effect	of	ADP	upon	chemotaxis	was	
no	longer	observable.	Specifically,	a	higher	number	of	macrophages	was	quantified	
within	the	membrane	and	tissue	culture	well	of	unstimulated	Boyden	chambers	than	
in	previous	experiments	 (fig	43).	A	mean	of	around	1000	cells	was	 counted	within	
the	membrane	of	unstimulated	 chambers,	with	only	between	1000	and	1300	 cells	
counted	 in	 ADP	 treated	 chambers.	 The	 number	 of	 cells	 counted	 at	 the	 bottom	of	
tissue	 culture	 wells	 under	 both	 stimulated	 and	 unstimulated	 conditions	 was	 also	
significantly	increased	in	these	experiments	compared	to	optimisation	experiments.	
Furthermore,	 no	 notable	 differences	 were	 observed	 between	 WT	 and	 LRRK2	 KO	
macrophage	chemotaxis	into	the	Boyden	membrane.	A	difference	could	be	observed	
in	chemotaxis	to	the	bottom	of	the	tissue	culture	membrane	with	a	mean	of	513	WT	
macrophages	compared	to	only	283	LRRK2	KO	macrophages	in	the	presence	of	ADP,	
however	 these	 differences	 were	 also	 reflected	 in	 the	 elevated	 number	 of	 cells	
quantified	in	unstimulated	chambers,	with	a	mean	of	158	WT	macrophages	counted	
compared	to	38	LRRK2	KO	macrophages.	This	suggests	 inaccuracies	in	cell	counting	
upon	initial	plating	of	cells	within	Boyden	membranes	may	outweigh	any	observable	
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Figure	43:	Chemotaxis	assays.	Quantification	of	cells	migrating	into	the	Boyden	membrane,	or	
to	 the	 bottom	 of	 tissue	 culture	 well	 as	 indicated	 in	 the	 presence	 of	 absence	 of	 ADP	
chemoattractant.	 24	 hour	 incubation,	 100,000	 cells	 plated.	 S.E.M.	 across	 three	 independent	
experiments	
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effect	 of	 genotype	 on	 chemotaxis.	 Thus	 full	 experiments	 showed	 unacceptable	
variability	 from	 previous	 optimisation	 experiments,	 and	 a	 hugely	 decreased	
observed	 effect	 of	 ADP	 on	measured	 chemotaxis.	 This	 was	 particularly	 true	 upon	
quantification	 of	 cells	 in	 the	 Boyden	 membrane.	 Further	 optimisation	 will	 be	
required	before	Boyden	chamber	assays	are	suitable	for	quantification	of	the	effect	
of	LRRK2	upon	chemotaxis.	
4.4.	Discussion		
The	 aim	 of	 this	 work	 was	 to	 investigate	 potential	 roles	 of	 LRRK2	 in	 the	
dynamic	 trafficking	 of	 TLRs	 and	dynamic	 cytoskeletal	 process	 of	 phagocytosis.	 The	
generation	of	pBMDMs	facilitated	these	studies	through	specificity	brought	about	by	
genetic	 knockout	 of	 LRRK2.	 The	 use	 of	 a	 genetic	 mouse	 model	 has	 important	
advantages	 over	 the	 use	 of	 knockdown	 systems	 or	 chemical	 inhibitors	 used	 by	
others	 in	 this	 field.	 B6.129X1(FVB)-Lrrk2tm1.1Cai/J	mice	 contain	 a	 premature	 stop	
codon	in	exon	3	of	LRRK2	mRNA,	resulting	from	excision	of	a	portion	of	exon	2	in	the	
DNA	of	 these	mice	 (Parisiadou	 et	 al.,	 2009).	 This	means	 that	while	mRNA	derived	
from	the	LRRK2	gene	may	be	expressed	and	detected	 in	cells	obtained	 from	these	
mice,	this	mRNA	will	undergo	nonsense-mediated	decay	at	the	ribosome	rather	than	
translation	to	mature	LRRK2;	as	such	these	mice	are	an	LRRK2	KO	genotype	 in	 line	
with	 published	 results	 (Parisiadou	 et	 al.,	 2009;	 Kervestin	 and	 Jacobson,	 2012).	
Perturbation	of	LRRK2	DNA	was	confirmed	by	genotyping	of	mice,	and	the	process	of	
degradation	 of	 LRRK2	 mRNA	 was	 reflected	 in	 a	 50	 %	 decrease	 in	 LRRK2	 mRNA	
detected	by	qRT-PCR;	an	observation	which	could	be	confirmed	by	RNA	sequencing.	
These	 considerations	 provided	 unequivocal	 evidence	 that	 LRRK2	 mRNA	 was	
perturbed	 in	 LRRK2	KO	mice.	 In	 comparison,	 the	use	of	 several	 currently	 available	
anti-LRRK2	 antibodies	 failed	 to	 specifically	 stain	 LRRK2	 in	 our	 hands,	 resulting	 in	 a	
large	amount	of	background	signal	by	immunofluorescent	microscopy.		
In	 WT	 primary	 macrophages,	 LRRK2	 transcription	 could	 be	 induced	 by	
activation	of	innate	immune	receptors,	most	notably	by	activation	of	TLR4	with	LPS.	
While	 at	 least	 a	 two-fold	 increase	 in	 LRRK2	 transcription	was	observed	 in	 all	mice	
tested,	 the	extent	of	 this	 increase	did	 vary	between	mice	more	 than	other	 stimuli	
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tested.	Confirmation	of	inducibility	of	LRRK2	expression	by	LPS	stimulation	was	later	
achieved	 through	 RNA	 sequencing.	 The	 variability	 of	 LRRK2	 inducibility	 observed	
using	qRT-PCR	perhaps	reflects	the	nature	of	the	literature,	where	there	are	mixed	
reports	 as	 to	whether	 LPS	 induces	 LRRK2	 transcription	at	 all	 (Dzamko	et	 al.,	 2012;	
Moehle	et	al.,	2012).	Within	this	context,	it	is	particularly	interesting	to	observe	that	
such	 a	 dramatic	 increase	 in	 LRRK2	 transcription	 in	 response	 to	 LPS	 stimulation.	
Reports	of	 Ifn-γ	 inducibility	of	 LRRK2	expression	are	 very	 consistent	 (Gardet	et	 al.,	
2010;	Thévenet	et	al.,	2011;	Kuss	et	al.,	2014),	therefore	it	was	surprising	that	only	a	
modest	 increase	 in	 transcription	as	observed.	 This	 is	most	 likely	 a	 consequence	of	
the	relatively	short	two-hour	incubation	with	Ifn-γ	that	was	applied.		In	comparison,	
an	almost	three-fold	increase	in	LRRK2	transcription	has	been	reported	as	measured	
by	microarray	after	24	hours	of	stimulation	of	mouse	macrophages	with	Ifn-γ	(Depke	
et	al.,	2014).	LRRK2	transcription	was	also	assessed	after	stimulation	with	MDP	and	
αSyn	 oligos.	 These	 innate	 immune	 activators	 were	 included	 due	 to	 their	 close	
functional	relationship	to	LRRK2.	NOD2	and	LRRK2	are	both	risk	factors	for	Crohn’s	
disease	 (Liu	and	Lenardo,	2012),	 sort	 lysozyme	 in	Paneth	cells	 (Zhang	et	al.,	2015),	
and	 are	 reported	 to	 jointly	 modulate	 IL-6	 production	 (Yan	 and	 Liu,	 2017).	 Alpha-
synuclein	 and	 LRRK2	 have	 been	 suggested	 to	 demonstrate	 synergy	 in	 their	
neurotoxic	 effects,	 through	 involvement	 in	 common	 pathways	 such	 as	 autophagy,	
neuronal	trafficking	and	proteosomal	degradation	(Liu	et	al.,	2012).	Further	to	this,	
alpha-synuclein	also	activates	immune	receptors	including	TLR1/2	heterodimers	(Kim	
et	 al.,	 2014;	 Daniele	 et	 al.,	 2015),	 and	 TLR4	 (Fellner	 et	 al.,	 2013).	 In	 spite	 of	 this,	
neither	MDP,	nor	alpha-synuclein	had	a	clear	effect	on	LRRK2	transcription.	The	use	
of	 alpha-synuclein	 is	 more	 problematic	 than	 other	 stimuli	 applied	 in	 these	
experiments	as	the	activity	of	alpha-synuclein	on	innate	immunity	varies	depending	
on	 the	precise	nature	of	 aggregation;	which	 is	 variable	between	batches	 and	with	
time	 (Kim	 et	 al.,	 2014;	 Tosatto	 et	 al.,	 2015).	 Access	 to	 a	 consistent	 and	 carefully	
controlled	source	of	aggregated	alpha-synuclein	would	allow	a	clearer	 indication	of	
macrophage	responses	to	the	proteins	oligomeric	 form.	These	results	utilise	LRRK2	
KO	mice	to	answer	basic	immunological	questions	about	LRRK2	function	without	the	
uncertainty	 of	 non-specific	 effects	 of	 inhibitors	 such	 as	 L2in1.	 Here	 it	 was	
demonstrated	 that	 LRRK2	 expression	 in	 primary	macrophages	 derived	 from	 these	
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mice	 is	 responsive	 to	 Ifn-γ,	 and	 that	 transcription	 of	 LRRK2	 is	 enhanced	 by	 LPS	
stimulation	at	an	early	time	point.	LRRK2	transcriptional	enhancement	was	specific	
to	 these	 stimuli,	 as	 MDP	 stimulation	 had	 no	 effect	 on	 transcription,	 while	 alpha-
synuclein	 had	 no	 clear	 effect.	 While	 LRRK2	 could	 be	 induced	 by	 LPS	 and	 Ifn-γ	
stimulation,	 no	 clear	 effect	 was	 observed	 upon	 LRRK2	 knockout	 on	 cytokine	
secretion	 in	 response	 to	 either	 LPS	 or	 Ifn-γ	 stimulation,	 nor	 other	 innate	 immune	
stimuli	including	MDP,	and	αSyn	oligos.	
Assays	to	measure	surface	 levels	of	TLR4	and	TLR2	were	successfully	set	up	
and	applied	to	measure	the	effect	of	LRRK2	on	the	dynamic	trafficking	of	TLR4,	and	
TLR2	expression	levels.	
The	 association	 between	 TLR4	 and	 LRRK2	 signalling	 has	 been	 extensively	
discussed.	 This	 relationship,	 combined	 with	 comparatively	 well-defined	 vesicular	
dynamics,	make	TLR4	a	perfect	 candidate	 for	 a	 receptor	whose	 trafficking	may	be	
influenced	by	LRRK2.	Perturbation	of	TLR4	trafficking	could	have	profound	effects	on	
the	balance	between	Myd88	and	TRIF	signalling,	or	termination	of	the	TLR4	response	
to	 LPS	 (Kagan	 et	 al.,	 2008;	 Husebye	 et	 al.,	 2010).	 Such	 changes	 in	 the	 balance	 of	
signalling	would	have	subsequent	effects	on	inflammatory	transcription	programmes	
downstream	 of	 TLR4.	 Knockout	 of	 LRRK2	 had	 no	 effect	 on	 either	 resting	 levels	 of	
TLR4,	or	TLR4	transcription	in	response	to	LPS.	This	means	that	while	TLR4	signalling	
regulates	 LRRK2	 transcription;	 reciprocal	 regulation	 does	 not	 appear	 to	 occur.	
Measurements	 of	 macrophage	 TLR4	 endocytosis	 were	 in	 line	 with	 observations	
made	by	other	groups.	TLR4	endocytosis	‘saturated’	at	about	70	%,	where	increased	
LPS	had	no	greater	effect	on	 surface	 levels	of	 TLR4.	 This	 required	10	 x	 less	 LPS	 to	
achieve	 than	 was	 used	 by	 another	 group	 (100	 ng/ml	 vs	 1	 ug/ml,	 after	 one	 hour	
incubation)	 (Zanoni	 et	 al.,	 2011).	 This	 observation	 could	 be	 a	 reflection	 of	 the	
increased	 responsiveness	 of	 primary	 macrophages	 compared	 to	 macrophage	 cell	
lines.	 Ultimately	 there	 were	 no	 detectable	 differences	 in	 TLR4	 at	 the	 cell	 surface	
between	 WT	 and	 LRRK2	 KO	 macrophages,	 either	 under	 resting	 conditions	 or	
following	 LPS	 stimulation.	 This	 finding	was	 consistent	 using	 two	 distinct	 anti-TLR4	
antibodies;	MTS-510	and	Sa15-21.	These	antibodies	 indicated	a	comparable	overall	
level	of	endocytosis	despite	binding	different	TLR4	epitopes,	and	followed	the	same	
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trend	of	 increasing	endocytosis	with	 time.	While	 it	would	 appear	 that	 LRRK2	does	
not	 affect	 TLR4	 localisation,	 TLR4	 signalling	 does	 appear	 to	 modulate	 LRRK2	
localisation.	 Indeed	 phosphorylation	 of	 LRRK2,	 which	 occurs	 downstream	 of	 TLR4	
activation,	has	even	been	reported	to	regulate	LRRK2	extracellular	 release	through	
exosomes,	with	 exosomal	 release	 reported	 in	 a	 diverse	 range	 of	 cellular	 contexts;	
both	 inside	 and	 outside	 of	 the	 brain	 (Fraser	 et	 al.,	 2013).	 In	 an	 innate	 immune	
context,	 activation	 of	 TLR4	 reportedly	 causes	 LRRK2	 dimerisation	 and	 membrane	
localisation	 (Schapansky	 et	 al.,	 2014).	 Therefore,	 TLR4	 signalling	modulates	 LRRK2	
trafficking,	 but	 as	with	 transcriptional	 responses,	 LRRK2	 does	 not	 appear	 to	 affect	
TLR4	trafficking.	Taken	together,	multiple	 lines	of	evidence	now	suggest	 that	while	
TLR4	and	LRRK2	do	interact,	LRRK2	acts	only	downstream	of	TLR4.	
	 	While	 TLR4	 is	 the	 pattern	 recognition	 receptor	most	 intimately	 associated	
with	 LRRK2,	 TLR2	 is	 highly	 involved	 in	 Parkinson’s	 disease	more	 generally.	 TLR2	 is	
reported	 as	 enriched	 in	 the	 Parkinson’s	 brain,	 and	 in	 pathologically	 relevant	
neuronal	regions	such	as	the	substantia	nigra	(Dzamko	et	al.,	2017).	A	recent	genetic	
discovery	has	even	suggested	 that	polymorphisms	 in	TLR2	may	be	a	 risk	 factor	 for	
the	 sporadic	 disease	 (Wu	 et	 al.,	 2015).	 This	would	 be	 logical	 as	 TLR2	 detection	 of	
alpha-synuclein	as	a	DAMP	is	thought	to	mediate	neuroinflammation	in	Parkinson’s	
disease.	 In	 primary	 macrophages,	 TLR2	 transcription	 was	 strongly	 induced	 by	
stimulation	with	LPS,	MDP	and	αSyn	oligos.	LPS	 induction	 resulted	 in	around	a	10-
fold	 increase	 in	 transcription,	 exactly	 in	 line	 with	 other	 reports	 for	 two	 hours	 of	
stimulation	(Nhu	et	al.,	2006).	Interestingly,	LRRK2	KO	macrophages	stimulated	with	
MDP	resulted	in	a	significantly	enhanced	transcription	of	TLR2	compared	to	WT	cells.	
This	appears	to	represent	a	trend,	as	stimulation	with	LPS	and	αSyn	oligos	similarly	
resulted	 in	 greater	 TLR2	 transcription,	 but	 did	 not	 reach	 statistical	 significance.	 	 It	
would	appear	that	LRRK2	acts	to	inhibit	TLR2	transcription	specifically	in	response	to	
inflammatory	 stimuli,	 as	 no	 differences	 were	 observed	 in	 TLR2	 transcription	 in	
unstimulated	 macrophages.	 The	 similarity	 in	 TLR2	 transcription	 in	 unstimulated	
macrophages	provides	 reassurance	 that	observed	differences	upon	 innate	 immune	
stimulation	 are	 not	 the	 result	 of	 a	 systematic	 error.	 Similarly,	while	 Ifn-γ	 failed	 to	
noticeably	 stimulate	 transcription	 of	 TLR2,	 more	 overall	 TLR2	 transcription	 was	
	 161	
observed	 in	WT	Ifn-γ	stimulated	macrophages	than	 in	LRRK2	KO	equivalent	cells.	A	
24-hour	 time	 course	 of	 TLR2	 cell	 surface	 expression	was	 performed	 to	 investigate	
the	 effect	 of	 enhanced	 transcription	 of	 TLR2	 on	 TLR2	 protein	 levels	 at	 the	 cell	
surface.	 No	 differences	 were	 observed	 across	 this	 time	 course.	 Potential	
explanations	for	this	 include	that	LPS	stimulation	results	 in	peak	TLR2	transcription	
only	 after	 six	 hours,	 meaning	 that	 at	 later	 time	 point	 TLR2	 transcription	 in	 WT	
macrophages	may	catch-up	with	that	of	LRRK2	KO	equivalent	cells	(Nhu	et	al.,	2006).	
It	would	 therefore	be	 interesting	 to	 look	 at	 a	more	 complete	 time	 course	of	 TLR2	
transcription	in	response	to	inflammatory	stimuli	to	see	if	this	is	the	case,	or	whether	
differences	 in	 TLR2	 transcription	 are	maintained	 over	 time.	 It	 is	 also	 possible	 that	
differences	 in	 TLR2	 transcription	 were	 not	 observed	 at	 the	 cell	 surface	 due	 to	 a	
compensatory	mechanism	in	TLR2	trafficking	to	maintain	homeostatic	levels	of	TLR2	
at	the	cells	surface	 in	the	absence	of	LRRK2.	To	address	this,	 total	TLR2	 levels,	and	
TLR2	 distribution	 could	 be	 compared	 between	 LRRK2	 genotypes	 by	
immunofluorescent	 microscopy	 upon	 stimulation	 with	 MDP.	 While	 the	 functional	
significance	of	TLR2	endocytosis	 is	not	understood,	TLR2	trafficking	dynamics	could	
be	investigated	by	flow	cytometry	in	response	to	stimulation	by	LTA	or	perhaps	even	
Staphylococcus	 aureus	 (Stuart	 et	 al.,	 2005).	 Such	 measurements	 would	 represent	
TLR2	 trafficking	 dynamics,	 and	 would	 complement	 data	 collected	 for	 TLR4	 in	
response	to	LPS.		
For	a	complete	understanding	of	the	role	of	LRRK2	in	phagocytosis,	different	
phagocytic	 targets	 were	 used;	 each	 introducing	 a	 higher	 level	 of	 signalling	
complexity	 to	 the	 system.	 An	 initial	 assay	 using	 carboxylate	 modified	 fluorescent	
beads	was	 used	 to	 optimise	 experimental	 parameters	 and	 to	 compare	 phagocytic	
uptake	of	simple	large	molecules.	Flow	cytometry	was	able	resolve	up	to	five	beads	
in	a	macrophage	through	discernable	jumps	in	MFI.	Applying	10	beads	per	cell	was	
optimal	 to	 achieve	 bead	 phagocytosis	 by	 WT	 macrophages	 within	 this	 resolvable	
range.	Application	of	beads	under	these	conditions	revealed	no	differences	in	uptake	
between	 LRRK2	 genotypes.	 Around	 35	 %	 of	 cells	 were	 seen	 to	 be	 phagocytically	
active	 after	 two	 hours	 of	 incubation	 during	 this	 round	 of	 experiments;	 a	 slight	
decrease	from	that	seen	during	optimisation.	This	most	likely	reflects	variation	in	the	
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dilution	of	beads	to	10	beads	per	cell,	but	could	also	be	affected	by	pre-incubation	
and	maintenance	of	cells	 in	DMSO	during	experiments.	Variability	 in,	and	between	
experiments	 is	a	weakness	of	 this	assay	as	 the	 ratio	of	beads	 to	cell	 is	affected	by	
small	differences	 in	cell	plating	density	and	bead	dilution.	Using	 the	same	stock	of	
beads	minimises	this	technical	issue	for	comparing	phagocytosis	between	genotypes,	
but	 not	 across	 different	 experiments	 where	 a	 new	 dilution	 of	 beads	 is	 prepared.	
With	 this	 in	 mind,	 repeat	 experiments	 showed	 remarkably	 strong	 reproducibility	
across	replicate	experiments.	The	uptake	of	different	materials	by	cells	is	an	area	of	
on-going	 research	 in	 biophysics.	 Biophysical	 properties	 such	 as	 charge,	 shape	 and	
hydrophobicity	affect	cellular	uptake	of	molecules	by	cells,	with	negatively	charged	
microparticles	 taken	 up	 more	 efficiently	 than	 positively	 charged	 microparticles	
(Fröhlich,	2012).	Opsonisation	of	beads	was	next	performed	in	order	to	measure	the	
effect	of	LRRK2	on	Fcγ	 receptor	mediated	phagocytosis.	Activation	of	phagocytosis	
receptors	 led	 to	 an	 increased	 proportion	 of	 cells	 to	 be	 phagocytically	 active	
compared	to	non-opsonised	beads	used	previously.	Further	to	this,	the	proportion	of	
cells	containing	5+	beads	was	tripled	when	using	opsonised	beads	compared	to	non-
opsonised.	 This	 enhancement	 of	 phagocytosis	 indicates	 that	 opsonisation	 was	
successful,	and	that	resulting	macrophage	stimulation	could	be	successfully	detected	
by	flow	cytometry	assay.	Resolution	was	lost	compared	to	non-opsonised	beads	due	
to	this	increased	proportion	of	cells	containing	5+	beads,	however	it	remained	clear	
that	LRRK2	has	no	effect	on	the	uptake	of	these	opsonised	beads.		
A	final	level	of	complexity	was	introduced	through	the	use	of	live	E.	coli	as	a	
phagocytic	target.	While	E.	coli	are	not	antibody	coated,	they	do	express	a	plethora	
of	PAMPs	on	their	cell	surface	including	LPS	and	flagellin	for	the	activation	of	TLRs;	
thus	 stimulating	 macrophage	 activation	 (Ribes	 et	 al.,	 2010).	 Importantly,	 this	
stimulation	occurs	via	a	different	mechanism	to	that	explored	previously,	and	more	
physiologically	than	in	experiments	performed	using	extensive	LPS	pre-incubation	of	
cells	 (Schapansky	et	al.,	2014).	 It	 should	be	noted	 that	while	 the	use	of	bacteria	 is	
more	 relevant	 to	 LRRK2	 in	 the	 context	 of	 Crohn’s	 disease	 than	Parkinson’s,	 alpha-
synuclein	 aggregates	 which	 form	 in	 Parkinson’s	 disease	 are	 immunogenic,	
stimulating	at	least	TLR4	and	TLR2,	thus	displaying	similarities	to	E.	coli	that	are	not	
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modelled	 in	 latex	 bead	 uptake.	 Analysis	 of	 bacterial	 phagocytosis	 was	 performed	
using	 confocal	 microscopy	 due	 to	 the	 non-uniform	 nature	 of	 E.	 coli	 in	 size	 and	
fluorescent	 intensity,	which	would	not	 register	as	discrete	 jumps	 in	MFI	 that	were	
used	 to	quantify	bead	phagocytosis	by	 flow	cytometry.	To	compensate	adequately	
for	 uncertainty	 associated	 with	 quantification	 of	 phagocytosis	 by	 microscopy,	 a	
minimum	 of	 500	 cells	 were	 counted	 for	 each	 genotype	 per	 experiment.	 No	
significant	 differences	 in	 bacterial	 phagocytosis	 were	 measured	 in	 this	 analysis.	
These	results	show	that	LRRK2	has	no	effect	on	the	phagocytosis	of	targets	under	a	
range	of	different	conditions	and	innate	immune	stimuli.	Thus,	using	a	genetic	LRRK2	
KO	 experimental	 system,	 further	 validation	 is	 provided	 to	 assertions	 made	 using	
LRRK2	knockdown	macrophages	(Schapansky	et	al.,	2014),	and	LRRK2	overexpressing	
G2019S	 immortalised	 cells	 (Moehle	 et	 al.,	 2015).	 Work	 described	 here	 has	 goes	
beyond	 the	 scope	 of	 these	 studies	 performed	 by	 other	 groups,	 by	 looking	 at	 the	
effect	of	LRRK2	KO	on	the	uptake	of	phagocytic	targets	triggered	by	different	levels	
of	 innate	 immune	 signalling.	 Importantly,	 these	 collective	 studies	 of	 phagocytosis	
using	 different	 cells	 and	 genetic	 systems	 refute	 findings	 made	 using	 the	 L2in1	
inhibitor,	which	suggests	 that	results	obtained	using	the	L2in1	system	were	 flawed	
by	off-target	effects	(Marker	et	al.,	2012).	One	potential	further	phagocytosis	assay,	
as	mentioned	in	the	context	of	vesicular	trafficking,	would	be	to	examine	the	cellular	
uptake	of	Staph.	aureus	–	a	Gram-positive	bacterium.	Such	an	assay	would	not	only	
be	 interesting	 in	 order	 to	 measure	 TLR2	 trafficking	 dynamics,	 but	 also	 in	 the	
activation	 of	 NF-κB	 signalling	 downstream	 of	 TLR2	 via	 Rac1;	 an	 LRRK2	 interaction	
partner	(Arbibe	et	al.,	2000).	
While	 phagocytosis	 is	 an	 actin	 dependent	 process	 directly	 involved	 in	
immunity,	 the	 actin	 cytoskeleton	 is	 similarly	 important	 in	 cell	 migration	 in	 the	
presence	and	absence	of	inflammatory	stimuli.	Chemotaxis	assays	were	established	
in	 an	 attempt	 to	 quantify	 the	 effect	 of	 LRRK2	 upon	 this	 process.	 Optimisation	 of	
these	 assays	was	 highly	 successful	with	 a	 clear	 effect	 of	 ADP	 upon	migration	 into	
Boyden	 chamber	 membranes,	 and	 through	 these	 membranes	 to	 the	 bottom	 of	
tissue	 culture	wells.	However,	 application	of	optimised	 conditions	 for	 these	assays	
failed	 to	 recapitulate	 the	 previously	 observed	 ability	 to	 observe	 the	 established	
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effect	of	ADP	upon	chemotaxis;	ultimately	no	conclusions	can	be	drawn	from	these	
assays	 in	 the	 current	 form,	 with	 further	 optimisation	 required	 in	 order	 to	 draw	
meaningful	 conclusions	 of	 the	 effect	 of	 LRRK2	 upon	 chemotaxis.	 The	 major	
difference	 between	 optimisation	 experiments	 and	 LRRK2	 chemotaxis	 assays	 is	 the	
scale	of	experiments,	with	twice	as	many	samples	used	required	per	experiment	to	
account	for	the	LRRK2	KO	macrophages,	but	also	inaccuracies	introduced	during	cell	
counting	of	 two	different	 cell	 populations.	 The	use	of	 a	 computerised	 cell	 counter	
may	be	able	 to	 reduce	 the	effect	of	 cell	 counting	 inaccuracies	upon	 this	 assay.	An	
alternative	approach	to	measure	the	effect	of	LRRK2	upon	cell	migration	may	be	to	
observe	cells	using	live	cell	imaging.	Such	an	assay	would	be	suitable	to	observe	the	
effect	 of	 LRRK2	 upon	membrane	 dynamics	 under	 non-pathological	 conditions,	 but	
lacks	the	immunological	chemoattractant	component	present	in	chemotaxis	assays.	
Cells	 may	 be	 transfected	 with	 lifact,	 a	 marker	 for	 F-actin	 visualisation,	 in	 the	
presence	or	absence	of	chemotactic	stimuli	(Riedl	et	al.,	2008).	Actin	structures	can	
also	be	fixed	and	imaged	with	fluorescently	labelled	phalloiden.		
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5.	Transcriptomic	and	 lipidomic	analysis	of	LRRK2	function	 in	 the	
innate	immune	response	
5.1	Aims	
- Stimulate	WT	 and	 LRRK2	 KO	macrophages	with	 LPS	 or	MDP,	 and	 apply	 an	
RNA	sequencing	approach	to	obtain	datasets	reflecting	the	role	of	LRRK2	 in	
macrophage	innate	immune	transcriptional	responses.	
- Apply	differential	gene	expression	analysis	on	WT	and	LRRK2	KO	datasets	to	
establish	baseline	differences	in	gene	expression	in	unstimulated	cells.	
- Apply	pathway	analysis	to	compare	between	WT	and	LRRK2	KO	datasets	and	
establish	broad	roles	of	LRRK2	in	innate	immune	responses	to	LPS	or	MDP.	
- Apply	two–parameter	analysis	to	determine	specific	differentially	responding	
genes	to	innate	immune	stimuli.	
- Assess	 lipidomic	changes	 in	 stimulated	macrophages	 in	order	 to	 investigate	
the	role	of	LRRK2	in	ceramide	metabolism.	
	
5.2	Background	
	 It	is	clear	that	the	role	of	LRRK2	is	extremely	diverse,	with	apparent	functions	
described	across	broad	areas	of	biology.	Such	diversity	breeds	complexity	 that	can	
be	 difficult	 to	 reconcile.	 As	 such,	 the	 specific	 pathogenic	 mechanism	 of	 LRRK2	 in	
Parkinson’s	 and	 other	 inflammatory	 disease	 remains	 unclear.	Modern	 approaches	
allow	 us	 to	 capture	 a	 snapshot	 of	 biologically	 complex	 situations.	 To	 this	 end,	 a	
transcriptomic	approach	was	taken	in	order	to	better	understand	the	role	of	LRRK2	
in	innate	immunity.	A	supplementary	metabolomic	approach	was	also	taken	to	allow	
specific	 questions	 to	 be	 answered	 about	 the	 effect	 of	 LRRK2	 on	 ceramide	
composition.	
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Transcriptomics	
	 	Innate	 immune	 programs	 need	 to	 be	 activated	 before	 the	 majority	 of	
transcriptional	 changes	 come	 into	 effect.	 These	 transcriptional	 changes	 can	 be	
considered	 part	 of	 the	 innate	 immune	 response.	 Following	 results	 of	 interest	 in	
previous	 work,	 an	 experiment	 was	 designed	 in	 which	 WT	 and	 LRRK2	 KO	
macrophages	would	be	stimulated	with	either	LPS	or	MDP.		
The	 relationship	 between	 TLR4,	 LPS	 and	 LRRK2	 has	 been	 extensively	
discussed.	Furthermore,	the	transcriptional	response	to	macrophage	LPS	stimulation	
is	 well	 understood,	 and	 so	 provides	 a	 good	 background	 upon	 which	 to	 establish	
potential	perturbations	of	a	normal	response	by	knockout	of	LRRK2	(Lu	et	al.,	2008).	
In	 comparison,	 the	 innate	 immune	 response	 to	 MDP	 has	 been	 less	 well	
characterised.	NOD2	is	the	intracellular	receptor	of	MDP,	a	PAMP	expressed	as	part	
of	bacterial	cell	walls	(Mo	et	al.,	2012).	NOD2	activation	leads	to	nucleotide	binding,	
receptor	 multimerisation,	 and	 complex	 formation	 with	 RIP2	 via	 CARD-CARD	
interactions	 (Boyle	 et	 al.,	 2014).	 An	 extremely	 diverse	 range	 of	 signalling	 results,	
including	 MAPK	 signalling	 cascades,	 as	 well	 as	 Nf-κB,	 and	 IRF7	 transcriptional	
activation	 (Correa	 et	 al.,	 2012).	 Nf-κB	 activation	 occurs	 via	 IKK	 family	 of	 proteins,	
which	 also	 phosphorylate	 LRRK2	 (Dzamko	 et	 al.,	 2012).	 Alternate	 activation	 can	
occur	via	interaction	with	‘mitochondrial	antiviral	signalling’	(MAVS),	a	mitochondrial	
protein	normally	associated	with	the	‘retinoic	acid-inducible	gene	I’	(RIG-I)	mediated	
antiviral	 response;	 this	 results	 in	 ‘TNF	 receptor	 associated	 factor	 3’	 (TRAF3)	
mediated	 signalling	 (Sabbah	 et	 al.,	 2009).	 Signalling	 occurs	 not	 just	 through	
phosphorylation	of	downstream	proteins,	but	also	via	the	formation	of	Lys63-linked	
polyubiquitin	 chains	 (Hasegawa	 et	 al.,	 2008).	 NOD2	 activation	 induces	 autophagy	
and	enhances	apoptosis;	 two	processes	associated	with	LRRK2	 (Ogura	et	al.,	2001;	
Travassos	et	al.,	2010).	Furthermore,	LRRK2	appears	to	play	a	role	in	modulating	the	
response	 to	 MDP	 inflammatory	 signalling;	 and	 in	 Paneth	 cells,	 has	 been	
demonstrated	 to	 form	 an	 interaction	with	NOD2	 (Zhang	 et	 al.,	 2015;	 Yan	 and	 Liu,	
2017).	 Finally,	 NOD2	 activation	 is	 able	 to	 modulate	 TLR	 signalling.	 NOD2	 acts	 to	
down-regulate	 the	 TLR2	 inflammatory	 response	 in	 mice	 (Watanabe	 et	 al.,	 2004;	
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Watanabe	et	al.,	2006),	while	modulating	inflammation	in	a	dose	dependent	manner	
in	humans	(Borm	et	al.,	2008).	A	similar	role	appears	to	be	present	in	modulation	of	
TLR4	signalling;	with	NOD2	acting	to	down	regulate	induction	of	IL-12	release	when	
stimulated	 with	 large	 doses	 of	 LPS,	 and	 up	 regulate	 IL-12	 production	 upon	
stimulation	with	low	LPS	dose	(Kim	et	al.,	2015).		
While	 LPS	 stimulation	 of	 TLR4	 represents	 a	 well	 known	 innate	 immune	
process	 upon	 which	 to	 assess	 the	 effects	 of	 LRRK2,	 MDP	 stimulation	 of	 NOD2	 is	
involved	 in	 an	 array	 of	 less	 well-characterised	 processes	 which	 overlap	 with	
described	roles	of	LRRK2.	
Ceramide	metabolism	
	 In	 parallel	 to	 RNA	 sequencing,	 metabolites	 were	 extracted	 for	 analysis.	 A	
recent	report	has	shown	a	role	of	LRRK2	in	ceramide	metabolism	in	brain	tissue;	with	
increased	 levels	 of	 ceramide	 observed	 in	 LRRK2	 KO	 cells	 (Ferrazza	 et	 al.,	 2016).		
Ceramide	 is	 linked	 to	 many	 cellular	 functions,	 including	 autophagy	 and	 apoptosis	
(Pattingre	 et	 al.,	 2009;	 Aflaki	 et	 al.,	 2012),	 but	 is	 also	 associated	 directly	 with	
inflammatory	 processes.	 For	 instance,	 ceramide	 is	 able	 to	 activate	 the	 NLRP3	
inflammasome	 in	 bone	marrow	 derived	macrophages,	 leading	 to	 cleavage	 of	 pro-
IL1β	 to	 its	mature,	 pro-inflammatory	 form	 (Vandanmagsar	 et	 al.,	 2011).	 Ceramide	
can	 be	 formed	 by	de	 novo	 synthesis,	 or	 through	 salvage	 pathways	 from	 ceramide	
derivatives	such	as	sphingolipids	or	sphingosine	(Maceyka	and	Spiegel,	2014).	GBA1	
encodes	 the	 enzyme	 glucocerebrosidase,	 which	 is	 involved	 in	 ceramide	 salvage	
through	 catalysis	 of	 glucocerebrosides	 to	 ceramide	 and	 glucose.	 Intriguingly,	
mutations	 to	 the	GBA1	gene	are	present	 in	 around	7	%	of	patients	 suffering	 form	
Parkinson’s	 disease,	 and	 carriers	 of	 GBA1	 mutations	 have	 increased	 risk	 of	
developing	Parkinson’s	(Sidransky	et	al.,	2009).	Furthermore,	patients	 lacking	GBA1	
expression	 develop	 Gaucher	 disease,	 through	 over	 accumulation	 of	
glucocerebroside.	 Severity	 of	 this	 Gaucher	 disease	 is	 linked	 to	 the	 level	 of	 GBA1	
deficiency,	with	more	 severe	manifestations	of	 the	disease	presenting	with	 severe	
neurological	defects	including	epilepsy	and	cognitive	impairment	(Aflaki	et	al.,	2017).	
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Therefore,	ceramide	can	be	linked	separately	to	altered	metabolism	in	neurones	via	
LRRK2,	 and	deficient	metabolism	 in	macrophages	 via	 the	Gaucher	 and	Parkinson’s	
disease	associated	gene;	GBA1.	As	a	result,	 it	 is	of	interest	as	to	whether	increased	
ceramide	 levels	 observed	 in	 LRRK2	 KO	 brain	 tissue	 are	 also	 seen	 in	 LRRK2	 KO	
macrophages.	
5.3	Results	
5.3.1	 Cell	 surface	markers	 show	 little	 variation	 in	macrophage	markers	 between	
triplicate	mice	
RNA	 sequencing	 is	 a	 sensitive	 genome	 wide	 method	 of	 analysis,	 with	 the	
potential	to	pick	up	a	lot	of	noise	in	macrophages	even	of	the	same	genotype	if	not	
controlled	appropriately	by	considerations	such	as	age-matching	mice.	As	discussed	
previously,	 pBMDM	 cells	 are	 derived	 in	 tissue	 culture	 from	 bone	 marrow.	 This	
differentiation	 process	 takes	 place	 over	 the	 period	 of	 a	 week	 in	 the	 presence	 of	
growth	factors	 including	macrophage	colony-stimulating	factor	(M-CSF);	and	so	has	
the	potential	 to	 introduce	such	a	source	of	noise.	Therefore,	efforts	were	made	to	
confirm	 the	 similarity	 in	 nature	 and	 purity	 of	 macrophage	 cultures	 before	 RNA	
extraction	 and	 RNA	 sequencing.	 One	 day	 prior	 to	 RNA	 extraction,	 a	 portion	 of	
differentiated	macrophages	were	prepared	for	flow	cytometry	analysis	and	stained	
for	 various	 cell	 surface	markers:	 CD11b	 for	 cells	 of	 the	myeloid	 lineage,	 F4/80	 for	
mouse	macrophages,	and	CD11c	for	monocytic-derived	cells,	including	macrophages	
(Murray	 and	Wynn,	 2012).	 These	markers	 revealed	 no	 dramatic	 differences	 in	 the	
differentiation	 state	 of	 cells,	with	 uniform	expression	of	 CD11b,	 and	highly	 similar	
expression	 levels	 of	 F4/80	 and	 CD11c.	 CD11c	 surface	 expression	 in	 LRRK2	 KO	
macrophages	 displayed	 a	 slightly	 higher	 level	 of	 variability	 between	 cultures	 than	
WT	 equivalent	 cells	 (fig	 44).	 Overall,	 cultures	 were	 considered	 similar	 enough	 to	
proceed	with	differential	gene	expression	analysis.	
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Antigen: CD11b F4/80 CD11c 
Marker: Myeloid	cells Mouse	macrophage Monocyte	derived	cells 
LRRK2	KO	
WT	
LRRK2	KO	
WT	
LRRK2	KO	
WT	
Figure	 44:	 Analysis	 of	 macrophage	 cell	 markers.	 Flow	 cytometry	 analysis	 of	 macrophage	 cell	
surface	markers.	Each	coloured,	unfilled	peak	are	stained	cells	of	a	macrophage	population	derived	
from	a	different	mouse.	Filled	grey	peaks	are	unstained	cells	derived	from	a	single	mouse.	
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5.3.2	mRNA	sequencing,	quality	control	and	read	mapping	
WT	 and	 LRRK2	 KO	 macrophages	 were	 next	 stimulated	 where	 appropriate	
with	either	LPS,	or	MDP	for	two	hours,	after	which	RNA	was	extracted	and	submitted	
to	‘Cambridge	Genomic	Services’	for	mRNA	sequencing.	A	mean	read	depth	of	over	
22.2x106	 reads/sample	 was	 achieved	 with	 a	 range	 of	 16.0x106	 -	 24.9x106	
reads/sample	(Table	12).	Reads	were	of	high	quality,	 requiring	a	mean	of	 less	than	
0.1	%	of	reads	to	be	trimmed	during	quality	control.	A	mean	of	87.5	%	of	reads	could	
be	unambiguously	mapped	 to	gene	encoding	 regions	of	 the	genome.	Therefore	by	
comparing	the	frequency	of	reads	per	gene	between	samples,	relative	expression	of	
genes	can	be	inferred.		The	resulting	datasets	could	now	be	analysed	for	differential	
gene	expression.		
	
			 	
	 Read	number	
Sample	
LRRK2	
Genotype	
Treatment	 Raw	 Trimmed		
Uniquely	mapped	
to	genes	
1	 KO	 LPS	 22,350,423	 22,337,177	 19,756,554	
2	 KO	 MDP	 20,864,607	 20,852,101	 18,035,498	
3	 KO	 Media	 24,584,270	 24,574,608	 21,373,819	
4	 KO	 LPS	 23,543,303	 23,526,041	 20,817,399	
5	 KO	 MDP	 23,633,755	 23,624,109	 20,888,105	
6	 KO	 Media	 20,997,179	 20,979,364	 18,387,880	
7	 KO	 LPS	 28,876,974	 28,863,515	 24,950,718	
8	 KO	 MDP	 21,917,338	 21,889,839	 18,953,616	
9	 KO	 Media	 22,083,849	 22,073,008	 19,232,352	
10	 WT	 LPS	 19,754,246	 19,746,221	 17,475,368	
11	 WT	 MDP	 23,022,129	 23,009,814	 19,887,489	
12	 WT	 Media	 23,088,368	 23,069,013	 19,908,328	
13	 WT	 LPS	 20,633,505	 20,608,724	 18,251,968	
14	 WT	 MDP	 21,367,108	 21,352,531	 18,693,589	
15	 WT	 Media	 25,560,513	 25,549,470	 22,693,200	
16	 WT	 LPS	 19,993,017	 19,980,006	 17,633,954	
17	 WT	 MDP	 18,222,162	 18,215,079	 16,008,576	
18	 WT	 Media	 20,019,319	 20,006,085	 17,641,459	
Table	12:	RNA	sequencing	quality	 control	and	mapping.	Number	of	reads	per	sample	after	
each	step	of	quality	control	and	read	mapping	is	indicated.	
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5.3.3		Differential	gene	expression		
Differential	gene	expression	analysis	was	performed	using	DEseq2.	Datasets	
of	mapped	counts	were	 interrogated	 for	differences	 in	each	LRRK2	genotype	upon	
innate	immune	stimulation,	as	well	as	for	underlying	differences	between	genotypes	
in	unstimulated	cells	(fig	45a).	DEseq2	determines	a	statistical	model	accounting	for	
variance	 in	 counts	 per	 gene,	 and	 base	 mean	 of	 counts	 allowing	 the	 statistical	
significance	 of	 apparent	 differences	 in	 gene	 expression	 to	 be	 estimated.	 This	 is	 a	
routinely	 used	 approach	 for	 differential	 gene	 expression	 analysis.	 Analysis	 of	 the	
effect	 of	 innate	 immune	 treatment	 of	 cells	 revealed	 5000	 differentially	 expressed	
genes	upon	LPS	stimulation	with	an	‘adjusted	p-value’	(padj)	for	multiple	tests	of	<	
0.01	 for	 both	 WT	 and	 LRRK2	 KO	 macrophages.	 4985	 genes	 were	 found	 to	 be	
significantly	 differentially	 expressed	 in	 WT	 macrophages,	 and	 5354	 genes	
differentially	expressed	in	LRRK2	KO	macrophages	after	LPS	treatment.	A	smaller,	yet	
still	substantial	number	of	genes	were	differentially	expressed	upon	treatment	with	
MDP.	In	total,	MDP	treatment	resulted	in	1483	significantly	differentially	expressed	
genes	in	WT	macrophages,	compared	to	1478	genes	in	LRRK2	KO	macrophages	(fig	
45b).			
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Figure	 45:	Differential	 gene	 expression	 analysis.	 a:	 LRRK2	genotype	 (red),	 and	 treatment	with	
innate	immune	stimuli	 (blue),	are	considered	separately	 in	these	experiments.	b:	Quantification	
of	 differentailly	 expressed	 genes.	 KO	 refers	 to	 the	 LRRK2	 KO	 genotype.	 Numbers	 refer	 to	
differentially	expressed	genes	between	annotated	samples	(padj	<	0.01).	
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When	comparing	unstimulated	cells	for	differences	in	gene	expression	owing	
simply	 to	 knockout	 of	 LRRK2,	 only	 eight	 genes	 were	 significantly	 differentially	
expressed	 (table	 13).	 One	 differentially	 expressed	 gene	 is	 LRRK2,	 this	 in	 line	 with	
earlier	 qPCR	 results	 and	 confirms	 the	 accuracy	 of	 RNAseq	 analysis	 (fig	 29).	 Other	
genes	include	Kif21a:	a	member	of	the	kinesin	family	of	motor	proteins,	Camk2b:	a	
calcium/calmodulin	responsive	protein	kinase,	Cd59a:	a	regulator	of	the	membrane	
attack	 complex	 in	mice,	 and	 Nnt:	 a	 NAD(P)	 transhydrogenase	with	 implications	 in	
defence	against	oxidative	stress.	Very	 little	 is	known	about	 the	Lrmda	gene	except	
that	 it	 consists	 of	 a	 region	 of	 LRRs.	 Remaining	 results	 are	 not	 represented	 at	 the	
protein	 level	 and	 so	are	unlikely	 to	have	 relevance	 to	 the	 current	 study.	The	gene	
detected	 as	 being	 of	 the	 highest	 significance,	 Gm14150,	 is	 described	 as	 a	
pseudogene,	 produced	by	 the	 incorporation	of	 reverse	 transcribed	mRNA	 into	 the	
genome,	 while	 Gm44305	 is	 a	 retained	 intron.	 These	 are	 likely	 not	 differentially	
expressed	genes,	but	pre-existing	genomic	difference	between	strains	 (Akagi	et	al.,	
2008).	
	 	
Ensembl	gene	ID	 baseMean	
Fold	change	
(KO/WT)	
Padj	 Gene	Symbol	
ENSMUSG00000082809	 177.98	 5.65	 2.52E-92	 Pseudogene	Gm14150	
ENSMUSG00000063458	 83.02	 0.44	 3.99E-20	 Lrmda	
ENSMUSG00000022629	 31.47	 1.93	 1.07E-14	 Kif21a	
ENSMUSG00000105703	 89.25	 2.01	 1.94E-13	 Gm43305	
ENSMUSG00000036273	 137.37	 0.54	 8.10E-10	 Lrrk2	
ENSMUSG00000057897	 58.28	 1.66	 1.17E-07	 Camk2b	
ENSMUSG00000032679	 297.27	 1.55	 1.02E-04	 Cd59a	
ENSMUSG00000025453	 784.61	 1.43	 9.56E-04	 Nnt	
Table	13:	Differentially	expressed	genes	between	unstimulated	macrophages.	Genes	with	padj	<	
0.01.	LRRK2	KO/WT	pBMDM	cells.	Genes	not	represented	at	the	protein	level	are	displayed	in	grey.		
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Visualisation	of	these	transcriptional	responses	affords	an	appreciation	of	the	
broad	 characteristics	 of	 the	 MDP	 and	 LPS	 responses,	 as	 well	 as	 similarities	 and	
differences	 between	 WT	 and	 LRRK2	 macrophages	 in	 their	 response	 to	 innate	
immune	activation.	Transcriptional	responses	were	visualised	in	two	ways:	MA	plots	
and	Volcano	plots.	Information	provided	by	these	methods	of	visualisation	overlap,	
but	combine	to	provide	a	good	overview	of	the	transcriptional	response.		
The	shapes	of	MA	plots	help	to	confirm	that	processing	of	mRNA	counts	was	
performed	successfully	by	the	distribution	of	plotted	genes.	As	the	mean	number	of	
counts	 increases,	 the	 fold	 change	 required	 to	 reach	 a	 statistically	 significant	
difference	between	treated	and	untreated	conditions	decreases.	Both	LPS	and	MDP	
treated	cells	showed	a	weighting	towards	gene	up-regulation	upon	stimulation,	with	
a	 greater	number	of	 genes	plotted	above	 log	 fold	 change	=	0	 than	below	 (fig	 46).	
Interestingly,	for	LPS	treated	cells,	it	appears	that	a	greater	number	of	genes	are	up-
regulated	 strongly	 in	 LRRK2	KO	macrophages	 than	 in	WT	macrophages	 (fig	 46a,b).	
Gene	distribution	otherwise	appeared	similar	upon	LPS	stimulation,	and	no	obvious	
bulk	differences	could	be	seen	in	the	MDP	transcriptional	response	(fig	46c,d).	
‘Volcano	 plots’	 provide	 a	 similar	 verification	 of	 mRNA	 count	 analysis	 with	
statistical	significance	of	differential	expression	of	genes	between	samples	increasing	
with	 fold	 change	 of	 that	 gene	 between	 treated	 and	 untreated	 samples,	 giving	 a	
characteristic	 ‘volcano	shape’.	This	 characteristic	distribution	of	genes	can	be	 seen	
for	all	data	sets	(fig	47).	As	was	observed	in	MA	plots,	it	can	be	seen	that	there	is	a	
greater	 weighting	 of	 up-regulated	 genes	 than	 down-regulated,	 this	 time	 seen	
through	a	larger	number	of	genes	plotted	above	log2	fold	change	=	0	than	below.	No	
obvious	differences	can	be	seen	between	WT	and	LRRK2	KO	genotypes	for	either	LPS	
or	MDP	treatment.	
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Figure	 46:	MA	 plot	 visualisation	 of	 transcriptional	 gene	 responses.	 Dots	 represent	 individual	
genes.	Red	indicates	padj	<	0.01.	a,c:	WT	pBMDM	cells.	b,d:	LRRK2	KO	pBMDM	cells.		
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Figure	 47:	 ‘Volcano	 plot’	 visualisation	 of	 transcriptional	 gene	 responses.	 Dots	 represent	
individual	genes.	Red	indicates	padj	<	0.01.	a,c:	WT	pBMDM	cells.	b,d:	LRRK2	KO	pBMDM	cells.		
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In	 order	 to	 quantify	 these	 observations	 in	 bulk	 gene	 transcription,	
significantly	 differentially	 expressed	 genes	 between	WT	 and	 LRRK2	 KO	 genotypes	
were	 filtered	for	significance,	 then	categorised	with	regard	to	whether	genes	were	
found	to	be	up	or	down-regulated	uniquely	 in	one	genotype,	shared	between	both	
genotypes,	 or	 whether	 a	 gene	 was	 up-regulated	 in	 one	 genotype	 and	 down-
regulated	in	another.	
	 As	observed	previously	in	both	LPS	and	MDP	experiments,	a	greater	number	
of	genes	were	up-regulated	than	down-regulated.	LPS	treatment	led	to	3192	genes	
being	up-regulated	and	2696	down-regulated	(fig	48a).	MDP	treatment	had	a	smaller	
effect	while	 1020	 genes	were	 up-regulated,	 compared	 to	 676	 down-regulated	 (fig	
48b).	 Furthermore,	 quantification	 confirmed	 that	 a	 greater	 number	of	 genes	were	
significantly	differentially	expressed	upon	LPS	treatment	 in	LRRK2	KO	macrophages	
than	WT	macrophages.	Perhaps	the	most	interesting	observation	from	this	analysis	
is	 that	a	single	gene	was	 found	to	be	down-regulated	 in	WT	macrophages	and	up-
regulated	in	LRRK2	KO	macrophages	upon	treatment	with	LPS	(fig	48a).	Transcription	
of	this	gene,	Rapgef3	is	almost	halved	upon	LPS	treatment	in	WT	macrophages	while	
being	 increased	 just	over	7-fold	 in	 LRRK2	KO	macrophages;	 a	 complete	 reversal	 in	
transcriptional	regulation	upon	loss	of	LRRK2.	
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Figure	48:		Quantification	of	up	and	down-regulated	differentially	expressed	genes	upon	innate	
immune	 stimulation.	 Scaled	 Venn	 diagrams.	 Gene	 numbers	 at	 padj	 <	 0.01.	 a:	 LPS	 treated	
macrophages.	b:	MDP	treated	macrophages.	
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5.3.4	Two-parameter	analysis	identifies	differentially	responding	genes	
	 Analysis	 so	 far	 could	 be	 described	 as	 conventional	 differential	 gene	
expression	 analysis,	 performed	 once	 in	 WT	 macrophages	 and	 once	 in	 LRRK2	 KO	
macrophages	for	each	treatment,	followed	by	manual	comparisons	between	results	
from	these	experiments.	A	more	powerful	analysis	is	able	to	consider	the	parameter	
of	 innate	 immune	 treatment	 and	 the	 parameter	 of	 LRRK2	 genotype	 together,	 in	
order	to	 isolate	differences	between	LRRK2	genotype	that	are	specifically	owing	to	
innate	immune	stimulation	(fig	49).	This	two-parameter	analysis	provides	a	method	
to	 identify	 specifically	 ‘differentially	 responding	genes’	between	genotypes.	 Such	a	
method	was	adapted	from	the	‘edgeR	Users	Guide’	(Chen	et	al.,	2008;	Robinson	et	
al.,	2009)	and	revealed	eleven	differentially	responding	genes	to	LPS	(Padj	<		0.1)	(fig	
50a,b).	All	differentially	responding	genes	showed	an	increased	level	of	transcription	
upon	LPS	stimulation	in	LRRK2	KO	cells	compared	to	WT	cells.	As	expected,	Rapgef3	
was	 identified	 as	 an	 overwhelmingly	 differentially	 regulated	 gene	 upon	 LPS	
stimulation,	reflecting	the	reversal	in	regulation	from	down	regulation	to	significant	
up-regulation	with	 the	 loss	of	LRRK2	observed	 in	 the	previous	analysis	 (fig	50b).	 In	
comparison,	 MDP	 treatment	 identified	 no	 significantly	 differentially	 responding	
genes	(fig	50c,d).	This	aligns	with	the	relatively	mild	and	slow	acting	nature	of	MDP	
compared	 to	 LPS	 stimulation,	 but	 perhaps	more	 importantly,	 demonstrates	 a	 high	
stringency	 of	 the	 applied	 method	 to	 identify	 differentially	 responding	 genes,	
including	those	identified	upon	LPS	treatment.	
Figure	49:		Two-parameter	analysis.	LRRK2	genotype,	and	treatment	with	innate	immune	
stimuli,	 are	 considered	 together	 in	 this	 analysis	 to	 identify	 a	 single	 set	 of	 differentially	
responding	genes	for	each	treatment.	
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Figure	 50:	 	 Visualisation	 of	 differentially	
responding	genes.	 	Fold	changes	are	ligand	
treated	 gene	 expression	 levels	 (LRRK2	
KO/WT).	 Dots	 represent	 individual	 genes.	
Red	dots	indicate	padj	<	0.1	
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	 Interestingly,	of	 identified	differentially	 responding	genes	 to	LPS,	 three	pro-
inflammatory	chemokines	were	identified	including	Ccl3,	Ccl4,	and	Ccl5	(table	14).	In	
comparison,	 no	 classical	 pro-inflammatory	 cytokines	 were	 identified.	 As	 well	 as	
chemokines	 themselves,	 the	 chemokine	 receptor	 Ccrl2	 was	 identified.	 ‘Activating	
transcription	factor	3’	(Atf3)	appears	to	be	biologically	relevant	to	the	role	of	LRRK2	
in	 innate	 immunity,	 as	 it	 has	 previously	 been	 identified	 as	 a	 negative	 regulator	 of	
TLR4	 (Gilchrist	 et	 al.,	 2006).	 Interestingly,	 the	 ‘hydroxycarboxylic	 acid	 receptor	 2’	
(Hcar2)	 has	 been	 previously	 linked	 to	 neurodegeneration	 and	 Parkinson’s	 disease,	
with	the	protein’s	 ligand	niacin	used	by	some	as	a	supplement	against	the	disease.	
‘Ankyrin	 repeat	 and	 BTB/POZ	 domain	 containing	 protein-2’	 (Abtb2)	 is	 a	 protein	
which	has	been	linked	to	inhibition	of	aggregation	of	alpha-synuclein	in	neurons	(Roy	
and	 Pahan,	 2013).	 ‘Rap	 guanine	 nucleotide	 exchange	 factor	 3’	 (Rapgef3)	 is	 better	
known	as	 ‘exchange	factor	directly	activated	by	cAMP	1’	 (EPAC1),	and	 is	by	far	the	
most	significantly	differentially	regulated	gene	detected.	‘Tripartite	motif-containing	
protein	25’	(TRIM25)	is	a	ubiquitin	ligase	involved	in	the	RIG-I	pathway	for	the	innate	
immune	 response	 to	 viral	 DNA	 (Sanchez	 et	 al.,	 2016).	 ‘Cysteine	 And	 Serine	 Rich	
Nuclear	Protein	1’	 (Csrnp1)	 is	 a	 transcription	 factor	 that	 is	 negatively	 regulated	by	
Ensembl	gene	ID	 baseMean	
Fold	change	
(KO/WT)	
Padj	 Gene	Symbol	
ENSMUSG00000022469	 176.34	 10.97	 4.98E-37	 Rapgef3	
ENSMUSG00000018930	 11796.25	 3.26	 1.94E-12	 Ccl4	
ENSMUSG00000026628	 2039.03	 2.72	 5.58E-07	 Atf3	
ENSMUSG00000000982	 4095.93	 2.24	 1.02E-03	 Ccl3	
ENSMUSG00000032515	 1117.61	 1.73	 1.07E-03	 Csrnp1	
ENSMUSG00000032724	 417.68	 2.80	 5.72E-03	 Abtb2	
ENSMUSG00000035042	 3664.77	 2.02	 2.75E-02	 Ccl5	
ENSMUSG00000043953	 1652.79	 3.39	 2.75E-02	 Ccrl2	
ENSMUSG00000045502	 249.85	 3.55	 4.19E-02	 Hcar2	
ENSMUSG00000001156	 477.83	 2.09	 9.07E-02	 Mxd1	
ENSMUSG00000000275	 8075.68	 1.40	 9.83E-02	 Trim25	
Table	 14:	 Differentially	 responding	 genes	 in	 LPS	 stimulated	macrophages.	 Genes	with	
padj	<	0.1.	LPS	treated	LRRK2	KO/WT	pBMDM	cells.	
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axin;	which	is	in	turn,	a	negative	regulator	of	the	Wnt	pathway	(Ishiguro	et	al.,	2001).	
Finally,	 ‘MAX	Dimerization	Protein	1’	 (Mxd1)	 is	 a	 transcriptional	 repressor	 for	Myc	
binding	(Cascón	and	Robledo,	2012).	
	 To	 validate	 differentially	 responding	 genes	 identified	 by	 two-parameter	
analysis,	 qRT-PCR	 was	 applied.	 This	 focused	 on	 candidate	 genes	 that	 had	 been	
identified	with	strong	statistical	significance	and	a	clear	link	to	innate	immunity.	LPS	
treated	 WT	 and	 LRRK2	 KO	 samples	 were	 directly	 compared	 for	 this	 analysis.	 	 A	
statistically	 significant	 increase	 in	mRNA	was	 observed	 in	 LRRK2	 KO	macrophages	
compared	to	LPS	treated	WT	macrophages	for	all	genes	except	that	of	Rapgef3,	as	
determined	by	paired	two-tailed	t-tests	(fig	51).	While	transcription	of	the	Rapgef3	
gene	 was	 not	 observed	 to	 be	 statistically	 significantly	 different	 in	 LRRK2	 KO	
compared	to	WT	macrophages,	a	p-value	of	0.06	was	still	observed.	This	was	most	
likely	due	to	a	large	standard	deviation	between	samples.	Fold	changes	in	mRNA	of	
all	tested	significant	genes	was	seen	to	be	slightly	lower	by	qRT-PCR	than	by	RNAseq.	
	 	
Figure	51:	Transcript	 levels	upon	LPS	stimulation.	qRT-PCR	with	beta-actin	and	GAPDH	as	
housekeeping	genes.	Each	point	is	a	different	LRRK2	KO	pBMDM	sample	compared	to	three	
different	WT	pBMDM	samples.	Error	bars	are	S.E.M.	Paired	two-tailed	t	tests	compared	to	a	
value	of	1.	
	
Cc
l3
Cc
l4
Cc
l5
Cc
rl2
Ra
pg
ef3 At
f3
0
1
2
3
10
15
20
25
Fo
ld
 c
ha
ng
e 
m
R
N
A
 K
O
 / 
W
T
*
**
*
*
p = 0.06
	 183	
5.3.5		Pathway	analysis		
	 Two-parameter	 analysis	 revealed	 a	 relatively	 small	 number	 of	 differentially	
regulated	genes	between	LRRK2	genotypes,	therefore	to	complement	this,	pathway	
analysis	was	performed	in	order	to	compare	innate	immune	stimulation	of	WT	and	
LRRK2	 KO	 macrophages	 on	 a	 signalling	 pathway	 level.	 Pathway	 analysis	 was	
performed	 by	 calculating	 gene	 enrichment	 against	 the	 ‘Reactome’	 database	 of	
biological	signalling	pathways.		
Pathways	 shared	 between	 WT	 and	 LRRK2	 KO	 macrophages	 demonstrated	
that	analysis	was	carried	out	 successfully.	Expected	broad	areas	of	biology	such	as	
‘innate	 immunity’	 were	 highlighted	 as	 shared	 between	 WT	 and	 LRRK2	 KO	
macrophages.	More	specific	pathways	were	also	highlighted;	ranging	from	‘toll-like	
receptor	 signalling	 cascades’,	 to	 ‘interferon	 and	 interleukin	 signalling’	 (appendix	
tables	3,	4).	At	the	most	stringent	statistical	cut	off	of	differential	gene	expression,	
only	 strongly	 differentially	 expressed	 genes	 were	 included,	 explaining	 why	 similar	
results	 were	 observed	 for	 LPS	 treated	 (appendix	 table	 3),	 and	 MDP	 treated	
(appendix	table	4)	macrophages.		
In	order	to	 identify	pathways	that	were	affected	by	the	knockout	of	LRRK2,	
pathway	analysis	was	performed	three	 times	on	 the	RNAseq	dataset,	using	cutoffs	
for	 differential	 gene	 expression	 of	 padj	 <	 0.01,	 0.05	 and	 0.1.	 The	 resulting	 list	 of	
pathways	 from	 each	 analysis	 was	 then	 sampled	 at	 a	 high	 and	 low	 stringency	 for	
pathways	uniquely	enriched	 in	either	WT	or	LRRK2	KO	macrophages.	Therefore,	 in	
total,	pathway	enrichment	analysis	was	performed	six	 times	 for	each	 treatment	of	
each	 genotype	 (appendix	 tables	 5-8).	 The	 reason	 such	 extensive	 analysis	 was	
performed	was	 in	 order	 to	 be	 able	 to	 score	 identified	 pathways	 for	 robustness	 of	
identification.	With	a	series	of	six	analyses	performed,	pathways	could	be	identified	
between	one	and	six	times	per	genotype:	therefore,	a	score	of	six	 indicates	robust	
identification,	 while	 pathways	 occurring	 only	 once	 were	 considered	 to	 be	 noise.
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WT	Macrophages	 LRRK2	KO	Macrophages	
4	 Association	of	TriC/CCT	with	target	proteins	during	biosynthesis	 5	 Signaling	by	NOTCH	
4	 PI	Metabolism	 5	 TRAF3-dependent	IRF	activation	pathway	
4	 Regulation	of	actin	dynamics	for	phagocytic	cup	formation	 4	 Cytosolic	sensors	of	pathogen-associated	DNA	
3	 Downstream	signal	transduction	 4	 p38MAPK	events	
3	 G	alpha	(12/13)	signalling	events	 3	 Loss	of	Nlp	from	mitotic	centrosomes	
3	 Hemostasis	 3	
Loss	of	proteins	required	for	interphase	microtubule	organization	
from	the	centrosome	
3	 Regulation	of	IFNG	signaling	 3	
Nucleotide-binding	domain,	leucine	rich	repeat	containing	
receptor	(NLR)	signaling	pathways	
2	 Constitutive	PI3K/AKT	Signaling	in	Cancer	 3	 Regulation	of	PLK1	Activity	at	G2/M	Transition	
2	 GAB1	signalosome	 3	 The	NLRP3	inflammasome	
2	 Interleukin-3,	5	and	GM-CSF	signaling	 2	 G2/M	Transition	
2	 Interleukin-6	signaling	 2	 Inflammasomes	
2	 Negative	regulators	of	RIG-I/MDA5	signaling	 2	 Interleukin-2	signaling	
2	 Phospholipid	metabolism	 2	 Mitotic	G2-G2/M	phases	
2	 PI-3K	cascade	 2	 Pre-NOTCH	Expression	and	Processing	
2	 PI3K	events	in	ERBB2	signaling	 1	
Antigen	Presentation:	Folding,	assembly	and	peptide	loading	of	
class	I	MHC	
2	 PI3K	events	in	ERBB4	signaling	 1	 Cell	Cycle,	Mitotic	
2	 PI3K/AKT	activation	 1	
DEx/H-box	helicases	activate	type	I	IFN	and	inflammatory	
cytokines	production	
Table	15:	Pathways	enriched	in	a	WT	or	LRRK2	KO	specific	manner	after	LPS	stimulation.	100	ng/ml	LPS.	Data	sampled	at	two	levels	of	statistical	
significance	of	pathway	enrichment.	Frequency	of	occurrence	of	pathway	across	sampling	is	indicated	in	green.	Unique	occurrences	in	grey.	
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WT	Macrophages	 LRRK2	KO	Macrophages	
2	 PI3K/AKT	Signaling	in	Cancer	 1	 Downstream	signal	transduction	
2	 PIP3	activates	AKT	signaling	 1	 ERKs	are	inactivated	
2	 Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	 1	 Extrinsic	Pathway	for	Apoptosis	
2	 Synthesis	of	PIPs	at	the	plasma	membrane	 1	 G	alpha	(12/13)	signalling	events	
2	 TCR	signaling	 1	 Interleukin	receptor	SHC	signaling	
2	 The	NLRP3	inflammasome	 1	 Interleukin-3,	5	and	GM-CSF	signaling	
1	 Downstream	TCR	signaling	 1	 Interleukin-6	signaling	
1	 ERK/MAPK	targets	 1	 Lysosphingolipid	and	LPA	receptors	
1	 Fc	epsilon	receptor	(FCERI)	signaling	 1	 Pre-NOTCH	Processing	in	Golgi	
1	 Folding	of	actin	by	CCT/TriC	 1	 Signaling	by	the	B	Cell	Receptor	(BCR)	
1	 Interleukin-2	signaling	 1	 TRAF6	mediated	IRF7	activation	
1	 Interleukin-7	signaling	
	 	
1	 Regulation	of	IFNA	signaling	
	 	
1	 Regulation	of	signaling	by	CBL	
	 	
1	 Role	of	phospholipids	in	phagocytosis	
	 	
1	 Signaling	by	EGFR	in	Cancer	
	 	
1	 Signaling	by	FGFR	in	disease	
	 	
1	 Signaling	by	FGFR1	fusion	mutants	
	 	
1	 Signaling	by	PDGF	
	 	
1	 Signaling	by	SCF-KIT	
	 	
1	 TAK1	activates	NFkB	by	phosphorylation	and	activation	of	IKKs	complex	
	 	
1	 TRAF6	mediated	NF-kB	activation	
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WT	Macrophages	 LRRK2	KO	Macrophages	
4	 Dissolution	of	Fibrin	Clot	 5	 FCGR	activation	
4	 GAB1	signalosome	 4	 Role	of	phospholipids	in	phagocytosis	
3	 Downstream	Signaling	Events	Of	B	Cell	Receptor	(BCR)	 3	 Cell	surface	interactions	at	the	vascular	wall	
3	 MAP	kinase	activation	in	TLR	cascade	 3	
Immunoregulatory	interactions	between	a	Lymphoid	and	a	non-
Lymphoid	cell	
3	 p38MAPK	events	 2	 Signaling	by	SCF-KIT	
3	 Rho	GTPase	cycle	 1	 Cell	junction	organization	
3	 Signaling	by	Rho	GTPases	 1	 DAP12	interactions	
3	 Signaling	by	the	B	Cell	Receptor	(BCR)	 1	 Fc	epsilon	receptor	(FCERI)	signaling	
2	 Adaptive	Immune	System	 1	 FCERI	mediated	NF-kB	activation	
2	 Constitutive	PI3K/AKT	Signaling	in	Cancer	 1	 GAB1	signalosome	
2	 Inflammasomes	 1	 Generation	of	second	messenger	molecules	
2	 Integrin	alphaIIb	beta3	signaling	 1	 Inflammasomes	
2	 NOTCH2	intracellular	domain	regulates	transcription	 1	 p75NTR	recruits	signalling	complexes	
2	 p75	NTR	receptor-mediated	signalling	 1	 Signaling	by	EGFR	in	Cancer	
2	 PI-3K	cascade	 1	 Signaling	by	GPCR	
2	 PI3K	events	in	ERBB2	signaling	 1	 Signaling	by	PDGF	
2	 PI3K	events	in	ERBB4	signaling	 1	 The	NLRP3	inflammasome	
2	 PI3K/AKT	activation	
	 	
2	 PI3K/AKT	Signaling	in	Cancer	
	 	
2	 PIP3	activates	AKT	signaling	
	 	
Table	16:	Pathways	enriched	in	a	WT	or	LRRK2	KO	specific	manner	after	MDP	stimulation.	10	ug/ml	MDP.		Data	sampled	at	two	levels	of	statistical	
significance	of	pathway	enrichment.	Frequency	of	occurrence	of	pathway	across	sampling	is	indicated	in	green.	Unique	occurrences	in	grey.	
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WT	Macrophages	 LRRK2	KO	Macrophages	
2	
Regulation	of	Lipid	Metabolism	by	Peroxisome	proliferator-activated	
receptor	alpha	(PPARalpha)	 	 	
2	 Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	
	 	
2	 Signaling	by	PDGF	
	 	
2	 ZBP1(DAI)	mediated	induction	of	type	I	IFNs	
	 	
1	 AKT	phosphorylates	targets	in	the	nucleus	
	 	
1	 Cross-presentation	of	particulate	exogenous	antigens	(phagosomes)	
	 	
1	 DAP12	interactions	
	 	
1	 DAP12	signaling	
	 	
1	 GPCR	ligand	binding	
	 	
1	 Hemostasis	
	 	
1	 Negative	regulators	of	RIG-I/MDA5	signaling	
	 	
1	 NGF	signalling	via	TRKA	from	the	plasma	membrane	
	 	
1	
Nucleotide-binding	domain,	leucine	rich	repeat	containing	receptor	
(NLR)	signaling	pathways	 	 	
1	 PPARA	Activates	Gene	Expression	
	 	
1	 Regulation	of	actin	dynamics	for	phagocytic	cup	formation	
	 	
1	 Signaling	by	EGFR	in	Cancer	
	 	
1	 Signaling	by	ERBB2	
	 	
1	 Signaling	by	FGFR	
	 	
1	 The	NLRP3	inflammasome	
	 	
1	 TRAF3-dependent	IRF	activation	pathway	
	 	
	
TRAF6	mediated	IRF7	activation	
	 	
1	
Transport	of	glucose	and	other	sugars,	bile	salts	and	organic	acids,	
metal	ions	and	amine	compounds	
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It	 was	 noted	 that	 pathways	 could	 be	 enriched	 for	 both	WT	 and	 LRRK2	 KO	
macrophage	datasets.	This	is	as	when	applying	different	differential	gene	expression	
cut-off	values,	a	different	set	of	genes	was	analysed.	Robustness	of	this	analysis	was	
observed	 from	 the	 fact	 that	 those	 pathways	 with	 the	 highest	 frequency	 of	
observation	were	far	less	likely	to	be	enriched	in	both	genotypes.	By	comparing	LPS	
datasets,	a	range	of	areas	of	biology	were	identified	(table	15).	Notably	some	of	the	
highest	 scoring	 pathways	 related	 to	 phospholipid	 metabolism	 and	 signal	
transduction,	and	phagocytosis.	Other	areas	of	biology	such	as	protein	biosynthesis	
and	signal	transduction	were	identified.	Signal	transduction	pathways	were	diverse,	
including	 ‘G-protein	coupled	receptors’,	 ‘phospholipid	signalling’,	and	 ‘direct	 innate	
immune	signalling	pathways’	such	as	‘cytosolic	sensors	of	pathogen-associated	DNA’,	
and	 ‘p38MAPK	 events’.	 There	 was	 some	 similarity	 in	 differentially	 regulated	
pathways	 upon	 MDP	 treatment	 of	 macrophages;	 including	 MAPK	 activation	 and	
phospholipid	related	signalling	(table	16).	A	stronger	representation	of	cytoskeleton	
associated	pathways	where	reported	as	differentially	regulated	by	LRRK2	upon	MDP	
stimulation,	with	 several	 levels	 of	 the	Rho	GTPase	 signalling	 pathway	 reported,	 as	
well	as	pathways	directly	relating	to	phagocytosis,	including	‘FCGR	activation’.	
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5.3.6		Metabolomics	
Shotgun	 lipidomics	 was	 carried	 out	 in	 parallel	 to	 RNA	 sequencing.	
Macrophages	were	treated	with	100	ng/ml	of	LPS	or	10	μg/ml	MDP	for	two	hours,	or	
were	starved	of	nutrients	for	two	hours	by	replacement	of	growth	media	with	EBSS.	
Following	 treatment,	methanol	 extraction	of	 lipids	 and	 fatty	 acids	was	 performed,	
and	 resulting	 metabolites	 analysed	 by	 mass	 spectroscopy.	 ‘Partial	 least	 squares	
discriminant	 analysis’	 (PLS-DA)	 revealed	 dramatic	 differences	 in	 lipid	 composition	
between	samples	from	nutrient	starved	macrophages	and	remaining	samples	(fig	52	
a).	This	reflects	dramatic	changes	in	lipid	composition	as	lipids	are	used	as	an	energy	
source.	 A	 difference	 between	WT	 and	 LRRK2	 KO	macrophages	was	 the	 next	most	
prevalent	factor	in	lipid	composition,	suggesting	LRRK2	does	have	an	effect	on	lipid	
metabolism.	To	assess	the	affect	of	innate	immune	treatment	on	lipid	composition,	
PLS-DA	analysis	was	performed	on	WT	and	LRRK2	KO	datasets	to	generate	separate	
models	(fig	52b).	As	before,	starvation	accounted	for	the	most	significant	change	in	
lipid	composition,	however	separation	was	also	observed	of	MDP	treated	samples	as	
compared	to	LPS	treated,	or	untreated	cells.	This	separation	of	MDP	treated	samples	
was	present	 in	both	WT	and	LRRK2	KO	models,	but	appeared	to	be	stronger	 in	WT	
macrophages,	 suggesting	 LRRK2	may	be	 affecting	 lipid	 composition	 following	MDP	
treatment.	
To	 assess	 the	 contribution	 of	 ceramides	 to	 overall	 changes	 in	 lipid	
composition	between	treatments,	loadings	plots	were	generated	for	each	genotype	
and	 the	 distribution	 of	 ceramides	 examined	 by	 PLS-DA	 analysis	 (fig	 53a).	 In	 WT	
macrophages,	clustering	of	ceramides	was	clearly	visible	separated	from	PLS-DA	axis	
1	and	2.	In	comparison,	much	weaker	separation	of	ceramides	was	visible	in	LRRK2	
KO	macrophages,	with	no	separation	evident	on	PLS-DA	axis	2	(fig	53b).		
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Figure	52:	PLS-DA	plots	of	lipid	composition.	a:	Combined	model	of	all	samples.	b:	Separated	
models	of	WT	and	LRRK2	KO	macrophages.	
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Figure	 53:	 Loadings	 plots	 suggest	 an	 LRRK2	 dependent	 effect	 of	 MDP	 treatment	 on	
ceramide	 metabolism.	 Greyed	 out	 symbols	 are	 non-ceramide	 metabolites	 a:	 WT	
macrophages.	b:	LRRK2	KO	macrophages.	
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To	address	ceramide	metabolism	more	directly,	 the	proportion	of	ceramide	
compared	 to	 total	measured	metabolite	was	 analysed.	 In	 untreated	macrophages,	
no	 statistically	 significant	 differences	 were	 observed	 between	 WT	 and	 LRRK2	 KO	
genotypes	 (fig	 54a).	 However,	 treatment	 with	 MDP	 resulted	 in	 a	 statistically	
significant	 increase	 in	 total	 ceramide	 compared	 to	 untreated	 cells	 in	 WT	
macrophages,	 while	 no	 difference	 was	 observed	 in	 LRRK2	 KO	 macrophages.	 In	
comparison,	 no	 changes	 in	 total	 ceramide	 were	 observed	 upon	 LPS	 treatment	 of	
macrophages	 (fig	 54b).	 This	 indicates	 an	 LRRK2	dependent	 increase	 in	 ceramide	 is	
observed	in	macrophages	upon	MDP	stimulation.	
In	 total,	 twelve	 different	 ceramide	 species	 could	 be	 detected	 by	 mass	
spectroscopy.	These	are	identified	by	the	total	number	of	carbons	in	the	molecules	
fatty	 acid	 acyl	 tails,	 followed	by	 the	number	of	 double	bonds	 in	 the	 acyl	 tails.	 For	
instance,	 ‘Ceramide	 (42:2)’	 will	 contain	 fatty	 acid	 acyl	 groups	 with	 a	 total	 of	 42	
carbons,	and	2	double	bonds.	It	should	be	noted	that	this	does	not	uniquely	identify	
a	 ceramide,	 as	 it	 does	 not	 provide	 information	 of	 the	 distribution	 of	 carbons	 or	
double	bonds	across	the	two	fatty	acid	acyl	chains	found	on	a	ceramide.	Of	twelve	
detected	 ceramide	 species,	 eight	 revealed	 LRRK2	 dependent	 increases	 upon	MDP	
stimulation,	 with	 the	 four	 remaining	 ceramide	 species	 detected	 at	 relatively	 low	
levels	(fig	55).	In	comparison,	only	the	proportion	of	ceramide	(36:1)	was	increased	
upon	LPS	stimulation	(data	not	shown).	
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Figure	54:	Proportion	of	ceramides.	Error	bars	are	S.E.M.	of	samples	extracted	from	three	mice.	Stats	are	paired	two-tailed	t	tests.	a:	Untreated	
macrophages.	b:	10	g/ml	MDP	or	100ng/ml	LPS	treated	macrophages	as	indicated.	
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Figure	55:	 Individual	 ceramide	 species	 respond	 to	MDP	 treatment	 in	 an	 LRRK2	dependent	manner.	Error	bars	are	S.E.M.	of	samples	
extracted	from	three	mice.	Stats	are	paired	two-tailed	t	tests.	
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5.4	Discussion	
The	 use	 of	 RNA	 sequencing	 technology	 allowed	 the	 role	 of	 LRRK2	 to	 be	
examined	 across	 the	 macrophage	 transcriptome	 in	 response	 to	 inflammatory	
stimuli.	Thus,	the	role	of	LRRK2	in	the	innate	immune	system	could	be	probed	very	
broadly.	 The	 transcriptome	 is	 dynamic	 in	 the	 innate	 immune	 response,	 changing	
over	time.	In	line	with	previous	experiments,	a	time-point	of	two	hours	after	innate	
immune	treatment	was	chosen	for	RNA	extraction.	This	was	deemed	appropriate	to	
detect	early	changes	in	gene	expression	profile,	which	may	be	modulated	by	LRRK2,	
without	 being	 complicated	 by	 secondary	 effects	 of	 cytokine	 signalling	 on	 the	
transcriptome.		
Reads	 obtained	 from	 RNA	 sequencing	 were	 of	 high	 quality	 and	 sufficient	
depth	 for	 differential	 gene	 expression	 analysis	 with	 a	 mean	 read	 depth	 of	 22.2	
million	reads/sample,	of	which	19.5	million	reads	could	be	uniquely	mapped	to	gene	
encoding	regions	of	the	genome.	As	a	guideline,	a	significant	positive	correlation	has	
been	 described	 between	 the	 detection	 of	 all	 but	 highly-abundant	 genes,	 with	
increasing	 read	 depth	 from	 1.6	 million	 to	 10	 million	 reads.	 No	 significant	
improvement	was	then	detected	between	10	million	and	20	million	reads	(Wang	et	
al.,	 2011).	 This	 places	 the	 present	 study	 as	 sufficient	 for	 the	 description	 of	
differential	 gene	 expression	 of	 all	 but	 very	 poorly	 expressed	 genes.	 Read	 quality	
control	 was	 performed	 by	 ‘Cambridge	 Genomic	 Services’	 using	 an	 automated	
pipeline,	with	manual	oversight.	Reads	were	judged	to	be	of	high	quality	by	criteria	
including	‘per	base	sequence	content’,	‘per	sequence	GC	content’,	‘sequence	length	
distribution’,	and	‘sequence	duplication	levels’.	Around	90	%	of	reads	were	uniquely	
mapped	 to	 genes,	 with	 only	 a	 small	 proportion	 of	 reads	 mapped	 to	 ribosomal,	
intronic	or	intergenic	regions	of	the	mouse	genome.	Ambiguity	in	read	mapping	due	
to	sequence	alignment	with	multiple	genes	could	be	minimised	by	the	use	of	longer	
read	lengths	or	paired-end	sequencing,	however	90	%	of	successfully	mapped	reads	
with	the	read	depth	described	was	sufficient	to	proceed	with	analysis	using	DEseq2.	
	It	 is	 interesting	 that	 only	 a	 low	 number	 of	 differentially	 expressed	 genes	
were	 observed	 between	 LRRK2	 genotypes	 under	 resting	 conditions.	 This	 may	
indicate	 that	 LRRK2	only	 exerts	 an	effect	 on	 the	macrophage	 transcriptome	under	
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stimulated	 conditions.	 This	 would	 agree	 with	 previous	 observations	 that	 LRRK2	
expression	 can	 be	 induced	 upon	 Ifn-γ	 or	 LPS	 stimulation.	 This	 finding	 also	 reflects	
work	by	another	group	that	identified	no	changes	in	gene	expression	in	unstimulated	
human	 fibroblasts	 or	 brain	 tissue	 between	 G2019S	 LRRK2	 carriers	 and	 controls	
(Devine	 et	 al.,	 2011).	 No	 obvious	 connection	 exists	 between	 the	 genes	 that	 are	
differentially	 expressed	 under	 unstimulated	 conditions,	 but	 previously	 explored	
themes	of	 LRRK2	 interactions	with	 the	cytoskeleton	and	 innate	 immunity	do	arise.	
This	 is	 through	 the	 microtubule	 motor	 protein,	 KIF21A;	 and	 a	 regulator	 of	 the	
membrane	attack	 complex,	CD59a	 (Brooimans	et	 al.,	 1992;	Marszalek	et	 al.,	 1999;	
Baalasubramanian	 et	 al.,	 2004),.	 KIF21A	 expression	 is	 enriched	 in	 the	 brain,	 with	
relatively	low	expression	in	innate	immune	cells.	The	fact	that	NNT	is	a	regulator	of	
oxidative	stress	is	interesting,	as	this	is	a	pathway	strongly	linked	to	degeneration	of	
dopaminergic	 neurons	 (Rydström,	 2006;	 Bolam	 and	 Pissadaki,	 2012).	 In	
macrophages,	 oxidative	 stress	 acts	 via	 the	 extracellular	 matrix	 to	 increase	 cell	
adhesion	 while	 also	 increasing	 inflammatory	 cytokine	 release	 via	 inhibition	 of	
‘histone	deacetylase	2’	(HDAC-2)	(Kirkham,	2007).		
By	 comparing	 bulk	 transcription	 data,	 it	 can	 be	 seen	 that	 compared	 to	
treatment	 with	 LPS,	 a	 smaller	 number	 of	 differentially	 expressed	 genes	 were	
detected	 upon	MDP	 treatment.	 This	 is	 to	 be	 expected	 given	 the	 requirement	 for	
MDP	 to	 pass	 through	 the	 cell	 membrane	 for	 detection	 by	 the	 cytosolic	 NOD2	
receptor	(Girardin	et	al.,	2003).	MDP	detection	by	NOD2	is	also	known	to	lead	to	an	
attenuated	 response	 compared	 to	 detection	 of	 PAMP	molecules	 by	 TLRs	 (Moreira	
and	 Zamboni,	 2012).	 Visualisation	 of	 data	 revealed	 that	 LRRK2	 KO	 macrophages	
appeared	to	be	more	responsive	to	differential	up-regulation	in	response	to	LPS	than	
WT	macrophages.	This	was	confirmed	by	quantification	of	gene	expression	data,	and	
also	 found	 to	 be	 true	 for	 differential	 down-regulation	 of	 gene	 transcription	 in	
response	to	LPS.	It	is	possible	that	this	observation	could	be	a	consequence	of	lower	
variability	 of	 gene	 expression	 in	 LRRK2	 KO	 macrophages	 compared	 to	 WT	
macrophages;	a	methodological	and	statistical	issue	rather	than	an	effect	of	LRRK2.	
Such	a	systematic	error	would	be	expected	to	manifest	in	the	MDP	treated	dataset.		
However,	in	contrast	to	LPS	datasets,	treatment	of	macrophages	with	MDP	resulted	
	 197	
in	remarkably	similar	bulk	gene	responses	between	LRRK2	genotypes.	This	suggests	
that	LRRK2	may	 indeed	act	 to	 ‘dampen’	 the	overall	 LPS	 transcriptional	 response	 in	
macrophages.		
With	this	 in	mind,	 it	 is	 interesting	that	following	two-parameter	analysis,	all	
LPS	differentially	 responding	genes	demonstrated	enhanced	 transcription	 in	 LRRK2	
KO	macrophages	compared	to	WT.	A	similar	effect	was	previously	seen	 in	qRT-PCR	
experiments	 for	 TLR2.	 Manual	 inspection	 of	 RNA	 sequencing	 data	 confirmed	
enhanced	 TLR2	 transcription	 in	 LRRK2	 KO	 macrophages	 compared	 to	 WT	
macrophages	upon	either	LPS	or	MDP	stimulation	(data	not	shown).	By	carrying	out	
two-parameter	 analysis,	WT	 and	 LRRK2	 KO	 datasets	 could	 be	 combined	 to	 give	 a	
rigorous	 analysis	 of	 statistically	 significantly	 responding	 genes	 to	 a	 treatment	 and	
between	 LRRK2	 genotype	 (Chen	 et	 al.,	 2008;	 Robinson	 et	 al.,	 2009).	 Only	 a	 small	
number	 of	 differentially	 responding	 genes	 could	 be	 identified	 this	way,	with	 none	
identified	 between	 MDP	 treatment	 datasets.	 The	 most	 striking	 finding	 of	 this	
analysis	 is	 that	 of	 11	 differentially	 responding	 genes	 to	 LPS	 stimulation,	 three	 are	
chemokines,	 and	 one	 is	 a	 chemokine	 receptor-like	 protein.	 CCL3	 and	 CCL4	 form	
isoforms	of	‘macrophage	inflammatory	protein	1’;	MIP-1α	and	MIP-1β	respectively.	
CCL5	is	also	known	as	‘regulated	on	activation,	normal	T	cell	expressed	and	secreted’	
(RANTES).	 These	 chemokines	 are	 all	 members	 of	 the	 ‘CC	 Chemokine/Receptor	
family’	and	share	a	common	receptor	 in	CCR5.	CCL3	and	CCL5	may	also	bind	CCR1,	
while	 CCL5	 binds	 a	 further	 receptor;	 CCR3	 (Zlotnik	 and	 Yoshie,	 2000).	 These	
chemokines	 are	 all	 classified	 as	 pro-inflammatory,	 meaning	 they	 are	 induced	 by	
inflammatory	stimuli	to	recruit	inflammatory	cells	to	a	site	of	inflammation.	This	is	as	
opposed	 to	homeostatic	 chemokines,	which	are	 constitutively	expressed	 in	 certain	
tissues	(Turner	et	al.,	2014).	CCRL2	is	chemokine	receptor-like	protein,	with	over	40	
%	 sequence	 identity	 to	 CCR1,	 CCR2,	 CCR3	 and	 CCR5	 (Migeotte	 et	 al.,	 2002),	 and	
highest	 amino	 acid	 sequence	 similarity	 to	 CCR1.	 Interestingly,	 CCRL2	 has	 been	
reported	as	a	non-canonical	receptor	for	CCL5	(Yoshimura	and	Oppenheim,	2011);	as	
well	 as	 CCL19	 and	 chemerin	 (Akram	 et	 al.,	 2016).	 While	 there	 have	 been	 mixed	
reports	as	to	the	effect	of	LRRK2	on	cytokine	production,	very	little	interest	has	been	
shown	in	the	potential	effect	of	LRRK2	on	chemokine	production;	which	makes	these	
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findings	particularly	exciting.	A	microarray	screen	of	unstimulated	mouse	microglia	
has	 shown	 that	 CX3CR1,	 a	 non-canonical	 chemokine	 receptor	 of	 fractalkine,	
expressed	exclusively	 in	microglia,	 is	upregulated	by	knockout	of	LRRK2	 (Ma	et	al.,	
2016).	This	reaffirms	that	chemokine	responses	may	be	involved	in	LRRK2	biology	in	
diverse	immunological	contexts.		
A	 number	 of	 transcription	 factors	 have	 been	 identified	 by	 two-parameter	
analysis	of	 the	 LPS	dataset.	ATF3	 is	 a	negative	 regulator	of	pro-inflammatory	TLR4	
signalling,	acting	as	part	of	the	LPS	induced	negative-feedback	loop	(Gilchrist	et	al.,	
2006).	Knockout	of	LRRK2	causes	increased	transcription	of	this	regulator	upon	LPS	
stimulation,	meaning	 that	 in	 the	 simplest	 scenario,	 it	 might	 be	 expected	 that	 the	
over-active	 kinase	 G2019S	 mutation	 of	 LRRK2	 would	 lead	 to	 a	 decrease	 in	
transcription	 of	 Atf3;	 resulting	 in	 attenuated	 negative	 feedback	 of	 TLR4	 signalling,	
enhanced	 inflammation,	 and	 greater	 neuronal	 stress.	 Two	 further	 transcription	
factors	were	identified	by	two-parameter	analysis.	MXD1	and	CSRNP1.	MXD1	acts	in	
a	 network	 with	 MYC	 and	 MAX,	 forming	 the	 MYC/MAX/MXD1	 axis	 (Cascón	 and	
Robledo,	 2012).	 MXD1	 is	 in	 competition	 with	 MYC	 for	 the	 binding	 of	 MAX;	 with	
balance	 of	 MXD1/MAX	 and	 MYC/MAX	 dimers	 controlling	 transcriptional	 output.	
Implications	 of	 the	 disruption	 of	 this	 regulatory	 axis	 are	mainly	 studied	 in	 cancer,	
where	overexpression	of	MYC	is	a	common	pathway	to	disease	(Dang,	2012).	As	part	
of	 its	 disease	 causing	 function,	 MYC	 signalling	 has	 been	 shown	 to	 affect	 cell	
adhesion,	 cell	 shape,	 and	 reduce	 cell	 migration	 through	 modulation	 of	 the	 actin	
cytoskeleton	 (Liu	et	 al.,	 2012);	 this	 in	 turn	 is	 thought	 to	occur	by	 inhibition	of	 JNK	
(Ma	et	al.,	2017).	Functional	relevance	to	LRRK2	exists	here,	as	LRRK2	is	a	member	of	
the	MLK	family	of	MAPKKK	proteins.	Indeed,	the	G2019S	overactive	kinase	mutation	
of	 LRRK2	 has	 been	 linked	 to	 activation	 of	 the	 MKK4-JNK	 pathway	 in	 neurons,	
resulting	in	disease	(Chen	et	al.,	2012).	Finally,	CSRNP1	is	a	transcription	factor	that	
is	upregulated	by	Axin,	as	well	as	inflammatory	stimuli	in	the	form	of	IL-2	(Ishiguro	et	
al.,	 2001;	 Gingras	 et	 al.,	 2007).	 Axin	 is	 a	 negative	 regulator	 of	 the	Wnt	 signalling	
pathway,	 acting	 to	 sequester	 the	 transcription	 factor	 β-catenin	 to	 the	 cytoplasm	
(Nakamura	 et	 al.,	 1998).	 Relevance	 of	 CSRNP1	 to	 LRRK2	 comes	 not	 just	 from	
induction	 by	 inflammatory	 stimuli,	 but	 also	 through	 interaction	 with	 the	 Wnt	
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pathway.	LRRK2	has	been	connected	to	 three	major	components	of	canonical	Wnt	
signalling:	dishevelled	(Sancho	et	al.,	2009),	 ‘lipoprotein	receptor-related	protein	6’	
(LRP6)	 (Berwick	 and	Harvey,	 2012),	 and	 ‘glycogen	 synthase	 kinase	3	beta’	 (GSK3β)	
(Lin	 et	 al.,	 2010).	 Interestingly,	 studies	 have	 shown	 LRRK2	 to	 affect	Wnt	 signalling	
remarkably	 similarly	 to	 axin,	with	 LRRK2	 suggested	 to	 inhibit	Wnt	 signalling	 in	 the	
absence	 of	 stimulation	 by	 participating	 in	 the	 β-catenin	 destruction	 complex,	 but	
enhancing	 formation	of	Wnt	 signalososmes	at	 vesicular	membranes	 following	Wnt	
stimulation;	 increasing	 Wnt	 signalling	 activity	 (Berwick	 and	 Harvey,	 2013).	 The	
significance	of	parallels	between	CSRNP1	and	Axin	is	unknown,	as	little	is	known	of	
the	function	of	CSRNP1	other	than	that	there	is	redundancy	with	other	members	of	
the	 Csrnp	 family	 (Gingras	 et	 al.,	 2007).	 However,	 a	 growing	 appreciation	 of	 Wnt	
signalling	 in	 modulating	 the	 macrophage	 inflammatory	 response	 is	 developing	
(Schaale	 et	 al.,	 2011).	While	 these	 studies	 highlight	 the	 interaction	 of	 LRRK2	with	
canonical	Wnt	signalling,	it	should	not	be	overlooked	that	LRRK2	has	also	been	linked	
to	 other	 branches	 of	Wnt	 signalling.	 For	 example,	 LRRK2	may	 play	 a	 role	 in	Wnt	
‘planar	 cell	 polarity’	 (PCP)	 signalling	 after	 a	 connection	 was	 established	 by	
proteomics	 (Salašová	 et	 al.,	 2017).	 The	 PCP	 pathway	 involves	 the	 cytoskeletal	
adaptors	Rac,	Cdc42	and	RhoA,	as	well	as	JNK;	all	of	which	have	been	discussed	as	
interaction	 partners	 of	 LRRK2.	 Similarly,	 the	 Wnt-Ca2+	 pathway	 results	 in	 nuclear	
translocation	 and	 activation	 of	 NFAT;	 a	 protein	 that	 has	 been	 shown	 to	 be	
maintained	in	the	cytoplasm	by	a	non-canonical	pathway	involving	interaction	with	
LRRK2	(Liu	et	al.,	2011).	The	regulation	of	Csrnp	transcription	by	LRRK2	reflects	and	
strengthens	the	established	role	of	LRRK2	in	Wnt	signalling.	
Two	genes	 identified	by	 two-parameter	analysis	 can	been	 linked	directly	 to	
Parkinson’s	 disease.	 Abtb2	 encodes	 ‘Ankyrin-rich	 BTB/POZ	 domain	 containing	
protein-2’	(BPOZ-2).	This	protein	is	the	subject	of	attention	in	Parkinson’s	research,	
as	 it	 appears	 to	 cause	 inhibition	 of	 alpha-synuclein	 aggregation	 (Roy	 and	 Pahan,	
2013).	 Lentiviral	 delivery	 of	 the	 BPOZ-2	 gene	 appears	 to	 stimulate	 autophagic	
clearance	of	alpha-synuclein,	 resulting	 in	 reduced	alpha-synuclein	pathology	 in	 the	
basal	ganglia	(Roy	et	al.,	2016).	It	is	interesting	that	such	a	gene	should	be	identified	
in	 macrophages,	 however	 the	 physiological	 significance	 is	 not	 clear,	 as	 alpha-
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synuclein	 pathology	 is	 only	 abundant	 in	 a	 neuronal	 context.	 Another	 protein	
identified	 by	 two-parameter	 analysis	 is	 the	 G	 protein-coupled	 receptor,	 HCAR2,	
otherwise	known	as	 ‘niacin	 receptor	1’.	Ketone	bodies	are	 thought	 to	be	 the	main	
substrate	for	HCAR2,	however	activation	by	niacin	is	also	observed.	Niacin	has	been	
touted	by	many	as	a	treatment	for	Parkinson’s	disease,	although	evidence	is	lacking	
(Wakade	 et	 al.,	 2014;	 Wakade	 and	 Chong,	 2014).	 Activation	 of	 HCAR2	 in	
macrophages	has	an	anti-inflammatory	effect.	The	precise	mechanism	of	this	effect	
is	a	matter	of	on-going	research,	however	activation	by	niacin	results	in	inhibition	of	
CCL2	induced	macrophage	migration	(Lukasova	et	al.,	2011),	as	well	as	an	inhibited	
response	to	LPS	stimulation;	as	measured	by	Nf-κB	activation	(Digby	et	al.,	2012)	or	
inflammatory	 cytokine	 release	 (Zandi-Nejad	 et	 al.,	 2013).	 A	 recent	 report	 has	
suggested	that	 inflammatory	 inhibition	by	HCAR2	activation	 is	mediated	via	a	Gβγ-
PKC-ERK1/2	pathway	(Shi	et	al.,	2017).	Unfortunately,	activation	of	ERK1/2	by	niacin	
in	 this	 pathway	 induces	 a	 strong	 flushing	 response	 in	 humans,	 limiting	 the	 use	 of	
niacin	 as	 a	 potential	 treatment	 for	 inflammatory	 disease	 (Richman	 et	 al.,	 2007).	
LRRK2	 has	 been	 suggested	 to	 be	 phosphorylated	 by	 PKC	 zeta;	 a	 Ca2+	 and	
diacylglycerol-independent	 kinase	 that	 functions	 in	 the	 PI3K	 pathway	 and	 MAPK	
cascade	(Zach	et	al.,	2010).	HCAR2	activation	also	leads	to	Gi-mediated	inhibition	of	
adenylyl	 cyclase,	 resulting	 in	 reduced	 cAMP	 levels,	 and	 increased	 levels	 of	
prostaglandins	 via	 activation	 of	 cyclooxygenase	 (Offermanns	 and	 Schwaninger,	
2015).	
Rapgef3	 is	 the	 strongest	 differentially	 responding	 gene	 to	 LPS,	with	 an	 11-
fold	 difference	 in	 expression	 observed	 between	 LRRK2	 KO	 and	 WT	 macrophages	
following	LPS	treatment.	Rapgef3	was	also	identified	following	analysis	of	individual	
RNA	 sequencing	datasets	 as	 the	only	 gene	 to	 experience	 inhibited	 transcription	 in	
WT	cells,	and	enhanced	transcription	following	LRRK2	knockout.	EPAC1	is	the	protein	
encoded	by	Rapgef3.	While	HCAR2	activation	reduces	intracellular	cAMP,	EPAC1	acts	
down-stream	 of	 cAMP.	 EPAC1	 is	 a	 GEF	 that	 functions	 in	 a	 parallel	 branch	 of	 cell	
signalling	to	PKA;	resulting	in	a	wide	range	of	cellular	consequences,	many	of	which	
are	 mediated	 through	 a	 direct	 interaction	 with	 Rap1	 (de	 Rooij	 et	 al.,	 1998).	
Downstream	 of	 Rap1	 signalling	 is	 Rac1	 (Arthur	 et	 al.,	 2004).	 Rac1	 controls	 many	
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areas	of	biology,	but	has	a	strong	association	with	the	cell	cytoskeleton	via	Arp2/3	
and	 Cofilin	 (Bid	 et	 al.,	 2013).	 It	 is	 therefore	 unsurprising	 that	 overexpression	 of	
EPAC1	 leads	 to	 strong	 phenotypes	 in	 cell	morphology.	 In	 primary	monocytes,	 the	
EPAC1-RAP1	axis	has	been	shown	to	affect	cell	adhesion	as	well	as	PKA-independent	
chemotaxis	towards	CCL2	(Lorenowicz	et	al.,	2006).	However,	a	later	report	suggests	
that	EPAC1	only	carries	out	immunological	functions	in	mature	macrophages,	and	in	
conjunction	 with	 PKA	 (Bryn	 et	 al.,	 2006).	 While	 the	 specific	 effect	 of	 cAMP	 and	
downstream	signalling	on	migration	appears	to	be	highly	context	dependent	(dose,	
time,	 space,	 cell	 type)	 (Howe,	2004),	 it	 seems	 indisputable	 that	EPAC1	does	play	a	
role	 in	 chemotaxis	 of	macrophages.	 In	 the	 light	 of	 RNA	 sequencing	 results,	 EPAC1	
may	 underlie	 reported	 LRRK2	 chemotatic	 phenotypes,	 and	 perhaps	 even	 explain	
contradictory	results	obtained	by	different	groups	(Choi	et	al.,	2015;	Moehle	et	al.,	
2015).	 It	would	be	 interesting	to	combine	chemotaxis	assays	on	WT	and	LRRK2	KO	
macrophages	 with	 cAMP	 or	 a	 EPAC1	 specific	 analogue	 of	 cAMP:	 8-CPT-2'-O-Me-
cAMP	(Kang	et	al.,	2003).	Linking	EPAC1	to	innate	immune	signalling	more	directly,	it	
was	 shown	 that	 EPAC1	 activation	 induces	 expression	 of	 ‘suppressor	 of	 cytokine	
signalling	 3’	 (SOCS-3)	 in	 response	 to	 cAMP,	 leading	 to	 potent	 anti-inflammatory	
effects	 (Sands	 et	 al.,	 2006),	 and	 may	 also	 modulate	 phagocytosis	 in	 neutrophils	
(Scott	et	al.,	2016).	Intriguingly,	EPAC1	has	been	linked	to	Ca2+	release	in	myocytes,	
through	 activation	 of	 ‘calcium-calmodulin-dependent	 protein	 kinase	 II’	 (CAMK2)	
(Pereira	 et	 al.,	 2007).	 CAMK2	 is	 a	 holoenzyme	 consisting	 of	 a	 variable,	 but	 tissue	
specific	 mix	 of	 six	 CAMK2	 subunits	 (Hanson	 and	 Schulman,	 1992);	 of	 which	 the	
CAMK2β	 subunit	was	 earlier	 identified	 as	 a	 differentially	 expressed	 gene	 between	
unstimulated	 WT	 and	 LRRK2	 KO	 macrophages.	 EPAC1	 and	 CAMK2	 are	 further	
associated	 in	 myocardial	 hypertrophy,	 a	 process	 which	 involves	 functional	
modulation	of	cell	morphology,	cytoskeletal	dynamics,	and	protein	synthesis;	all	of	
which	 are	 functions	 also	 attributed	 to	 LRRK2	 in	 different	 cellular	 contexts.	 In	
myocytes,	 EPAC1	 induces	 hypertrophy	 via	 Ca2+	 dependent	 activation	 of	 Rac,	
calcineurin	 and	 the	 downstream	 transcription	 factor	 NFAT	 (Morel	 et	 al.,	 2005).	 If	
LRRK2	is	involved	in	this	pathway	through	modulation	of	EPAC1	expression,	then	this	
Ca2+	 dependent	 modulation	 of	 NFAT	 would	 complement	 the	 previously	 described	
Ca2+	 independent	 LRRK2-NFAT	pathway	 (Liu	 et	 al.,	 2011).	 Indeed,	 Ca2+	 signalling	 is	
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emerging	as	playing	a	role	in	innate	immune	signalling	(Feske,	2007).	Finally,	EPAC1	
activation	has	been	linked	to	enhanced	neurite	outgrowth	in	both	PC12	and	SH-SY5Y	
neuronal	cell	lines	(Mains	et	al.,	1990;	Monaghan	et	al.,	2008).	It	is	remarkable	that	
the	strongest	gene	to	be	identified	in	this	screen	is	tied	to	so	many	areas	of	LRRK2	
biology.	As	mentioned,	 EPAC1	 is	 a	 cAMP	 regulated	gene,	 functioning	 in	parallel	 to	
PKA.	 As	 such,	 untangling	 the	 respective	 contributions	 of	 EPAC1	 and	 PKA	 to	 cAMP	
induced	processes	is	an	on-going	process.	Indeed,	several	connections	exist	between	
LRRK2	and	PKA,	with	LRRK2	thought	to	be	both	a	ligand	of	PKA	(Li	et	al.,	2011;	Muda	
et	 al.,	 2014),	 and	 a	 negative	 regulator	 of	 PKA	 activity	 (Parisiadou	 et	 al.,	 2014).	
Therefore,	it	may	be	necessary	to	review	where	EPAC1	may	be	contributing	to	these	
observed	effects.	
TRIM25	 is	 involved	 in	 the	 antiviral	 response	by	 regulating	 the	 formation	of	
the	RIG-I	signalosome,	leading	to	fine-tuning	of	interferon	production	(Sanchez	et	al.,	
2016).	The	RIG-I	signalosome	is	formed	by	interaction	of	the	CARD	domain	of	MAVS	
with	 a	 tetrameric	 assembly	 of	 CARD	 domains	 formed	 by	 RNA-bound	 RIG-I.	 RIG-I	
CARD	domains	are	only	available	for	MAVS	binding	when	activated	by	RNA	binding,	
and	it	is	this	active	form	of	RIG-I	that	may	be	stabilised	by	TRIM25	activity.	TRIM25	
generates	 K63	 polyubiquitin	 chains	 that	 bind	 around	 and	 stabilise	 active	 RIG-I,	
enhancing	anti-viral	responses	and	IRF3	activation	(Blander,	2014).	
	 To	complement	the	specificity	of	genes	identified	by	two-parameter	analysis,	
pathway	 analysis	 against	 the	 reactome	 database	 identified	 broad	 areas	 of	 biology	
that	 appeared	 to	 be	 perturbed	 by	 LRRK2	 KO	 in	 the	 context	 of	 LPS	 or	 MDP	
stimulation.	 Perhaps	 the	 most	 notable	 feature	 of	 these	 results	 was	 the	 strong	
representation	 of	 pathways	 relating	 to	modulation	 of	 the	 cellular	 cytoskeleton,	 in	
both	 LPS	 and	 MDP	 datasets.	 These	 include	 relatively	 specific	 pathways	 such	 as	
‘signalling	by	Rho	GTPases’,	‘Rho	GTPase	cycle’,	and	events	further	upstream	of	Rho	
GTPases,	such	as	‘G	alpha	(12/13)	signalling	events’.	Identification	of	these	pathways	
corresponds	 with	 the	 idea	 that	 LRRK2	 is	 modulating	 cytoskeletal	 dynamics	 in	 an	
inflammatory	 context.	 Indeed,	 phagocytosis	 related	 pathways	 are	 identified	 in	
pathway	 analysis.	 In	 response	 to	 LPS,	 ‘regulation	 of	 actin	 dynamics	 for	 phagocytic	
cup	formation’	is	identified,	while	in	response	to	MDP	stimulation,	‘FCGR	activation’	
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is	 identified	 as	 modulated	 by	 LRRK2,	 as	 well	 as	 ‘role	 of	 phospholipids	 in	
phagocytosis’.	 Indeed	 phospholipid	 metabolism	 is	 another	 set	 of	 pathways	 that	
appear	to	be	strongly	identified	in	this	analysis.	Many	aspects	of	PI3K	signalling	and	
metabolism	 are	weakly	 identified	 as	 LRRK2	 dependent,	 following	 stimulation	with	
either	LPS	or	MDP,	as	well	as	the	‘GAB1	signalosome’,	required	for	activation	of	PI3K	
activity.	Phospholipid	metabolism	is	important	in	a	wide	range	of	cellular	signalling,	
but	 is	 notable	 for	 its	 role	 in	 regulating	 actin	 dynamics	 and	 phagocytosis	 via	 Rho	
GTPases	 (Araki	 et	 al.,	 1996;	 Beemiller	 et	 al.,	 2010;	 Schlam	 et	 al.,	 2015).	 Innate	
immune	 signalling	 processes	 were	 identified	 as	 expected,	 however	 it	 is	 perhaps	
surprising	that	these	were	less	prevalent	than	the	pathways	mentioned	above,	given	
that	cells	had	been	activated	by	PRR	ligands.	LPS	stimulation	resulted	in	differences	
in	 ‘p38MAPK	 events’,	 but	 also	 ‘cytosolic	 sensors	 of	 pathogen-associated	 DNA’,	
‘Nucleotide-binding	domain,	 leucine	rich	repeat	containing	receptor	(NLR)	signaling	
pathways’	and	‘the	NLRP3	inflammasome’.	These	latter	pathways	relate	to	cytosolic	
sensors	 and	 signalling	molecules	 for	 the	detection	 and	 immunological	 response	 to	
intracellular	PAMPs	(Rathinam	et	al.,	2012).	In	comparison,	stimulation	with	MDP	led	
to	differential	expression	of	genes	involved	in	‘MAP	kinase	activation	in	TLR	cascade’,	
and	 ‘p38MAPK	 events’;	 signalling	 events	 that	 generally	 occur	 downstream	 of	 cell	
surface	PRRs	 (Akira	and	Takeda,	2004).	This	 is	 intriguing	given	 that	LPS	 is	primarily	
detected	 at	 the	 cell	 surface	 by	 TLR4,	 and	MDP	 is	 detected	 by	 intracellular	 NOD2.	
Ultimately,	pathway	analysis	provides	a	way	to	look	broadly	at	RNA	sequencing	data	
and	identify	trends	that	may	be	missed	by	looking	only	at	specific	genes	identified	by	
two-parameter	analysis.	Pathways	identified	this	way	reaffirm	the	idea	that	LRRK2	is	
involved	 in	 regulation	 of	 the	 cytoskeleton	 of	 macrophages,	 and	 resulting	
immunological	processes	such	as	motility	and	phagocytosis.	Perhaps	 in	 the	 light	of	
identified	 differentially	 regulated	 genes	 such	 as	 Rapgef3	 (encoding	 EPAC1),	
examination	 of	 phagocytosis	 and	 macrophage	 motility	 and	 chemotaxis	 should	 be	
revisited	with	a	focus	on	cAMP	induced	signalling.			
Isolation	 and	 analysis	 of	 metabolites	 from	 macrophages	 revealed	 no	
difference	 in	 ceramide	 levels	 between	 WT	 and	 LRRK2	 KO	 unstimulated	
macrophages.	 This	 is	 in	 contrast	 to	 observations	 made	 in	 brain	 homogenate	
	 204	
(Ferrazza	 et	 al.,	 2016).	 In	 fact,	 a	 non-significant	 trend	 of	 decreasing	 ceramide	was	
observed	 in	 LRRK2	 KO	 macrophages.	 The	 metabolism	 of	 ceramides	 is	 not	
straightforward.	Six	ceramide	synthase	isoforms	exist	in	mammalian	cells,	each	with	
different	 tissue	 specificities	 and	 substrate	 preference	 for	 the	 generation	 of	
ceramides.	On	top	of	 this,	cells	 types	display	differences	 in	 the	balance	of	de	novo	
ceramide	synthesis	compared	to	ceramide	salvage	through	the	breakdown	of	more	
complex	 sphingolipids	 and	 glucosylceramide	 (Gillard	 et	 al.,	 1998;	 Mullen	 et	 al.,	
2012).	 Due	 to	 this,	 it	 is	 unsurprising	 that	 differences	 in	 ceramide	 levels	 in	
unstimulated	 cells	 do	 not	 replicate	 what	 is	 seen	 in	 the	 brain.	 Stimulation	 of	
macrophages	with	MDP	 did	 result	 in	 an	 increase	 in	 ceramide	 levels.	 This	 increase	
was	 dependent	 on	 the	 expression	 of	 LRRK2,	 suggesting	 LRRK2	 does	 regulate	
pathways	 responsible	 for	 the	 generation	 of	 ceramide	 in	 macrophages	 as	 well	 as	
neurons.	 In	 contrast	 to	MDP,	 stimulation	with	 LPS	 did	 not	 result	 in	 an	 increase	 in	
ceramide,	most	likely	due	to	the	early	time	point	at	which	metabolites	were	isolated	
after	 stimulation.	 Ceramide	 de	 novo	 synthesis	 is	 induced	 by	 lipid	 A	 only	 after	
approximately	 12	 hours	 (Sims	 et	 al.,	 2010).	 Whether	 ceramide	 increase	 is	
exacerbated	by	pathogenic	 LRRK2	mutants	 remains	 to	be	addressed.	As	discussed,	
ceramide	 accumulation	 is	 able	 to	 activate	 the	 NLRP3	 inflammasome	 leading	 to	
inflammation	(Vandanmagsar	et	al.,	2011).	As	a	counter-point	to	this,	accumulation	
of	 glucosylceramide	 following	 GBA1	 deficiency	 has	 also	 been	 shown	 to	 drive	
inflammation,	 via	 the	 formation	 of	 anti-glucosylceramide	 immune	 complexes	
(Pandey	et	al.,	2017).	 In	neurons,	accumulation	of	glucosylceramide	has	even	been	
shown	 to	 stabilise	 oligomeric	 forms	 of	 alpha-synuclein,	 driving	 neuroinflammation	
and	 degeneration	 (Mazzulli	 et	 al.,	 2011).	 Clearly,	 perturbation	 of	 ceramide	
metabolism	 can	 cause	 inflammatory	 dyshomeostasis	 by	 a	 range	 of	 mechanisms.	
Indeed,	 ceramide	salvage	pathways	have	been	suggested	 to	be	more	 important	 to	
macrophage	 inflammasome	 driven	 inflammation	 than	 de	 novo	 ceramide	 synthesis	
(Camell	et	al.,	2015).	Therefore,	an	increase	in	ceramide	may	cause	a	corresponding	
decrease	 in	 other	 ceramide	 derivatives	 including	 other	 sphingolipids	 and	
sphingosine;	 with	 overall	 consequences	 on	 immunological	 signalling.	 A	 shotgun	
approach	 of	 lipids	 analysis	 using	 ESI-QTOF	was	 applied	 in	 these	 experiments.	 This	
method	 lacks	 the	 resolution	 to	 identify	 specific	 ceramides.	 Given	 findings	 made	
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during	 this	 study,	 a	 future	 experiment	 should	 be	 designed	 to	 analyse	 not	 just	
ceramides,	 but	 also	 sphingolipids	 and	 sphingosine;	 molecules	 which	 may	 also	 be	
modulated	during	 innate	 immune	stimulated	 lipid	metabolism.	By	applying	a	 triple	
quadrupole	 approach,	 specific	 identification	of	 these	 lipids	 can	be	 achieved.	 Triple	
quadrupole	mass	spectrometry	employs	fragmentation	of	lipids	of	interest,	allowing	
analysis	 of	 lipid	 fatty	 acid	 acyl	 chain	masses;	 facilitating	 high-resolution	 detection	
and	identification	of	lipids.	Future	experiments	should	also	follow	ceramide	levels	at	
later	time	points,	to	assess	if	LRRK2	is	involved	in	TLR4	induced	ceramide	generation.	
Summary	
	 To	summarise,	the	application	of	global	analysis	techniques	has	allowed	the	
identification	of	 roles	of	 LRRK2	 in	 the	 innate	 immune	 response.	 It	 is	 interesting	 to	
observe	how	some	of	these	roles	fit	into	areas	of	biology	already	described,	but	in	a	
new	 context.	 For	 example,	 identification	 of	 Csrnp1	 as	 an	 LRRK2-differentially	
responding	 gene	 to	 LPS	 stimulation	 ties	 into	 association	 of	 LRRK2	 with	 the	 Wnt	
pathway,	but	now	in	an	immunological	context.	Another	example	is	the	association	
of	LRRK2	with	cAMP	signalling	raised	by	EPAC1	differential	regulation	by	LRRK2.	The	
reciprocal	regulation	between	LRRK2	and	PKA	has	been	described	in	the	context	of	
neurons,	but	an	association	of	the	parallel	cAMP	signalling	regulated	by	EPAC1	with	
LRRK2	has	never	been	described.	Indeed	that	EPAC1	activation	has	been	previously	
linked	 to	 neurite	 extension	 in	 neurons,	 a	 highly	 reproducible	 phenotype	 of	 LRRK2	
knockout	 or	 mutation,	 reinforces	 the	 fundamental	 efficacy	 of	 exploring	 neuronal	
LRRK2	functions	in	an	innate	immune	context.	
		 The	 identification	 of	 EPAC1	 and	 CAMK2β	 ties	 LRRK2	 to	 Ca2+	 signalling	 in	
macrophages,	 coinciding	 with	 previous	 reports	 of	 LRRK2	 involvement	 in	 the	
regulation	 of	 NFAT	 signalling	 and	 the	 Wnt-Ca2+	 pathway.	 These	 areas	 of	 LRRK2	
involvement	 are	 broad	 areas	 of	 biology	 that	 are	 emerging	 as	 relevant	 to	 innate	
immune	 signalling.	 Genes	 and	 pathways	 identified	 here	 also	 tie	 LRRK2	 to	 better	
understood	 areas	 of	 biology,	 as	 exemplified	 by	 the	 small	 network	 of	 chemokine	
proteins	CCL3,	CCL4,	CCL5,	 the	 chemokine-like	 receptor	CCRL2,	 EPAC1,	 and	HCAR2	
which	 appears	 to	 regulate	 inflammation	 via	 CCL2;	 and	 has	 been	 connected	 to	 a	
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cAMP	dependent	mechanism.	There	are	conflicting	reports	on	the	effect	of	LRRK2	on	
macrophage	 cytokine	 release,	 but	 almost	 nothing	 published	 on	 the	 links	 between	
LRRK2	 and	 chemokines.	 These	 results	 reflect	 previous	 work	 that	 was	 aimed	 at	
identifying	 immunological	 functionality	 of	 LRRK2	 interactions	 with	 the	 cell	
cytoskeleton	 and	 vesicular	 trafficking	 machinery.	 Genes	 identified	 by	 RNA	
sequencing	reaffirm	this	association,	via	Camk2b	that	associates	directly	with	the	cell	
cytoskeleton;	 as	 well	 as	 EPAC1,	 which	 regulates	 the	 Rho	 GTPase	 protein	 Rac1.	
Reactome	pathway	analysis	places	further	emphasis	on	a	role	of	LRRK2	in	membrane	
dynamics	and	cytoskeletal	processes	such	as	phagocytosis,	but	also	in	the	regulation	
of	 phosphatidylinositol	 processing.	 Lipid	 analysis	 revealed	 no	 differences	 between	
ceramide	levels	in	resting	macrophages,	in	contrast	to	findings	made	in	brain	tissue,	
but	 also	 revealed	 an	 LRRK2	 dependent	 increase	 in	 ceramide	 levels	 in	 response	 to	
MDP	stimulation.	
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6.	Project	discussion	
6.1	Taking	results	into	the	future	
	 The	 task	of	 identifying	 the	 role	of	 LRRK2	 in	 innate	 immunity	has	been	approached	
from	 multiple	 angles	 during	 this	 project.	 These	 include	 both	 structural	 and	 functional	
studies,	and	a	focus	that	has	ranged	in	scale	from	biophysical	features	of	LRRK2,	all	the	way	
up	to	genome	wide	analysis	of	the	effect	of	LRRK2	knockout	on	the	macrophage	response	to	
innate	 immune	 stimuli.	 As	 a	 result,	 these	 approaches	 have	 managed	 to	 answer	 specific	
questions	that	have	been	raised	by	contradictory	reports	within	the	LRRK2	literature,	while	
also	 uncovering	 apparent	 new	 areas	 of	 LRRK2	 biology	 that	 may	 prove	 important	 to	 our	
understanding	 of	 the	 underlying	 pathological	 mechanisms	 of	 Parkinson’s	 disease,	 and	
inflammatory	disease	more	generally.	
	 Structural	 studies	 were	 focused	 on	 the	 LRR	 domain	 of	 LRRK2,	 a	 non-enzymatic	
domain	 directly	 adjacent	 to	 S910	 and	 S935	 phosphorylation	 sites,	 important	 for	 14-3-3	
chaperone	 binding	 (Dzamko	 et	 al.,	 2010;	 Nichols	 et	 al.,	 2010).	 It	 is	 unfortunate	 that	
characterisation	 of	 this	 LRR	 domain	 was	 not	 successful	 during	 this	 project,	 however	
significant	steps	were	taken	towards	this	aim	through	the	generation	of	multiple	constructs	
for	the	expression	of	the	LRR	domain.	Recent	molecular	modelling	and	electron	microscopy	
studies	have	suggested	that	expression	of	individual	domains	such	as	that	of	the	LRR,	may	
prove	 difficult	 due	 to	 the	 tight	 packing	 of	 domains	 of	 LRRK2	 within	 a	 larger	 globular	
structure	(Guaitoli	et	al.,	2016).	In	particular,	the	use	of	VLR	hybridisation	for	the	generation	
of	 VLR-capped	 constructs	 may	 overcome	 the	 need	 for	 such	 intramolecular	 contacts	
between	 domains,	 and	 provide	 a	 route	 towards	 successful	 LRR	 expression	 in	 the	 future.	
Much	attention	is	focused	on	the	enzymatic	core	of	LRRK2.	While	this	is	where	clustering	of	
pathogenic	mutations	within	LRRK2	have	been	identified,	it	is	not	the	only	source	of	LRRK2	
functionality.	For	example,	the	WD40	domain	of	LRRK2	has	been	identified	as	required	for	
the	 function	 of	 the	 adjacent	 kinase	 domain,	 yet	 has	 not	 been	 the	 focus	 of	 structural	
investigation	(Jorgensen	et	al.,	2009).	Less	is	known	about	the	interaction	between	the	LRR	
domain	of	LRRK2	and	 functional	activity,	as	 the	central	 location	of	 the	LRR	domain	within	
the	 LRRK2	 gene	means	 it	 cannot	 simply	 be	 truncated.	 The	 value	 of	 expressing	 individual	
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domains	may	also	be	questioned	following	the	discovery	of	the	tightly	packed	nature	of	the	
LRRK2	protein	(Guaitoli	et	al.,	2016;	Sejwal	et	al.,	2017).	LRR	expression	may	prove	useful	to	
‘fish’	 for	 binding	 ligands,	 and	 to	 our	 understanding	 of	 protein	 folding	 more	 generally.	
However,	the	LRR	domain	itself	will	always	be	‘out	of	context’	without	surrounding	domains	
which	will	likely	be	required	to	constitute	physiologically	relevant	LRRK2	binding	interfaces.	
The	 ultimate	 way	 to	 overcome	 these	 limitations	 is	 through	 the	 generation	 of	 full-length	
proteins	for	structural	and	biochemical	analysis	(fig	56).	As	discussed	previously,	full-length	
LRRK2	 expression	 has	 proven	 difficult	 by	 other	 groups,	 but	 represents	 a	 possible	 future	
direction	 for	 biophysical	 LRRK2	 research	 (Sejwal	 et	 al.,	 2017).	 Establishment	 of	 specialist	
mammalian	 cell	 culture	 expression	 systems	 such	 as	 a	 WAVE	 bioreactor	 will	 facilitate	 a	
potential	 move	 towards	 full-length	 LRRK2	 research	 in	 the	 future	 with	 the	 use	 of	 high	
quantities	of	non-adherent	HEK293	cells	for	protein	expression	(fig	56).	
	 	
	
Figure	56:	Experimental	designs	for	protein	expression:	towards	biophysical	and	biochemical	LRRK2	
analysis.	 Development	 of	 mammalian	 protein	 expression	 systems	 may	 allow	 full-length	 LRRK2	
expression	 in	 the	 future,	 thus	 overcoming	 the	 need	 to	 truncate	 domains.	 Globular	 LRRK2	 from	
Guaitoli	et	al.,	2016.	ARM	=	Armadillo	repeats,	ANK	=	Ankyrin	repeats,	LRR	=	Leucine	rich	repeats,	Roc	
=	Ras	of	complex	proteins,	COR	=	C-terminal	of	Roc,	KIN	=	Kinase.	
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Functional	studies	 into	the	role	of	LRRK2	in	macrophage	 immunology	followed	two	
routes:	regulation	of	TLR	trafficking,	and	control	of	phagocytosis.	These	have	been	described	
as	dependent	on	vesicular	 trafficking	and	cytoskeleton	dynamics	 respectively;	but	may	be	
better	considered	as	overlapping	processes	(Kamal	and	Goldstein,	2000).	For	example,	the	
LRRK2	 interaction	 partner	 Rab5	 actively	 stimulates	 association	 of	 early-endosomes	 with	
microtubules,	 and	 the	 motility	 of	 those	 endosomes	 along	 microtubules	 (Nielsen	 et	 al.,	
1999).	Investigation	into	the	roll	of	LRRK2	on	TLR	trafficking	was	focused	on	TLR4	and	TLR2,	
two	innate	immune	receptors	with	relatively	well-characterised	involvement	in	Parkinson’s	
disease	 through	 the	 detection	 of	 alpha-synuclein,	 and	 disease	 pathology	 in	 Parkinson’s	
patients;	even	in	the	absence	of	pathological	LRRK2	involvement	(Fellner	et	al.,	2013;	Kim	et	
al.,	2014;	Daniele	et	al.,	2015).	Such	analysis,	while	tailored	to	a	Parkinson’s	disease	context,	
is	 still	 limited	 in	 scope	as	 there	are	eight	other	TLRs	expressed	 in	humans	 (Barreiro	et	al.,	
2009),	 and	 a	whole	 range	 of	 other	 families	 of	 PRR	 proteins	 involved	 in	 innate	 immunity.	
These	 include	 NLRs,	 but	 also	 ‘C-type	 lectin	 receptors’	 (CLRs),	 ‘RIG-I-like	 receptors’	 (RLRs),	
and	 ‘AIM2-like	 receptors’	 (ALRs)	 (Brubaker	 et	 al.,	 2015).	 It	 is	 due	 to	 these	 considerations	
that	 a	 later	 approach	 of	 RNA	 sequencing	 was	 applied.	 None-the-less,	 indications	 of	 a	
difference	 in	 TLR2	 transcription	 between	 LRRK2	 genotypes	 in	 response	 to	MDP	 led	 to	 an	
interest	 in	 the	 potential	 for	 LRRK2	 to	modulate	 cytoplasmic	 PRR	 signalling.	 In	 contrast	 to	
vesicular	trafficking,	a	role	of	LRRK2	in	phagocytosis	has	previously	been	described,	but	has	
ultimately	led	to	a	conflicted	understanding	of	the	role	of	LRRK2	in	this	process	through	the	
use	of	different	experimental	setups	(Marker	et	al.,	2012;	Schapansky	et	al.,	2014;	Moehle	
et	 al.,	 2015).	 The	 use	 of	 primary	 macrophages	 from	 LRRK2	 KO	 mice	 represents	 a	 step	
forward	in	this	particular	area	of	research,	allowing	clarification	that	LRRK2	does	not	appear	
to	be	directly	involved	in	phagocytosis	in	a	range	of	different	phagocytic,	and	immunological	
contexts.	 However,	 while	 phagocytosis	 can	 be	 measured	 in	 vitro,	 this	 may	 not	 be	
representative	of	physiological	conditions.	 Indeed,	pathway	analysis	of	genes	 identified	by	
RNA	 sequencing	 did	 identify	 potential	 involvement	 of	 LRRK2	 in	 phagocytosis	 that	 may	
warrant	future	research.	Identification	of	genes	such	Rapgef3,	Csrnp1,	and	Camk2b	by	RNA	
sequencing,	 suggest	 that	 LRRK2	may	be	 involved	 in	broad	areas	of	biology	 such	as	 cAMP,	
Wnt,	and	Ca2+	signalling;	the	contributions	of	which	are	only	recently	being	appreciated	by	
innate	 immunologists	 (fig	 57).	 With	 these	 considerations	 in	 mind,	 to	 assess	 the	 role	 of	
LRRK2	 in	 particular	 processes	 such	 as	 phagocytosis	 faithfully,	 in	 vivo	 experiments	 where	
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such	secondary	messengers	can	be	closely	accounted	for	may	yield	more	meaningful	results	
than	equivalent	 in	vitro	experiments.	Such	experiments	would	 require	 the	combination	of	
genetic	 LRRK2	 mouse	 models	 with	 a	 method	 such	 as	 lentiviral	 delivery	 of	 the	 alpha-
synuclein	 encoding	 gene	 to	 induce	 alpha-synuclein	 pathology	 (Decressac	 et	 al.,	 2012).	 In	
contrast,	 the	 basic	 involvement	 of	 LRRK2	 in	 modulating	 secondary	 messengers	 such	 as	
cAMP	or	Ca2+	may	be	better	 studied	 in	vitro;	where	specific	perturbations	of	homeostasis	
can	 be	 applied	 and	 secondary	 messenger	 responses	 assessed.	 For	 example,	 cultured	
macrophages	may	be	stained	with	fluo-4,	a	Ca2+	responsive	fluorescent	dye	to	measure	Ca2+	
flux	 in	 response	 to	 stimulation	 of	 TLR4,	 and	 this	 response	 compared	 between	 LRRK2	
genotypes	(Paredes	et	al.,	2008).	A	commercially	available	 ‘enzyme-linked	 immunosorbent	
assay’	(ELISA)	may	be	applied	to	the	measurement	of	cAMP	perturbations	in	macrophages,	
as	 more	 sophisticated	 ‘fluorescence	 resonance	 energy	 transfer’	 (FRET)	 methods	 require	
macrophage	transfection	with	fluorescent	reporter	constructs	(Börner	et	al.,	2011).		
The	finding	that	LRRK2	appears	to	modulate	chemokine	signalling	in	response	to	LPS	
stimulation	is	an	exciting	development	in	our	understanding	of	the	role	of	LRRK2	in	innate	
immunity	(fig	57).	Perturbations	to	chemokine	release	by	LRRK2	knockout	or	mutation	may	
be	expected	 to	 lead	 to	 a	 relatively	 subtle	 inflammatory	phenotype	as	 compared	 to	direct	
perturbation	 of	 classical	 inflammatory	 cytokines.	 Indeed	 the	 uncovering	 of	 a	 chemokine	
related	phenotype	of	LRRK2	knockout	in	response	to	LPS	stimulation	was	unexpected,	as	the	
majority	of	similar	experiments	have	focused	on	classical	 inflammatory	cytokine	signalling;	
which	has	resulted	in	conflicting	reports	(Gillardon	et	al.,	2012;	Kim	et	al.,	2012;	Moehle	et	
al.,	2015).	In	alignment	with	findings	by	RNA	sequencing,	one	very	recent	report	in	microglia	
has	uncovered	an	underlying	difference	in	the	microglia	specific	CX3CR1	receptor	(Ma	et	al.,	
2016).	Findings	described	using	macrophages	here,	and	by	others	using	microglia,	 suggest	
that	chemotactic	signalling	may	be	the	focus	of	LRRK2	immunological	research	in	the	near	
future.	Indeed,	effects	of	LRRK2	knockout	on	chemotaxis	have	previously	been	described	in	
both	microglia	and	macrophages.	These	experiments	were	performed	towards	a	gradient	of	
ATP,	 but	 again	 led	 to	 conflicting	 results.	 Specifically,	 the	 LRRK2	 G2019S	 mutation	 was	
suggested	 to	 enhance	 chemotactic	 responses	 in	 macrophages,	 while	 inhibition	 of	
chemotaxis	 was	 observed	 using	microglia	 (Choi	 et	 al.,	 2015;	Moehle	 et	 al.,	 2015).	 These	
conflicts	 may	 be	 attributed	 to	 differences	 to	 experimental	 setup	 or	 a	 cell-type	 specific	
effect,	however	overall	they	further	demonstrate	a	role	of	LRRK2	in	chemotaxis.	It	would	be	
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particularly	interesting	to	repeat	such	experiments	using	pBMDM	cells	from	WT	and	LRRK2	
KO	 mice,	 and	 to	 compare	 chemotaxis	 towards	 a	 range	 of	 chemoattractant	 agents.	 In	
particular,	 CCL2	 and	CCL5	 should	be	 trialled	 in	 such	 assays	 following	 the	discovery	of	 the	
differential	regulation	of	Rapgef3	and	Ccrl2	transcription	following	LPS	stimulation	by	RNA	
sequencing.	 This	 is	 as	 EPAC1	 (encoded	 by	 Rapgef3)	 and	 Hcar2	 have	 been	 linked	 to	
chemotaxis	towards	CCL2	(Lorenowicz	et	al.,	2006;	Lukasova	et	al.,	2011),	while	CCRL2	has	
been	 reported	 as	 a	 non-canonical	 receptor	 for	 CCL5	 (Yoshimura	 and	 Oppenheim,	 2011).	
Such	experiments	would	however	require	the	use	of	macrophages	pre-treated	with	LPS	to	
induce	the	LRRK2-regulated	expression	of	chemokine	receptors.	
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Figure	 57:	 Developing	 an	 understanding	 of	 LRRK2	 signalling	 in	 innate	 immunity.	
Transcriptomic	analysis	in	response	to	innate	immune	stimuli	highlights	involvement	of	LRRK2	
in	Ca2+,	Wnt,	and	cAMP	associated	processes.	A	particular	regulation	of	chemokine	signalling	
by	LRRK2	was	also	highlighted	suggesting	a	role	for	LRRK2	in	cell	migration	and	chemotaxis.	
Overall,	 these	 results	 indicate	 that	 LRRK2	 involvement	 in	 phagocytosis	 and	 innate	 immune	
signalling	may	be	best	studied	with	a	particular	focus	on	developing	areas	of	innate	immune	
research,	including	Ca2+,	Wnt	and	cAMP	signalling.	Future	work	could	be	taken	into	microglia	
in	order	to	understand	if	such	processes	may	be	directly	relevant	to	Parkinson’s	disease	and	
neuroinflammatory	signalling.	
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6.2	LRRK2	as	a	research	topic,	and	as	a	therapeutic	target	
Findings	made	using	a	transcriptomic	approach	illustrate	perfectly	how	the	study	of	
LRRK2	may	 inform	 our	 understanding	 of	 Parkinson’s	 disease	more	 generally.	 Each	 of	 the	
discussed	signalling	pathways	of	cAMP,	Wnt,	and	Ca2+	have	previously	been	independently	
linked	to	both	 innate	 immunity,	and	LRRK2.	For	 instance,	cAMP	has	been	shown	to	 inhibit	
inflammatory	 TNFα	 signalling	 in	 response	 to	 LPS,	 demonstrating	 a	 level	 of	 cross-talk	
between	cAMP	and	TLR	signalling	 (Wall	et	al.,	2009).	A	 later	 report	has	shown	that	cAMP	
sensitises	macrophages	to	LPS	signalling,	and	increases	the	production	of	pro-inflammatory	
IL-33	 (Sato	et	 al.,	 2016).	A	 complex	 regulatory	network	has	been	described	between	Wnt	
and	 NF-κB	 signalling.	 The	 activation	 of	 Wnt	 signalling	 results	 in	 a	 context	 dependent	
modulation	of	the	inflammatory	output	of	cells,	with	either	pro	or	anti-inflammatory	effects	
mediated	 via	 β-catenin	 and	 GSK3	 (Ma	 and	 Hottiger,	 2016).	 Finally,	 involvement	 of	 Ca2+	
signalling	 in	 innate	 immunology	 is	 exemplified	 by	 a	 very	 recent	 report	 showing	 that	
extracellular	 Ca2+	 potentiates	 inflammatory	 signalling	 upon	 stimulation	 of	 TLR4,	 TLR3	 and	
TLR9	 via	 a	 Rap1	 dependent	 mechanism	 (Tang	 et	 al.,	 2014;	 Tang	 et	 al.,	 2017).	 Rap1,	 as	
discussed	 extensively,	 is	 the	 canonical	 target	 of	 EPAC1	 signalling.	 Taken	 together,	 the	
association	 provided	 by	 this	work,	 and	 the	work	 of	 others,	 between	 these	 pathways	 and	
LRRK2	 really	 emphasise	 that	 cAMP,	 Wnt	 and	 Ca2+	 signalling	 may	 not	 just	 be	 linked	 to	
inflammation,	but	also	to	neuroinflammation	and	Parkinson’s	disease;	even	in	cases	of	the	
truly-sporadic	disease.	
Inversely,	much	is	made	of	the	potential	use	of	inhibition	of	LRRK2	kinase	activity	as	
a	potential	treatment	for	Parkinson’s	disease	(Atashrazm	and	Dzamko,	2016;	Taymans	and	
Greggio,	 2016).	While	 there	 is	 some	mileage	 to	 this	 approach,	 it	 seems	 to	 be	 commonly	
overlooked	that	mutations	to	LRRK2	account	for	only	a	very	small	proportion	of	the	overall	
Parkinson’s	 disease	burden,	with	 the	most	 prevalent	 LRRK2	mutation	of	G2019S	 found	 in	
only	up	to	2	%	of	sporadic	cases	of	Parkinson’s	disease	in	general	western	populations	(Gilks	
et	 al.,	 2005).	 While	 modulation	 of	 LRRK2	 enzymatic	 activity	 would	 inherently	 affect	
pathways	 relevant	 to	 disease	 pathology,	 the	 sheer	 number	 of	 pathways	 in	 which	 LRRK2	
appears	 to	 be	 involved	 suggests	 that	 such	 modulation	 may	 lead	 to	 broad,	 un-targeted	
downstream	effects;	and	so	may	lead	to	significant	undesired	outcomes	in	patients	without	
underlying	pathogenic	mutations	to	LRRK2.	These	fears	are	substantiated	by	the	finding	that	
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LRRK2	kinase	 inhibitor	 treatment	causes	autophagy-related	pathology	 in	 the	 lungs	of	non-
human	 primates	 (Fuji	 et	 al.,	 2015).	 Furthermore,	 while	 the	 much	 focused	 upon	 G2019S	
mutation	accounts	 for	 the	majority	of	 LRRK2	associated	 cases	of	 Parkinson’s	disease,	 it	 is	
not	 the	 only	 pathogenic	 mutation	 associated	 with	 pathology.	 It	 is	 unclear	 whether	
mutations	 to	R1441	of	 the	LRRK2	GTPase	domain	cause	pathology	by	distinct	or	 common	
mechanisms	to	that	of	G2019S	mutation.	In	comparison	however,	it	is	well	established	that	
mutations	to	R1441	do	not	share	the	consistent	three-fold	enhancement	of	kinase	activity	
caused	by	 the	G2019S	mutation	 (Smith	 et	 al.,	 2006;	Guo	et	 al.,	 2007;	 Jaleel	 et	 al.,	 2007).	
Therefore,	 therapeutic	 inhibition	 of	 LRRK2	 kinase	 activity	 may	 not	 be	 appropriate	 for	 all	
LRRK2	linked	cases	of	disease.	
Finally,	work	presented	here	has	highlighted	differences	in	LRRK2	function	between	
cell	 types.	 For	 example,	while	 an	 increase	 in	 ceramide	 levels	 has	 been	described	 in	 brain	
tissue	 upon	 knockout	 of	 LRRK2,	 this	 effect	 was	 not	 observed	 in	 primary	 macrophages	
(Ferrazza	et	al.,	2016).	However,	MDP	treated	macrophages	did	display	an	LRRK2	dependent	
increase	 in	 ceramide	 levels	 upon	 stimulation.	 It	 would	 be	 interesting	 to	 assess	 ceramide	
responses	to	MDP	treatment	in	neuronal	or	microglial	cultures	in	order	make	a	comparison	
between	 neuronal	 and	 immunological	 cell	 ceramide	 responses.	 Transcriptome	 analysis	
revealed	few	differences	in	gene	expression	between	LRRK2	KO	and	equivalent	WT	resting	
macrophages.	This	reflects	findings	made	using	a	similar	approach	with	G2019S	LRRK2	brain	
tissue	(Devine	et	al.,	2011).	The	finding	of	differential	gene	responses	to	LPS	in	macrophages	
highlights	that	LRRK2	function	varies	not	just	by	cell	type,	but	also	in	a	cell	signalling	context	
dependent	manner.	That	EPAC1	relates	directly	to	neurite	extension	in	a	neuronal	context	
(Mains	 et	 al.,	 1990;	Monaghan	 et	 al.,	 2008),	 and	 is	 also	 the	 gene	 identified	 as	 the	most	
statistically	 significant	 differentially	 responding	 gene	 to	 LPS	 stimulation	 between	 LRRK2	
macrophage	 genotypes,	 reaffirms	 that	 LRRK2	 phenotypes	 and	 interactions	 identified	 in	 a	
neuronal	 context	 are	 able	 to	 inform	 our	 understanding	 of	 LRRK2	 in	 innate	 immunity.	
Overall,	many	 cell-type	 specific	 effects	 of	 LRRK2	 can	be	observed:	 from	 the	 cytoskeletally	
dependent	morphological	phenotypes	which	have	been	 the	 indirect	 focus	of	 this	work,	 to	
effects	 on	 lysozyme	 sorting	 in	 gut	 Paneth	 cells	 (Zhang	 et	 al.,	 2015),	 and	 autophagy	
associated	 phenotypes	 in	 the	 kidneys	 and	 lungs	 (Herzig	 et	 al.,	 2011;	 Tong	 et	 al.,	 2012).	
Accordingly,	 it	 should	 not	 be	 forgotten	 that	 the	 targeting	 of	 LRRK2	 enzymatic	 activity	 to	
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modulate	neuronal	or	inflammatory	LRRK2	phenotypes	would	likely	cause	a	broad	range	of	
undesired	effects	in	many	areas	of	biology.	
6.3	Moving	beyond	LRRK2	knockout	in	murine	macrophages		
	 The	 use	 of	 primary	 macrophages	 derived	 from	 LRRK2	 KO	 mice	 has	 enabled	 the	
clarification	 of	 the	 role	 of	 LRRK2	 where	 non-specific	 LRRK2	 knockdown	 or	 chemical	
inhibition	 has	 led	 to	 uncertainty.	 Indeed,	 benefits	 associated	 with	 the	 use	 of	 genetic	
knockout	 systems	 towards	 uncovering	 the	 underlying	 biochemistry	 of	 proteins	 is	 well	
established.	 However,	 in	 the	 case	 of	 LRRK2	 associated	 Parkinson’s	 disease,	 the	 best	
characterised	pathological	LRRK2	mutation,	G2019S,	appears	to	pertain	to	a	gain-of-function	
mechanism	rather	 than	 loss-of-function	 (West	et	al.,	2005;	MacLeod	et	al.,	2006;	 Jaleel	et	
al.,	 2007;	Greggio	and	Cookson,	2009).	The	use	of	mice	expressing	G2019S	mutant	 LRRK2	
would	 therefore	 complement	 the	 use	 of	 LRRK2	 KO	mice	 for	 the	 specific	 study	 of	G2019S	
LRRK2	 associated	 pathobiology	 of	 Parkinson’s	 disease.	 That	 said,	 and	 as	 mentioned	
previously,	 simply	 studying	 the	 G2019S	 mutation	 of	 LRRK2	 would	 result	 in	 functions	 of	
LRRK2	 that	may	be	mediated	outside	of	 the	kinase	domain,	or	 that	are	 involved	 in	LRRK2	
biology	 but	 are	 not	 necessarily	 associated	 with	 disease,	 being	 missed.	 Many	 non-kinase	
domain	 associated	 LRRK2	 functions	 are	 likely	 to	 be	 relevant	 to	 Parkinson’s	 disease	
pathology	given	the	existence	of	three	different	pathological	mutations	at	position	R1441	of	
the	LRRK2	Roc	domain	alone	(Simón-Sánchez	et	al.,	2006;	Haugarvoll	et	al.,	2008;	Ross	et	al.,	
2009).	While	the	use	of	LRRK2	KO	mice	does	provide	a	great	insight	to	fundamental	LRRK2	
biology,	the	use	of	such	mice	does	still	have	limitations.	Again,	this	comes	down	to	the	fact	
that	 LRRK2	 knockout	 does	 not	 result	 in	 the	 loss	 of	 functional	 activity	 alone,	 but	 actually	
results	in	the	loss	of	both	functional	activity	and	a	major	protein	scaffold	that	other	enzymes	
may	 require	 for	 protein	 complex	 formation.	 To	 explain,	 LRRK2	 contains	 a	 huge	 array	 of	
repeat	 structures	 either	 side	 of	 the	 catalytic	 core,	 any	 of	 which	 may	 act	 alone	 or	 in	
combination	to	bind	other	proteins	and	ligands	(Mills	et	al.,	2014).	Knockout	of	LRRK2	will	
affect	 the	 formation	 of	 such	 complexes	 even	 if	 LRRK2	 does	 not	 enzymatically	modify	 the	
complex	 itself.	 Therefore,	 while	 LRRK2-associated	 immunological	 phenotypes	 may	 be	
identified	 by	 comparison	 of	 WT	 and	 LRRK2	 KO	 macrophages,	 the	 use	 of	 ‘kinase	 dead’	
D1994A	 LRRK2	 could	 help	 to	 identify	 and	 separate	 the	 role	 of	 LRRK2	 as	 a	 kinase,	 as	
compared	to	a	molecular	scaffold	(West	et	al.,	2007).		
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A	 further	 feature	of	 this	 study	 is	 the	use	of	bone	marrow	derived	macrophages	as	
compared	 to	microglia.	 Bone	marrow	 derived	macrophages	 are	 a	 powerful	 tool	 to	 study	
macrophage	function,	with	many	advantages	over	the	use	of	cell	lines	that	have	undergone	
an	 immortalisation	 process.	 In	 comparison	 to	murine	macrophages	 generated	 from	 bone	
marrow,	 classical	 isolation	of	 primary	microglia	 requires	 neonatal	mice,	 is	 extremely	 time	
consuming,	and	 is	costly	 in	terms	of	animals	required.	From	three	neonatal	mouse	brains,	
only	around	900,000	microglia	would	be	 isolated,	after	 two	weeks	of	 culture	 (Giulian	and	
Baker,	 1986;	 Floden	and	Combs,	2007).	 This	 compares	 to	around	30	million	pBMDM	cells	
from	a	single	adult	mouse,	after	a	single	week	of	culture.	It	is	also	easy	to	forget	that	LRRK2	
is	 functional	 in	 non-pathogenic	 contexts,	 as	 well	 as	 in	 conditions	 other	 than	 Parkinson’s	
disease	and	neuroinflammation;	such	as	Crohn’s	disease	and	Leprosy	 (Barrett	et	al.,	2009;	
Zhang	 et	 al.,	 2009;	 Franke	 et	 al.,	 2010;	 Wang	 et	 al.,	 2014).	 Indeed,	 LRRK2	 has	 a	 broad	
expression	pattern	 involving	many	tissues	outside	of	the	brain;	and	 is	enriched	in	 immune	
cells	 (Gardet	et	al.,	2010;	Maekawa	et	al.,	2010).	The	use	of	microglia	 therefore	comes	at	
considerable	cost,	and	 is	perhaps	a	 less	suitable	model	 than	 that	of	primary	macrophages	
for	 the	 study	 of	 LRRK2	 in	 innate	 immunity	 as	 a	 whole.	 While	 differences	 between	
macrophages	 and	 microglia	 exist	 (Hickman	 et	 al.,	 2013),	 so	 too	 do	 differences	 between	
innate	 immune	 responses	 in	 mice	 and	 humans	 (Mestas	 and	 Hughes,	 2004).	 Again,	
maintaining	a	focus	on	Parkinson’s	disease	in	particular	exacerbates	species	differences,	as	
mice	do	not	naturally	develop	neurodegenerative	disorders.	Ultimately,	mouse	models	are	
limited,	but	provide	the	most	efficient	basis	upon	which	to	identify	a	role	for	LRRK2	in	innate	
immunity	due	to	the	availability	and	identical	genetic	backgrounds	of	mice.	An	ideal	model	
for	 future	 research	would	 be	 the	 continued	 use	 of	 primary	murine	macrophages	 for	 the	
identification	 of	 immunological	 phenotypes	 of	 LRRK2	 knockout,	 then	 the	 subsequent	
utilisation	of	primary	murine	microglia	and	perhaps	human	‘induced	pluripotent	stem	cell’	
(iPSC)	 derived	 macrophages	 or	 microglia	 from	 patients	 suffering	 from	 LRRK2	 associated	
Parkinson’s	disease	(Muffat	et	al.,	2016;	Pandya	et	al.,	2017).	This	would	allow	the	relevance	
of	 phenotypes	 identified	 in	murine	macrophages	 to	 be	 confirmed	 in	 the	 disease-relevant	
cell	type	of	primary	microglia,	and	human	innate	immune	cells.	
An	 alternate	 approach	 would	 negate	 the	 need	 for	 the	 routine	 use	 of	 primary	
macrophages	 at	 all.	 This	 would	 be	 the	 knockout	 or	mutation	 of	 LRRK2	 in	 cell	 lines	 using	
CRISPR/Cas9	technology	(Ran	et	al.,	2013;	Hsu	et	al.,	2014).	Murine	RAW264.7	macrophages	
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or	BV-2	microglia	both	express	LRRK2,	and	could	be	modified	this	way	to	(Schapansky	et	al.,	
2014).	 The	 human	 THP-1	 cell	 line	 also	 expresses	 LRRK2,	 and	 could	 be	 similarly	 modified	
(Gardet	 et	 al.,	 2010),	 although	 a	 widely	 available	 human	microglial	 cell	 line	 is	 lacking	 to	
complement	 this.	 Resulting	 cell	 lines	 would	 be	 extremely	 convenient,	 and	 would	
dramatically	 reduce	 the	 need	 for	 animals	 in	 LRRK2	 research,	 as	 primary	 cells	 and	 tissues	
would	be	 limited	 to	 follow-up	experiments.	 This	would	 improve	 the	 compliance	of	 LRRK2	
research	 with	 the	 policy	 of	 replacement,	 reduction	 and	 refinement	 of	 animal	 testing	 in	
research.	
6.4	The	future	of	LRRK2	research	
	 Innate	immunity	has	re-emerged	over	the	past	few	years	as	a	topic	of	interest	to	the	
LRRK2	research	community.	This	research	effort	has	been	aided	by	the	development	of	tools	
such	as	 the	 LRRK2	mouse	models	 as	used	 in	work	described	here,	 but	 also	new	methods	
such	 as	 the	 aforementioned	CRISPR/Cas9	 technology	which	 facilitate	 in	 vitro	 experiments	
that	 had	 previously	 not	 been	 possible.	 The	 specific	 nature	 of	 such	 tools	 will	 render	 the	
development	of	LRRK2	specific	kinase	 inhibitors	obsolete	 for	basic	 research	purposes,	and	
will	vastly	improve	the	quality	of	LRRK2	research.	LRRK2	is	clearly	involved	in	a	large	number	
of	 cellular	 processes,	 as	 is	 fitting	 of	 a	 protein	with	 not	 one,	 but	 two	 enzymatically	 active	
domains,	 and	 a	whole	 range	 of	 potential	 protein-protein	 interaction	 surfaces.	 The	 LRRK2	
interaction	 network	 that	 results	 is	 highly	 elaborate,	 and	 has	 proved	 difficult	 to	 unpick	
(Manzoni	et	al.,	2015;	Porras	et	al.,	2015).	Efforts	to	establish	meaningful	LRRK2	functions	
and	relevance	 to	pathology	have	not	been	aided	by	 the	use	of	 the	particularly	misleading	
L2in1	inhibitor;	which	is	thankfully	becoming	less-and-less	prevalent	in	LRRK2	research.	It	is	
perhaps	 telling	 that	 over	 the	 past	 few	 years,	 many	 of	 the	 most	 interesting	 discoveries	
relating	 to	 LRRK2	 function	 have	 come	 from	 groups	 without	 a	 previous	 interest	 in	 LRRK2	
itself;	and	so	have	been	able	to	view	LRRK2	with	a	fresh	perspective.	This	is	exemplified	by	
the	discovery	of	roles	of	LRRK2	in	NFAT	signalling	(Liu	et	al.,	2011),	lysozyme	sorting	(Zhang	
et	al.,	2015),	and	protein	translation	(Imai	et	al.,	2008).	The	debunking	of	erroneous	LRRK2	
functions	that	has	been	occurring,	in	part	through	work	such	as	that	described	here,	should	
lead	 to	 the	 development	 of	 a	 greater	 consensus	 on	 the	 cellular	 roles	 of	 LRRK2	 and	 their	
relative	importance	to	pathogenicity.	
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	 The	dichotomous	nature	of	LRRK2	in	neurons	and	immune	cells	will	always	exist,	and	
it	will	be	interesting	to	see	how	much	overlap	truly	exists	between	LRRK2	function	in	these	
two	 specialised	 cell	 types.	 Ultimately,	 significant	 pathological	 phenotypes	 such	 as	
neurodegeneration	 may	 develop	 from	 the	 accumulation	 of	 many	 small	 changes	 on	 a	
molecular	scale;	this	 is	the	basis	of	modern	systems	biology	based	approaches	to	research	
(Chuang	et	al.,	2010).	Therefore,	effects	of	LRRK2	 in	neurons,	microglia,	macrophages	and	
even	 astrocytes	 most	 likely	 act	 in	 combination	 to	 cause	 conditions	 such	 as	 Parkinson’s	
disease,	 with	 no	 one	 factor	 truly	 acting	 in	 isolation.	 While	 studying	 these	 systems	
individually	is	fundamental	to	developing	our	understanding	of	LRRK2	function,	it	should	not	
be	 forgotten	 that	 immunology	 and	 neuroscience	 are	 intimately	 linked	 all	 the	 way	 from	
neurogenesis,	 through	 neuroplasticity,	 to	 neurodegeneration.	 That	 LRRK2	 is	 expressed	 in	
the	archetypal	cell	type	of	both	systems	only	acts	to	strengthen	this	link.	
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9.	Appendix	
	
	
	
	 	
Analyser	mode	 Resolution	
Data	format	 Centroid	
Scan	time		 0.3	sec	
Detector	range		 50	–	1200	Da	
Run	time	 8.5	minutes	
Source	temperature	 120	⁰C	
Desolvation	temperature	 550	⁰C	
Capillary	voltage	 1.5	kV	
Sampling	cone	voltage	in	Positive	mode	 30	V	
Sampling	cone	voltage	in	Negative	mode	 25	V	
Extraction	cone	voltage	 4	V	
Desolvation	gas	flow	 900	L/h	
Cone	gas	flow	 50	L/h	
Collision	energy		 6	eV	
Column	type	 Waters	Acquity	CSH	C18	1.7	µm	(100	x	2.1	mm)	
Column	temperature	 55	⁰C	
Sample	temperature	 10	⁰C	
Mobile	phase	A	 60/40	Acetonitrile/water	+	10	mM	ammonium	formate	(v/v)	
Mobile	phase	B	 10/90	Acetonitrile/propan-2-ol	+	10	mM	ammonium	formate	(v/v)		
Injection	volume	 Positive	-	2	µL	Negative	-	6	µL	
Run	time	 9.0	minutes	
Gradient	 Time	(min)	 0.0	 7.5	 7.7	
%	A	 55	 2	 55	
Appendix	table	1:		Chromatographic	conditions	for	the	adapted	Waters	Corporation	lipid	method.	
	
Appendix	table	2:	Mass	spectrometry	conditions	for	the	adapted	Waters	Corporation	lipid	method.	
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Reactome	Pathway	
Pathway	enrichment	
WT	 LRRK2	KO	
Activated	TLR4	signalling	 0.000	 0.000	
Cytokine	Signaling	in	Immune	system	 0.000	 0.000	
ERK/MAPK	targets	 0.001	 0.005	
Immune	System	 0.000	 0.000	
Innate	Immune	System	 0.000	 0.000	
Interferon	alpha/beta	signaling	 0.002	 0.001	
Interferon	gamma	signaling	 0.000	 0.000	
Interferon	Signaling	 0.000	 0.000	
Interleukin-1	signaling	 0.006	 0.007	
MAP	kinase	activation	in	TLR	cascade	 0.000	 0.001	
MAPK	targets/	Nuclear	events	mediated	by	MAP	kinases	 0.000	 0.002	
MyD88	cascade	initiated	on	plasma	membrane	 0.000	 0.000	
MyD88	dependent	cascade	initiated	on	endosome	 0.000	 0.000	
MyD88-independent	cascade		 0.000	 0.000	
MyD88:Mal	cascade	initiated	on	plasma	membrane	 0.000	 0.000	
Nuclear	Events	(kinase	and	transcription	factor	activation)	 0.001	 0.003	
Regulation	of	IFNA	signaling	 0.005	 0.003	
Rho	GTPase	cycle	 0.009	 0.005	
RIG-I/MDA5	mediated	induction	of	IFN-alpha/beta	pathways	 0.000	 0.001	
Signal	Transduction	 0.000	 0.000	
Signaling	by	Interleukins	 0.000	 0.000	
Signaling	by	Rho	GTPases	 0.009	 0.005	
Signalling	by	NGF	 0.001	 0.000	
Toll	Like	Receptor	10	(TLR10)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	2	(TLR2)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	3	(TLR3)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	4	(TLR4)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	5	(TLR5)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	7/8	(TLR7/8)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	9	(TLR9)	Cascade	 0.000	 0.001	
Toll	Like	Receptor	TLR1:TLR2	Cascade	 0.000	 0.000	
Toll	Like	Receptor	TLR6:TLR2	Cascade	 0.000	 0.000	
Toll-Like	Receptors	Cascades	 0.000	 0.001	
TRAF6	mediated	induction	of	NFkB	and	MAP	kinases	upon	TLR7/8	or	9	
activation	 0.000	 0.000	
TRAF6	Mediated	Induction	of	proinflammatory	cytokines	 0.000	 0.000	
TRIF-mediated	TLR3/TLR4	signaling		 0.000	 0.000	
Appendix	 table	3:	Enriched	pathways	 shared	between	WT	and	LRRK2	KO	macrophages	after	 LPS	
treatment.	100	ng/ml	LPS.	Differential	gene	expression	padj	<	0.01,		pathway	enrichment	padj	<	0.01.	
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Reactome	Pathway	
Pathway	enrichment	
WT	 LRRK2	KO	
Activated	TAK1	mediates	p38	MAPK	activation	 0.004	 0.006	
Activated	TLR4	signalling	 0.000	 0.000	
Chemokine	receptors	bind	chemokines	 0.000	 0.000	
Class	A/1	(Rhodopsin-like	receptors)	 0.000	 0.001	
Cytokine	Signaling	in	Immune	system	 0.000	 0.000	
Fcgamma	receptor	(FCGR)	dependent	phagocytosis	 0.002	 0.004	
GPCR	downstream	signaling	 0.009	 0.010	
Immune	System	 0.000	 0.000	
Innate	Immune	System	 0.000	 0.000	
Interferon	gamma	signaling	 0.000	 0.000	
Interferon	Signaling	 0.000	 0.001	
Interleukin-1	signaling	 0.001	 0.001	
MyD88	cascade	initiated	on	plasma	membrane	 0.001	 0.000	
MyD88	dependent	cascade	initiated	on	endosome	 0.001	 0.000	
MyD88-independent	cascade		 0.000	 0.000	
MyD88:Mal	cascade	initiated	on	plasma	membrane	 0.001	 0.000	
p75NTR	signals	via	NF-kB	 0.002	 0.003	
RIG-I/MDA5	mediated	induction	of	IFN-alpha/beta	pathways	 0.000	 0.000	
Signal	Transduction	 0.000	 0.000	
Signaling	by	GPCR	 0.003	 0.002	
Signaling	by	Interleukins	 0.000	 0.002	
Signaling	by	the	B	Cell	Receptor	(BCR)	 0.008	 0.010	
TAK1	activates	NFkB	by	phosphorylation	and	activation	of	IKKs	complex	 0.000	 0.000	
TCR	signaling	 0.000	 0.001	
Toll	Like	Receptor	10	(TLR10)	Cascade	 0.001	 0.000	
Toll	Like	Receptor	2	(TLR2)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	3	(TLR3)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	4	(TLR4)	Cascade	 0.000	 0.000	
Toll	Like	Receptor	5	(TLR5)	Cascade	 0.001	 0.000	
Toll	Like	Receptor	7/8	(TLR7/8)	Cascade	 0.001	 0.000	
Toll	Like	Receptor	9	(TLR9)	Cascade	 0.002	 0.000	
Toll	Like	Receptor	TLR1:TLR2	Cascade	 0.001	 0.000	
Toll	Like	Receptor	TLR6:TLR2	Cascade	 0.000	 0.000	
Toll-Like	Receptors	Cascades	 0.001	 0.000	
TRAF6	 mediated	 induction	 of	 NFkB	 and	 MAP	 kinases	 upon	 TLR7/8	 or	 9	
activation	 0.001	 0.000	
TRAF6	Mediated	Induction	of	proinflammatory	cytokines	 0.001	 0.000	
TRAF6	mediated	NF-kB	activation	 0.000	 0.000	
TRIF-mediated	TLR3/TLR4	signaling		 0.000	 0.000	
Appendix	table	4:	Enriched	pathways	shared	between	WT	and	LRRK2	KO	macrophages	after	MDP	
treatment.	Differential	gene	expression	padj	<	0.01,		pathway	enrichment	padj	<	0.01.	
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Pathway	enrichment	padj	<	0.05	 Pathway	enrichment	padj	<	0.1	
Reactome	Pathway	
LRRK2	
KO	
WT	 Reactome	Pathway	
LRRK2	
KO	
WT	
D
G
Ep
ad
j	<
	0
.0
1	
Association	of	TriC/CCT	with	target	proteins	during	
biosynthesis	 0.439	 0.020	
Folding	of	actin	by	CCT/TriC	
0.694	 0.066	
Regulation	of	IFNG	signaling	
0.223	 0.044	
Association	of	TriC/CCT	with	target	proteins	during	
biosynthesis	 0.439	 0.020	
Regulation	of	actin	dynamics	for	phagocytic	cup	formation	 0.207	 0.034	 Signaling	by	EGFR	in	Cancer	 0.351	 0.089	
PI3K/AKT	activation	 0.199	 0.035	 Interleukin-7	signaling	 0.344	 0.095	
Hemostasis	 0.184	 0.032	 Regulation	of	IFNG	signaling	 0.223	 0.044	
Interleukin-6	signaling	
0.122	 0.016	
Regulation	of	actin	dynamics	for	phagocytic	cup	
formation	 0.207	 0.034	
Constitutive	PI3K/AKT	Signaling	in	Cancer	 0.144	 0.041	 Signaling	by	FGFR	in	disease	 0.253	 0.081	
PI-3K	cascade	 0.130	 0.035	 PI3K/AKT	activation	 0.199	 0.035	
PI3K	events	in	ERBB2	signaling	 0.130	 0.035	 Hemostasis	 0.184	 0.032	
PI3K	events	in	ERBB4	signaling	 0.130	 0.035	 Downstream	TCR	signaling	 0.223	 0.074	
PI3K/AKT	Signaling	in	Cancer	 0.130	 0.035	 Signaling	by	PDGF	 0.194	 0.051	
PIP3	activates	AKT	signaling	 0.130	 0.035	 Interleukin-6	signaling	 0.122	 0.016	
TCR	signaling	 0.119	 0.033	 Constitutive	PI3K/AKT	Signaling	in	Cancer	 0.144	 0.041	
Downstream	signal	transduction	 0.105	 0.026	 PI-3K	cascade	 0.130	 0.035	
Fc	epsilon	receptor	(FCERI)	signaling	 0.071	 0.008	 PI3K	events	in	ERBB2	signaling	 0.130	 0.035	
Signaling	by	SCF-KIT	 0.097	 0.035	 PI3K	events	in	ERBB4	signaling	 0.130	 0.035	
Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	 0.105	 0.047	 PI3K/AKT	Signaling	in	Cancer	 0.130	 0.035	
GAB1	signalosome	 0.070	 0.016	 PIP3	activates	AKT	signaling	 0.130	 0.035	
Role	of	phospholipids	in	phagocytosis	 0.059	 0.011	 TCR	signaling	 0.119	 0.033	
Appendix	table	5:	Pathways	uniquely	enriched	in	WT	macrophages	after	LPS	treatment.	100	ng/ml	LPS.	Pathways	uniquely	highlighted	at	a	single	
differential	gene	expression	p	adjusted	value	(DGEpadj)	or	pathway	analysis	padj	are	shown	in	grey.	
	 289	
	 	
TAK1	activates	NFkB	by	phosphorylation	and	activation	of	
IKKs	complex	 0.059	 0.035	
Downstream	signal	transduction	
0.105	 0.026	
	
	
	
Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	 0.105	 0.047	
D
G
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j	<
	0
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PI	Metabolism	 0.259	 0.026	 Phospholipid	metabolism	 0.577	 0.053	
Regulation	of	actin	dynamics	for	phagocytic	cup	formation	 0.234	 0.039	 Hemostasis	 0.547	 0.079	
G	alpha	(12/13)	signalling	events	 0.084	 0.041	 PI	Metabolism	 0.259	 0.026	
Negative	regulators	of	RIG-I/MDA5	signaling	
0.055	 0.037	
Regulation	of	actin	dynamics	for	phagocytic	cup	
formation	 0.234	 0.039	
	
	
	
Synthesis	of	PIPs	at	the	plasma	membrane	 0.195	 0.054	
	
	
	
GAB1	signalosome	 0.124	 0.052	
	
	
	
Downstream	signal	transduction	 0.111	 0.082	
D
G
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	0
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Interleukin-3,	5	and	GM-CSF	signaling	 0.398	 0.021	 Phospholipid	metabolism	 0.596	 0.088	
Association	of	TriC/CCT	with	target	proteins	during	
biosynthesis	 0.398	 0.030	
Regulation	of	signaling	by	CBL	
0.540	 0.083	
PI	Metabolism	 0.353	 0.042	 Interleukin-3,	5	and	GM-CSF	signaling	 0.398	 0.021	
G	alpha	(12/13)	signalling	events	
0.229	 0.042	
Association	of	TriC/CCT	with	target	proteins	during	
biosynthesis	 0.398	 0.03	
The	NLRP3	inflammasome	 0.204	 0.018	 Regulation	of	IFNG	signaling	 0.398	 0.083	
Regulation	of	IFNA	signaling	 0.079	 0.006	 Signaling	by	FGFR1	fusion	mutants	 0.395	 0.083	
ERK/MAPK	targets	 0.057	 0.030	 PI	Metabolism	 0.353	 0.042	
TRAF6	mediated	NF-kB	activation	 0.055	 0.030	 Interleukin-2	signaling	 0.297	 0.073	
	
	
	
Synthesis	of	PIPs	at	the	plasma	membrane	 0.289	 0.066	
	
	
	
G	alpha	(12/13)	signalling	events	 0.229	 0.042	
	
	
	
The	NLRP3	inflammasome	 0.204	 0.018	
	
	
	
Negative	regulators	of	RIG-I/MDA5	signaling	 0.170	 0.089	
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Pathway	enrichment	padj	<	0.05	 Pathway	enrichment	padj	<	0.1	
Reactome	Pathway	
LRRK2
KO	
WT	 Reactome	Pathway	
LRRK2	
KO	
WT	
D
G
Ep
ad
j	<
	0
.0
1	
Inflammasomes	 0.050	 0.540	
Antigen	Presentation:	Folding,	assembly	and	
peptide	loading	of	class	I	MHC	
0.100	 0.914	
The	NLRP3	inflammasome	 0.023	 0.259	 Extrinsic	Pathway	for	Apoptosis	 0.080	 0.713	
Nucleotide-binding	domain,	leucine	rich	repeat	containing	
receptor	(NLR)	signaling	pathways	
0.034	 0.257	 Inflammasomes	 0.050	 0.540	
Signaling	by	NOTCH	 0.036	 0.243	 Cytosolic	sensors	of	pathogen-associated	DNA		 0.072	 0.378	
Interleukin	receptor	SHC	signaling	 0.023	 0.093	 The	NLRP3	inflammasome	 0.023	 0.259	
ERKs	are	inactivated	 0.034	 0.095	
Nucleotide-binding	domain,	leucine	rich	repeat	
containing	receptor	(NLR)	signaling	pathways	
0.034	 0.257	
Pre-NOTCH	Processing	in	Golgi	 0.034	 0.095	 Signaling	by	NOTCH	 0.036	 0.243	
Interleukin-3,	5	and	GM-CSF	signaling	 0.035	 0.086	
DEx/H-box	helicases	activate	type	I	IFN	and	
inflammatory	cytokines	production		
0.056	 0.256	
Interleukin-2	signaling	 0.023	 0.062	
	 	
	
p38MAPK	events	 0.018	 0.052	
	 	
	
TRAF3-dependent	IRF	activation	pathway	 0.018	 0.052	
	 	
	
G	alpha	(12/13)	signalling	events	 0.030	 0.060	
	 	
	
D
G
Ep
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j	<
	0
.0
5	 Cytosolic	sensors	of	pathogen-associated	DNA		 0.031	 0.536	 Loss	of	Nlp	from	mitotic	centrosomes	 0.051	 0.728	
TRAF3-dependent	IRF	activation	pathway	 0.017	 0.208	
Loss	of	proteins	required	for	interphase	
microtubule	organization	from	the	centrosome	
0.051	 0.728	
Signaling	by	NOTCH	 0.037	 0.221	 Cytosolic	sensors	of	pathogen-associated	DNA		 0.031	 0.536	
TRAF6	mediated	IRF7	activation	 0.005	 0.088	
Nucleotide-binding	domain,	leucine	rich	repeat	
containing	receptor	(NLR)	signaling	pathways	
0.062	 0.538	
Appendix	table	6:	Pathways	uniquely	enriched	in	LRRK2	KO	macrophages	after	LPS	treatment.	100	ng/ml	LPS.	Pathways	uniquely	highlighted	at	
a	single	differential	gene	expression	p	adjusted	value	(DGEpadj)	or	pathway	analysis	p	adjusted	value	are	shown	in	grey.	
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Signaling	by	the	B	Cell	Receptor	(BCR)	 0.017	 0.079	 The	NLRP3	inflammasome	 0.100	 0.569	
Interleukin-6	signaling	 0.013	 0.073	 Regulation	of	PLK1	Activity	at	G2/M	Transition	 0.055	 0.516	
p38MAPK	events	 0.017	 0.065	 Cell	Cycle,	Mitotic	 0.080	 0.347	
Pre-NOTCH	Expression	and	Processing	 0.017	 0.053	 Interleukin-2	signaling	 0.081	 0.292	
	 	
	 TRAF3-dependent	IRF	activation	pathway	 0.017	 0.208	
	 	 	 Signaling	by	NOTCH	 0.037	 0.221	
	 	 	 	 	 	 	 	
D
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Mitotic	G2-G2/M	phases	 0.018	 0.418	 Lysosphingolipid	and	LPA	receptors	 0.091 0.798	
Loss	of	Nlp	from	mitotic	centrosomes	 0.022	 0.378	 Mitotic	G2-G2/M	phases	 0.018	 0.418	
Loss	of	proteins	required	for	interphase	microtubule	
organization	from	the	centrosome	
0.022	 0.378	 Loss	of	Nlp	from	mitotic	centrosomes	 0.022	 0.378	
G2/M	Transition	 0.027	 0.330	
Loss	of	proteins	required	for	interphase	
microtubule	organization	from	the	centrosome	
0.022	 0.378	
Regulation	of	PLK1	Activity	at	G2/M	Transition	 0.025	 0.276	 G2/M	Transition	 0.027	 0.330	
p38MAPK	events	 0.047	 0.130	 Regulation	of	PLK1	Activity	at	G2/M	Transition	 0.025	 0.276	
TRAF3-dependent	IRF	activation	pathway	 0.047	 0.130	 Signaling	by	NOTCH	 0.091	 0.208	
	 	
	 p38MAPK	events	 0.047	 0.130	
	 	
	 TRAF3-dependent	IRF	activation	pathway	 0.047	 0.130	
	 	
	 Pre-NOTCH	Expression	and	Processing	 0.055	 0.124	
	 	
	 Downstream	signal	transduction	 0.069	 0.130	
	 	
	 Cytosolic	sensors	of	pathogen-associated	DNA		 0.083	 0.130	
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Pathway	enrichment	padj	<	0.05	 Pathway	enrichment	padj	<	0.1	
Reactome	Pathway	
LRRK2	
KO	
WT	 Reactome	Pathway	
LRRK2	
KO	
WT	
D
G
Ep
ad
j	<
	0
.0
1	
Dissolution	of	Fibrin	Clot	 0.729	 0.026	 Dissolution	of	Fibrin	Clot	 0.694	 0.066	
Inflammasomes	 0.335	 0.038	 Inflammasomes	 0.439	 0.020	
Integrin	alphaIIb	beta3	signaling	 0.085	 0.033	 p38MAPK	events	 0.351	 0.089	
MAP	kinase	activation	in	TLR	cascade	 0.065	 0.014	 p75	NTR	receptor-mediated	signalling	 0.344	 0.095	
Rho	GTPase	cycle	 0.094	 0.049	
Regulation	of	Lipid	Metabolism	by	Peroxisome	
proliferator-activated	receptor	alpha	(PPARalpha)	 0.223	 0.044	
Signaling	by	Rho	GTPases	 0.094	 0.049	 The	NLRP3	inflammasome	 0.207	 0.034	
TRAF6	mediated	IRF7	activation	 0.092	 0.005	 TRAF3-dependent	IRF	activation	pathway	 0.253	 0.081	
D
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	0
.0
5	
Adaptive	Immune	System	 0.203	 0.046	 Adaptive	Immune	System	 0.046	 0.157	
Cross-presentation	of	particulate	exogenous	antigens	
(phagosomes)	 0.075	 0.012	 Dissolution	of	Fibrin	Clot	 0.061	 0.257	
Downstream	Signaling	Events	Of	B	Cell	Receptor	(BCR)	 0.074	 0.042	 GAB1	signalosome	 0.044	 0.079	
GAB1	signalosome	 0.123	 0.044	 GPCR	ligand	binding	 0.089	 0.041	
NOTCH2	intracellular	domain	regulates	transcription	 0.204	 0.044	 Integrin	alphaIIb	beta3	signaling	 0.053	 0.223	
Nucleotide-binding	domain,	leucine	rich	repeat	containing	
receptor	(NLR)	signaling	pathways	 0.077	 0.006	 MAP	kinase	activation	in	TLR	cascade	 0.059	 0.144	
p38MAPK	events	 0.153	 0.047	 Negative	regulators	of	RIG-I/MDA5	signaling	 0.087	 0.116	
Signaling	by	the	B	Cell	Receptor	(BCR)	 0.061	 0.038	
NOTCH2	intracellular	domain	regulates	
transcription	 0.044	 0.16	
ZBP1(DAI)	mediated	induction	of	type	I	IFNs	 0.111	 0.029	 p38MAPK	events	 0.047	 0.106	
	 	 	 PPARA	Activates	Gene	Expression	 0.061	 0.151	
Appendix	table	7:	Pathways	uniquely	enriched	in	WT	macrophages	after	MDP	treatment.	10	ug/ml	MDP.	Pathways	uniquely	highlighted	at	a	single	
differential	gene	expression	p	adjusted	value	(DGEpadj)	or	pathway	analysis	p	adjusted	value	are	shown	in	grey.	
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Regulation	of	Lipid	Metabolism	by	Peroxisome	
proliferator-activated	receptor	alpha	(PPARalpha)	 0.097	 0.051	
	 	 	 Rho	GTPase	cycle	 0.051	 0.115	
	 	 	 Signaling	by	Rho	GTPases	 0.051	 0.115	
	 	 	 ZBP1(DAI)	mediated	induction	of	type	I	IFNs	 0.029	 0.082	
D
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Constitutive	PI3K/AKT	Signaling	in	Cancer	 0.133	 0.047	 AKT	phosphorylates	targets	in	the	nucleus	 0.274	 0.064	
DAP12	interactions	 0.066	 0.022	 Constitutive	PI3K/AKT	Signaling	in	Cancer	 0.133	 0.047	
Downstream	Signaling	Events	Of	B	Cell	Receptor	(BCR)	 0.115	 0.015	 DAP12	signaling	 0.236	 0.086	
GAB1	signalosome	 0.123	 0.006	 Dissolution	of	Fibrin	Clot	 0.408	 0.086	
Hemostasis	 0.054	 0.011	
Downstream	Signaling	Events	Of	B	Cell	Receptor	
(BCR)	 0.115	 0.015	
MAP	kinase	activation	in	TLR	cascade	 0.074	 0.043	 GAB1	signalosome	 0.123	 0.006	
NGF	signalling	via	TRKA	from	the	plasma	membrane	 0.054	 0.022	 p75	NTR	receptor-mediated	signalling	 0.316	 0.054	
PI-3K	cascade	 0.229	 0.022	 PI-3K	cascade	 0.229	 0.022	
PI3K	events	in	ERBB2	signaling	 0.229	 0.022	 PI3K	events	in	ERBB2	signaling	 0.229	 0.022	
PI3K	events	in	ERBB4	signaling	 0.229	 0.022	 PI3K	events	in	ERBB4	signaling	 0.229	 0.022	
PI3K/AKT	activation	 0.274	 0.034	 PI3K/AKT	activation	 0.274	 0.034	
PI3K/AKT	Signaling	in	Cancer	 0.229	 0.022	 PI3K/AKT	Signaling	in	Cancer	 0.229	 0.022	
PIP3	activates	AKT	signaling	 0.229	 0.022	 PIP3	activates	AKT	signaling	 0.229	 0.022	
Regulation	of	actin	dynamics	for	phagocytic	cup	formation	 0.074	 0.043	 Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	 0.316	 0.047	
Rho	GTPase	cycle	 0.074	 0.022	 Signaling	by	EGFR	in	Cancer	 0.316	 0.092	
Role	of	LAT2/NTAL/LAB	on	calcium	mobilization	 0.316	 0.047	 Signaling	by	ERBB2	 0.166	 0.056	
Signaling	by	PDGF	 0.15	 0.036	 Signaling	by	FGFR	 0.325	 0.088	
Signaling	by	Rho	GTPases	 0.074	 0.022	 Signaling	by	PDGF	 0.15	 0.036	
Signaling	by	the	B	Cell	Receptor	(BCR)	 0.117	 0.012	 Signaling	by	the	B	Cell	Receptor	(BCR)	 0.117	 0.012	
	 	 	
Transport	of	glucose	and	other	sugars,	bile	salts	
and	organic	acids,	metal	ions	and	amine	
compounds	 0.236	 0.087	
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Pathway	enrichment	padj	<	0.05	 Pathway	enrichment	padj	<	0.1	
Reactome	Pathway	
LRRK2	
KO	
WT	 Reactome	Pathway	
LRRK2	
KO	
WT	
D
G
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ad
j	<
	0
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1	
Fc	epsilon	receptor	(FCERI)	signaling	 0.050	 0.540	 Cell	junction	organization	 0.094	 0.13	
FCGR	activation	 0.023	 0.259	 DAP12	interactions	 0.065	 0.107	
Signaling	by	SCF-KIT	 0.034	 0.257	 FCERI	mediated	NF-kB	activation	 0.085	 0.104	
	 	
	 GAB1	signalosome	 0.09	 0.126	
	 	
	
Immunoregulatory	interactions	between	a	
Lymphoid	and	a	non-Lymphoid	cell	 0.094	 0.258	
	 	
	 p75NTR	recruits	signalling	complexes	 0.094	 0.111	
	 	
	
Signaling	by	EGFR	in	Cancer	 0.094	 0.239	
Signaling	by	PDGF	 0.08	 0.129	
D
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Cell	surface	interactions	at	the	vascular	wall	 0.036	 0.156	 Cell	surface	interactions	at	the	vascular	wall	 0.036	 0.156	
FCGR	activation	 0.011	 0.149	 FCGR	activation	 0.011	 0.149	
Role	of	phospholipids	in	phagocytosis	 0.012	 0.137	
Immunoregulatory	interactions	between	a	
Lymphoid	and	a	non-Lymphoid	cell	 0.098	 0.122	
	 	
	 Role	of	phospholipids	in	phagocytosis	 0.012	 0.137	
	 	
	 Signaling	by	SCF-KIT	 0.075	 0.108	
	 	
	 Signaling	by	NOTCH	 0.184	 	
D
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	 FCGR	activation	 0.019	 0.258	 Cell	surface	interactions	at	the	vascular	wall	 0.089	 0.112	
Generation	of	second	messenger	molecules	 0.028	 0.086	 FCGR	activation	 0.019	 0.258	
Inflammasomes	 0.02	 0.077	
Immunoregulatory	interactions	between	a	
Lymphoid	and	a	non-Lymphoid	cell	 0.086	 0.103	
Role	of	phospholipids	in	phagocytosis	 0.008	 0.257	 Role	of	phospholipids	in	phagocytosis	 0.008	 0.257	
The	NLRP3	inflammasome	 0.015	 0.077	 Signaling	by	GPCR	 0.072	 0.125	
Appendix	table	8:	Pathways	uniquely	enriched	in	LRRK2	KO	macrophages	after	MDP	treatment.	10	ug/ml	MDP.	Pathways	uniquely	highlighted	
at	a	single	differential	gene	expression	p	adjusted	value	(DGEpadj)	or	pathway	analysis	p	adjusted	value	are	shown	in	grey.	
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Expression	and	Puriﬁca0on	Trials	of	the	Leucine	
Rich	Repeat	Domain	of	LRRK2	
IntroducOon	
Parkinson’s	Disease	
Parkinson’s	 disease	 is	 the	 second	 most	 common	 neurodegenera0ve	 disorder,	
aﬀec0ng	 approximately	 1%	 of	 people	 over	 the	 age	 of	 65	 years.	 With	 an	 ageing	
popula0on,	 this	 severely	 debilita0ng,	 chronic	 disease	 will	 become	 of	 increasing	
prevalence,	 and	 represent	 a	 large	 burden	 on	 healthcare	 systems.	 Thus,	 a	 greater	
understanding	of	 the	pathological	mechanisms	underlying	the	condi0on	 is	urgently	
required.	Parkinson's	disease	 is	characterised	by	the	degenera0on	of	dopaminergic	
neurones	within	the	substan0a	nigra	pars	compacta	(ﬁg	2),	resul0ng	in	loss	of	motor	
control	 as	 well	 as	 other	 cogni0ve	 and	 psychiatric	 problems	 from	 damage	 to	
surrounding	neuronal	0ssue.	
LRR	domain	expresses	successfully	in	Sf9	insect	cells	
LRR	domain	boundaries	and	construct	design	
References	
Modelling	of	LRRK2	LRR	domain	reveals	homology	to	TLR3		
There	is	no	known	ligand	for	LRRK2,	so	the	discovery	that	the	poten0al	ligand	binding	LRR	domain	has	homology	
to	TLR3	suggests	that	LRRK2	could	have	a	role	in	innate	immune	signalling.	TLR3	is	a	receptor	for	RNA;	sugges0ng	
LRRK2	could	poten0ally	bind	nucleic	acids	via	discrete	charged	surfaces	(ﬁg3b,c)	(Gangloﬀ,	unpublished).	
To	inves0gate	the	validity	of	our	model,	a	high	yield	of	protein	ﬁrst	had	to	be	reproducibly	obtained.	Best	results	
were	obtained	using	Sf9	(Spodoptera	frugiperda)	insects	cells	with	a	baculovirus	expression	system.	
OpOmised	puriﬁcaOon	of	MBP-LRR6	
Table	1:	Expression	systems	and	tags	trialled	
•  LRR6	 is	 a	 soluble	 and	 stable	 form	of	 the	 LRR	domain	of	 LRRK2,	 amenable	 to	 short-term	puriﬁca0on	and	
biophysical	analysis.	
•  A	combina0on	of	Ni	aﬃnity	and	Anion	exchange	has	been	op0mised	and	u0lised	to	obtain	puriﬁed	LRR6.	
•  At	neutral	pH	LRR6	binds	heparin,	strongly	indica0ng	that	nucleic	acid	may	be	a	ligand	for	LRRK2.	This	result	
validates	previous	modelling	showing	homology	of	the	LRR	domain	to	TLR3.	
•  LRR6	in	PEG	precipitants	at	around	pH9	forms	spherulites;	indica0ng	the	poten0al	for	further	screening	to	
yield	crystals	for	x-ray	crystallographic	analysis.	
•  Generate	 fresh	MBP-LRR6	baculovirus	 to	 improve	 LRR6	yields,	or	 adempt	 to	 improve	 solubility	of	protein	
expressed	by	bacterial	expression	systems.	
•  Con0nue	op0misa0on	of	puriﬁca0on	including	incorpora0on	of	heparin	aﬃnity	as	a	‘polishing	step’.	
•  Trial	LRR6s	capacity	to	bind	heparin	at	high	pH	in	order	to	eliminate	TEV	protease	binding.	
•  Inves0gate	the	ability	of	LRR6	to	bind	diﬀerent	nucleic	acids	by	‘electrophore0c	mobility	shig	assay’.	
•  Con0nue	 screening	 crystallisa0on	 condi0ons	 and	 LRR6	 concentra0ons	 to	 obtain	 crystals	 for	 x-ray	
crystallographic	analysis.	
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Expression	System	 Tag	 Comment	
BL21(DE3)	 None	 Poor	expression,	Insoluble	
BL21(DE3)	 MBP	 Insoluble	
Roseda(DE3)pLysS	 None	 Poor	expression,	Insoluble	
Roseda(DE3)pLysS	 MBP	 Insoluble	
Sf9	 MBP	 Soluble	
Tn5B1-4	(High	Fives)		 MBP	 Soluble,	Viscous	
Roc	 COR	 Kinase	 WD40	
690	 860	 984	 1278	 1335	 1510	 1511	 1878	 1879	 2138	 2142	 2498	
ANK	 LRR	 2527	
Figure	1:	Predicted	Domain	structure	of	LRRK2.		
ANK:	 Ankyrin	 Repeats,	 LRR:	 Leucine	 rich	 repeats	 Roc:	
Ras	of	complex	proteins,	COR:	C-terminal	of	ROC.	
	
Even	 in	Sf9	cells,	protein	precipita0on	was	found	to	be	a	major	 limi0ng	factor	 in	the	puriﬁca0on	process,	
despite	the	increased	solubility	brought	about	by	inclusion	of	an	MBP	tag	in	the	construct.	
	
To	op0mise	puriﬁca0on	of	the	LRR	domain,	six	constructs	were	designed	with	varying	staggered	N-termini	
around	the	predicted	N-terminus	of	the	LRR	domain	(ﬁg	5a).	The	C-terminus	was	ﬁxed	at	a	posi0on	known	
to	crystallise	the	Roc	domain.	
	
Each	construct:	LRR1-6,	was	N-terminally	tagged	with	a	TEV	cleavable	His6-MBP	tag	(ﬁg	5b).	
I	thank	Monique	Gangloﬀ,	Nick	Gay	and	members	
of	 the	 Gay	 Lab	 for	 their	 support	 during	 this	
project.	
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Figure	3:	Model	of	LRR	domain	of	LRRK2	based	on	TLR3.	
(A)	 Cartoon	 representa0on	 showing	 leucine	 rich	 repeats	 of	 LRRK2.	 (B,C)	 Coulombic	 surface	 colouring	
showing	dis0nc0ve	charged	patches.	
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Using	 constructs	 LRR1,	 LRR3	 and	 LRR6	 various	 puriﬁca0on	 strategies	 and	 condi0ons	 were	 trialled	 allowing	
comparison	of		the	eﬀec0veness	of	diﬀerent:	
	
• 		Puriﬁca0on	techniques	
• 		Puriﬁca0on	buﬀer	condi0ons	
• 		LRR	constructs	
LRR:	1				-				6	
Fixed	C-terminus	
LRR	 Roc	
N-terminus	
Figure	5:	LRR	construct	design.	(A)	Six	constructs	designed	with	varying	N	termini;	named	LRR1-6.	
(B)	LRR	constructs	were	tagged	with	His6	and	Maltose	Binding	Protein.	
LRR:	Leucine	rich	repeats	Roc:	Ras	of	complex	proteins	MBP:	Maltose	Binding	Protein	
C	LRR1-6	MBP	N	-	His6	
A	 B	 TEV	cleavage	site	
Figure	4:	MBP-LRR6	 test	
expression	in	Sf9	cells.	
Protein	 puriﬁed	 by	 the	 previously	 described	 op0mised	 protocol	 (ﬁg	 6)	 was	 found,	 at	 neutral	 pH,	 to	 bind	
heparin;	 a	 highly	 nega0vely	 charged	 glycosaminoglycan	 known	 for	 binding	 to	 DNA	 binding	 proteins	 -	 thus	
‘mimicking’	nega0vely	charged	DNA.	This	validates	modelling	performed	showing	homology	to	TLR3	(ﬁg	3).	
(B)	 Eluted	 protein	 was	 found	 to	 be	
extremely	 pure	 	 of	 unknown	 conta-
minants;	 an	 improvement	 over	 a	 Ni	
aﬃnity	 ﬁnal	 puriﬁca0on	 step	 (ﬁg	 4).	
However	 TEV	 protease	 was	 found	 to	
bind	 by	 a	 ca0on	 exchange	 eﬀect	 on	
account	 of	 its	 high	 pI.	 Western	 blot	
(right)	 conﬁrms	 the	 iden0ty	 of	 LRR6,	
which	 is	 not	 detected	 by	 α-His6	 Ab	
ager	 TEV	 cleavage	 of	 the	 MBP-His6	
tag.	
	
LRR6	=	~40kDa	
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Figure	8:	LRR6	forms	spherulites	in	PEG	precipitants	at	~pH9.	Condi0ons	were	part	of	a	JCSG+	pre-dispensed	
crystallisa0on	plate.	Spherulite	examples	indicated	by	red	arrows.	Condi0ons	of	interest	indicated	in	white.	
Puriﬁed	LRR6	formed	‘spherulites’	under	condi0ons	including	polyethylene	glycol	(PEG)	precipitants	at	pH	~9.	
These	condi0ons	indicate	that	further	op0misa0on	may	yield	crystals	for	analysis	by	x-ray	crystallography.	
This	 approach	 established	 a	 general	 protocol	 for	 puriﬁca0on	 of	 quan00es	 of	 LRR6	 amenable	 for	 basic	
biophysical	analysis,	although	further	op0misa0on	is	required.		Interes0ngly	use	of	MBP	for	aﬃnity	puriﬁca0on	
was	found	to	be		ineﬀec0ve	due	to	large	amounts	of	protein	precipita0on.	
Interplay	with	innate	immunity	
Post-mortem	 analysis	 of	 Parkinson’s	 suﬀerers	 has	 shown	 increased	 levels	 of	 ac0vated	 microglia	 and	 pro-
inﬂammatory	cytokines	within	the	aﬀected	region	of	the	brain.	Microglia	are	the	resident	 immune	cells	of	the	
brain,	expressing	a	wide	range	of	innate	immune	Toll	Like	Receptors	(TLRs).	It	is	theorised	that	hyper	ac0va0on	
of	microglia	causes	inﬂamma0on	and	cellular	damage,	crea0ng	a	feed-forward	cycle	of	further	cellular	damage	
and	immune	cell	ac0va0on.	
	
LRRK2	
Leucine	Rich	Repeat	Kinase	2	(LRRK2)	 is	a	 large	mul0	domain	protein	(ﬁg	1)	of	unknown	func0on	expressed	in	
microglia	 as	 well	 as	 other	 peripheral	 immune	 cells.	 Muta0ons	 in	 LRRK2	 have	 been	 strongly	 associated	 by	
genome	 wide	 associa0on	 studies	 to	 the	 familial	 form	 of	 Parkinson's	 disease	 as	 well	 as	 other	 inﬂammatory	
diseases	such	as	Crohn's	Disease.	There	are	a	large	number	of	such	muta0ons	across	diﬀerent	domains,	which	
have	 been	 shown	 to	 aﬀect	 kinase	 ac0vity	 diﬀeren0ally.	 Cellular	 studies	 have	 revealed	 possible	 eﬀects	 of	
diﬀerent	muta0ons	to	LRRK2,	however	no	clear	primary	func0on	or	pathological	mechanism	in	Parkinson's	has	
become	 clear.	 This	work	 focuses	 on	 	 biophysical	 analysis	 of	 the	 poten0al	 ligand	binding	 Leucine	Rich	Repeat	
(LRR)	domain	of	LRRK2.	
Of	note	is	that	LRRs	are	by	deﬁni0on	similar	mo0fs	across	diﬀerent	proteins;	so	much	further	work	is	needed	to	
validate	the	signiﬁcance	and	accuracy	of	this	homology	model.	
Figure	2:		SchemaOc	of		
brain	regions	
-20	
0	
20	
40	
60	
80	
100	
-5	
0	
5	
10	
15	
20	
25	
0	 5	 10	 15	 20	
Percentage	of	1	M
	N
aCl	
A 2
80
	/	
m
Au
	
	 	
	
	
	
Figure	7:	LRR6	has	aﬃnity	for	heparin.	
(A)	 TEV	 cleaved	 LRR6	 was	 puriﬁed	 using	 a	
HiTrap	 Heparin	 HP	 column	 in	 20	mM	NaPO4	
pH7.0.	 Elu0on	 was	 performed	 by	 increasing	
NaCl	concentra0on	to	1	M	(blue	doded	line).	
Protein	Absorbance	(red).	
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Figure	6:	LRR6	puriﬁcaOon	strategy	summary	gel.		
MBP-LRR6	expressed	in	Sf9	cells		was		harvested	as	previously	(ﬁg	
4).	 Lysis	 was	 performed	 by	 sonica0on,	 and	 soluble	 extract	
isolated	by	ultracentrifuga0on.	
	
1.  Ni	 Aﬃnity	 puriﬁca0on	 was	 performed	 using	 a	 HiTrap	
Chela0ng	column	pre-equilibrated	with	Ni.	Protein	was	eluted	
by	 increasing	 Imidazole	 concentra0on	 to	 250	 mM	 over	 20	
column	volumes	(CV)	of	buﬀer.		
2.  The	eluted	protein	frac0on	was	dialysed	to	150	mM	NaCl,	20	
mM	Tris	pH8.0	overnight,	and	loaded	onto	a	HiTrap	Q	column	
at	50	mM	NaCl	for	anion	exchange.	Elu0on	was	performed	by	
increasing	NaCl	concentra0on	to	0.5	M	over	20	CV.		
3.  MBP-LRR6	 was	 concentrated	 and	 cleaved	 to	 LRR6	 by	
incuba0on	with	TEV	protease	overnight	at	4	°C.		
4.  Cleaved	 product	was	 re-puriﬁed	 using	 a	Ni	 HiTrap	 Chela0ng	
column	 but	 with	 now	 untagged	 LRR6	 present	 in	 the	 ﬂow	
through	(FT),	indicated	by	a	red	arrow.	(LRR6	=	~40kDa).	
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